

CURRICULUM VITAE

E. David Crawford, M.D.

TITLE:

E. David Crawford, M.D.
Professor of Urology
University of California San Diego
Koman Family Outpatient Pavilion
La Jolla, CA 92037

Chairman, Prostate Conditions Education Council

Editor in Chief
Grand Rounds in Urology

1590 Little Raven # 408
Denver, CO 80202
cell-303 668 8393
david.crawford@ucdenver.edu
edc@edavidcrawford.com

Emeritus: Professor of Surgery, Urology, and Radiation Oncology
Head, Urologic Oncology
University of Colorado Denver, Anschutz Cancer Pavilion
Urologic Oncology Department
Mail Stop F710
1665 Aurora Court, Rm. 1004
Aurora, Colorado 80045, USA
Academic Office - 720-848-0195
Fax - 720-848-0203
E-mail: david.crawford@ucdenver.edu

PLACE OF BIRTH: Cincinnati, Ohio

EDUCATIONAL BACKGROUND

College:

University of Cincinnati, Cincinnati, Ohio
BS Chemistry

Medical School:

University of Cincinnati, Cincinnati, Ohio

POSTGRADUATE TRAINING

Internship:		
	Good Samaritan Hospital, Department of Surgery, Cincinnati, Ohio	1973-74
Residency:		
	Good Samaritan Hospital, Department of Surgery, Cincinnati, Ohio	1974-77
Fellowship:		
	Clinical Fellow in Urology under auspices of Dr. Donald G Skinner, University of California Medical Center, Los Angeles, California	1977-78

HONORS AND AWARDS

Bachelor of Science Degree with Honors in Chemistry, University of Cincinnati, 1969
Phi Lambda Upsilon Honorary Chemistry Fraternity, University of Cincinnati, 1968
Alpha Omega Alpha, University of Cincinnati School of Medicine, 1972
Health Profession Scholarship, University of Cincinnati School of Medicine, 1970-1973
Chairman, GU Committee, Southwest Oncology Group, 1980-2010
Chairman, Intergroup Prostate Cancer Study, 1984-1989
National Prostate Cancer Education Council, 1989
National Prostate Cancer Education Council, Chairman, 1990-present
Honorary Member, Leicester Medical Society, Leicester, England, 1993
Cited in The Best Doctors in America 1992-93, 1993-94, 1994-95, 1996-97, 1998-99, 2000-2012.
Cited in "Town & Country's" Best Medical Specialists in North America, 1995
Cited in International Who's Who of Professional Specialties, 1997, 1998, 2000-2004.
"Freddie Award" for *ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating)*, hosted by E. David Crawford with special guest retired General Norman Schwarzkopf. Presented at the 1997 AMA International Health & Medical Film Competition.
American Cancer Society's televised "A Journey of Hope", June 16, 1999.
CaP Cure Annual Award for Scientific Presentation. Co-recipient at Annual American Urological Association Meeting, 1999.
The National Registry of Who's who – Life Member, 1999. (Registry #146620)
The National Registry of Who's who, 2000, 2001
"Freddie Award" for *ITV: 2nd episode of Advanced Prostate Cancer Show*. Time Warner, November, 2000.
America's Top Physicians, Guide to America's Top Physicians Consumer's Research Council of America, Urologic Oncology, 2003, 2004.
"Champions in Healthcare Award," Top Healthcare Provider, Denver Metropolitan Area, Denver Business Journal and Anthem Blue Cross and Blue Shield, 2006.
America's Top Doctors for Men, Men's Health Magazine, March 24, 2007.
Global Clinical Research & Development Certificate, January, 2008.
"Legends in Urology," The Canadian Journal of Urology, June, 2008.
Best of Posters Award, "Use of PSA Threshold to identify an increased 4-year risk of a prostate cancer diagnosis in US men", American Urologic Association meeting, Chicago, IL, 2009.
Scientific and Advisory Board Committee, 7th Men's Health World Congress, 2010.
Robert J. Krane Prize for the Best Clinical Paper "Prostate danger zone." British Journal of Urology, 2011.
Best Doctors, Inc. Best doctors in America 2015-present
Outstanding Alumnus of the Year, University of Cincinnati School of Medicine, 2018
American Urological Association: Presidential Citation for genitourinary cancer research that has benefited countless urologic cancer patients, 2019
2nd Place Award, Best Posters, "Impact of Late Dosing on Testosterone Suppression for In Situ Gel Compared to Microsphere Delivered Leuprolide Acetate – An Analysis of US Clinical Data", Western Section AUA Meeting, Indan Wells, CA, 2021.
Executive Committee for the AdMeTech Foundation's Multi-Disciplinary Working Group on Image-Guided Focal Treatment of Prostate Cancer, 2023
Top Doctors Urology, 15 consecutive years, 2023

SPECIALTY CERTIFICATION

Board Certified, American Board of Urology, 1980

LICENSURE

Ohio, 1974: No. 037262 (expiration: 12/31/86)
California, 1977(expiration: 6/06/78)
New Mexico, 1978: No. 78-143 (expiration: 6/30/94)
Mississippi, 1983: 10142 (expiration: 6/30/86)
Colorado, 1986: No. 27530 (expiration: 04/30/23)
California, 2019: No. G35350(expiration: 05/31/23)

PROFESSIONAL MEMBERSHIPS

Fellow, American College of Surgeons, 1981
Member, American Fertility Society, 1978
Member, South Central Section of American Urology Association, 1979
GU Committee, Southwest Oncology Group (SWOG), 1979
Member, American Urological Association, 1980
Chairman, GU Committee, Southwest Oncology Group (SWOG), 1980
Active Member, American Society of Clinical Oncology (ASCO), 1981
Member, Board of Governors, Southwest Oncology Group (SWOG), 1981
Member, Advisory Board, United Ostomy Association, 1981-1993
Member, the International Society of Preventive Oncology, Inc., 1982-1992
Member, American Association for Advancement of Science, 1982
Member, Association for Academic Surgery, 1982
Member, American Medical Association, 1983
Member, Medical Society of the United States and Mexico, 1983-1992
Member, Association of Military Surgeons of the United States, 1985-1993
Member, American Association for the Advancement of Science, 1997
Member, European Academy of Sciences, 2003 – present
Member, Western Section of American Urology Association, 2020

PROFESSIONAL SOCIETIES

Member (Founding Member), Society of Urologic Oncology, 1984
Member, Society Internationale d'Urologie, 1985
Member, Inter-American Society for Chemotherapy, 1985
Honorary Member, Asociacion Costarricense de Urologia, 1985
Member, American Association of Clinical Urologists, Inc., 1989
Charter Member, Academic Urologic Cooperative Group, 1989
Member, Society of University Urologists, 1986
Member, Society of Laparoendoscopic Surgeons, 1991
Member, American Association for the Advancement of Science, 1997
Member, International Society of Cancer Chemoprevention, 1997
Member, European Association of Urology, 1998
Member, Scientific Council, Foundation for Men's Health, Head of Prostate Cancer
Advisory Committee, 2011
Founding Member, American Society of Men's Health, 2011

ACADEMIC APPOINTMENTS

Lecturer in Surgery, University of California Medical Center, Los Angeles, California	1977-78
Assistant Professor of Urology, University of New Mexico School of Medicine, Albuquerque, New Mexico	1978-82
Associate Professor of Urology, University of New Mexico School of Medicine, Albuquerque, New Mexico	1982-83
Director of GU Oncology, University of New Mexico School of Medicine, Albuquerque, New Mexico	1979-83
Chief of Urology, Cancer Research and Treatment Center, Albuquerque, New Mexico	1979-83
Associate Professor of Surgery/Urology, Division of Urology, University of Mississippi Medical Center, Jackson, Mississippi	1983-85
Director, Urologic-Oncology, University of Mississippi Medical Center, Jackson, Mississippi	1983-86
Attending Physician, Division of Urology, Veterans Administration Hospital, Jackson, Mississippi	1983-86
Professor of Surgery/Urology, Division of Urology, University of Mississippi Medical Center, Jackson, Mississippi	1985-86
Professor and Chairman, Division of Urology, University Of Colorado Health Sciences Center, Denver, Colorado	1986 -1996
Director, Clinical Cancer Unit, University of Colorado Health Sciences Center, Denver, Colorado	1987-1999
Associate Director, University of Colorado Cancer Center, Denver, Colorado	1987-2019
Professor of Surgery and Radiation Oncology; Chair, Division Of Urologic Oncology, Denver, Colorado	1999-2019
Senior Associate Director for Clinical and Community Development University of Colorado Cancer Center, Denver, Colorado	2002-2019
Professor of Urology, University of California San Diego, LaJolla, CA	2019-present

EDITORIAL REVIEWER/CONSULTANT

Journal of the American Medical Association
Urology
Journal of Urology
New England Journal of Medicine
Annals of Internal Medicine
Cancer
Journal of Clinical Oncology
European Urology
The Prostate
Prostate Cancer (and Prostatic Diseases) – Consulting Editor
European Urology
Drugs & Aging
Clinical Prostate Cancer

Open Access Journal of Clinical Trials
 Update in Cancer Therapeutics
 Oncology *REALTIME* – Editorial Board Member

ADVISORY BOARDS/OTHERS

Southwest Oncology Group	1992 to 2005
Us Too	1993 to 2004
Prostate Health Council	1993 to 2004
Prostate Cancer Trialists Collaborative Group	1996 to present
AUA Special Committee to Study Urology Research Efforts At NIH	1996 to 2002
Scientific Advisory Board, Southwest Oncology Group	1997 to 2004
Spalding Community Foundation	1997 to 2001
Oncology Live Advisory Board	2015
Alliance for Prostate Cancer Prevention	2002 to 2018
The Journal of Men’s Health and Gender	2005 to present

EDITORIAL BOARDS

United Ostomy Quarterly	1983-1991
Editor, Urology Grand Rounds Oncology	1986-present 1995-present
Primary Care & Cancer	1995-present
Time/Life Medical Editorial Board	1996-1997
Journal of Cellular Biochemistry (Chemoprevention Supplements)	1994-2010
Editor, American Cancer Society’s Complete Guide to Prostate Cancer	2004
The Journal of Men’s Health & Gender	2005 – 2009
The Annals of Urology	2010
Section Editor, Journal of Men’s Health , Urologic Oncology	2010 – present
Asian Journal of Andrology	2012-present
Grand Rounds in Urology (GRU)	2010-present
Grand Rounds in Urology (GRU) Editor in Chief	2018-present

II. SOUTHWEST ONCOLOGY GROUP AND NCI PROTOCOLS

1. #8104: Treatment of Advanced Seminoma (Stages B3 and C) with Combined Chemotherapy and Radiation. (Drs. E. David Crawford and Mirkutub Khan).
2. #8221: Treatment of Advanced Bladder Cancer with Combined Preoperative Radiation and Radical Cystectomy. (Drs. E. David Crawford, JA Smith, and Jorge C. Paradelo).
3. #8110: Treatment of Advanced Germ Cell Neoplasms of the Testis: A Comparison of Remission Induction with Vinblastine, Bleomycin, Cis-platinum with or without VP-16-213; Surgical Removal of all Residual Tumor Following Remission Induction; Comparison of Maintenance Therapy with Cytosan, Actinomycin and Vinblastine versus Observation. (Drs. Michael K Samson and E. David Crawford).
4. #8219: Evaluation of Combined or Sequential Chemo Endocrine Therapy in the Treatment of Advanced Adenocarcinoma of the Prostate. (Drs. C. Kent Osborne and E. David Crawford).
5. #8494: Intergroup Prostate Protocol, a Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D₂ Cancer of the Prostate. E. David Crawford, M.D., Intergroup Protocol Chairman. Executive Committee: Drs. David McLeod, Walter Reed Army Medical Center; Ralph Benson, Mayo Clinic, and Joseph Spaulding, NCOG.

6. #8517: Phase II Study of Platinum and Mitoxantrone in the Treatment of Metastatic Adenocarcinoma of the Prostate. (Drs. Kent Osborne and E. David Crawford).
7. #8519: Phase II Evaluation of Methyl-Glyoxal Bis-Guanylhydrazone (MGBG) in Patients with Advanced Bladder Cancer. (Drs. Daniel D. VonHoff and E. David Crawford).
8. #8806: A Phase II Study of Recombinant Tumor Necrosis Factor (rTNF) in Patients with Advanced Bladder Cancer. (Dr. E. David Crawford).

III. SELECTED GRANTS AND RESEARCH SUPPORT

1. Eli Lilly Company, Study of Moxalactam in Urinary Tract Infections, 1979 (\$38,000).
2. Smith, Kline and French Laboratories, Study of Ceftizoxime in Urinary Tract Infections, 1980.
3. Roerig Division of Pfizer, Study of UTI Following Prostatic Biopsy, 1979 (\$50,000).
4. Roerig Division of Pfizer, Study of UTI Following Transurethral Resection of the Prostate, 1982. (\$50,000)
5. CIBA-GEIGY, Cytadren in Advanced Prostate Cancer, 1983 (\$30,000).
6. Roerig Division of Pfizer, Prostatitis, 1984 (\$15,000).
7. CIBA-GEIGY, Aminoglutethimide versus Hydrocortisone for Advanced Prostate Cancer, 1985 (\$15,000).
8. VACO Grant #246, Prostatic Surgery in Elderly Men, 1986 (\$225,000).
9. G. H Besselaar, Prostate Cancer, 1986 (\$10,000).
10. G. D. Searle, Roche, Abbott Labs, A Multicenter Comparison of Lomefloxacin vs Parenteral Cefotaxime as Prophylactic Agents in Transurethral Surgery, 1988 (\$50,000).
11. Genentech, #87-946, a Phase I Study of Intravesical Therapy of Refractory Superficial Bladder Cancer with Recombinant Tumor Necrosis Factor, 1988. (\$65,000).
12. Southwest Oncology Group, Genitourinary Committee; Chairman, Genitourinary Committee, 1986-present (\$25,000/year).
13. Urological Cancer Outreach Program, Administrative Support, 1988-present (\$65,000/year).
14. Hoffman-LaRoche, Fleroxacin versus Norfloxacin in Urinary Tract Infection, 1988 (\$15,000).
15. Merck, Sharp, & Dohme, MK-906 Post-Radical Prostatectomy, 1990.
16. Schering-Plough, Dose Response Study of Effect of Flutamide on Benign Prostatic Hypertrophy, 1990 (\$22,000).
17. Abbott Laboratories, A Study of Doxazosin for the Possible Prevention of Urinary Retention in Patients Undergoing Anterior Cruciate Ligament Reconstruction (ACLR), 1990 (\$31,000).
18. NIH, Prostate, Lung, Colorectal, Ovarian Screening, 1993 to present. (\$20,106,369 - \$1,595,773 annual direct)
19. NIH, Treatment of BPH: Pilot Study /5 U01 DK, 1992 to 2003.
20. Long-term Effects of Finasteride (MK-906) in Patients with BPH, 1993 (\$41,000).
21. Safety and Efficacy of Depo-Lupron for D2 Prostate Carcinoma/M91-583, 1992 (\$15,000).
22. A Phase III Open-Label, Multicenter Trial Actimmune in Patients with Metastatic Renal Cell Carcinoma/SPS 3014, 1993 (\$25,000).
23. Treatment of Stage C Carcinoma of the Prostate with Neoadjuvant Hormonal Therapy by Radical Prostatectomy/SPS 0376, 1992 (\$25,000).
24. Phase II Study of Oral Bropirimine in Patients with Superficial Bladder Cancer (Carcinoma in situ), 1992 (\$75,000).
25. Southwest Oncology Group: Prostate Cancer Prevention Trial/3 U10, 1992 (\$52,000).
26. Cancer League of Colorado: Prostate Cancer Screening by Application of the TRAP Assay, 1996 to 1998 (\$15,000).
27. Schramm Foundation: Prostate Cancer Research, 1991 to present (\$25,000/year).
28. Arista: Centrorelax in Hormone-Refractory Prostate Cancer, 1997 (\$45,000).
29. Schering: LHRH Receptors in Prostate Cell Lines, 1997 (\$60,000).
30. University of Colorado: Mapping Biopsy Sites of Specific Prostate Tissue, 1997 (\$10,000).

31. NIH/NIDDK: Minimally Invasive Surgical Therapies (MIST) for Benign Prostatic Hyperplasia, 2001-2006. (\$256,900)
32. NCI/NIH: University of Colorado Cancer Center Support Grant 2001-2006 (\$25,000/year).
33. NIH/NIDDK: Trans Urethral Microwave Therapy versus Medical Therapy in Treatment of Benign Prostate Hyperplasia, 2001-2006. \$1,363,127 - \$256,900/year
34. NIH/NIDDK: Complementary and Alternative Medicine for Urological Symptoms (CAMUS), 2002-2010. (\$109,900)
35. SWOG: Southwest Oncology Group SELECT Trial, 2000-2012 (\$250,000).
36. SWOG: S02017 Southwest Oncology Group Central Office/Urologic Cancer Outreach Program, 2002-present (\$5,000).
37. SWOG: S00005 Southwest Oncology Group Central Office/Genitourinary Cancer, 2002-present. (\$10,252/year)
38. NIH/NCI/DCPC: National Lung Screening Trial (NLST), 2002-2011. (\$9,636,933 - \$1,242,168/year).
39. Aeterna Zentaris: Cetrorelix Pamoate Intermittent IM Dosage Regimens in Patients with Symptomatic BPH: A One Year Placebo-Controlled Efficacy Study of Long-Term Safety Assessment, 2007-2010.
40. EDAP Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU) Indicated for the Treatment of Low Risk, Localized Prostate Cancer, 2007 to present.
41. Ferring Pharmaceuticals: An Open-Label, Multi-Center, Randomized, Parallel-Arm, One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy, 2009 to 2011.
42. Ferring Pharmaceuticals: A Randomized, Controlled, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in Patients with Carcinoma of the Prostate with Biochemical Failure after Localized Therapy, 2009 to present.
43. Aureon Biosciences: Immunohistochemical Prognostic Assays for Prostate Biopsies and Prostatectomy Specimens as Related to Clinical and Pathologic Outcomes, 2011-2012.
44. Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial- Subcontract Extension, 2011 to present.
45. Jansen Biotech, Inc.: Impact of Abiraterone Acetate in Prostate Specific Antigen Study, 2011 to present.
46. Millennium Pharmaceuticals: A Phase III, Randomized Double-Blind, Multicenter Trial Comparing Oteronel plus Prednisone with placebo Plus Prednisone in Patients with Chemotherapy, 2011 to present.
47. Ferring Pharmaceuticals: An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy, 2011 to present.
48. Precision Biopsy, LLC: Preliminary Assessment of Optical Spectroscopically-Guided Needle Biopsies for Diagnostic Accuracy of Prostatic Carcinoma: A Feasibility Study, 2012 to present.

IV. VISITING PROFESSOR

1. Georgia Baptist Medical Center, June 1982
2. University of Mississippi, June 1983
3. Touro Infirmary, December 1983
4. University of Utah, December 1986
5. University of Kansas, February 1987

6. University of Cincinnati, November 30, 1987
7. Baylor University, March 8, 1988
8. Louisiana State University, April 15-16, 1988
9. University of Arkansas, September 8-9, 1988
10. Louisiana State University, November 9-11, 1988
11. University of California, Irvine, January 19, 1989
12. St. Louis University, August 21, 1989
13. Wayne State University, March 7, 1990
14. Ohio State University, March 10, 1990
15. Tufts University, September 6-8, 1990
16. University of Washington, April 6, 1991
17. Royal Society of Medicine, London, April 24-26, 1991
18. Louisiana State University-Schreveport, October 3, 1991
19. University of Tennessee- July 28, 1992.
20. Vanderbilt University, April 8-9, 1994.
21. University of Nebraska, April 22-23, 1994.
22. Duke University, Sep 13, 1994.
23. University of California at Davis, July 27, 1995.
24. University of Gratz, Gratz, Austria, October 16-17, 1995.
25. Tulane University, New Orleans, Louisiana, January 18-19, 1996.
26. New York University, New York City, April 17, 1996.
27. University of Nijmegen, Nijmegen, the Netherlands, June 3-6, 1996.
28. Brown University, Providence, Rhode Island, October 9-10, 1997.
29. Sixth Annual Hershey Visiting Professor, Harvard Medical School, Boston, MA, November 12-13, 2002
30. Washington University in St. Louis, School of Medicine, St. Louis, MO, September 17, 2004.
31. Brown University, Providence, Rhode Island, April 18, 2006.
32. University of Toronto, Toronto, Canada, April 26-27, 2007.
33. Wake Forest School of Medicine, Winston-Salem, NC, May 4-5, 2012.
34. Thomas Jefferson University, Philadelphia, PA, June 1, 2012.
35. Arkansas Urological, Little Rock, AK, September 27, 2012.
36. UCSD Moores Cancer Center, La Jolla, CA, Feb 20, 2013.
37. Texas Tech University, March 9-10, 2017.

V. LOCAL COMMITTEES

Senior Associate Director, University of Colorado Cancer Center
 Laser Committee, 1986-1998
 Surgical and Recovery Suite Committee, 1990 to 2000
 Cancer Committee, 1986 to present
 American Cancer Society Education Committee, 1996 to 2000
 Space Committee, Head, and 1996 to 2000
 Ambulatory Care Committee, 1989 to 2001
 Management Committee, Cancer Center, 1986 to present
 Chairman, Clinical Building Committee, Cancer Center, 1995 to 2000
 Research and Development, VA Medical Center, 1986 to 2001
 Space Committee, VA Medical Center 1986-1995
 Chairman, local American Cancer Society Task Force for Prostate Cancer, 1993-1997
 Clinical Trials Committee, 1999-2019

VI. NATIONAL COMMITTEES

Program Committee, American Society of Clinical Oncology, 1987-1990.
Residents' Program Committee, South Central Section of American Urological Association, 1989, 1990, 1991
External Referee, Medical Research Council of Canada, 1989 to present
American Arbitration Association's Panel of Arbitrators, 1989 to present
Program Committee, American Urological Association, 1990-1995
Vasectomy & Prostate Cancer Committee, American Urological Association, 1993
NIH Special Committee to Study Urology Efforts, 1996 to 2000
AUA Committee to Study Urologic Research Funding, 1997 to 2000
AUA Prostate Cancer Clinical Trials Subcommittee, 1997 to 2001
AUA nominating Committee 2010-2012

VII. PUBLICATIONS: Peer Reviewed Journals

1969-1979

1. Reinert R, and Crawford ED: The effect of ozone on plant tissue cultures. *Phytopathology* 59:1046, 1969.
2. Crawford ED, Dumbadze I, and Vester J: [Diagnosis of pelvic lipomatosis by CT scan](#). *Am J Med* 65:1020, 1978.
3. Crawford ED, Dumbadze I, Ratledge HW, Mulvaney WR, and Wendel RG: Deep venous thrombosis following transurethral resection of the prostate: A new method of diagnosis. *J Urol* 120:438, 1978.
4. Crawford ED and Mulvaney WP: [Rapid increase in calculus size: A possible hazard of phenazopyridine hydrochloride therapy](#). *J Urol* 119:280, 1978.
5. Crawford ED: Bladder cancer. *Surg Rounds* 1:40, 1978.
6. Crawford ED, Skinner DG, and Caparell DG: [Intercostal nerve block with thoracoabdominal incision](#). *J Urol* 121:290, 1979.
7. Crawford ED, Skinner DG, and Malano JT: [Renal arteriovenous fistulae secondary to bilateral renal cell carcinoma](#). *Urology* 7:525, 1979.
8. Crawford ED, Henning DG, and Wendel RG: [Renal cell carcinoma in a horseshoe kidney associated with von Hippel-Lindau disease](#). *J Urol* 121:677, 1979.
9. Dumbadze I, Crawford ED, and Mulvaney, WP: [Giant dendritic struvite calculus associated with transitional cell carcinoma of ipsilateral renal pelvis](#). *J Urol* 122:692, 1979.
10. [Crawford ED and Borden TA: Evaluation of a renal mass](#). *N. Eng. J Med.* 300:1117, 1979 (Letter to the Editor).
11. Dumbadze I, Crawford ED, and Mulvaney WP: [Lymphomatoid tumor infiltration of renal veins](#). *J Urol* 121:88, 1979.

1980

12. Crawford ED and Skinner DG: [Salvage cystectomy after irradiation failure](#). *J Urol* 123:32, 1980.
13. Crawford ED: Prostate cancer. *Surgical Rounds* 3:12, 1980.
14. Skinner DG, Crawford ED, and Kaufman JJ: [Complications of radical cystectomy for carcinoma of the bladder](#). *J Urol* 125:640, 1980.

15. Crawford ED, Mettler FA, and Rogers HW: Ultrasonic detection of renal cell carcinoma extending into the inferior vena cava. J Urol 124:538, 1980.
16. Woodside JR, Borden TA, Goldman R, and Crawford ED: [Flank pain and microhematuria in a young woman](#). C.P.C., J Urol 123:756, 1980.
17. Woodside JR and Crawford ED: [Dissolution of vesicle calculi with Renacidin in a paraplegic man](#). Paraplegia 18:69, 1980.
19. Woodside JR and Crawford ED: [Urodynamic features of pelvic plexus injury](#). J Urol 124:657-58, 1980.
20. Crawford ED, Borden TA, Woodside R Jr., Peters P, and Butler C: CPC: [Renal mass in man with eosinophilic granuloma](#). Urology 15:520, 1980.
21. Crawford ED and Borden TA: [New instrument for placement of circle tube nephrostomy](#). J Urol 124:324, 1980.
22. Mettler PA, Wicks S, and Crawford ED: [Co-existent renal eosinophilic granuloma and renal adenocarcinoma](#). Urol Radiol 1:247, 1980.
23. Crawford ED and Skinner DG: RE: Salvage cystectomy. J Urol 124:577, 1980 (Letter to the Editor).

1981-1982

24. Crawford ED and Woodside JR: [RE: Calculi complicating intermittent catheterization](#). J Urol 125:134, 1981 (Letter to the Editor).
25. Wendel RG, Crawford ED, and Hehman KN: RE: [“Nutcracker” phenomenon: An unusual cause for renal varicosities with hematuria](#). J Urol 125:134, 1981 (Letter to the Editor).
26. Crawford ED and Skinner DG: [Intercostal nerve block following thoracoabdominal and flank incisions](#). Urology 19:25, 1982.
27. Crawford ED, Haynes AL, Story MW, and Borden TA: [Prevention of urinary tract infection and sepsis following transrectal prostate biopsy](#). J Urol 127:449, 1982.
28. Crawford ED and Skinner DG: [RE: Salvage cystectomy for bladder cancer after failure of definitive irradiation](#). J Urol 127:784, 1982 (Letter to the Editor).
29. Crawford ED and Sindiong RL: Blind-ending branch of bifid ureter: Diagnosis by intravenous pyelogram. Scientific Journal GBMC 2:33, 1982.
30. Plimpton HW and Crawford ED: [Ceftizoxime in the treatment of urinary tract infections](#). J Urol 128:1231, 1982.

1983

31. Khan K, Crawford ED, and Johnson E.L: [Transperineal percutaneous iridium-192 implant of the prostate](#). International Journal of Radiation Oncology, Biology and Physics. 9:1391, 1983.
32. Crawford ED, Cain DE, and Black WC: [Inguinal lymph node metastasis following Toreck orchiopexy](#). Urology 21:3, 1983.
33. Crawford ED, Smith RB, and deKernion JB: [Treatment of advanced seminoma with preradiation chemotherapy](#). J Urol 129:752, 1983.
34. Crawford ED and Kiker JD: [Radical retropubic prostatectomy](#). J Urol 129:1145, 1983.
35. Robbins DN, Crawford ED, and Lackner HL: [Priapism secondary to prazosin overdose](#). J Urol 130:975, 1983.
36. Osborne CK, Drelichman A, Von Hoff DD, and Crawford ED: Mitoxantrone: [Modest activity in a phase II trial in advanced prostate cancer](#). Cancer Treatment Reports 67:1133, 1983.

1984

37. Crawford ED, Mettler FA, and Duncan PR: [Retrocrural lymphadenopathy in testicular cancer](#). J Urol 131:343, 1984.

38. Crawford ED, et al: Aminoglutethimide in metastatic adenocarcinoma of the prostate. Proceedings of American Society of Clinical Oncology 3:157, 1984.
39. Crawford ED, Woodside JR, Skinner DG, Blanks BH, and Kiker JD: [Vena cava tumor thrombus from renal cell carcinoma arising from the adrenal vein](#). Urology 23:538, 1984.
40. Gagliano RG, Stephens RL, Costanzi JJ, Oishi N, Stuckey WJ, Grozea PN, Frank J, and Crawford ED: [A randomized trial of hexamethylmelamine \(HEX\) vs. 5-FU, adriamycin and cytoxan \(FAC\) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group Study](#). Cancer Treatment Reports 68:1025, 1984.
41. Robbins DM, Crawford ED, and Lackner HC: [Late development of a urethrocaavernous fistula after cavernospongiosum shunt for priapism](#). J Urol 132:126, 1984.
42. Rudy DC, Woodside JR, and Crawford ED: [Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retro pubic prostatectomy: A prospective study](#). J Urol 132:708, 1984.
43. Crawford ED: [Editorial comment: Combined prostatectomy](#). J Urol 132:687, 1984.
44. Crawford ED: The SWOG study for advanced testicular cancer. Seminars in Urol 2:244, 1984.
45. Crawford ED: [Review: Radical ilioinguinal lymphadenectomy](#). Urol Clin North Am 11(3):543-52, 1984.

1985

46. Gottesman JE., Crawford ED, Grossman HB, Scardino PT, and McCracken JD: [Infarction-nephrectomy for metastatic renal carcinoma](#). Urology 25(3):248-250, 1985.
47. Crawford ED: Clinical Case Report: Steroid-induced skin atrophy. Ostomy Quarterly 22:82, 1985.
48. Crawford ED: [Diagnosis and treatment of prostatitis](#). Hospital Practice 20:77, 1985.
49. Al-Sarraf M, Frank J, Smith JA, O'Bryan RM, Costanzi JJ, Stephens RL, Caraveo J, and Crawford ED: [Phase II trial of cyclophosphamide, doxorubicin and cisplatin \(CAP\) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group Study](#). Cancer Treatment Reports 69:189, 1985.
50. Plimpton HW, Crawford ED, and Goldhan RT: [Nephrogenic adenoma associated with interstitial cystitis](#). Urology 26:498, 1985.
51. Crawford ED: [Vena cava tumor thrombus from renal cell carcinoma arising from adrenal vein](#). Excerpta Medica Cancer 61:371, 1985.

1986

52. Crawford ED and Dawkins CA: [Diagnosis and management of prostate cancer](#). Hospital Practice 21(3):159, 1986.
53. Stephens RL, Kirby R, Crawford ED, Bukowski RL, Rivkin SE, and O'Bryan RM: [High-dose AZQ in renal cancer. A Southwest Oncology Group Phase II Study](#). Invest New Drugs 4:57-59, 1986.
54. Nabors WL and Crawford ED: Establishing the cause of prostatitis. Diagnosis 8(12):52-56, 1986.
55. Crawford ED: Updates in urostomies: Guest Editorial. Ostomy Quarterly p. 13, April, 1986.
56. Crawford ED, McKenzie D, Mansson W, Totonchy M, Grossman HB, Davis MA, Lamm DL, and Duchek M: [Adverse reactions to intravesical administration of doxorubicin hydrochloride: Report of six cases](#). J Urol 136:668-669, 1986.
57. Crawford ED: [Some thoughts on the future of clinical trials in cancer](#). Cancer Treatment Reports 70(9):1131, 1986.
58. Mori K, Lamm DL, and Crawford ED: [A trial of bacillus calmette-guerin versus adriamycin in superficial bladder cancer. A Southwest Oncology Group study](#). Urol Int 60, 1986.
59. Spaulding JT, Stablein DM, Einhorn LH, Donohue JP, Muggia FM, Cummings K, Crawford ED, et al.: Resectable stage II testicular carcinoma: A randomized comparison of post-

lymphadenectomy chemotherapy and initial observation--A Cooperative Intergroup Study. Am J Clin Oncol, 9:103, 1986.

1987

60. Saiers JH, Slavik M, Stephens RL, and Crawford ED: [Therapy of advanced renal cell cancer with spirogermanium: A Southwest Oncology Group Study](#). Cancer Treatment Reports 71:207-208, 1987.
61. Oishi N, Berenberg J, Blumenstein BA, Johnson K, Rivkin SE, Bukowski R, O'Bryan RM, Stephens RL, Quagliana J, Saiers JH, and Crawford ED: [Teniposide in metastatic renal and bladder cancer: A Southwest Oncology Group Study](#). Cancer Treatment Reports 71:1307-1308, 1987.
62. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT, DeWys WD, and Crawford ED: [Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer](#). NEJM 317(23):1433-1438, 1987.
63. Saiers JH, Blumenstein B, Slavik M, Costanzi JH, and Crawford ED: [Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: A Southwest Oncology Group Study](#). Cancer Treatment Reports 71(12):1305-1306, 1987.
64. Crawford ED, Ahmann FR, Kreis W, Davis MA, and Levasseur YJ: Aminoglutethimide plus hydrocortisone in the treatment of castration refractory advanced adenocarcinoma of the prostate. J Endocrinol Invest. 10 (Suppl. 2):31, 1987.
65. Crawford ED: Review article--Current status of chemotherapy for urothelial tract tumors (Sternberg, CN and Scher, HI) Oncology 1:50, 1987.
66. Balducci L, Blumenstein B, Von Hoff D, Davis M, Hynes H, Bukowski R, and Crawford ED: [Evaluation of fludarabine phosphate in renal cell carcinoma: A Southwest Oncology Group Study](#). Cancer Treat. Reports 71(5):543, 1987.
67. Ahman RF, Crawford ED, Kries W, and Levasseur Y: [Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone](#). Cancer Research 47:4736-4739, 1987.
68. Crawford ED, Das S, Smith JA Jr: [Preoperative radiation therapy in the treatment of bladder cancer](#). Urol Clin North Am 14(4):781-7, 1987.

1988

69. Balducci L, Athar M, Smith GF, Khansur T, McKenzie D, and Crawford ED: [Metastatic extramammary Paget's disease: Dramatic response to combined modality treatment](#). J Surg Oncol 38:38-44, 1988.
70. Foote JE. and Crawford ED: [Total androgen suppression: Are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma](#). Sem in Oncol 6:4, 1988.
71. Balducci L, Crawford ED, Smith GF, Lambuth B, McGehee R, and Hardy C: [Extramammary Paget's disease: An annotated review](#). Clin Invest 6(3):293-303, 1988.
72. Crawford ED, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M and Blumenstein B: A comparison of leuprolide with flutamide and leuprolide in untreated stage D2 prostate cancer, Int-0036. Gynecol Endocrinology 2:63, 1988.

1989

73. Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA, and Costanzi JJ: [Cis-diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: A Southwest Oncology Group Study](#). J Urol 141:66-67, 1989.

74. Crawford ED: Guest Editor: [The role of ultrasound in prostatic imaging. Introduction and overview.](#) Suppl. to Urology 33(6):2, 1989.
75. Osborne CK, Craig JB, Klein K, Crawford ED, and Turner J: [Phase II trial of a new biological response modifier \(ImuVert\) in advanced prostate cancer.](#) Invest New Drugs 7:243-245, 1989.
76. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman P: [A controlled trial of leuprolide with and without flutamide prostatic carcinoma: A placebo-controlled randomized trial.](#) A Southwest Oncology Group Study; A National Cancer Institute Intergroup Study. NEJM 321:419, 1989.
77. Crawford ED and Chodak GW, Guest editors: Advances in the treatment of urologic malignancies. Urology 34(4):3-4, 1989.
78. Crawford ED: [Combined androgen blockade.](#) Urology 34(4):22, 1989.
79. Crawford ED: Moderator, panel discussion: Problems in the management of prostate cancer. Urology 34(4):46, 1989.
80. Lamm DL, Crissman J, Blumenstein B, Crawford ED, et al: [Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.](#) Prog Clin Biol Res 310:263-270, 1989.
81. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman P: A comparison of leuprolide with and without flutamide in previously untreated patients with disseminated prostatic carcinoma: A placebo-controlled randomized trial. A Southwest Oncology Group Study; A National Cancer Institute Intergroup Study. Stampa Medica N.477, October 15, 1989.

1990

82. Nabors W and Crawford ED: [LHRH Agonists: The United States Experience.](#) J of Internat'l. Med Research 18:31, 1990.
83. Crawford ED: Editorial Comment: [On the importance of clinical trials.](#) J Urol 143:787, 1990.
84. Crawford ED and Nabors WL: Diagnosing prostate cancer: Role of the primary care physician. Prim. Care and Cancer 10(3):19-25, 1990.
85. Crawford ED and Nabors WL: A stage-by-stage guide to the treatment of prostate cancer. Prim. Care and Cancer 10(3):27-44, 1990.
86. Crawford ED, Guest Editor, Prim Care and Cancer 10(3), 1990.
87. Kuebler JP, Goodman PJ, Brown TD, Crawford ED, Reitz CL, Knight WA, and Kish JA: [Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma: A Southwest Oncology Group Study.](#) Invest. New Drugs 8:307-309, 1990.
88. Osborne CK, Blumenstein B, Crawford ED, Coltman CA, Smith AY, Lambuth BW, Chapman RA: [Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a Southwest Oncology Group Study.](#) J Clin Oncol 8(10):1675-1682, 1990.
89. VonHoff DD, Blumenstein B, Pollock TW, Crawford ED, Weick JK, Guy JT, Eisenberger M, Fletcher WS, and Natale RB: Letter: [Methylglyoxal bis-guanylhydrazone \(MGBG\) in advanced bladder cancer.](#) European J of Ca 26(7):848-849, 1990.
90. Olsson CD and Crawford ED: Editorial comment: [Predictive accuracy of staging transurethral resection of prostate in management of stage A cancer of prostate: Comparative evaluation.](#) J Urol 143(6): 142, 1990.
91. Nabors W and Crawford ED: Metastatic prostate cancer: Hormonal treatment. World J Urol 8:34-39, 1990.
92. Crawford ED, Goodman P, and Blumenstein B: [Combined androgen blockade: Leuprolide and flutamide versus leuprolide and placebo. Semin.](#) in Urol 8(3):154-158, 1990.
93. Stephens R, Goodman P, Crawford ED, Spicer CF, Lower BA, Ahmann FR, Chapman R, and Natale RB: [Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study \(8504\).](#) Invest. New Drugs 8:S69-S71, 1990.

94. Rawls WH, Lamm DL, Lowe BA, Crawford ED, et al.: [Fatal sepsis following intravesical bacillus calmette-Guerin administration for bladder cancer](#). J Urol 144:1328-1330, 1990.
95. Crawford ED: [Combination studies with leuprolide](#). Eur. Urol, 18(suppl 3):30-33, 1990.
96. Crawford ED: [Hormonal therapy of prostatic carcinoma: Defining the challenge](#). Cancer 66(5): 1035-1038, 1990.
97. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, et al.: [Leuprolide with and without flutamide in advanced prostate cancer](#). Cancer 66(5):1039-1044, 1990.
98. Philpott AC, Crawford ED, and Miller GJ: [A new method for assaying antimicrobials in the prostate](#). Infection 18 suppl:1-4, 1990.
99. Bukowski RM, Crawford E.D, et al.: [Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group Study](#). J of NCI 82(2):143-146, 1990.
100. Crawford ED, Smith JA, Jr., Soloway MS, et al.: Treatment of stage D2 prostate cancer with leuprolide and anadron compared to leuprolide and placebo. Recent Adv. in Urol Cancers Diag. and Treat. American Cancer Society, June 1990.
101. Shipley WU, Kaufman DS, Heney NM: Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer. Crawford ED: The Article Reviewed. Oncology 4 (7): 2539, 1990.
102. Lile R, Thickman D, Miller GJ, and Crawford ED: Prostatic Comedocarcinoma: Correlations of Sonograms with Pathologic Specimens. Am J Roent 155:303-306, 1990.
103. Stephens RL, Goodman P, Crawford ED, et. al: [Evaluation of Menogaryl in Renal Cell Carcinoma](#). Invest. New Drugs 8:S69-S71, 1990.

1991

104. Seligman PA and Crawford ED: [Treatment of Advanced Transitional Cell Carcinoma of the Bladder with Continous-Infusion Gallium Nitrate](#). J NCI 83(21):1582-1584, 1991.
105. Crawford ED and Allen JA: [Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III, Intergroup study 0036](#). J Steroid Biochem Molec Biol, 1991.
106. Crawford ED: Editorial Comment: Johansson, JE., et al: Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--A randomized study: Results after 7 to 10 years of followup. J Urol 145:519-523, 1991.
107. Crawford ED and Nabors W: [Hormone therapy of advanced prostatic carcinoma: Where we stand today](#). Oncol 5(1):21-37, 1991.
108. Crawford ED and Nabors W: [Hormone therapy of advanced prostatic carcinoma: Where we stand today](#). Primary Care and Cancer, 13-20, April, 1991.
109. Crawford ED: Letter to the editor (RF Gittes). NEJM 324(26):1892-1893, 1991.
110. Crawford ED Combined Androgen Blockade Urology 37:355, 1991.
111. Crawford ED: Routine screening for cancer of the Prostate: Letter to editor. JNCI 83:1346, 1991.
112. Crawford ED, Smith JA, Soloway MS, Lange PH, Lynch DF, Al-Juburi A, Bracken RB, Heyden N, and Bertagna C: Treatment of stage D2 prostate cancer with leuprolide and anadron compared to leuprolide and placebo. Proceed. of 2nd International Symp. on Recent Adv. in Urolog Ca Diagn. and Treat, June 1990. New York, J Wiley & Sons, Inc. 1991.
113. Crawford ED and Mayer F: Organic causes of male sexual dysfunction: The evaluation and treatment of impotence. Mod Med 59:63-82, 1991.
114. Crawford ED, Saiers JH, Baker LH, Costanzi JJ, and Bukowski R: [Gallium nitrate in advanced bladder carcinoma: A Southwest Oncology Group study](#). Urology 38(4):355-357, 1991.
115. Lamm DL, Blumenstein B, Crawford ED, et al.: [A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin\(BCG\) for transitional cell carcinoma of the bladder](#). NEJM 325(17):1205-09, 1991.

116. Crawford ED: Editorial Comment: Prognostic Factors in Progression Free Survival and Corrected Survival in Patients with Advanced Prostatic Carcinoma: Results from a Randomized Study Comprising 150 Patients Treated with Orchiectomy or Estrogens. *J Urol* 146:1327, 1991.
117. Crawford ED: [Benign and Malignant Prostatic Diseases](#). *Am Fam Phys* 44: (5)65S-70S, 1991.
118. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED et al: [Randomized Study of Cisplatin Dose Intensity in Poor-Risk Germ Cell Tumors: A Southeastern Cancer Study Group and Southwest Oncology Group Protocol](#). *J Clin Oncol* 9(7):1163-1172, 1991.
119. Benson RC Jr, Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Dorr FA: [National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo](#). *Semin Oncol* 5 (Suppl 6):9-12, 1991.
120. Wozniak AJ, Samson MK, Shah NT, Crawford ED, et al.: [A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: A Southwest Oncology Group Study](#). *J Clin Oncol* 9(1):70-76, 1991.
121. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD, and Behrens BB: [Phase II Studies of Recombinant Human Tumor Necrosis Factor Alpha in Patients with Malignant Disease: A Summary of the Southwest Oncology Group Experience](#). *J Immunotherapy* 10:426-431, 1991.
122. Higano CS, Goodman P, Craig JB, Baker LH, Rivkin SE, Blumenstein B, and Crawford ED: [Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group Study](#). *Invest. New Drugs* 9:361-363, 1991.

1992

123. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella LG, Austenfeld M, Stone NN, Miles BJ, and Thomson R: [The effect of digital rectal examination on prostate specific antigen levels](#). *JAMA* 267(16):2227-2228, 1992.
124. Mohler JL, Gomella LG, Crawford ED, Glode LM, Zippe CD, Fair WR, and Marshall ME: [Phase II evaluation of coumarin \(1,2-Benzopyrone\) in metastatic prostatic carcinoma](#). *Prostate* 20:123-30, 1992.
125. Crawford ED, Berger NS, Davis MA, and Donohue RE.: [Prevention of urinary tract infection and bacteremia following transurethral surgery: Oral lomefloxacin compared to parenteral cefotaxime](#). *J Urol* 147(4):1053-55, 1992.
126. Allen A, Wolf M, Crawford ED et al . [Phase II Evaluation of Piroxantrone in Renal Cell Carcinoma: A Southwest Oncology Group Study](#). *Invest. New Drugs* 10:129-132, 1992.
127. McLeod DC, Crawford ED, Blumenstein BA, Eisenberger MA, and Dorr FA: [Controversies in the Treatment of Metastatic Prostate Cancer](#). *Cancer* 70(1):324-328 1992.
128. Crawford ED: Editorial Comment: Clinical Trials: Conflicting Opinions. *J Urol* 148:387-88, 1992.
129. Meyers FJ, Blumenstein BA, Crawford ED et al: [Combination Cisplatin and Dichloromethotrexate in Patients with Advanced Bladder Cancer Phase II A Southwest Oncology Group Study](#). *J Urol* 148: 52-54, 1992.
130. Seligman PA, Moran PL, Schleicher RB, Crawford ED [Treatment with Gallium Nitrate: Evidence for Interference with Iron Metabolism in vivo](#). In *American Journal of Hematology* 41:232-240, 1992
131. Crawford E D: Recent Advances in Treatment of Superficial Bladder Cancer. Editor Supplement to *Urology* 40:1, 1992
132. Crawford ED, Goodman P, Nabors WL, Stephens RL, Khan K, Pass LM, Smith AY, Christie DW: [Treatment of Stages B3 and C Seminoma with Chemotherapy Followed by Irradiation Therapy](#). *Urology* 39(5) 457-460, 1992.
133. Crawford ED: The Hanks Article Reviewed. *Oncology* 6:93-94, 1992.
134. Daneshgari F and Crawford ED: Cancer of the Prostate. *Hospital Physician* 28(10):13-27, 1992.

135. Schutz MJ and Crawford ED: Treating prostate cancer at Stage D2: What are the options. Contemporary Urology 4(12):21-28, 1992.
136. Levin RM and Crawford ED: [Re: Pharmacological Erection Program using Prostaglandin E1](#). J Urol 148(6):1920-1921, 1992.
137. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, et al.: [A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study](#). J Clin Oncology 10(7):1066-1073, 1992.
138. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, and Larimer MR: [Phase II study of platinum and mitoxantrone in metastatic prostate cancer: A Southwest Oncology Group study](#). Eur J Cancer 28:477-78, 1992.
139. Taylor SA, Blumenstein B, Crawford ED, Stuckey WJ, Stephens RL, and Fisher RI: [Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney: A Southwest Oncology Group Study](#). J of NCI Invest New Drugs 10:55-56, 1992.
140. Crawford ED et al: Chemoprevention of Prostate Cancer: Guidelines for Possible Intervention Strategies (Panel Consensus Statement). J Cell Biochem Supplement 16H:140-145, 1992.
141. Meyers FJ, Blumenstein B, Crawford ED, Natale RB, et al.: [Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer, phase II: A Southwest Oncology Group](#). J Urol 148(1):52-4, 1992.
142. Schutz MJ and Crawford ED Treating Prostate Cancer at Stage D2: What Are The Choices? Contemporary Urology 4(12): 21, 1992.
143. Thrasher JB and Crawford ED: [Complications of intravesical chemotherapy](#). Urol Clin North Am 19(3):529-539, 1992.
144. Crawford ED and Daneshgari F: [Management of regional lymphatic drainage in carcinoma of the penis](#). Urol Clin North Am 19(2):305-317, 1992.
145. Sarosdy MF, Lamm DL, Williams RD, Moon TD et. al.: [Phase I trial of oral bropridine in superficial bladder cancer](#). J Urol 147(1):31-33, 1992.
146. Crawford ED, Daneshgari F, and Majeski SA: [Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate](#). Seminars in Oncology 19(6), 53-57, 1992.

1993

147. Janknegt CC, Abbou R, Bartoletti L, Bernstein-Han, Bracken B, Brisset JM, DaSilva FC, Chisholm G, Crawford ED, DeBruyne FM, Dijkman GD, Goedhals FL, Knøngel H, and Venner PM: [Orchiectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double-blind randomized trial](#). J Urol 149(1):77-82, 1993.
148. Bukowski RM, Blumenstein BA, Levine HA, and Crawford ED: [Phase II Trial of Mitotane and Cisplatin in Patients with Adrenal Carcinoma: A Southwest Oncology Group Study](#). J Clin. Oncol. 11:161-165, 1993.
149. Crawford ED: Would you use PSA to screen for Prostate Cancer in Men with Normal DREs? Primary Care and Cancer 13(1):25-26, 1993.
150. Daneshgari F and Crawford ED: [Endocrine therapy of Advanced Carcinoma of the Prostate](#). Cancer 71(3):1089-97, 1993.
151. Marcus AC, Cella D, Sedlacek S, Crawford ED, Crane, LA, Garrett K, Quigel C and Gonin R: Psychosocial Counseling of Cancer Patients by Telephone: A Brief Note on Patient Acceptance of an Outcall Strategy. Psycho-Oncology 2:209-214, 1993.
152. Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, and Fletcher WS: [Cyclophosphamide, Methotrexate, and 5-Fluorouracil in the Treatment of Metastatic Prostate Cancer](#). Cancer 71(12):3975-3978, 1993.

153. Donatucci CF, Donohue RE., Berger N, Raife MJ, Kreder KJ, and Crawford ED: [Randomized Clinical Trial Comparing Balloon Dilatation to Transurethral Resection of Prostate for Benign Prostatic Hyperplasia](#). Urology 42(1):42, 1993.
154. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Schjer HI, Geller NL, Fair WR, Herr H, Sogani P, Sheinfeld J, Russo P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED and Bosl GJ: [Randomized Trial of Etoposide and Cisplatin Versus Etoposide and Carboplatin in Patient with Good-Risk Germ Cell Tumors: A Multi-institutional Study](#). Journal of Clinical Oncology 11(4):598-606, 1993.
155. McCullough DL, Roth RA, Babayan RK, Gorgon JO, Resse JH, Crawford ED, Fuselier HA, Smith JA, Murchison RJ and Kaye KW: [Transurethral laser incision of the prostate: National Human Cooperative Study results](#). J Urol 150(5):1607-1611, 1993.
156. Crawford ED: Might Neutropenia be a Sign of Occult Solid Malignancy? Primary Care & Cancer, 13(7):16, 1993.
157. Crawford ED and Wolach M: Perineal Cystoprostatectomy. Current Surgical Techniques in Urology 6:2, 1993.
158. Crawford ED and DeAntoni EP: [PSA as a screening test for prostate cancer](#). Urol Clin North Am 20(4):637-646, 1993.
159. Daneshgari F and Crawford ED: [Benign Prostatic Disease: A Growing Challenge in the 1990s](#). Postgraduate Medicine 93(7):84-92, 1993.
160. Bukowski RM, Wolf M, Kulander BG, Montie J, Crawford ED and Blumenstein B: [Alternating Combination Chemotherapy in Patients with Extragenital Germ Cell Tumors](#). Cancer 71:8, p 2631-2638, 1993.
161. DeAntoni E and Crawford ED: Prostate Cancer Awareness: What Pharmacists Need to Know. Pharmacy Times 12: 29-35, 1993.
162. Mayer FM and Crawford ED: Optimal Therapy for Metastatic Prostate Cancer. Recent Advances in Urology/Andrology 6:159-175, 1993.
163. Marshall ME, Wolf MK, Crawford ED, Taylor S, Blumenstein B, Flanigan R, Meyers FJ, Hynes HE, Barlogie B, and Eisenberger M: [Phase II Trial of Echinomycin for the Treatment of Advanced Renal Cell Carcinoma](#). Investigational New Drugs 11:207-209, 1993.
164. McLeod DG, Benson RC Jr, Eisenberger MA, Crawford ED, Blumenstein BA, Spicer D, and Spaulding JT: [The Use of Flutamide in Hormone-Refractory Metastatic Prostate Cancer](#). Cancer Sup. 72(12):3870-3873, 1993.
165. Thrasher JB, Crawford ED: [Current management of invasive and metastatic transitional cell carcinoma of the bladder](#). J Urol 149(5): 957-972, 1993.
166. Blumenstein B, Crawford ED, et. al.: [Doxorubicin, Mitomycin-C and 5-Fluorouracil in the Treatment of Hormone Refractory Adenocarcinoma of the Prostate: A Southwest Oncology Group Study](#). J Urol 150:411-413, 1993.
167. Crawford ED, Thompson IM, and Scardino PT: How PSA Testing Has Improved and Complicated Therapeutic Decision-Making. Oncol. 13:15-17, 1993.
168. Andros EA, Daneshgari F and Crawford ED: [Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate](#). Clin. Invest. Med. 16(6):510-515, 1993.
169. DeAntoni EP, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, Gambert SR and Staggers F: [Prostate Cancer Awareness Week 1992: A Summary of Key Findings](#). Clin. Invest. Med. 16:448-457, 1993.

1994

170. Meyer FJ and Crawford ED: [Prostate-specific antigen in screening for prostate cancer](#). West. J Med. 160(2):168, 1994.

171. Grampsas SA, Kahn K, and Crawford ED: [Intravesical RTNF Therapy of Superficial Bladder Cancer](#). Curr. Clin. Trials #117, March 1994.
172. Taylor SA, Blumenstein BA, Stephens RL, Crawford ED et. al.: [Phase II trial of menogaril in metastatic adenocarcinoma of the prostate: A Southwest Oncology Group study](#). Invest. New Drugs 12:67-70, 1994.
173. Sher CM, Crawford ED, et. al.: Clinical use of FUDR in the treatment of metastatic renal cell carcinoma. Cancer Res., Ther., and Control 4:57-60, 1994.
174. Hussain M, Wolf M, Marshall E, Crawford ED, and Eisenberger M: [Effects of Continued Androgen-Deprivation Therapy and Other Prognostic Factors on Response and Survival in Phase II Chemotherapy Trials for Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Report](#). J Clin. Oncol. 12(9):1868-1875, 1994.
175. Kish JA, Wolf M, Crawford ED, et. al.: [Evaluation of Low Dose Continuous Infusion 5-Fluorouracil in Patients with Advanced and Recurrent Renal Cell Carcinoma: A Southwest Oncology Group Study](#). Cancer 74(3):916-919, 1994.
176. DeAntoni EP and Crawford ED: [Pretreatment of Metastatic Disease \(Prostate Cancer in the Older Male\)](#). Cancer 74(7):2182-2187, 1994.
177. Crawford ED et al: [The Use of Strontium 89 for Palliation of Pain from Bone Metastases Associated with Hormone-Refractory Prostate Cancer](#). Urology 44(4):481-485, Oct 1994.
178. Crawford ED: Should Androgen Ablation for Metastatic Prostate Cancer be Total? Point/Counterpoint. Yes; Total Androgen Ablation is the Gold Standard. Contemp. Urol 6(11): 39-55, Nov 1994.
179. Flanigan RC, Saiers JH, Wolf M, Kraut EH, Smith AY, Blumenstein B, and Crawford ED: [Phase II Evaluation of Merbarone in Renal Cell Carcinoma](#). Invest. New Drugs 12:147-149, 1994.
180. Mayer FJ and Crawford ED: [The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy](#). Urol Clin North Am 21(4):707-715, 1994.
181. Thompson IM, Paradelo JC, Crawford ED, Coltman CA, and Blumenstein B: [An Opportunity to Determine Optimal Treatment of pT3 Prostate Cancer: The Window May Be Closing](#). Urology 44:804-811, Dec 1994.
182. Moon TD, Brannan W, Stone NN, Ercole C, Crawford ED, Chodak G, Brawer M, Heisey D, and Bruskewitz RC: [Effect of Age, Educational Status, Ethnicity and Geographic Location on Prostate Symptom Scores](#). J Urol 152: 1498-1500, Nov 1994.
183. Marshall ME, Blumenstein B, Crawford ED, Thompson IM, Craig JB, Eisenberger M, and Ahmann F: [Phase II Trial of Amonafide for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate](#). Am. J Clin. Oncol. 17(6):514-515, 1994.
184. DeAntoni EP, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, Gambert SR, and Staggers F: [Prostate Cancer Awareness Week 1992: A Summary of Key Findings](#). Clin. Invest. Med. 16:448-457, 1994.
185. Crawford ED and DeAntoni EP: Introduction to Symposium Issue. Urology 44(6A):1, Dec 1994.
186. Stone NN, DeAntoni EP, Crawford ED and the Prostate Cancer Education Council: Screening for Prostate Cancer by Digital Rectal Examination and Prostate Specific Antigen. Urology 44(6A):18, Dec 1994.
187. Talley DR, Hartman DM, Clejan S, and Crawford ED: Effect of Digital Rectal Examination on Monoclonal Hybritech and Polyclonal Yang Prostatic Specific Antigen. Urology 44(6A):26, Dec 1994.
188. Pummer K, Crawford ED, Daneshgari F, Andros B, Pfister S, and Miller GJ: Hormonal Pre-treatment Does Not Affect the Final Pathologic Stage in Locally Advanced Prostate Cancer. Urology 44(6A):38, Dec 1994.
189. Crawford ED: Changing Concepts in the Management of Advanced Prostate Cancer. Urology 44(6A):67, Dec 1994.

190. Nishiya M, Miller GJ, Lookner DH, and Crawford ED: [Prostate Specific Antigen Density in Patients with Histologically Proven Prostate Cancer](#). *Cancer* 74(11):3002-3009, 1994.
191. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, Dorr FA, Benson M, Spaulding JT: [Prognostic Factors in Stage D2 Prostate Cancer: Important Implications for Future Trials](#). *Seminars in Oncology* 21(5):613-619, 1994.
192. Mayer FJ and Crawford ED: Update on Combined Androgen Blockade for Metastatic Prostate Cancer. *Adv. Urology* 7:93-107, 1994.

1995

193. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED, Oliff AI, and Pastan IH: [Phase I Clinical Study of the Recombinant Oncotoxin TP40 in Superficial Bladder Cancer](#). *Clin Ca Research* 1:57-61, January 1995.
194. Cox RL and Crawford ED: [Estrogens in the treatment of prostate cancer](#). *J Urol* 154(6):1991-1998, 1995.
195. Crawford ED: Editorial Comment: [Evaluation of Age-Specific Normal Ranges for Prostate-Specific Antigen](#). *Urology* 45(3):454, 1995.
196. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford ED, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middleton R, Ng J, Ferguson D, and Gormley G: [Treatment with Finasteride following Radical Prostatectomy for Prostate Cancer](#). *Urology* 45(3):491-497, 1995.
197. Daneshgari F, Taylor GD, Miller GJ, and Crawford ED: [Computer Simulation of the Probability of Detecting Low Volume Carcinoma of the Prostate with Six Random Systematic Core Biopsies](#). *Urology* 45(4):604-609, 1995.
198. Hillner BE, McCloud DG, Crawford ED, Bennett CL: [Estimating the Cost Effectiveness of Total Androgen Blockade with Flutamide in M1 Prostate Cancer](#). *Urology* 45(4):633-640, 1995.
199. Crawford ED: Editorial Comment: [A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in situ of the Bladder](#). *J Urol* 153:929-933, 1995.
200. Wasson JH, Red DM, Bruskewitz RC, Elinson J, Keller AM, Henderson WG (Crawford ED participating investigator): [A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia](#). *NEJM* 332(2):75-79, 1995.
201. Crawford ED, DeAntoni EP, Labrie F, Schroder FH, and Geller J: [Endocrine Therapy of Prostate Cancer: Optimal Form and Appropriate Timing](#). *J Clin. Endocrinology and Metabolism* 80(4):1062-1066, 1995.
202. Cox RL and Crawford ED: [Complications of Cryosurgical Ablation of the Prostate to Treat Localized Adenocarcinoma of the Prostate](#). *Urology* 45(6):932-935, 1995.
203. Grampsas SA, Miller GJ and Crawford ED: [Salvage Radical Prostatectomy After Failed Transperineal Cryotherapy: Histologic Findings from Prostate Whole-Mount Specimens Correlated with Intraoperative Transrectal Ultrasound Images](#). *Urology* 45(6):936-941, 1995.
204. Gospodarowicz MK, Quilty PM, Scalliet P, Tsujii H, Fossa SD, Horenblas S, Isaka S, Prout GR, Shipley WU, Wijnmaalen AJ, Crawford ED, Jones WG and Kawai T: [The Place of Radiation Therapy as Definitive Treatment of Bladder Cancer](#). *International J of Urology* 2(2):41-48, 1995.
205. DeAntoni EP and Crawford ED: Prostate Cancer Awareness Week--Education, Service, and Research in a Community Setting. *Cancer* 75(7):1874-1879, 1995.
206. Werahera P, Miller GJ, Taylor GD, Brubaker T, Daneshgari F, Crawford ED: [A Three-Dimensional Reconstruction Algorithm for Interpolation and Extrapolation of Planar Cross-Sectional Data](#). *IEEE Transactions on Medical Imaging* 14(4):765-761, 1995.

207. Marshall ME, Wolf M, Crawford ED, et. al.: [Evaluation of Low Dose Alpha-Interferon \(Roferon-A®\) in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study](#). Cancer Biotherapy 10(3):205, 1995.
208. DeAntoni EP and Crawford ED: Recent American Multicenter Trials for Patients with Metastatic Prostate Cancer. Urologe Ausgabe A (German Journal of Urology) 34:382-388, 1995.
209. Crawford ED: [Editorial Comment: Intravesical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer: An Eastern Cooperative Oncology Group Study](#). J Urol 154:66-68, 1995.
210. Crawford ED, DeAntoni EP, Labrie F, Schroder FH and Geller J: [Endocrine Therapy of Prostate Cancer: Optimal Form and Appropriate Timing](#). J Clin Endocrin & Metab 80(4):1062-1078, 1995.
211. Crawford ED: Editorial Comment: [A controlled trial of bicalutamide versus flutamide, each in combination with lutenizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer](#). Urology 46(6): 899-901, 1995.
212. Whitehead RP, Wolf MK, Solanki DL, Benedetto P, Richman SP, Flanigan RC and Crawford ED: [A Phase II Trial of Continuous Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study](#). J Immunotherapy 18(2):104-114, 1995
213. Marshall ME, Wolf MK, Crawford ED, Weiss GR, Ahmann F, Meyers FJ, Eisenberger M and Einstein AB: [Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate: A Southwest Oncology Group Study](#). Amer J of Clin Oncology 18(5):400-402, 1995.
214. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, and Grossman, HB: [Randomized Intergroup Comparison of Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Chemotherapy Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder](#). Urologic Oncology 1:119-126, 1995.
215. Williamson SK, Blumenstein BA, Eisenberger MA, Balcerzak SP, Brannon W, and Crawford ED: [Phase II Evaluation of Didemnin-B in Hormonally Refractory Metastatic Prostate Cancer](#). Invest. New Drugs 13:167-170, 1995.
216. Crawford ED, Hussain M, DeAntoni EP, Thompson IM, Eisenberger MA, Blumenstein BA, and Coltman CA Jr: [Southwest Oncology Group strategies in prostatic carcinoma](#). Seminars in Surgical Oncology 11:60-64, 1995.

1996

217. Bennett CL, Matcher D, McCrory D, McLeod D, Crawford ED and Hillner BE: [Cost- Effective Models of Flutamide for Prostate Cancer: Are They Helpful Policy Makers?](#) Cancer 77(9):1854-1861, 1996.
218. Berry DL, Blumenstein BA, Magyary DL, Lamm DL and Crawford ED: [Local Toxicity Patterns Associated with Intravesical bacillus Calmette-Guerin: A Southwest Oncology Group Study](#). Int J Urol 3:98-100, 1996.
219. Das S and Crawford ED: Laparoscopic Procedures in Urologic Oncology. Guest editors for Seminars in Surgical Oncology 12(2), 1996.
220. Crawford ED: [Diagnosis and Treatment of Superficial Bladder Cancer: An Update](#). Seminars in Urologic Oncology 14(1) Sup 1:1-9, 1996.
221. Einstein AB, Wolf M, Halliday KR, Miller GJ, Hafermann M, Lowe BA, Meyers FJ, Leimert JT and Crawford ED: [Combination Transurethral Resection, Systemic Chemotherapy, and Pelvic Radiotherapy for Invasive \(T2-T4\) Bladder Cancer Unsuitable for Cystectomy: A Phase I/II Southwest Oncology Group Study](#). Urology 47(5):652-657, 1996.

222. Marshall ME, Wolf M, O'Rourke M, Barnett TC and Crawford ED: [Treatment of Stage D2 Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A®: A Southwest Oncology Group Study](#). Cancer Biotherapy and Radiopharmaceuticals 11(5):119-123, 1996.
223. Safford HR, Crawford ED, MacKenzie SH, and Capriola M: [The Effect of Bicycle Riding on Serum Prostate Specific Antigen Levels](#). J Urol 156:103-105, 1996.
224. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA, for the Prostate Cancer Education Council: [Serum Prostate-Specific Antigen and Digital Rectal Examination for the Early Detection of Prostate Cancer in a National Community-Based Program](#). Urology 47:863-869, 1996.
225. Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, and Crawford ED: [A Phase II Trial of Interferon- \$\alpha\$ and 5-Fluorouracil in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study](#). Cancer 78: 1085-1088, 1996.
226. deVere White RW, Deitch AD, Tesluk H, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA Jr, Schellhammer PF, Stanistic TH, Grossman HB, Messing E, Crissman JD, and Crawford ED: [Prognostic Significance of DNA Ploidy in Ta/T1 Bladder Cancer: A Southwest Oncology Group Study](#). Urol Oncol 2:27-34, 1996.
227. Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, and Crawford ED: [Phase II Evaluation of Ifosfamide/Mesna in Metastatic Prostate Cancer: A Southwest Oncology Group Study](#). Am J Clin Oncol 19(4):368-370, 1996.
228. Cox RL and Crawford ED: [Cryosurgical Ablation of the Prostate: The Con Side in 1996](#). Urology 48(2):181-183, 1996.
229. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, and Stone NN: [Age- and Race-Specific Reference Ranges for Prostate-Specific Antigen from a Large Community-Based Study](#). Urology 48(2):234-239, 1996.
230. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, et. al.: [Optimized Microvessel Density Analysis Improves Prediction of Cancer Stage from Prostate Needle Biopsies](#). Urology 48(1):47-57, 1996
231. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr., Grossman HB, See WA, Peabody JA, Moon TD, Flanigan RC, Crawford ED, and Morganroth J: [Oral Bropirimine Immunotherapy of Carcinoma in situ of the Bladder: Results of a Phase II Trial](#). Urology 48:21-27, 1996.
232. Crawford ED, DeAntoni EP, and Ross CA: [The Role of Prostate Specific Antigen in the Chemoprevention of Prostate Cancer](#). J Cell Biochem Suppl 25(5):149-155, 1996.

1997

233. Waxman S, Stevens AK, Walsh RA, Mackenzie SH, and Crawford ED: [Management of Asymptomatic Rising PSA after Prostatectomy or Radiation Therapy](#). Oncology 11(4):457-469, 1997.
234. Crawford ED: Commentary: [Prostate Cancer: To Screen or Not to Screen?](#) Oncology 11(1):50-59, 1997.
235. Hussain MA, Blumenstein B, Eisenberger M, and Crawford ED: [Southwest Oncology Group Studies in Hormone Refractory Prostate Cancer](#). Seminars in Oncol 23(6) Sup 14:24-27, 1996.
236. Smith JA, Crawford ED, Paradelo JC, Blumenstein B, Herschman BR, Grossman HB, and Christie DW: [Treatment of Advanced Bladder Cancer with Combined Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone: A Phase III Intergroup Study](#). J Urol 157:805-808, 1997.
237. Nishiya M and Crawford ED: [Perineal Cystoprostatectomy and Ureterosigmoidostomy for Invasive Bladder Cancer](#). J Urol 157(6):2227-2229, 1997.
238. Cox RL and Crawford ED: Cryosurgical Ablation of the Prostate: A Brief Guide for the Clinician. Infections in Urol 10(3):70-74. 1997.

239. Kish JA, Wolf MK, Schellhammer PF, Hussain M, Einstein AB, Crawford ED: [Continuous Infusion 5-fluorouracil and Cisplatin for Advanced/Recurrent Transitional Cell Carcinoma of the Bladder](#). Am. J Clin. Oncol. 20 (4):327-330, 1997.
240. McLeod DG, Crawford ED, and DeAntoni EP: Combined Androgen Blockade: [The Gold Standard for Metastatic prostate Cancer](#). European Urol 32 (S3):70-77, 1997.
241. Crawford ED, DeAntoni EP, Hussain M, Thompson IM and Coltman CA: [Prostate Cancer Clinical Trials of the Southwest Oncology Group](#). Oncology 11 (8): 1154-1163, 1997.
242. Crawford ED: Adjuvant Radiation Therapy Following Radical Prostatectomy. New Diagnostic and Treatment Modalities in Prostate Cancer: 25-31, 1997.
243. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ and Trump D: [Long-Term Follow-up of a Phase III Intergroup Study of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urethelial Carcinoma: A Cooperative Group Study](#). J Clin Oncol 15 (7): 2564-2569, 1997.
244. Crawford ED: Prostate Cancer Awareness Week: September 22 to 28, 1997. CA A Cancer J for Clinicians 47 (5): 288-296, 1997.
245. Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni EP, Sharp L, Garnick MB and Porterfield HA: [Comparison of Perspectives on Prostate Cancer: Analyses of Survey Data](#). Urology 50 (3): 366-372, 1997.
246. DeAntoni EP, Goktas S, Stenner J, O'Donnell C, and Crawford ED: [A Cross-Sectional Study of Vasectomy, Time Since Vasectomy, and Prostate Cancer](#). Prostate Ca and Prostatic Diseases 1:73-78, 1997.
247. DeAntoni EP and Crawford ED: [Eight Years of Prostate Cancer Awareness Week: Lessons in Screening and Early Detection](#). Cancer 80(9):1845-1851, 1997.

1998

248. Hirano D, Werahera PN, Crawford ED, Lucia MS, DeAntoni EP and Miller GJ: [Morphological Analysis and Classification of Latent Prostate Cancer Using a 3-Dimensional Computer Algorithm: Analysis of Tumor Volume, Grade, Tumor Doubling Time, and Life Expectancy](#). J Urol 159:1265-1269, 1998.
249. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH and Loehrer PJ: [Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study](#). J Clin. Oncol. 16 (4): 1287-1293, 1998.
250. Crawford ED, Hirano D, Werahera PN, Lucia MS, DeAntoni EP, Daneshgari F, Brawn PN, Speights VO, Stewart JS and Miller GJ: Computer Modeling of Prostate Biopsy: [Tumor Size and Location -- Not Clinical Significance -- Determine Cancer Detection](#). J Urol 159(4):1260-1264, 1998.
251. Stenner J, Holthaus K, Mackenzie SH and Crawford ED: [The Effect of Ejaculation on Prostate Specific Antigen in a Prostate Cancer Screening Population](#). Urology 51 (3):455-459, 1998.
252. Crawford ED et al: [Proposed Substages for Metastatic Prostate Cancer](#). Urology 50(6):1027-1028, 1998.
253. Crawford ED (moderator of symposium panel: Fradet, Y, Boccon-Gibod, L, Bennett, C and Schalken, JA): The Role of Antiandrogens in Hormonal Therapy. Contemp. Urology 10(6):43-57, 1998.
254. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED et. al.: [Treatment with Finasteride Preserves Usefulness of Prostate Specific Antigen in the Detection of Prostate Cancer: Results of a Randomized, Double Blind, Placebo Controlled Clinical Trial](#). Urology 52(2)195-202, 1998.

255. Eisenberger MA, Blumenstein BA, Crawford ED et. al.: [Bilateral Orchiectomy With or Without Flutamide for Metastatic Prostate Cancer](#). NEJM 339(15):1036-1042, 1998.
256. Vogelzang NJ, Crawford ED and Zietman A: [Current Clinical Trial Design Issues in Hormone-Refractory Prostate Carcinoma](#). Consensus Panel. Cancer 82(11):2093-2101, 1998.
257. Leewansangtong S, Goktas S, Lepoff R, Holthaus K and Crawford ED: [Comparability of Serum Prostate Specific Antigen Measurement Between the Hybritech Tandem-R and Abbott AxSYM Assays](#). Urology 52(3):467-469, 1998.
258. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED and Meyskens FL: [Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial](#). J of Natl Ca Inst 90(20):1537-1544, 1998.
259. Schroder LE, Blumenstein BA, Flanigan RL, Borst JR, and Crawford ED: [Phase II Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors Trifluoperazine/ Verapamil of P-Glycoprotein in Patients with Advanced Renal Carcinoma](#). Urol Oncol 3:94-98, 1998.
260. Leewansangtong S and Crawford ED: Maximal Androgen Withdrawal for Prostate Cancer Therapy: Current Status and Future Potential. Endocrine-Related Ca. 5:325-339, 1998.
261. Stenner J, DeAntoni EP, O'Donnell C, Stone NN, McLeod DG and Crawford ED: [Prevalence and Natural History of Urinary Symptoms in a Longitudinal National Prostate Cancer Screening \(Community-Based\) Study](#). Prostate Cancer and Prostatic Diseases 5: 262-267, 1998.

1999

262. Crawford ED, Leewansangton S, Goktas S, Holthaus K and Baier M: [Efficiency of Prostate Specific Antigen and Digital Rectal Examination in Screening Using 4.0 ng/ml and Age Specific Reference Range as a Cutoff for Abnormal PSA The Prostate](#) 38(4):296-301, 1999.
263. Crawford ED et. al.: [The Utility of PSA as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials](#). Eur. Urol 35:511, 1999.
264. Moinpour CM, Troxel A, Lovato LC, Eisenberger M, Blumenstein BA and Crawford ED: Response to: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. J of the Natl. Ca. Institute 91(4):381-382, 1999.
265. Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M and Crawford ED: [Cis-platinum, Methotrexate, and Bleomycin for the Treatment of Carcinoma of the Penis: A Southwest Oncology Group Study](#). J of Urol 161:1823-1825, 1999.
266. Moul JW: [Rising PSA After Local Therapy Failure: Immediate vs. Deferred Treatment](#). Crawford ED: The Article Reviewed. Oncology 13(7):985-999, 1999.
267. Crawford ED, et. al. (The International Prostate Screening Trial Evaluation Group): [Rationale for Randomised Trials of Prostate Cancer Screening](#). European J of Ca. 35(2):262-271, 1999.
268. Ziada A, Rosenblum M and Crawford ED: [Benign Prostatic Hyperplasia: An Overview](#). Urology 53(3A):1-6, 1999.
269. Crawford ED: Current Topics in Urology (Guest Editor). Urology 53(3A), 1999.
270. Crawford ED: Editorial Comment: Suture Ligation of the Dorsal Vein Complex During Radical Retropubic Prostatectomy. Infections in Urology 12(3):77-78, 1999.
271. Rosenblum M, Ziada A, and Crawford ED: Advanced Prostate Cancer. Presented at 9th International Prostate Cancer Update, Beaver Creek, CO. Reviews in Urology, Supplement 1(4S): Fall, 1999.
272. Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Chodak GW, Mitchell P, Porter L: [Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer](#). BJU Int 83(7):801-6, 1999.

273. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, and Trump D: [Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer](#). NEJM: 341 (24):1781-1788, 1999.
274. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford ED: [Docetaxel \(Taxotere\) and Estramustine versus Mitoxantrone and Prednisone for Hormone-Refractory Prostate Cancer: Scientific Basis and Design of Southwest Oncology Group Study 9916](#). Seminars in Oncology 26(5) Supp 17:55-60, October, 1999.
275. Ziada A, Grover F, and Crawford ED: [The use of trans-esophageal echocardiography in the management of intra-arterial thrombus in a patient with renal cell carcinoma \(case report\)](#). Br J Urol Intl 84:737-738, 1999.
276. Goktas S, Crawford ED: [Optimal hormonal therapy for advanced prostatic carcinoma](#). Seminars in Oncology (review) 26(2): 162-73, 1999.
277. Crawford ED: [The Role of the Urologist in Chemotherapy of Hormone Refractory Prostate Cancer](#) (summary). Urology 54 (6A Suppl): 51-2, 1999.
278. Crawford ED, Rosenblum M, Ziada AM, Lange PH: [Hormone Refractory Prostate Cancer](#). (review) Urology 54 (6A Suppl): 1-7, 1999.
279. Ziada AM, Price BC, Lisle TC and Crawford ED: Antegrade Retropubic Approach to Radical Prostatectomies Makes Minimal Blood Loss Surgery Possible. Infections in Urol, 1999.
280. Meyers FJ, Lew D, Lara PN, Williamson S, Marshall ME, Balcerzak SP, Rivkin SE, Samlowski W and Crawford ED: [Phase II Trial of Edatrexate in Relapsed or Refractory Germ Cell Tumors: A Southwest Oncology Group Study](#). Invest New Drugs 16(4):347-51, 1999.
281. Ziada AM and Crawford ED: [Advanced Prostate Cancer](#) (Session from the Eighth International Prostate Cancer Update). Prostate Cancer and Prostatic Diseases, 2:21-26, 1999.
282. Goktas S, Ziada A, Crawford ED: [Combined androgen blockade for advanced prostatic carcinoma](#). Prostate Cancer and Prostatic Diseases, 2(4):172-179, 1999.

2000

283. Hussain M, Fisher EI, Petrylak DP, O'Connor J, Wood DP, Small EJ, Eisenberger MA and Crawford ED: [Androgen Deprivation and Four Courses of Fixed-schedule Suramin Treatment in Patients with Newly Diagnosed Metastatic Prostate Cancer: A Southwest Oncology Group study](#). Journal of Clinical Oncology, 18 (5):1043-1049, 2000.
284. Crawford ED: Review article - Cancer and Male Sexual Dysfunction (Costabile, RA) Oncology 14(2):204, 2000.
285. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED: [Maintenance Bacillus Calmette-Guerin Immunotherapy for Recurrent TA, T1 and Carcinoma in Situ Transitional Cell Carcinoma of the Bladder: a Randomized Southwest Oncology Group Study](#). J Urol 163(4):1124-9, 2000.
286. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED: [Phase II Evaluation of Cisplatin and Etoposide Followed by Mitotane at Disease Progression in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma: A Southwest Oncology Group study](#). Cancer 88(5):1159-65, 2000.
287. Weil MD, Crawford ED, Cornish P, Dzingle W, Stuhr K, Pickett B, Roach M: [Minimal Toxicity with 3-FAT Radiotherapy of Prostate Cancer](#). Seminars in Urologic Oncology 18(2):127-132, 2000.
288. Crawford ED: Editorial Comment: [Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality](#). Urology 55(3): 328-333, 2000.
289. Prostate Cancer Trialists Collaborative Group: [Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials](#). Lancet 355 (#9214): 1491-1498, 2000.

290. Crawford ED: [Editorial Comment: Prostate Specific Antigen Response To Mitoxantrone and Prednisone In Patients with Refractory Prostate Cancer: Prognostic Factors And Generalizability Of A Multicenter Trial To Clinical Practice](#). J Urol 163:1481-1485, 2000.
291. Crawford ED, Batuello JT, Snow P, Gamito EJ, McLeod DG, Partin AW, Stone N, Montie J, Stock R, Lynch J, and Brandt J.: [The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma](#). Cancer 88(9):2105-9, 2000.
292. Thompson I, Tolcher A, Crawford ED, Eisenberger M, Tangen C, Fisher E: African American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer. J Urol 163(4):56 Suppl (#242), 2000.
293. Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, and Crawford ED: [A Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional Cell Carcinoma: The Importance of Survival as a Clinical Trial Endpoint](#). Journal of Clinical Oncology, 18 (13) 2537-2544, 2000.
294. Vesella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, and Crawford ED: [Probability of Prostate Cancer Detection Based on Results of a Multicenter Study Using the AxSYM Free PSA and Total PSA Assays](#). Urology 55(6):909-914, 2000.
295. deVere White RW, Deitch AD, Daneshmand S, Tesluk H, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA Jr, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD and Crawford ED: [The Prognostic Significance of S-Phase Analysis in Stage Ta/T1 Bladder Cancer: A Southwest Oncology Group Study](#). Eur Urol, 37(5):595-600, 2000.
296. Elias L, Lew D, Figlin RA, Flanigan RC, Thompson ME, Triozzi PL, Belt RJ, Wood DP, Rivkin SE and Crawford ED: [Infusional Interleukin-2 and Flurouracil with Subcutaneous Interferon- \$\alpha\$ for Advanced Renal Cell Carcinoma: A Southwest Oncology Group Phase II Study](#). Cancer 89 (3): 597-603, 2000.
297. Suh CI, Shanafelt T, May DJ, Shroyer KR, Bobak JB, Crawford ED, Miller GJ, Markham N, Glode LM: [Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer](#). Molecular and Cellular Probes, 14(4):, 211-217, 2000.
298. Chung TDK, Park II, Ignacio L, Catchatourian R, Kopnick M, Davison E, Conrad G, Awan AM, Crawford ED and Vijayakumar S: [Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial](#). Int J Cancer 90, 302-304, 2000.
299. Management of advanced/metastatic prostate cancer: 2000 Update. (Reviewed by Crawford ED). Oncology Vol 14 (12):1688-1691, 2000. Brawer MK, Crawford ED, Fowler J Jr, Lucia MS, Schröder FH,: [Prostate Cancer: Epidemiology and Screening](#). Reviews in Urology 1 (Suppl 4): S5-9, 2000.
300. Resnick MI, Crawford ED, Gleave ME, Lynch J, Mulhall JP, Pummer K, Vallancien G: [Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy](#), Reviews in Urology, 1 (Suppl 4): S23-29, 2000.
301. Ziada A, Crawford ED, Schröder FH, Gleave ME, Miller PD, and Garnick MB: [Advanced prostate cancer: An update](#). Reviews in Urology 1 (Suppl 4): S35-39, 2000.
302. Gleave ME, Higano C, Glodé LM, Goluboff E, Pummer K, Crawford ED: New horizons in the management of hormone-refractory prostate cancer. Reviews in Urology 1 (suppl 4): S40-48, 2000.

2001

303. Hussain MHA, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, Jones J, Balcerzak SP, Crawford ED and Grossman HB: [Combination cisplatin, 5-Fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group study](#). Jour Urol 165, 56-61, 2001.
304. Crawford ED and Lerner SP: [Clinical trials and protocols update](#). Urologic Oncology 6 (1), 31-32, 2001.

305. Thompson IM, Tangen CM, Tolcher A, Crawford ED, Eisenberger M, and Moinpour CM: [Association of African-American Ethnic Background with Survival in Men with Metastatic Prostate Cancer](#). J Natl Cancer Inst. 93(3):219-225, 2001.
306. Batuello JT, Gamito EJ, Crawford ED, Han Mi, Partin AW, McLeod DG, and O'Connell C: [Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer](#). Urology 57 (3), 481-485, 2001.
307. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, and Bennett CL: [Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review](#). Urology 57(4): 727-732, 2001.
308. Thompson IA Jr (moderator), Crawford ED, and deKernion JB: Hormonal therapy for prostate cancer: Early or late? (part 1) Contemporary Urology 13 (2):22-34, 2001.
309. Thompson IA Jr (moderator), Crawford ED, and deKernion JB: Hormonal therapy for prostate cancer: Early or late? (part 2) Contemporary Urology 13 (3):33-45, 2001.
310. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, and Hussain MHA: [A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group study](#). The Prostate 46 (4) 257-261, 2001.
311. Ziada AM, Lisle TC, Snow PB, Levine RF, Miller G, Crawford ED: [Impact of different variables on the outcome of patients with clinically confined prostate carcinoma](#). Cancer. 15;91(S8):1653-60, 2001.
312. Campbell T, Blasko J, Crawford ED, et al: [Clinical staging of prostate cancer: reproducibility and clarification of issues](#). Int J Cancer 96:198-209, 2001.
313. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MHA, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA and Crawford ED: [Phase II Trial of bicalutamide in patients with advanced prostate cancer who failed conventional hormonal therapy: A Southwest Oncology Group \(SWOG\) Study \(SWOG 9235\)](#). Urology 58: 53-57, 2001.
314. Schroder LE, Lew D, Flanigan RC, Eisenberger MA, Seay TE, Hammond N, Needles BM, Crawford ED: [Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study](#). Urologic Oncology 6: 145-148, 2001.
315. Crawford ED: Editorial Comment: Bicalutamide (Casodex) 150 mg. as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58 (2): 150-151, 2001
316. Crawford ED: Therapeutic options for patients with advanced prostate cancer. Advances in Prostate Cancer 5 (2): 9-11, 2001.
317. Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, and Glode LM: [Prostate cancer pathology, screening and epidemiology](#). Reviews in Urology 3 (suppl 2): S3-10, 2001.
318. Lynch JH, Batuello JT, Crawford ED, et al: [Therapeutic strategies for localized prostate cancer](#). Reviews in Urology 3 (suppl 2): S39-48, 2001.
319. Gelmann EP, Chia D, Pinsky PF, Andriole GL, Crawford ED, Reding D, Hayes RB, Kramer BS, Woodrum DL, Gohagan JK, and Levin DL: [Relationship of demographic and clinical factors to free and total prostate-specific antigen](#). Urology 58 (4):561-566, 2001.
320. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, and Crawford ED: [Nephrectomy followed by interferon alfa-2b compared with interferon alfa 2-b alone for metastatic renal cell cancer](#). NEJM 345:1655-1659, 2001.
321. Akduman B and Crawford ED: [Terazosin, Doxazosin, and Prazosin: current clinical experience](#). Urology 58 (Supplement 6A):49-54, 2001.
322. Crawford ED: Combination chemotherapy may increase life expectancy for patients with advanced bladder cancer. Convention Highlights, American Urological Association 2001 Annual Meeting News Bulletin. 16:1 & 5, 2001.

2002

323. Lerner SP, Crawford ED: Introduction to the special section on the ethics of marker tumors in clinical investigation. *Urologic Oncology* 7:29, 2002.
324. Gatenby RA, Gawlinski ET, Tangen CT, Flanigan RC, and Crawford ED: [The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy](#). *Cancer Research* 62:5218-5222, 2002.
325. Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Donohue R, Nedrow A, Crawford ED: [High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade](#). *Clinical Prostate Cancer* Vol 1, 1:1-3, 2002.
326. Crawford ED: Prostate-specific antigen as a marker of disease activity in prostate cancer, Part 2 – The Partin article reviewed. *Oncology* Vol 16, 9:1228-1234, 2002.
327. Crawford ED: Early hormonal therapy is better than delayed. *AUA News* Vol 7, 1:1-5, 2002.
328. Errejon A, Crawford ED: [Monotherapy versus combined androgen blockade in patients with advanced prostate cancer](#). *Cancer* Vol 95, 2:209-210, 2002.
329. Thompson IM, Tangen C, Basler J and Crawford ED: [Impact of previous local therapy for prostate cancer on subsequent metastatic disease](#). *The Journal of Urology*, 168:1008-1012, 2002.
330. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode LM, Dakhil SR, and Crawford ED: [Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: A Southwest Oncology Group study](#). *Journal of Immunotherapy* 24(4): 352-358, 2002.
331. Klein CE, Tangen CM, Braun TJ, Hussain MHA, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR and Crawford ED: [SWOG 9510: Evaluation of Topotecan in hormone refractory prostate cancer: A Southwest Oncology Group study](#). *The Prostate* 52:264-268, 2002.
332. Crawford ED, Chia D, Andriole GL, Reding D, Gelman EP, Gohagan JK, Pinsky P, Hayes RB, Levin DL, Fagerstrom RM and Kramer BS: PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Abstract 86: *International Journal of Cancer, Supplement 13*: 97, 2002.
333. Grossman HB; Cordon-Cardon S, Cote R, Waldman FM, Tangen C, and Crawford ED: SWOG 9458: Evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 9710. Abstract 140: *International Journal of Cancer, Supplement 13*: 114, 2002.
334. Porter CR, O'Donnell C, Crawford ED, Gamito EJ, Sentizimary B, DeRosalia A, Tewari A, and Errejon A: Neural network to predict positive biopsies of the prostate: a prospective study. Abstract 743: *International Journal of Cancer, Supplement 13*: 371, 2002.
335. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVere White R, Thompson IM Jr, Crawford ED: [Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109](#). *J Urol* 168(5):2016-9, 2002.
336. Porter CR, O'Donnell C, Crawford ED, Gamito EJ, Sentizimary B, De Rosalia A, Tewari A: [Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study](#). *Urology* 60(5):831-5, 2002.
337. Crawford ED: [A 72-year-old man with prostate cancer](#). *Oncology* 16(8):1014-1016, 1119-1121, 2002.
338. Crawford ED: [Intravesical therapy for superficial cancer: need for more options](#). *J Clin Oncol* 20(15):3185-3186, 2002.
339. Crawford ED: Patient selection for therapy in prostate cancer. *European Urology (suppl)* 1(2):2-6, 2002.
340. Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED: [Chemoprevention Strategies in the Prostate: An Overview](#), *Reviews in Urology* 4 (2) 69-77, 2002.

2003

341. Glass TR, Tangen CM, Crawford ED, Thompson I: [Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning](#). The Journal of Urology, 169:164-169, 2003.
342. Crawford, E. David: [Early Versus Late Hormonal Therapy: Debating the Issues](#). Urology 61 (Supplement 2A): 8-13, 2003.
343. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D: [Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial](#). J Clin Oncol 21(7):1214-22, 2003.
344. Bautista OM, Kusek JW, Nyberg, Jr. LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, et al: [Study design of the Medical Therapy of Prostatic Symptoms \(MTOPS\) trial](#). Control Clin Trials, 24 (2): 224-243, 2003.
345. Crawford ED, Wood DP, Petrylak DP, Scott J, Coltman CA Jr, Raghavan D: [Southwest Oncology Group Studies in Bladder Cancer](#). Cancer Vol 97, #S8 2099-2108, Supplement: Perspectives in Bladder Cancer, 2003.
346. Oottamasathien S and Crawford ED: [Rebuttal: An argument against routine prostate cancer screening](#). Arch Intern Med 163(6):661-2; discussion 666, 2003.
347. Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ: [A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study \(E3893\)](#). Cancer Invest 21(1):41-6, 2003.
348. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, Crawford ED, Vogelzang N, Trump D, Loehrer PJ Sr.: [Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors](#). Cancer 15;97(8):1869-75, 2003.
349. Akduman B and Crawford ED: [The Management of High Risk Prostate Cancer](#). Journal of Urology; 169(6):1993-1998, 2003.
350. Kawata N, Miller GJ, Crawford ED, Torkko KC, Stewart JS, Lucia MS, Miller HL, Hirano D, and Werahera PN: [Laterally Directed Biopsies Detect More Clinically Threatening Prostate Cancer: Computer Simulated Results](#). The Prostate 57:118 -128, 2003.
351. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED: [Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer](#). NEJM, 349(9):859-66, 2003.
352. Oottamasathien S, Crawford ED: [Recent advances in hormonal therapy for advanced prostate cancer](#). Oncology 17(8):1047-52, 1054-1058, 2003.
353. Crawford ED: [The role of the urologist in treating patients with hormone-refractory prostate cancer](#). Reviews in Urology 5(2) S48-52, 2003.
354. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R: [Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma](#). Cancer 98(8):1643-1648, 2003.
355. Porter CR and Crawford, ED: [Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer](#). Oncology 17(10):1395-9; discussion 1399, 1403-6, 2003.
356. Crawford, ED: Editorial Comment: Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. Br J Urol 92: 549-550, 2003.
357. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr. GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg, Jr LM, Clarke HS, Crawford ED, et al for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: [The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia](#), NEJM 349 (#25) 2385-2396, 2003.
358. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED: [Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary Therapy](#). Urology, 52 (5) 872-876, 2003.

359. Barqawi A., Akduman B, Abouelfadel Z, Robischon M, Crawford ED: [The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer](#). BJU Int 92(7):695-698, 2003.
360. Crawford ED: Prostate Cancer Supplement. Introduction. Urology 62 (6 Suppl 1):1-2, 2003.
361. Crawford ED: [Epidemiology of prostate cancer](#). Urology 62 (6 Suppl 1):3-12, 2003.
362. Crawford ED: [Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks](#). Urology 62 (6 Suppl 1):13-19, 2003.
363. Crawford, ED: [Complementary medicine, chemoprevention and staging of prostate cancer](#). Reviews in Urology, 5 (Suppl 6): S23-32, 2003.
364. Wilson SS, Crawford ED: [Prostate cancer update](#). Minerva Urol Nefrol, 55: 199-203.

2004

365. Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McManis MC: [First international conference on chemoprevention of prostate cancer](#). Jour Urology 171(2):S3-S4, 2004.
366. Barqawi A, Thompson IM, Crawford ED: [Prostate cancer chemoprevention: an overview of United States trials](#). Jour Urology 171(2):S5-S9, 2004.
367. Crawford ED. Bono AV: Introduction. European Urology Supplement 3 (1): Page 1, 2004.
368. Crawford ED: The role of hormonal therapy in the treatment of locally advanced prostate cancer-regional perspectives: USA. European Urology Supplement 3 (1): 17-21, 2004.
369. Barqawi A, Gamito E, O'Donnell C, and Crawford ED: [Herbal and vitamin supplement use in a prostate cancer screening population](#). Urology 63(2) 288-292, 2004.
370. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, and Crawford ED: [Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis](#). Jour Urology 171(3): 1071-1076, 2004.
371. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED: [The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer](#). Urol Oncol 22(1):16-9. 2004.
372. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R and Menon: [Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities](#). Jour Urology 171(4):1513-1519, 2004.
373. Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, and Glode LM: [Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor](#). Cancer Res 64(6):2090-2095, 2004.
374. Tewari A, Gamito EJ, Crawford ED, Menon M: [Biochemical Recurrence and Survival Prediction Models for the Management of Clinically Localized Prostate Cancer](#). Clinical Prostate Cancer, 2(4), 220-227, 2004.
375. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia, MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, and Coltman, CA Jr: [Prevalence of prostate cancer among men with a prostate-specific antigen level \$\leq\$ 4.0 ng per milliliter](#), NEJM 350(22):2239-2246, 2004.
376. Kang D, Andriole GL, Van De Vooren RC, Crawford ED, Chia D, Urban Da, Reding D, Huang W-Y, and Hayes RB: [Risk behaviours and benign prostatic hyperplasia](#). BJU 93:1241-1245, 2004.

377. Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, and Lucia MS: [Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models](#). Human Pathology, Vol 35(7), 798-807, July 2004.
378. Crawford ED and Barqawi A: Second opinion: multidisciplinary consultations on challenging cases. Oncology, Vol 18(4), 474. August 2004.
379. Wilson SS and Crawford ED: [Screening for prostate cancer](#). Clinical Prostate Cancer 3(1), 21-25, June, 2004.
380. Herr HW, Faulkner JR, Grossman HB, Crawford ED: [Pathologic evaluation of radical cystectomy specimens: a cooperative group report](#). Cancer 100(11):2470-2475, 2004.
381. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED: [Surgical factors influence bladder cancer outcomes: a cooperative group report](#). J Clin Oncol 22(14):2781-9, 2004.
382. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED: [Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894](#). J Urol. 172 (6, Part 1 of 2):2213-2217, 2004.
383. Crawford ED, Barqawi A: [Intermediate- to high-risk prostate cancer patient treated with radiation therapy](#). Oncology 18(9):1105-1110, 2004.
384. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: [Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer](#). NEJM 351(15):1513-1520, 2004.
385. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED: [The use of trastuzumab in the treatment of hormone refractory prostate cancer: phase II trial](#). The Prostate 60(4):332-337, 2004.
386. Crawford ED: Skeletal complications in men with prostate cancer: effects on quality-of-life outcomes throughout the continuum of care. European Urology Supplements 3(5):10-15, 2004.
387. Crawford ED: Invited commentary. Urology 64 (5 Suppl 1):15-16, 2004.
388. Crawford ED: Introduction. Urology 64 (5 Suppl 1):1, 2004.
389. Crawford ED: Panel discussion: Questions and answers. Urology 64 (5 Suppl 1):17-18, 2004
390. Crawford ED: Introduction: Challenges in the treatment of advanced Symptomatic prostate cancer patients. Reviews in Urology 6(suppl 7): S1-2, 2004.
391. Crawford ED: [Hormonal therapy in prostate cancer: historical Approaches](#). Reviews in Urology 6(suppl 7): S3-11, 2004.

2005

392. Barqawi A, Crawford ED: [Focal therapy in prostate cancer: future trends](#). BJU Int 95(3):273-4, 2005.
393. Maroni PD and Crawford ED: [Surgical management of prostate cancer: optimizing patient selections and clinical outcome](#). Surg Oncol Clin N Am, 14(2):301-19, 2005.
394. Van Veldhuizen PJ, Faulkner JR, Lara PN Jr, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED: [A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109](#). Cancer Chemother Pharmacol, 2005.
395. Barqawi A, O'Donnell C, Kumar R, Koul H, and Crawford ED: [Correlation between LUTS \(AUA-SS\) and erectile dysfunction \(SHIM\) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week \(PCAW\)](#). Int J Impot Res. 17, 370-374, 2005.

396. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; [PLCO Project Team: Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian \(PLCO\) Cancer Screening Trial: findings from the initial screening round of a randomized trial](#). J Natl Cancer Inst 16:97(6):433-8, 2005.
397. Porter CR, Gamito EJ, Crawford ED, Bartsch G, Presti JC Jr, Tewari A, O'Donnell C: [Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting](#). Urology, May; 65(5):937-41, 2005.
398. Crawford ED: Editorial Comment: [PSA testing: what is the use?](#) Lancet, 365 (9469): 1447-1449, 2005.
399. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED: [Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program](#). Urology 65 (4) 708-712, 2005.
400. Crawford, ED: Testosterone substitution and the Prostate. European Urology, Supplement 4, 16-23, 2005.
401. Crawford ED: [Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile](#). BJU Intl, (95) Supplement 4, 1-5, 2005.
402. Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, Gamito EJ, Wei J, Taub D, Montie J, Porter C, Divine GW, Bartsch G, and Mani Menon: [Racial differences in serum prostate-specific antigen \(PSA\) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer](#). BJU Intl, (96), 29-33, 2005.
403. Kumar RJ, Barqawi A, and Crawford ED: [Adverse events associated with hormonal therapy for prostate cancer](#). Reviews in Urology, (7) Supplement 5, 37-43, 2005.
404. Vaishampayan UN, Faulkner JR, Small EJ, Redman RG, Keiser WL, Petrylak DP, Crawford ED: [Phase II Trial of Carboplatin and Paclitaxel in Cisplatin-Pretreated Advanced Transitional Cell Carcinoma - A Southwest Oncology Group Study](#). Cancer, 104 (8), 1627-1632, 2005.
405. Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, and Werahera PN: [Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy](#). BJU Intl, (96) 999-1004, 2005.
406. Crawford ED: Editorial Comment: 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, Section Rotterdam. Urology, 174:493, 2005.
407. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED: [Ixabepilone \(Epothilone B Analogue BMS-247550\) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: A Southwest Oncology Group Trial S0111](#). J Clin Oncol 23(34):8724-8729, 2005.
408. Sarosdy MF, Tangen CM, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP Jr, Crawford ED: [A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guerin for carcinoma in situ of the bladder: A Southwest Oncology Group Study](#). Urol Oncol 23(6):386-9, 2005.
409. Tewari A, Horninger W, Pelzer AE, Demers R, Crawford ED, Gamito EJ, Divine G, Johnson CC, Bartsch G, Menon M: [Factors contributing to the racial differences in prostate cancer mortality](#). BJU Int'l (9):1247-52, 2005.
410. Barqawi A, Crawford ED: Review: [Testosterone replacement therapy and the risk of prostate cancer. Is there a link?](#) International Journal Impotence Research, 18: 323-328, 2005.
411. Akduman B, Barqawi AB, Crawford ED: [Minimally invasive surgery in prostate cancer: current and future perspectives](#). Cancer J. 11(5):355-61, 2005.
412. Crawford ED: Prostate cancer awareness: Much has changed since '89. Urology Times, Perspective, 2005.

413. Barqawi AB, Crawford, ED: Alpha-blockers may improve erectile dysfunction in men with LUTS. *Urology Times*, 33 (12): 6-7, 2005.

2006

414. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS: [A 12-Month Clinical Study of LA-2585 \(45.0 MG\): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer](#). *Urology*, (175), 533-536, 2006.
415. Akduman B, Crawford ED: pT3 Prostate Cancer: When to recommend adjuvant radiotherapy. *Contemporary Urology*, 18 (4): 26-29, 2006.
416. Flaig, TW, Barqawi, Miller, G, Kane, M, Zeng, C, Crawford, ED, Glode, LM: [A Phase II Trial of Dexamethasone, Vitamin D, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer](#). *Cancer*, 107 (2): 266-274, 2006.
417. Akduman, B, Crawford, ED: The PCPT: New Findings, New Insights, and Clinical Implications for the Prevention of Prostate Cancer. *European Urology Supplements*, 5 (9): 634-639, 2006.
418. Akduman, B, Crawford, ED: Treatment of Localized Prostate Cancer. *Reviews in Urology*, 8 (Suppl. 2): S15-S21, 2006.
419. Beer, TM, Tangen, CM, Bland, LB, Hussain, M, Goldman, BH, DeLoughery, TG, Crawford, ED: [The Prognostic Value of Hemoglobin Change After Initiating Androgen-Deprivation Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of Southwest Oncology Group Study 8894](#). *Cancer*, 107 (3): 489-496, 2006.
420. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. [Absolute Prostate-Specific Antigen Value after Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data from Southwest Oncology Group Trial 9346 \(INT-0162\)](#). *Journal of Clinical Oncology*, 24(24):3984-3990, 2006.
421. Crawford ED, Kavanagh BD. [The Role of \$\alpha\$ -Blockers in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated with Radiation Therapy](#). *American Journal of Clinical Oncology*, 29(5), 2006.
422. Swanson G, Thompson I, Basler J, Crawford ED. [Metastatic Prostate Cancer – Does Treatment of the Primary Tumor Matter?](#) *Urology*, 176: 1292-1298, 2006.
423. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford, ED. [Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial](#). *JAMA*, 296(19): 2329-2335, 2006.
424. Krygiel JM. [Comparison of Biochemical Progression Rates After Radical Prostatectomy and Radiotherapy for Localized Prostate Cancer](#). Commentary by Crawford ED, Akduman B. *Urology, Nature Clinical Practice*, 3(2): 78-79, 2006.
425. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. [Southwest Oncology Group Phase II Study of Arsenic Trioxide in Patients with Refractory Germ Cell Malignancies](#). *Cancer*, 106(12): 2624-2629, 2006.
426. Kaplan SA, Crawford ED. [Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men](#). *Diabetes Care*, 29(3), Letters, 2006.
427. Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM. [Trends and Predictors of Aggressive Therapy for Clinically Locally Advanced Prostate Carcinoma](#). *BJU International*, 98: 335-340, 2006.
428. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB. [A Prospective Study of Lycopene and Tomato Product Intake and Risk of Prostate Cancer](#). *Cancer Epidemiology Biomarkers & Prevention*, 15:92-98, 2006.

429. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. [Genetic Polymorphisms of Interleukin-1B \(IL-1B\), IL-6, IL-8, and IL-10 and Risk of Prostate Cancer](#). *Cancer Research* 66:4525-4530, 2006.
430. Pinsky PF, Crawford ED, Barnett SK, Andriole GL, Gelmann EP, Grubb R, Greenlees R, Gohagan JK. [Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial](#). *BJU International* 99:775-779, 2006.
431. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. [Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia](#). *Cancer Epidemiol Biomarkers Prev* 15(8):1479-1484, 2006.
432. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED. [Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group study](#). *Oncology Reports* 16:807-810, 2006.
433. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MHA, Lara Jr. PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. [Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16](#). *Journal of the National Cancer Institute* 98(8):516-521, 2006.
434. Messing EM, Manola J, Yai J, Kiernan M, Crawford D, Wilding G, di Sant Agnese, P A, Trump D, on behalf of the Eastern Cooperative Oncology Group study EST 3886. [Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy](#). *The Lancet Oncology* 7 (6):472-479, 2006.
435. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG (for the MTOPS Research Group). [Baseline Factors and Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated with Placebo](#). *Journal of Urology*, 175(4):1422-1427, 2006.
436. Pinsky PF, Barnett SK, Crawford ED, Grubb RL, Urban DA, Andriole GL, Chia D, Levin DL, Gohagan JK. [Prostate Volume and Prostate-Specific Antigen Levels in Men Enrolled in a Large Screening Trial](#). *Urology*, 68:352-356, 2006.
437. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. [Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study](#). *Clin Cancer Res* 12(7):2178-84, 2006.

2007

438. Berndt SI, Chatterjee N, Huang W-Y, Chanock SJ, Welch R, Crawford ED, Hayes RB. [Variant in the Sex-Hormone Binding Globulin Gene and Risk of Prostate Cancer](#). *Cancer Epidemiology Biomarkers and Prevention*, 16:165-168, 2007.
439. Peters U, Foster CB, Chatterjee N, Schatzkin A, Reding D, Andriole GL, Crawford ED, Sturup S, Chanock SJ, Hayes RB. [Serum Selenium and Risk of Prostate Cancer-A Nested Case-Control Study](#). *American Journal Clinical Nutrition*, 85:209-217, 2007.
440. Crawford ED, Barqawi A. [Targeted Focal Therapy: A Minimally Invasive Ablation Technique for Early Prostate Cancer](#). *Oncology* 21(1):27-34, 2007.
441. Childs SJ, Crawford ED, Glode LM. *Bladder Cancer: The Latest Thinking*. *Issues in Urology*, 19 (1):15-18, 2007.
442. Crawford ED, Morley JE, Morgentaler A, Seidman, Stuart. *Testosterone Replacement Therapy: Ask the Experts*. *Aging Health*, 3(2), 2007.

443. Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crichton F, Glode LM. [Second Opinion – Prostate Cancer in a Man with Multiple Previous Cancers](#). *Oncology* 21(5): 611-614, 2007.
444. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. [Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794](#). *Journal of Clinical Oncology* 25(16):2225-2229, 2007.
445. Childs SJ, Crawford ED, Glode LM. Renal Cancer: Current Directions. *Issues in Urology*, 19(2):63-65, 2007.
446. Maroni P and Crawford ED. Commentary, Practice Point. [Do tumor characteristics and prognostic factors differ between subsequent rounds of PSA screening for prostate cancer?](#) *Nature Clinical Practice* 4(5):252-253, 2007.
447. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. [Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder Cancer](#). *Journal of Urology*, 177:1727-1731, 2007.
448. Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. [The association of time of day and serum testosterone concentration in a large screening population](#). *BJU International*, 100:509-513, 2007.
449. Barqawi AB, Myers JB, O'Donnell C, Crawford ED. [The effect of a-blocker and 5a-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms](#). *BJU International*, 100:853-857, 2007.
450. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. [Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794](#). *Journal of Clinical Oncology*, 25(16):225-2229, 2007.
451. Swanson GP, Carpenter WR, Thompson IM, Crawford ED. [Urologists' attitudes regarding cancer clinical research](#). *Urology*, 70(1):19-24, 2007.
452. Crawford ED, Thompson IM. [Controversies regarding screening for prostate cancer](#). *BJU International*, 100(Supplement 2):5-7, 2007.
453. Ryan CW, Goldman BH, Lara, Jr. PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. [Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group](#). *Journal of Clinical Oncology*, 25(22):3296-3301, 2007.
454. Crawford ED. [Is a screening interval of every 4 years for prostate cancer acceptable?](#) *JNCI Editorials*, 99(17), 2007.
455. Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED. [Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group Trials 8894 and 9916](#). *The Journal of Urology*, 178:1946-1951, 2007.
456. La Rosa FG, Flaig TW, Wilson S, Crawford ED, Kim FJ. [Sarcoidosis in a Man with Renal Carcinoid Tumor](#). *Oncology-Second Opinion*, 21(13): 1593-96, 2007.
457. Abouelfadel Z, Lugg JA, Crawford ED. AUA 2007 Annual Meeting Highlights, Symposium – The Changing Dynamics of Advanced Prostate Cancer: Maintaining Skeletal and Bone Health, AUA News, 4-9, November, 2007.
458. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. [Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial](#). *Journal of the National Cancer Institute*, 99:1375-1383, 2007.
459. Weiss, JM, Huang W-Y, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, Hayes RB. IGF-1 and IGFBP-3: Risk of Prostate Cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *International Journal of Cancer*, 121(10), 2267-2273, 2007.

2008

460. Moinpour CM, Hayden KA, Unger JM, Thompson, Jr. IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford, ED. [Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy](#). Journal of Clinical Oncology, 26(1):112-120, 2008. International Journal of Cancer, Wiley Interscience (soon to be published – article online in advance of print), 2008.
461. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. [Endrogenous Sex Hormones and the Risk of Prostate Cancer: A Prospective Study](#).
462. Barqawi AB, Crawford ED. [Emerging Role of HIFU to Treat Localized Prostate Cancer](#). Oncology, 22(2): 123-129, 2008
463. Crawford D. [Is a screening interval of every 4 years for prostate cancer acceptable?](#) Journal of the National Cancer Institute/Correspondence, 100 (3): 222-224, 2008.
464. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED. [The Metabolites Citrate, Myo-Inositol, and Spermine Are Age-Independent Markers of Prostate Cancer in Human Expressed Prostatic Secretions](#). The Prostate (Wiley Interscience, (soon to be published – article online in advance of print), 2008.
465. Sartor AO, Tangen CM, Hussain MH, Eisengerger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED. [Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer: A Southwest Oncology Group Trial \(SWOG 9426\)](#). Cancer, 112, 2393-2400, 2008.
466. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford, ED, Glode LM. [Randomization Reveals Unexpected Acute Leukemias in Southwest Oncology Group Prostate Cancer Trial](#). Journal of Clinical Oncology, 26(9), 1532-1536, 2008.
467. Abouelfadel Z, Crawford ED. [Leuprorelin depot injection: patient considerations in the management of prostatic cancer](#). Therapeutics and Clinical Risk Management, 4(2), 513-526, 2008.
468. Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russel KJ, Crawford ED. Treatment Options for Muscle-invasive Urothelial Cancer for Patients [Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy with Methotrexate, Vinblastine, Doxorubicin, and Cisplatin – A Report of Southwest Oncology Group Trial 8733](#). Cancer, 112(10): 2181-2187, 2008.
469. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. [Failure to Achieve a Complete Response to Induction BCG Therapy is Associated with Increased Risk of Progression and Death in Patients with High Risk Non-Muscle Invasive Bladder Cancer \(SWOG S8507\)](#). Urologic Oncology, 2008. (Epub ahead of print).
470. Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED. [Southwest Oncology Group Phase II Study \(SWOG 0306\) of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium that Progressed after Platinum-Based Chemotherapy](#). Clinical Genitourinary Cancer, 6(1):36-39, 2008.
471. Swanson GP, Goldman B, Tangen CM, Chin JL, Messing EM, Canby-Higino ED, Forman JD, Thompson IM, Crawford ED. [The Prognostic Impact of Seminal Vesicle Involvement Found at Prostatectomy and the Effects of Adjuvant Radiation in Those Patients: Data from SWOG 8794](#). Accepted by the Journal of Urology, July, 2008.

472. Lara PN, Tangen CM, Conlon S, Flanigan RC, Crawford ED. [Predictors of Survival in Advanced Renal Cell Carcinoma: Long-Term Results from Southwest Oncology Group Trial S8949](#). Submitted to Journal of Urology, April, 2008.
473. Petrylak DP, Chansky K, Van Veldhuizen PJ, Goodwin W, Twardlowski PW, Atkins JN, Dakhil SR, Crawford ED. [Results of Southwest Oncology Group Phase II Evaluation \(Study S0031\) of ZD 1839 for Advanced Transitional Cell Carcinoma of the Urothelium](#). Submitted to British Journal of Urology, July, 2008.
474. Van Veldhuizen PJ, Hussey M, Lara PN, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford ED. [A Phase II Study of Gemcitabine and Capecitabine in Patients with Advanced Renal Cell Cancer \(RCC\): Southwest Oncology Group Study S0312](#). Submitted to Cancer, May, 2008.
475. Gordon MS, Hussey M, Nagle R, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford ED. [A Phase II Study of Erlotinib \(OSI-774\) in Patients with Locally-Advanced or Metastatic Papillary Histology Renal Cell Cancer \(SWOG S0317\)](#). Submitted to Journal of Clinical Oncology, July, 2008.
476. Crawford ED. Legends in Urology. The Canadian Journal of Urology, 15(3): 4044-4046, 2008.
477. Crawford ED, Abrahamsson PA. [PSA-Based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?](#) European Urology, 54(2):262-273, 2008.
478. Crawford ED. Monitoring and Treatment after Prostatectomy or Brachytherapy. Testosterone Update, 1 (1): 14-16, 2008.
479. Wei L, Werahera PN, Shinohara K, Li L, Khemka A, Kumar D, Miller S, Simoneau AR, Barqawi A, Crawford ED, Suri JS. Accurate and Reproducible 3-Dimensional Transrectal Ultrasound-Guided Prostate Biopsy for Diagnosis and Treatment of Prostate Cancer. Grand Rounds in Urology, 7 (2): 15-19, 2008.
480. Cunningham GR, Shabsigh R, Bhasin S, Crawford ED, Dobs AS, Marks LS, Morgentaler A, Nehra A, Sadovsky R. Proceedings from the TU 1st Annual Conference on Improving Clinical Outcomes in Hypogonadism, Monitoring and Treatment after Prostatectomy or Brachytherapy. Grand Rounds in Urology, 7 (3): 11-13, 2008.
481. Chang SS, Crawford ED, Pruthi R. Treating BCG-Resistant Superficial Bladder Cancer: Evidence-Based Options. Urology Times Supplement, CME Certified, 2-8, May, 2008.
482. Sartor AO, Tangen CM, Hussain MHA, Eisengerger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED. [Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer: A Southwest Oncology Group Trial \(SWOG 9426\)](#). Cancer, 112 (11): 2393-2400, 2008.
483. Feimo S, Shinohara K, Kumar D, Khemka A, Simoneau AR, Werahera PN; Li I, Guo Y, Narayanan R, Wei L, Barqawi A, Crawford ED, Davatzikos C, Suri JS. [Three-Dimensional Sonography with Needle Tracking: Role in Diagnosis and Treatment of Prostate Cancer](#). Journal of Ultrasound Medicine, 27:895-905, 2008.
484. Narayanan R, Werahera PN, Barqawi A, Crawford ED, Shinohara K, Simoneau AR, Suri JS. [Adaptation of a 3-D Prostate Cancer Atlas for Transrectal Ultrasound Guided Target-Specific Biopsy](#). Physics in Medicine and Biology, 53: N397-N406, 2008.
485. Crawford, ED. Answering Key Clinical Questions: An interview with renowned urology researcher E. David Crawford, M.D., about the state of clinical trials on prostate health. Harvard Health Publication, 2(4), 6-27, 2008.
486. Anderson J, Abrahamsson PA, Crawford ED, Miller K, Tombal B. [Management of Advanced Prostate Cancer: Can We Improve on Androgen Deprivation Therapy?](#) BJU International, 101(12), 1497-1501, 2008.

2009

487. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford, LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden III JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz

- PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens Jr. FL, Balkr LH, Coltman Jr. CA. [Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Cancer Prevention Trial \(SELECT\)](#). Journal of the American Medical Association, 301 (1), 39-51, 2009.
488. Lara, Jr. PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. [Predictors of Survival of Advanced Renal Cell Carcinoma: Long-Term Results from Southwest Oncology Group Trial S8949](#). The Journal of Urology, 181, 512-517, 2009.
489. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. [Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial](#). The Journal of Urology, 181, 956-962, 2009.
490. Crawford ED, Abrahamsson PA. Letter to the Editor. European Association of Urology, 55, 90-91, 2009.
491. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. [Mortality Results from a Randomized Prostate-Cancer Screening Trial](#). New England Journal of Medicine, 360, 1310-1319, 2009.
492. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. [Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer](#). Urologic Oncology: Seminars and Original Investigations 27, 155-159, 2009.
493. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF, Thomas G, Hunter DJ, Dean M, Chanock SJ. [Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility](#). Proceedings of National Academy of Sciences: 12:106(19):7933-7938, 2009.
494. Crosswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu J-L, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE. [Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening](#). Ann Fam Med, 7:212-222, 2009.
495. Hou AH, Sullivan KF, Crawford ED. [Targeted focal therapy for prostate cancer: a review](#). Curr Opin Urol, 19:283-289, 2009.
496. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. [Prostate-specific antigen predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 \(Intergroup Study 0162\) and 9916](#). J Clin Oncol, 27:2450-2456, 2009.
497. Crawford ED. [A review of the use of histrelin acetate in the treatment of prostate cancer](#). BJUI, 103:Suppl 2, 14-22, 2009.
498. deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MHA, Crawford ED. [A sequential treatment approach to myoinvasive urothelial cancer: A phase II Southwest Oncology Group trial \(S0219\)](#). J Urol, 181:2476-2481, 2009.
499. Crawford ED, Tangen CM. [Clinical integration: laudable, but challenging](#). Nature Reviews Urology, 6:297-298, 2009.
500. Mirabello L, Huang W-Y, Wong YY, Chatterjee N, Reding D, Crawford ED, DeVivo I, Hayes RB, Savage SA. [The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer](#). Aging Cell, 8:405-413, 2009.

501. Crawford ED. [Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.](#) Urology, 73:(5A):4-10, 2009.
502. Guo Y, Werahera PN, Narayanan R, Li L, Kumar D, Crawford ED, Suri JS. [Image Registration Accuracy of a 3-Dimensional Transrectal Ultrasound-Guided Prostate Biopsy System.](#) J Ultrasound Med, 28:1561-1568, 2009.
503. Malmstrom P-U, Sylvester RJ, Crawford ED. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C Versus Bacillus Calmette-Gue' rin For Non-Muscle-Invasive Bladder Cancer. Eur Urol, 56:247-256, 2009.
504. Lee JY, Andriole G, Avins A, Crawford ED, Foster H, Kaplan S, Kreder K, Kusek JW, McCullough A, McVary K, Meleth S, Naslund M, Nickel JC, Nyberg LM, Roehrborn C, Williams OD, Barry MJ. [A negative finding from a single center study led to redesign of a large-scale clinical trial of phytotherapy for benign prostatic hyperplasia: The CAMUS study.](#) J Soc for Clin Trials, 6(6):628-636, 2009.

2010

505. Crawford ED, Black L, Eaddy M, Kruep EJ. [A Retrospective Analysis Illustrating the Substantial Clinical and Economic Burden of Prostate Cancer.](#) Prostate Cancer and Prostatic Diseases, 1-6, 2010.
506. Rove KO, Sullivan KF, Crawford ED. [High Intensity Focused Ultrasound: Ready for Primetime.](#) Urol Clin North Am, 37(1):27-35, 2010.
507. Laiyemo AO, Doubin C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD. [Race and Colorectal Cancer Disparities: Health-Care Utilization vs Different Cancer Susceptibilities.](#) J Natl Cancer Inst, 102:1-9, 2010.
508. Flaig TW, Kondo KL, LaRosa FG, Kavanagh B, Crawford ED. [A Young Woman with Multiple Kidney Lesions.](#) Oncology 24(3):282-286, 2010.
509. Akduman B, Tandberg DJ, O'Donnell CI, Hughes A, Moyad MA, Crawford ED. [Effect of Statins on Serum Prostate-specific Antigen Levels.](#) Urology 76:1048-1051, 2010.
510. Crawford ED, Grubb R III, Black A, Andriole GL, Chen M-H, Izmirlian G, Berg CD, D'Amico AV. [Comorbidity and Mortality Results from a Randomized Prostate Cancer Screening Trial.](#) J Clin Onc 29:355-361, 2010.
511. Shore ND, Crawford ED. [Intermittent Androgen Deprivation Therapy: Redefining the Standard of Care?](#) Rev Urol 12(1):1-11, 2010.
512. Prokunina-Olsson L, Fu Y-P, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Gronberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M. [Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2.](#) Cancer Epidemiol Biomarker Prev 19(5): 1349-1355, 2010.
513. Crawford ED, Rove KO. [Incomplete testosterone suppression in prostate cancer.](#) N Engl J Med 363:1976, 2010.
514. Crawford ED, Petrylak D. [Castration-resistant prostate cancer: descriptive yet pejorative?](#) J Clin Oncol 28:7664, 2010.
515. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, De Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. [Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study \(S8710\).](#) British J Urol 10:1464, 2010.

516. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J. [A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-1 and IGFBP-3 blood levels and prostate cancer risk among Caucasians](#). *Hum Mol genet* 1;19(15):3089-3101, 2010.
517. Koutros S, Schumacher FR, Hayes RB, Ma J, Huang WY, Albanes D, Canzian F, Chanock SJ, Crawford ED, Diver WR, Feigelson HS, Giovanucci E, Haiman CA, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Riboli E, Siddiq A, Stampfer MJ, Stram DO, Thomas G, Travis RC, Thun MJ, Yeager M, Berndt SI. [Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer](#). *Cancer Res* 15;70(6):2389-2396, 2010.
518. Flaig TW, Glode LM, Gustafson D, Van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. [A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer](#). *Prostate* 1;70(8):848-855, 2010.
519. Crawford ED, Andriole GL, Marberger M, Rittmaster RS. [Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial](#). *Urology* 75(3):502-509, 2010.
520. Schroder FJ, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. [Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study](#). *British J Urol* 106(2):182-187, 2010.
521. Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. [Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial \(CS21\) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics](#). *Eur Urol* 57(5):836-842, 2010.
522. Petrylak DP, Tangen CM, VanVeldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED. [Results of the Southwest Oncology Group phase II evaluation \(study S0031\) of ZD1839 for advanced transitional cell carcinoma of the urothelium](#). *British J Urol* 105(3):317-321, 2010.
523. Rove KO, Crawford ED. [Metastatic Cancer in Solid Tumors and Clinical Outcome: Skeletal-Related Events](#). *Cancer Network*, 2010.

2011

524. Rove KO, Crawford ED. [Dutasteride: Novel Milestones in Prostate Cancer Chemoprevention](#). *Drugs of Today* 47(2):135-144, 2011.
525. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu J-L, Prorok PC, Gohagan JK, Berg CD. [Effect of Screening on Ovarian Cancer Mortality – The Prostate, Lung, Colorectal and Ovarian \(PLCO\) Cancer Screening Randomized Controlled Trial](#). *Journal of the American Medical Association* 305(22):2295-2303, 2011.
526. Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood Jr DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. [Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study](#). *J Clin Oncol* 29:2040-2045, 2011.
527. Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford

- ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF Jr., Hunter DJ, Thomas G, Chanock SJ. [Large-scale fine mapping of the HNF1B locus and prostate cancer risk](#). *Hum Mol Genet* 20(16): 3322-29, 2011.
528. Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CL, Koul H, Crawford ED. [The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer](#). *J Urol* 186:80-85, 2011.
529. Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SL, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Gronberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF Jr., Hunter DJ, Thomas G, Chatterjee N, Chanock SJ. [Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer](#). *Hum Mol Genet* 20(14):2869-78, 2011.
530. Barqawi AB, Turcanu R, Gamito EJ, Lucia MS, O'Donnell CI, Crawford ED, LaRosa DD, LaRosa FG. [The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer](#). *Int J Clin Exp Pathol* 4(5):468-475, 2011.
531. Crawford ED, O'Donnell CI, Barqawi AB, O'Leary M, Sullivan KF, Hughes A, Roehrborn CG, Maroni P. [Validation of the Modified American Urological Association Symptom Score](#). *J Urol* 186:945-948, 2011.
532. Barqawi AB, Sullivan KF, Crawford ED, Roehrborn CG, Hughes A, O'Leary M, Stone N, O'Donnell CI. [Methods of Developing UWIN, the Modified American Urological Association Symptom Score](#). *J Urol* 186:940-944, 2011.
533. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Mynderse LA, Roehrborn CG, Smith CP, Bruskewitz R. [Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial](#). *J Urol* 186:965-970, 2011.
534. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Moul JW, Jensen J-K, Olesen TK, Persson B-E. [A Phase III Extension Trial with a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer](#). *J Urol* 186:889-897, 2011.
535. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, and McVary KT. [Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms: A Randomized Trial](#). *Journal of the American Medical Association* 306(12):1344-1351, 2011.
536. Pohlman GD, Pohlman EA, Crawford ED. Dutasteride: A Review of its Use in the Management of Prostate Disorders. *Clinical Medicine Insights: Therapeutics*, 2011:3.
537. Oken MM, Hocking WG, Kvale PA, Andriole GA, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD. [Screening by Chest Radiography and Lung Cancer Morality: The Prostate, Lung, Colorectal,](#)

- [and Ovarian \(PLCO\) Randomized Trial](#). The Journal of the American Medical Association 306(17): 1865-1873, 2011.
538. Kirby M, Hirst C, Crawford ED. [Characterizing the Castration-Resistant Prostate Cancer Population: A Systematic Review](#). Int J Clin Pract 65:1180-1192, 2011.
 539. Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. [Prostate-specific Antigen 1.5-4.0ng/mL: a diagnostic challenge and danger zone](#). BJU International 108:1743-1749, 2011.
 540. Higano CS, Crawford ED. [New and Emerging Agents for the Treatment of Castration-Resistant Prostate Cancer](#). Urologic Oncology 29(6): S1-S8, 2011.
 541. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaxiano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. [Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917](#). AACR 4:1761-1769, 2011.
 542. Philips JM, Crawford ED. [Prostate-specific antigen \(PSA\) screening: has the pendulum swung too far?](#) Asian Journal of Andrology 13:655-656, 2011.
 543. Croswell JM, Kramer BS, Crawford ED. [Screening for Prostate Cancer With PSA Testing: Current Status and Future Directions](#). Oncology 4(5):468-75, 2011.
 544. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Olama AA, Kote-Jarai Z, Guy M, Severi G, Gronberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Driver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Marchand LL, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Feigelson HS, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P. [Genome-wide association](#)

- [study identifies new prostate cancer susceptibility loci](#). *Herman Molecular Genetics* 20(19):3867-75, 2011.
545. Crawford ED, Phillips JM. [Six-month gonadotropin releasing hormone \(GnRH\) agonist depots provide efficacy, safety, convenience, and comfort](#). *Cancer Management and Research* 3:201-209, 2011.
546. Warehera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T. [Proliferative Tumor Doubling Times of Prostatic Carcinoma](#). *Prostate Cancer* 2011:301850, 2011.
547. Maroni P, Crawford ED. [Assessment of Men before Androgen Deprivation Therapy](#). *Journal of Urology* 186:371-372, 2011.
548. Rove KO, Crawford ED. [Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts](#). *World J Urol* 2011.
549. Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED. [Testosterone in prostate cancer: the Bethesda consensus](#). *BJU International* 2011.
550. Rove KO, Crawford ED. [Evolution of Treatment Options for Patients with CRPC and Bone Metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival](#). *Oncology* 25 (14): 1362-1387, 2011.
551. The National Lung Screening Trial Research Team. [Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening](#). *NEJM* 365(5): 395-409, 2011.
552. Crawford ED, Moul JW, Shore N, Meulen E, Persson B. Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix Versus Degarelix Following Leuprolide Treatment. *The Journal of Urology* 184 (4S): e289-90, 2011.

2012

553. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohgan JK, Prorok PC. [Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Morality Results after 13 Years of Follow-up](#). *JNCI* 104 (2): 1-8, 2012.
554. Crawford ED, Flaig TW. [Optimizing Outcomes of Advanced Prostate Cancer: drug sequencing and novel therapeutic approaches](#). *Oncology* 26(1): 70-77, 2012.
555. Burglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, White RD, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. [Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109](#). *Urology* 79(3):633-7, 2012.
556. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD, PLCO Project Team. [Flexible Sigmoidoscopy in the Randomized Prostate, Lung, Colorectal, and Ovarian \(PLCO\) Cancer Screening Trial: Added Yield from a Second Screening Examination](#). *JNCI* 104 (4): 280-289, 2012.
557. Rove KO, Crawford ED. Editorial Comment: [Accuracy of Primary Systematic Template Guided Transperineal Biopsy of the Prostate for Locating Prostate Cancer: A Comparison With Radical Prostatectomy Specimens](#). *The Journal of Urology* 187: 2044-50, 2012.
558. Lindstrom S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, Andriole G, Berndt SI, Boeing H, Bueno-de-Mesquita, Crawford ED, et al. [Common Genetic Variants in Prostate Cancer](#)

- [Risk Prediction- Results from the NCI Breast and Prostate Cancer Cohort Consortium \(BPC3\).](#) Cancer Epidemiol Biomarkers Prev 21 (3):437-444, 2012.
559. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, et al. [Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy.](#) The New England Journal of Medicine 366 (25):2345-2357.
560. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. [Role of Testosterone in Managing Advanced Prostate Cancer.](#) Urology 80: 754-762, 2012.
561. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H. [Projecting Prostate Cancer Mortality in the PCPT and REDUCE Chemoprevention Trials.](#) Cancer 2012.
562. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schellhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. [Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience \(S8494, S8894 and S9346\).](#) The Journal of Urology 188: 1164-1169, 2012.
563. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Grover WL, Bostwick DG. [Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases.](#) The Journal of Urology 188(5):1726-31, 2012.
564. Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O'Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. [Optimization of Prostate Cancer Diagnosis by Increasing the Number of Core Biopsies Based on Gland Volume.](#) Int J Clin Exp Pathol 5(9):892:899, 2012.
565. Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE. [Androgen Deprivation Therapy: Past, Present and Future.](#) BJUI Supplement 6: 1-12, 2012.
566. Rove, KO, Crawford ED. Advanced Prostate Cancer Management. Hospital Physician Board Review Manual 15(1):1-12, 2012.
567. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. [Clinical-Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three-Dimensional Reconstruction of Prostatectomy Specimens.](#) Prostate, 2012.
568. Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. [New Considerations for ADT in Advanced Prostate Cancer and the Emerging role of GNRH antagonists.](#) Prostate Cancer and Prostatic Diseases. 1-9, 2012.
569. Helfand BT, Lee JY, Sharp V, Foster H, Naslund M, Williams OD, McVary KT, CAMUS Study Group. [Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial.](#) J Urol 188(6):2288-93, 2012.
570. Crawford ED, Rove KO. [Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications.](#) Am J Manag Care 18(5):SP250-3, 2012.

2013

571. Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A, CAMUS Study Group. [The Effects of Increasing Doses of Saw Palmetto Fruit Extract on Serum Prostate Specific Antigen: Analysis of the CAMUS Randomized Trial.](#) Journal of Urology 189(2): 486-92, 2013.
572. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Sundaram SK, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Waishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM.

- [Intermittent versus Continuous Androgen Deprivation in Prostate Cancer](#). NEJM 368: 1314-25, 2013.
573. Rove KO, Crawford ED. [Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer](#). Current Opinion Urology. 23(3):208-213, 2013.
574. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. [Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer](#). Expert Reviews 13(2): 251-259, 2013.
575. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. [Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer](#). Expert Reviews 13(2): 261-270, 2013.
576. Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. [Association Between Race and Follow-Up Diagnostic Care After a Positive Prostate Cancer Screening Test in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial](#). Cancer. 1-7, 2013.
577. Barry MJ, Cantor A, Roehrborn CG, for the CAMUS Study Group (Crawford ED, PI, University of Colorado). [Relationships Among Participant International Prostate Symptom Score, Benign Prostatic Hyperplasia Impact Index Changes and Global Ratings of Change in a Trial of Phytotherapy in Men with Lower Urinary Tract Symptoms](#). J Urol 189: 987-992, 2013.
578. Crawford ED, Eisner J, Persson BE. [Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry](#). J Urol 189(3):987-92, 2013.
579. Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindstrom S, Albanes D, Ziegler RG, McCullough ML, Siddiq A, Barricarte A, Berndt SI, Buenode-Mesquita HB, Chanock SJ, Crawford ED, Diver WR, Gapstur SM, Giovannucci E, GU F, Haiman CA, Hayes RB, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Overvad K, Polidoro S, Riboli E, Schumacher FR, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Key TJ. [Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium](#). Int J Cancer 133(2):495-504, 2013.
580. Tombal B, Crawford ED. [Landmarks in hormonal therapy for prostate cancer](#). BJU Int. 111(3):E12-3, 2013.
581. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. [The utility of prostate-specific antigen in the management of advanced prostate cancer](#). BJU Int. 112(5):548-60, 2013.
582. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J, National Lung Screening Trial Research Team. [Results of the two incidence screenings in the National Lung Screening Trial](#). N Engl J Med 369(10):920-31, 2013.
583. Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, van Bokhoven A, Lucia MS, Kim FJ. [Anterior tumors of the prostate: diagnosis and significance](#). Can J Urol 20(5):6897-906, 2013.
584. Wiedel C, Pohlman G, Arangua P, Crawford ED. [Definice vhodného Kandidáta s karcinomem prostaty pro pozorování a pro cílenou fokální terapii](#). Urologické listy 11(3)6-12, 2013.
585. Krughoff K, Eid k, Phillips J, Stoimenova D, Smith D, O'Donnell C, Crawford ED, Barqawi A. [The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound- Guided Biopsy Compared to 3-Dimensional Transperineal Approach](#). Advances in Urology 10.1155/2013/249080, 2013.

2014

586. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP, and the Prostate Cancer Radiographic Assessments for

- Detection of Advanced Recurrence (RADAR) Group. [Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer](#). Urology 83(3):664-669, 2014.
587. Shui IM, Lindstrom S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Marchand LL, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. [Prostate Cancer \(PCa\) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium](#). European Association of Urology 0302-2838, 2014.
588. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. [Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists](#). European Association of Urology 0302-2838, 2014.
589. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK. [Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer: Results from an ongoing registry](#). Current Medical Research & Opinion (In Process).
590. Barqawi AB, Stoimenova D, Krughoff K, Eid K, O'Donnell C, Phillips JM, Crawford ED. [Targeted Focal Therapy for the Management of Organ Confined Prostate Cancer](#). JUrol 749-753, 2014.
591. Crawford ED, Shore ND, Mlul JW, Tombal B, Schroder FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Koltz L. [Long-term Tolerability and Efficacy of Degarelix: 5-Year](#)

- [Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix.](#) Elsevier 1122-1128, 2014.
592. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. [The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Popular-Based Study.](#) International Journal of Radiation Oncology 1064-73, 2014.
593. Crawford ED, Bo-Eric Persson. [Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer.](#) European Association of Urology e34-e35, 2014.
594. Crawford ED, Ventii K, Shore ND. [New Biomarkers in Prostate Cancer.](#) Oncology 135-42, 2014.
595. Rove KO, Crawford ED, Perachino M, et al. [Maximal Testosterone Suppression in Prostate Cancer-Free vs Total Testosterone.](#) Urology 1217-22, 2014.
596. Rove KO, Crawford ED. [Traditional androgen ablation approaches advanced prostate cancer: new insights.](#) The Canadian Journal of Urology 14-21, 2014.
597. Pokharel SS, Patel NU, Garg K, La Rosa FG, Arangua P, Jones C, Crawford ED. [Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transrectal mapping biopsy.](#) Abdom Imaging, 2014.
598. Stone NN, Miner M, Poage WL, Patel A, Crawford ED. [Male Androgen Deficiency Syndrome Screening Questionnaire: A Simplified Instrument to Identify Testosterone-Deficient Men.](#) Journal of Men's Health 11(1) 28-37, 2014.
599. Koo PJ, Crawford ED. [¹⁸F-NaF PRT/CT and ¹¹C-choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.](#) Oncology (Williston Park) 28(12): 1057-62, 1065-5, 2014
600. Crawford ED, Rove KO, Schally AV, et al. [The role of the FSH system in the development and progression of prostate cancer.](#) The American Journal of Hematology Oncology. 10(6): 5-13, 2014
601. Werahera P, Crawford ED. [Diagnosis of High Grade Prostatic Cancer Using Diffuse Reflectance Spectroscopy.](#) Journal of Urology, MP53-13. 191:4S, e593. 2014. <http://www.ncbi.nlm.nih.gov/pubmed/26360789>
602. Bournon MT, Glode LM, Crawford ED. [Base of the skull metastases castration-resistant prostate cancer.](#) Oncology (Williston Park). 2014 Dec;28(12):1115-6, 1124. No abstract available. PMID: 25510811 Free Article.
603. Crawford ED, Persson BE, Klotz L. [Reply by the authors.](#) Urology. 2014 Nov;84(5):1250-1. Doi: 10.1016/j.urology.2014.08.004. Epub 2014 Oct 24. No abstract available. PMID: 25443944

2015

604. Crawford ED, Moul JW. [ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury](#). *Oncology (Williston Park)* 29(1): 55-8, 65-6, 2015
605. Stone NN, Crawford ED. [To screen or nor to screen: the prostate cancer dilemma](#). *Asian Journal of Andrology* 17; 44-45, 2015.
606. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. [Avoiding obsolescence in advanced prostate cancer management: a guide for urologists](#). *British Journal of Urology* 115(2):188-97, 2015
607. Crawford ED, Poage W, Nyhuis A, Price D, Dowsett S, Muram D. [Effects of Testosterone Level on Lower Urinary Tract Symptoms](#). *American Journal of Men's Health*. June 14, 2015
608. Crawford ED, Moul JW, Sartor O, Shore ND. [Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl](#). *Expert Opin Drug Metab Toxicol*. 2015 Sep;11(9):1465-74.
609. E. David Crawford, MD Urologic Oncology, University of Colorado, CO, USA, Wendy Poage, Porstate Conditions Education Council, Centennial, CO, USA - [Measurement of testosterone: how important is a morning blood draw?](#) September 11 2015.
610. E. David Crawford, MD Daniel P. Petrylak, MD Celestia S. Higano, MD, Adam S. Kibel, MD, Philip W. Kantoff, MD, Eric J. Small, MD, Neal D. Shore, MD, Anna Ferrari, MD – [Optimal timing sipuleucel-T treatment in metastatic castration-resistant prostate cancer](#). *The Canadian Journal of Urology*; 22(6); December 2015
611. Batley KE, Schade H, Purcell WT, Crawford ED. [Subacute headache in a patient with metastatic gastric cancer](#). *Oncology (Williston Park)*. 2015 May;29(5):390, C3. No abstract available. PMID: 25979548 Free Article
612. Kessler ER, Amini A, Wilson SS, Anp-C KB, Raben D, LaRosa FG, Crawford ED. [Lymphoepithelioma-Like Carcinoma of the Urinary Bladder](#). *Oncology (Williston Park)*. 2015 Jun;29(6):462, C3. No abstract available. PMID: 26089221 Free Article
613. Bournon C, Vargas-Serafin C, Bournon MT, La Pena-Lopez RD, Crawford ED. [Biphenotypic Extramedullary Blast Crisis of Chronic Myeloid Leukemia With Variant Philadelphia Chromosome Translocation](#). *Oncology (Williston Park)*. 2015 Aug 15;29(8). pii: 212854. No abstract available. PMID: 26281843 Free Article
614. Shore ND, Kella N, Moran B, Boczko J, Bianco FJ, Crawford ED, Davis T, Roundy KM, Rushton K, Grier C, Kaldate R, Brawer MK, Gonzalzo ML. [Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer](#). *J Urol*. 2015 Sep 25. pii: S0022-5347(15)04811-9. Doi: 10.1016/j.juro.2015.09.072.[Epub ahead of print] PMID: 26403586
615. Werahera PN, Jasion EA, Yongjun Liu, Daily JW, Arangua P, Jones C, Nash SR, Morrell M., Crawford ED. [Human feasibility study of fluorescence spectroscopy guided optical biopsy needle for prostate cancer](#). *Conf Proc IEEE Eng Med Biol Soc*. 2015 Aug;2015:7358-61. Doi 10.1109/EMBC.2015.7320091. PMID 26737991

2016

616. Sutton SS, Crawford ED, Moul JW, Hardin JW, Kruep E. [Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System](#). *World J Urol*. 2016 Jan 11.[Epub ahead of print] PMID: 26753559
617. Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED. [Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer](#).

BJU Int. 2016 Mar 17. doi: 10.1111/bju.13482. [Epub ahead of print] PMID: 26991743 DOI: 10.1111/bju.13482

618. Catarinicchia S, Crawford ED. - [The Role of FSH in Prostate Cancer: A Case Report.](#) – Urol Case Rep. 2016 Apr 24;7:35. Doi 10.1016/j.eucr.2016.03.011. eCollection 2016 Jul. – PMID: 27335783
619. Stone NN, Mouraviev V, Schechter D, Goetz J, Lucia MS, Smith EE, Crawford ED. – Deflection [Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy.](#) – Technol Cancer Res Treat. 2016 Oct 5. Pii: 1533034616671007. [Epub ahead of print] PMID: 27708117
620. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA. [An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.](#) Urology. 2016 Oct;96:116-120. doi: 10.1016/j.urology.2016.07.001. Epub 2016 Jul 19.

2017

621. Crawford ED, Shore ND, Petrylak DP *et al.* [Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.](#) *Ther Adv Med Oncol* 2017; 9(5): In Press. doi: 10.1177/1758834017698644
622. Arya Amini, M.D.a, David Raben, M.D.a, E. David Crawford, M.D.b, Thomas W. Flaig, M.D.b, Elizabeth R. Kessler, M.D.b, Elaine T. Lam, M.D.b, Paul Maroni, M.D.c, Thomas J. Pugh, M.D. [Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database](#) Received 4 November 2016; received in revised form 10 January 2017; accepted 16 January 2017
623. E. David Crawford, M.D. Andrew Schally, Ph.D., M.D.hc. (Multi)., D.Sc., hc b,c,d, Jehonathan H. Pinthus, M.D. Ph.D e, Norman L. Block M.D. b,c,d, Ferenc G. Rick, M.D., Ph.D b,f, Marc B. Garnick, M.D.g, Robert H. Eckel, M.D.h, Thomas E. Keane, M.B.B.Ch., F.R.C.S.I., F.A.C.S, Neal D. Shore, M.D., F.A.C.S., C.P.O.j, David N. Dahdal, M.S., Ph.D.k, Thomas J.R. Beveridge, M.Sc., Ph.D.k, Dennis C. Marshall, R.N., M.S., Ph. D.k – May 5, 2017 [The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy](#) - <http://dx.doi.org/10.1016/j.urolonc.2107.01.025>
624. Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H. – [Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel](#) – J Urol. 2017 Apr;197(4):1041-1047. doi: 10.1016/j.juro.2016.10.089. Epub 2016 Nov 1. PMID: 27810449
625. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Grohagan JK, Crawford ED, Grubb RL, Andriole GL. – [Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.](#) Cancer. 2017 Feb 15; 123(4):592-599. doi: 10.1002/ncr.30474. Epub 2016 Dec 1.

626. Crawford ED, Petrylak DP, Shore N, Saad F, Solvin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY, - [The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer \(Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II.](#) - Urology. 2017 Jun; 104:150-159. Doi: 10.1016/j.urology.2016.12.033. Epub 2017 March 14.
627. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC. - [The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy.](#) - Urol Oncol. 2017 May; 35(5):183-191. Doi: 10.1016/j.urolonc.2017.01.025. Epub 2017 Mar 18. Review. PMID:28325650
628. Stone NN, Mouraviev V, Schechter D, Lucia MS, Smith EE, Arangua P, Hoenemeyer J, Rosa J, Bawa R, Crawford ED. - [The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator and Specimen Collection Device Allowing Sampling of the Individualized Prostate Lengths between 20 and 60 mm.](#) - Urology 2017 Jun 7. Pii: S00090-4295(17)3060-9. doi: 10.1016/j.urology.2017.05.046 [Epub ahead of print] PMID: 28601561
629. Petrylak DP, Crawford ED. - [Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.](#) - Target Oncol. 2017 Jun 16. Doi: 1007/s11523-017-0500-y. [Epub ahead of print] - PMID: 28620691
630. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R. - [Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials](#) - Ann Intern Med. 2017 Sep 5. doi: 10.7326/M16-2586. [Epub ahead of print] PMID: 28869989
631. Wilson SS, **Crawford ED.** - [Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.](#) *Eur Urol.* 2018 Feb;73(2):233-235
632. Daniel Saltzstein, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang and E. David Crawford - [Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects](#) - Ther Adv Urol 1–8 DOI: 10.1177/ 1756287217738150 © The Author(s), 2017. Reprints and permissions: <http://www.sagepub.co.uk/journalsPermissions.nav>

2018

633. M. Vasileios Skouteris, MD,¹ E. David Crawford, MD,² Vladimir Mouraviev, MD,³ Paul Arangua, D,² Marios Panagiotis Metsinis, MD,¹ Michael Skouteris, MD,¹ George Zacharopoulos, MD,¹ Nelson N. Stone, MD - Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison - [Rev Urol. 2018;20\(1\):38–40 doi: 10.3909/riu0789](#)] © 2018 MedReviews

634. Harry J. de Koning, MD1; Roman Gulati, MS 2; Sue M. Moss, PhD3; Jonas Hugosson, MD4; Paul F. Pinsky, PhD5;Christine D. Berg, MD6; Anssi Auvinen, MD7; Gerald L. Andriole, MD8; Monique J. Roobol, PhD9; E. David Crawford, MD10; Vera Nelen, MD11; Maciej Kwiatkowski, MD12; Marco Zappa, MD13; Marcos Luján, MD14; Arnauld Villers, MD15; 6;Eveline A. M. Heijnsdijk, PhD 1; and Ruth Etzioni, PhD2 BAC - The Efficacy of Prostate-Specific Antigen Screening: Impact of Key Components in the ERSPC and PLCO Trials -

[DOI: 10.1002/cncr.31178](https://doi.org/10.1002/cncr.31178) –Cancer. 2018 Mar 15; 124(6): 1197–1206.

635. Maccini MA¹, Westfall NJ¹, Van Bokhoven A¹, Lucia MS¹, Poage W², Maroni PD¹, Wilson SS¹, Glodé LM¹, Arangua P¹, Newmark J³, Steiner M³, Werahera PN¹, Crawford ED¹. - The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer - [Prostate. 2018 May;78\(7\):506-511. doi: 10.1002/pros.23495. Epub 2018 Feb 19.](https://doi.org/10.1002/pros.23495)

636. Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, John Francis PS, Phillips J, McGowan T, Kantoff PW. - The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. [J Urol. 2018 Apr 6. pii: S0022-5347\(18\)42900-X. doi: 10.1016/j.juro.2018.03.125. \[Epub ahead of print\] PMID:29630978](https://doi.org/10.1016/j.juro.2018.03.125)

637. Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J. - Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. - [J Urol. 2018 Apr 6. pii: S0022-5347\(18\)42900-X. doi: 10.1016/j.juro.2018.03.125. \[Epub ahead of print\] – PMID : 29630978](https://doi.org/10.1016/j.juro.2018.03.125)

638. Crawford ED. - [Editorial Comment](#) - [J Urol. 2018 Nov;200\(5\):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. PMID: 29730201](https://doi.org/10.1016/j.juro.2018.04.083)

639. Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. - Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens. - [J Urol. 2018 Nov;200\(5\):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. PMID: 29730201](https://doi.org/10.1016/j.juro.2018.04.083)

640. Crawford, ED, Axel Heidenreich, Nathan Lawrentschuk, Bertrand Tombal, Antonio C. L. Pompeo, Artur Mendoza-Valdes, Kurt Miller, Frans M. J. Debruyne, Laurence Klotz. - Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations [Prostate Cancer Prostatic Dis. 2019 Mar;22\(1\):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21.](https://doi.org/10.1038/s41391-018-0079-0)

641. Hussain M, Tangen CM, Thompson IM Jr, et al. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 [published correction appears in *J Clin Oncol*. 2018 Jul 10;36(20):2131]. [J Clin Oncol. 2018;36\(15\):1498–1504. doi:10.1200/JCO.2017.76.4126](https://doi.org/10.1200/JCO.2017.76.4126)

642. Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. [Integr Cancer Ther. 2018 Dec;17\(4\):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5. PubMed PMID: 30289005; PubMed Central PMCID: PMC6247557.](https://doi.org/10.1177/1534735418803755)

2019

643. E. David Crawford, B. Tombal, T. Keane, F. Boccardo, K. Miller, N. Shore, J. W. Moul, J.-E. Damber, L. Collette & B.-E. Persson (2019) FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist . *Scandinavian Journal of Urology*, Volume 52(- Issue 5-6), 2018 <https://doi.org/10.1080/21681805.2018.1522372>

644. Nelson N., E. David Crawford, Vassilios M. Skouteris, Paul Arangua, Panagiotis-Marios Metsinis, M. Scott Lucia, Francisco G. La Rosa and Priya N. Werahera The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate *J.Urol.* Vol. 202, 264-271, August 2019

645. Skouteris Vassilios M.1, Stone Nelson N., Werahera Priya N., Metsinis Marios-Panagiotis, Dounis Athanasios1, Lucia M. Scott, La Rosa Francisco G., Crawford E. David
Comparison of the results and complications for transrectal ultrasound guided versus transperineal mapping biopsy of the prostate. *Hellenic Urology* Vol. 31(2), 28-35, 2019

646. Paul F. Pinsky , Eric Miller, Crawford, ED et al Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial *BJU Int* 2019 May;123(5):854-860
<http://dx.doi.org/10.1111/bju.14580>

647. Crawford, E.D Unraveling the Research on Prostate Disparities. *Oncology* Vol 33, 258-259, 2019

648. Crawford E. Definitive and Sustained Increase in Prostate Cancer Metastases in the United States. *PracticeUpdate* website. Available at: <https://www.practiceupdate.com/content/definitive-and-sustained-increase-in-prostate-cancer-metastases-in-the-united-states/89517/65/3/1>. Accessed October 02, 2019

649. Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. [Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.](#)
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21.
PMID: 30131604 . Review.

650. [A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer \(RADAR III\).](#)

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.
J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164.
PMID: 30077557 Review.

651. [FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.](#)

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2018 Oct-Dec;52(5-6):349-357. doi: 10.1080/21681805.2018.1522372. Epub 2019 Jan 9.
PMID: 30624128 Clinical Trial.

2020

652. [Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.](#)

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.

J Clin Oncol. 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9.
PMID: 32516092

653. [Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.](#)

Crawford ED, Stanton W, Mandair D.

Cancer Manag Res. 2020 Jul 13;12:5667-5676. doi: 10.2147/CMAR.S227583. eCollection 2020.

PMID: 32765070 . Review.

654. [Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.](#)

Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM, Hafron J, Harris RG, Saltzstein D, Brown GA, Henderson J, Lowentritt B, Spier JM, Concepcion R.

Prostate. 2020 May;80(6):527-544. doi: 10.1002/pros.23967. Epub 2020 Mar 4.

PMID: 32130741 . Review

655. [The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.](#)

Crawford ED, Twardowski PW, Concepcion RS, Hafron JM, Harris RG, Moul JW, Gordan LN, Petrylak DP, Atkinson SN, Boldt-Houle DM, Keane TE, Higano CS, Henderson RJ, Kader AK, Hussain MH, Shore ND.

J Urol. 2020 Apr;203(4):743-750. doi: 10.1097/JU.0000000000000577. Epub 2019 Oct 3.

PMID: 31580749

656. [69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.](#)

Gonzalez-Ochoa E, Verduzco-Aguirre H, Crawford ED, Bournalon MT.

Oncology (Williston Park). 2020 Apr 10;34(4):693611.

PMID: 32293692

657. [Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.](#) Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN.

Can J Urol. 2020 Feb;27(1):10080-10085.

PMID: 32065862

658. ["PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older.](#)

Carlsson SV, Eastham JA, Crawford ED, Harris RG.

Eur Urol. 2020 Aug;78(2):136-137. doi: 10.1016/j.eururo.2020.03.028. Epub 2020 Apr 6.

PMID: 32273182

659. [Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.](#)

Crawford ED, Andriole G, Freedland SJ, Garnick M, Gomella LG, Henderson J, Higano CT, Kader AK, Kane C, Keane TE, Koo PJ, Petrylak DP, Reiter RE, Slovin SF, Yu EY.

Can J Urol. 2020 Oct;27(5):10352-10362.

PMID: 33049187

660. [Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data.](#)

Crawford ED, Hafron JM, Tagawa ST, Twardowski PW, Harris RG, Moul JW, Keane TE, Concepcion RS, Higano CS, Gordan LN, Petrylak DP, Cross CK, Kader AK, Shore ND.

J Urol. 2020 Oct 22:101097JU0000000000001392. doi: 10.1097/JU.0000000000001392. Online ahead of print.

PMID: 33090917

661. [EDITORIAL COMMENT.](#) Stone NN, Crawford ED. Urology. 2020 Dec;146:30-31. doi: 10.1016/j.urology.2020.01.059. PMID: 33272439.

2021

662. [Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.](#)

Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA,

Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM. Prostate Cancer Prostatic Dis. 2021 May 3. doi: 10.1038/s41391-021-00367-8. Epub ahead of print. PMID: 33941866.

663. [Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial.](#) Barqawi AB, Rodrigues

Pessoa R, Crawford ED, Al-Musawi M, MacDermott T, O'Donnell C, Kendl RM. Prostate Cancer Prostatic Dis. 2021 Sep;24(3):750-757. doi: 10.1038/s41391-021-00321-8. Epub 2021 Feb 8.

PMID: 33558662.

664. [Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer.](#)

Bryce AH, Petrylak DP. Oncology (Williston Park). 2021 Apr 19;35(4):166. doi:

10.46883/ONC.2021.3504.0166. PMID: 33872479.

665. [Editorial Comment.](#) Crawford ED. J Urol. 2021 Oct;206(4):958. doi:

10.1097/JU.0000000000001879.01. Epub 2021 Jul 14. PMID: 34259538.

666. [Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial \(PCombi\)](#). Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, Debruyne FMJ. *Eur Urol Open Sci*. 2021 May 6;28:52-61. doi: 10.1016/j.euros.2021.04.005. PMID: 34337526; PMCID: PMC8317802.

667. [Editorial Comment](#). Crawford ED. *J Urol*. 2021 Nov;206(5):1175. doi: 10.1097/JU.0000000000001946.01. Epub 2021 Aug 12. PMID: 34383587.

2022

668. [Optimization of prostate biopsy - Micro-Ultrasound versus MRI \(OPTIMUM\): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer](#).

Klotz L, Andriole G, Cash H, Cooperberg M, Crawford ED, Emberton M, Gomez-Sancha F, Klein E, Lughezzani G, Marks L, Montorsi F, Salomon G, Sanchez-Salas R, Shore N, Taneja S. *Contemp Clin Trials*. 2022 Jan;112:106618. doi: 10.1016/j.cct.2021.106618. Epub 2021 Nov 1. PMID: 34728381

669. [Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer](#).

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. *N Engl J Med*. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. PMID: 35179323

671. [Editorial Comment](#). Crawford ED. *J Urol*. 2022 Aug;208(2):324. doi: 10.1097/JU.0000000000002676.01. Epub 2022 May 5. PMID: 35510427

672. [Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer](#). Crawford ED. *Clin Adv Hematol Oncol*. 2022 Jul;20 Suppl 14(7):1-8. PMID: 35905311

673. [Low-grade prostate cancer should still be labelled cancer](#). Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GJLH, La Rosa FG, van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Leite KRM, Samaratunga H, Srigley J, Varma M, Tsuzuki T, Lucia MS, Crawford ED, Harris RG, Stricker P, Lawrentschuk N, Woo HH, Fleshner NE, Shore ND, Yaxley J, Bratt O, Wiklund P, Roberts M, Cheng L, Delahunt B. *BJU Int*. 2022 Sep 9. doi: 10.1111/bju.15886. Online ahead of print. PMID: 36083240

VIII. PUBLICATIONS: Non-Refereed Journals

1. Crawford ED: Treatment of advanced prostate cancer. *Genitourinary Med*. May, 1979.
2. Crawford ED: Salvage cystectomies: the sooner the better. *Welcome Trends in Urology*, November, 1979.

3. Kiker, JD and Crawford ED: Radical retropubic prostatectomy: modified Campbell technique. *Surgical Rounds* 5:16, 1982.
4. Crawford ED and Davis MA: New directions in urinary diversion. *Ostomy Quarterly*, 21 (3):72-75, 1984.
5. Crawford ED: Planting radiation outside the OR. *Welcome Trends in Urology*, March, 1983.
6. Dawkins, CA and Crawford ED: Current concepts in the treatment of prostate cancer. *Surgical Rounds* 8:99, 1985.
7. McKenzie, DR and Crawford ED: Letter to the Editor - Heparinization in the surgical patient. *Infections in Surgery* 4:474, 1985.
8. Dawkins, CA and Crawford ED: Recent advancements in the treatment of prostate cancer. *Journal of the Mississippi State Medical Association* 26:245, 1985.
9. Crawford ED: Is Labrie regimen next big advance? Intergroup Prostatic Cancer study may provide the answer. *Clinical Cancer Newsletter*, 8:1, 1985.
10. Smith, R and Crawford ED: Radical ilioinguinal lymphadenectomy. *Surgical Rounds*: 23-32, 1986.
11. Nabors, WL and Crawford ED: Future direction of urinary diversion. *Ostomy Quarterly*, 23(2):14, 1986.
12. Crawford ED: Flutamide assessed in therapy of cancer of the prostate: Results promising. *Symposium Observer*, 2(3):13-14, 1987.
13. Crawford ED, and Davis, MA: Categorizing and treating prostatitis. *Infections in Surg.*, 593-598, 1987.
14. Lamm DL, Mori K, Crawford ED: A comparative clinical trial of intravesical BCG and adriamycin treatment in superficial bladder cancer. A South West Oncology Group Study. *Nippon Hinyokika Gakkai Zasshi* (11):1784-9, 1986.
15. Crawford ED: Another look at flutamide. *Oncology update--ASCO reports*. *Cope*, 2:8-9, 1988.
16. Crawford ED and Davis, M: Prostatitis in the older man. *Geriatric Medicine Today*, 7(9):41, 1988.
17. Crawford ED: Toxicities associated with intravesical therapy for superficial bladder cancer. *Urologists' Correspondence Club*, 12/28, 1988.
18. Crawford ED: Leuprolide-flutamide better for prostate cancer. *Cancer Reporter*, 4:4, October 1989.
19. Crawford ED and Davis, M: Prostatitis: Etiology, diagnosis, and treatment. *Cont., Urol*. 1989.
20. Crawford ED and Davis, M: The knotty problem of prostatitis. *Cont. Urol*, 12:13, 1989.
21. Crawford ED: Alpha-interferon tested in recurrent bladder cancer. *Nat'l. Ca Bulletin*, p. 7, December 1989.
22. Crawford ED: Cutting-edge clinical trials: Prostate cancer. *Urologists' Correspondence Club*, March 1990.
23. Crawford ED and Davis M: Mechanism and action of androgen deprivation in prostate cancer. *Ca. of the Prostate*, Part IV, 20, 1990.
24. Crawford ED, Reviewer: Intravesical thiotepa versus mitomycin C in patients with Ta, T1, and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study. Heney, NM, Koontz, WW, Barton, B, et al. *Urology Forum*, 1(10), 1990.
25. Crawford ED: Combined androgen blockade. *Urology Digest* 14:1, 1991.
26. Mayer FJ and Crawford ED: Endocrine therapy of prostate cancer: New approaches. *AUA Decision Making*, 1991.
27. Crawford ED: Revisiting Neoadjuvant Hormonal Therapy. *Urology Times* 11:19-22, 1991.
28. Crawford ED: Treatment of Stage C Prostate Cancer. *Urology Correspondence Club*, Dec 19, 1991.
29. Bruskewitz RC, Chu, TM, Crawford ED, Dixon CM, Huben RP: Overcoming the #1 prostate problem. *Prevention* 44(1): 53-58, 1992.
30. Crawford ED: Can PSA be used in screening for prostate cancer? In: *Primary Care & Cancer* 12(4) 57-58 April 1992
31. Crawford ED: Is it safe to delay treatment of this patient with low-grade prostate cancer? In: *Primary Care & Cancer* 12(6) June 1992
32. Nash, K Prostate Cancer Screening: What Role Does PSA Play? *Urology Times*, March, 1992.

33. Crawford ED: Using PSA to Detect Prostate Cancer. CAP Today, College of American Pathologists, 7:3, March and April 1993.
34. Crawford ED: Cancer Consultation Reply. Primary Care and Cancer.
35. Crawford ED, Thompson IM, Scardino PT: Clinical Dilemmas in Diagnosis and Management of Prostate Cancer. Oncology Bulletin. #13, January 1993.
36. Crawford ED: Treatment Options for Advanced Disease. In Us Too 1:3, 1993.
37. Crawford ED, Thompson IM and Scardino PT: Clinical Dilemmas in Diagnosis and Management of Prostate Cancer. Oncology Bulletin #13, 1993.
38. Crawford ED: Celebrity Deaths Renew Prostate Screening Debate. USA Today, Dec 8, 1993, pg D1.
39. Crawford ED: Everyman's Prostate Problem. Men's Confidential 9:12, Dec 1993.
40. DeAntoni E and Crawford ED: Diagnosis and Treatment of Prostate Cancer. New Perspectives in Cancer Diagnosis and Management 2 (#1):3-10, 1994.
41. DeAntoni E and Crawford ED: Prostate Cancer Awareness Week -- Nationwide Education, Service, and Research. Family Urology (a publication of AFUD):8, Summer 1995.
42. Crawford ED: Medical Advancements in Prostate Cancer: Early Detection and Treatment. Family Urology (a publication of AFUD), Summer, 1996.
43. Crawford ED: Chemoprevention and prostate cancer. Family Urology, Summer, 1997.
44. Ziada A and Crawford ED: Securing Urethral Catheters in Patients Undergoing Ureterovesical Anastomosis. Techniques in Urology, 1998.
45. Ziada AM and Crawford ED: Pain Management in Hormone Refractory Prostate Cancer, Home HealthCare Consultant 5(1): 2-8, 1998.
46. Crawford ED: Rising PSA After Failed Local Therapy. Family Urology, Vol IV (No. 3):13-16, 1999.
47. Crawford ED, Kennedy, JS, Sieve, V: Use of the LigaSure™ Vessel Sealing System in Urologic Cancer Surgery. Grand Rounds in Urology, Vol 1 (4): 10-17, 1999.
48. Lisle TC, Ziada AM, Andros E, Crawford ED: Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate and Incidence of Biochemical Recurrence. Molecular Urology, Vol 3 (No. 3) 263-268, 1999.
49. Ziada AM and Crawford ED: Radiation Therapy After Radical Prostatectomy. Digital Urology Journal, 1999.
50. Gamito EJ, Stone NN, Batuello JT, Crawford ED: Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. Tech Urol 6(2):60-63, 2000.
51. Crawford ED: Immediate versus delayed therapy for prostate cancer. Family Urology, Vol VI (No 3):18-21, 2001.
52. Hudes GR, Logothetis CJ, Crawford ED: Prostate cancer treatment catching up to breast cancer in use of adjuvant chemotherapy. Special Report, Oncology Times: 23(11) 53-55, 2001.
53. Tewari A, Issa M, El-Galley R, Stricker H, Peabody J, Pow-Sang J, Shukla A, Wajzman Z, Rubin M, Wei J, Montie J, Demers R, Johnson CC, Lamerato L, Divine GW, Crawford ED, Gamito EJ, Farah R, Narayan P, Carlson G, and Menon M: Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5(4):163-169, 2001.
54. Porter A, Ben-Josef E, Crawford ED, et al: Advancing Perspectives on Prostate Cancer: Multihormonal Influences in Pathogenesis (Review). Mol Urol 5 (4):181-187, 2001.
55. Porter C, O'Donnell C, Crawford ED, Gamito EJ, Errejon A, Genega E, Sotelo T, Tewari A: Artificial neural network model to predict biochemical failure after radical prostatectomy. Mol Urol 5(4):159-162, 2001.
56. Errejon A, Crawford ED, Dayhoff J, O'Donnell C, Tewari A, Finkelstein J, Gamito EJ: Use of artificial neural networks in prostate cancer. (Review) Mol Urol 5(4):153-158, 2001.
57. Tewari A, Porter C, Peabody J, Crawford ED, Demers R, Johnson CC, Wei JT, Divine GW, O'Donnell C, Gamito EJ, Menon M: Predictive modeling techniques in prostate cancer. (Review) Mol Urol 5(4):147-152, 2001.

58. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control Clin Trials* 21(6 Suppl):273S-309S, 2001.
59. Crawford ED: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. (Review of abstract presentation at ASCO meeting) *Urology Times* 30(7): 1, 32-33, 2002.
60. Crawford ED: Complementary and alternative medicine for prostate health. *Family Urology*, 7(3):8-9 & (concludes) 20, 2002.
61. Crawford ED: Annual PSA testing probably not needed for many men. *OT ASCO Reporter* 15, 2002.
62. Crawford ED: Most men don't need yearly PSA screening: PLCO study. *Oncology News International* 11(7) 1 and 21, 2002.
63. Crawford ED: Men with low PSA may not need annual screening. *Urology Times*, 7:1 and 32-33, 2002.
64. Crawford ED: Men with low PSA scores may not need annual tests, data from PLCO trial suggests. *The Clinical Cancer Letter*. Vol 25 5:1-3. 2002.
65. Crawford ED and Wilson S: Using bisphosphonates to treat PCa-related bone events. *Urology Times* 31 (9): 44-45, 2003
66. Barqawi A and Crawford ED: Current options for the treatment of prostate cancer after biochemical failure of primary therapy. *New Urology*, 1(1) 1-7, 2003.
67. Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H: Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. *Control Clin Trials* 24(2):224-43, 2003.
68. Crawford ED: Adjuvant therapy in prostate cancer: Answers are on the horizon. *Editorial Perspective*. *Urology Times*, 32(7):2-3, 2004.
69. Crawford ED: Third-generation Bisphosphonates: a new area of clinical interest. *A Peer Viewpoint: Pathophysiology of bone metastases: how this this knowledge may lead to therapeutic intervention* by Allan Lipton, MD. *Journal Supportive Oncology*, 2(3):219-220, 2004.
70. Crawford ED: Low testosterone in a man with prostate cancer: what are his options? *Consultant*, 44(7): 903, 2004.
71. Wilson SS and Crawford ED: Screening for Prostate Cancer. *Clin Prostate Cancer* 3(1): 21-25, 2004.
72. Crawford ED: PSA reduction, velocity during chemo predict survival. *Urology Times*, pp:18 and 20 September, 2004.
73. Ziada AM, Crawford ED: Radiation therapy after radical prostatectomy. *Scientific World Journal* 07(4) Suppl 1:377-381, 2004.
74. Crawford ED: Clinical evidence for including bisphosphonates as standard therapy for metastatic prostate cancer. *Peer View in Review*, October, 2004.
75. Crawford ED: Benign prostatic hyperplasia and prostate cancer in a 68 year old man. *Urology Leaders' Forum CME Newsletter, Benign Prostatic Hyperplasia and Prostate Cancer*, 6:1-3, 2005.
76. Crawford ED: Letter from the Editor. *Grand Rounds in Urology*, Volume 4, #2, 2005.
77. Crawford ED: Editorial comment: Lessons from the Super Scan. *Issues in Urology*, May/June, 2007.
78. Crawford ED, Shabsigh R. Hypogonadism and Testosterone Replacement Therapy: The Controversy and the Evidence. *Urology Times*. Based on a symposium held during Urology Congress, 2007.
79. Crawford, ED. Initiation and Follow-up of Testosterone Replacement Therapy. *Urology Times*. Based on a symposium held during Urology Congress, 2007.
80. Crawford ED. There is Documentation That You Can Use TRT. It Is Safe with Appropriate Medical Monitoring. *Urology Times*, 35(15):13-14, 2007.
81. Crawford ED. 3-D Mapping Technique Guides Prostate Cancer Biopsies, Treatment. *Urology Times*. May, 2008.
82. Crawford ED. Perspectives on the new PSA Screening Recommendations. *Oncology*. 25,12:1190-91, 2011.
83. Crawford ED. Tracing Prostate Cancer Spread: Prostate cancer metastasis tracked with 89Zr-5A10 radiotracer. *DailyRX*. 2012.

84. Crawford ED. Radiation Vs. Surgery for Prostate Cancer: Prostate cancer treated with radiotherapy offers long term survival rates. March 2, 2013.
85. Rove KO, Higuchi TT, Crawford ED. Long-Term Complications of Prostate Cancer Treatment May Have Been Underappreciated. *The ASCO Post* 5(6), 2014.
86. Chad G. Rusthoven, Bernard L. Jones, Thomas W. Flaig, E. David Crawford, Matthew Koshy, David J. Sher, Usama Mahmood, Ronald C. Chen, Brian F. Chapin, Brian D. Kavanagh and Thomas J. Pugh – Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men with Newly Diagnosed Metastatic Prostate Cancer. – *Journal of Clinical Oncology* August 20, 2016
87. Paul F. Pinsky, PhD, Phillip C. Prorok, PhD, Kelly YU, PhD, Barnett S. Kramer, MD, MPH; Amanda Black PhD, John K. Gohagan, PhD, E. David Crawford, MD; Robert L. Grubb, MD; and Gerald L. Andriole, MD – Extended Mortality Results for Prostate Cancer Screening in PLCO Trial With Median Follow-Up of 15 years. October 2016

X. BOOK CHAPTERS

1. Crawford ED, and Borden TA: Genitourinary Tumors. In Conn's Current Therapy, pp. 597-610, 1981.
2. Crawford ED and Borden TA, Editors, Genitourinary Cancer Surgery. Philadelphia, Lea & Febiger, pp. 554, 1982.
3. Crawford ED: Radical retropubic prostatectomy: Modified Campbell Technique. In Genitourinary Cancer Surgery. Edited by E.D Crawford and TA Borden. Philadelphia, Lea & Febiger, 1982, pp. 153-165.
4. Crawford ED and Scardino PT: Testicular carcinoma: An overview. In Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 249-261, 1982.
5. Kiker JD and Crawford ED: Partial cystectomy. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 217-222, 1982.
6. Crawford ED: Salvage cystectomy after irradiation therapy. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 223-225, 1982.
7. Crawford ED: Chemotherapy of testicular carcinoma. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 379-386, 1982.
8. Crawford ED: Loop-end ileostomy. In Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, pp. 240-245, 1982.
9. Crawford ED: Bladder carcinoma: An overview. In: Genitourinary Cancer Surgery. Edited by ED Crawford and TA Borden. Philadelphia, Lea & Febiger, 1982, pp. 191-198.
10. Crawford ED: Ilioinguinal lymphadenectomy. Urology Clinics of North America 11:543, 1984.
11. Crawford ED: Radical cystectomy and urinary diversion. In: Modern Technics in Surgery. Futura Publishing Co, pp. 30-1, 1984.
12. Smith JA, Jr., and Crawford ED: Southwest Oncology Group experience with randomized protocols for bladder cancer. In: Controlled Clinical Trials in Urologic Oncology. Edited by L Denis, G Murphy, G Prout, and F Schroeder. New York, Raven Press, pp. 249-254, 1984.
13. Crawford ED, Davis MA, Ahmann R, and Levasseur YJ: Objective responses and adrenocorticosteroid levels in castrated men with prostate cancer treated with aminoglutethimide plus hydrocortisone. In: Recent Advances in Chemotherapy. Edited by J Ishigami. Tokyo, University of Tokyo Press, p. 1180, 1985.
14. Crawford ED, Samson M, Klugo RC, Dawkins CA, and Davis MA: High-dose versus low-dose Cisplatin combined with vinblastine and bleomycin and selective surgical resection of residual disease in patients with disseminated testicular cancer: A Southwest Oncology Group Study. In: Testicular Cancer. Edited by S Khoury, R Kuss, G Murphy, and AR Liss. New York, 1986.
15. Smith RA and Crawford ED: Cost implications of transurethral prostatectomy in cost-effective surgery. Edited by B Eiseman, p. 271, 1986.

16. Williams SD, Stabelin D, Muggia F, Einhorn LH, Hahn R, Donohue JP, Brunner K, DeWys W, Crawford ED, et al.: Early stage testis cancer. The Testicular Cancer Intergroup Studies. In Adjuvant Therapy of Cancer V. SE. Salmon, editor. New York, Grune & Stratton, Inc., pp. 587-592, 1987.
17. Crawford ED and Davis MA: Management of non-transitional cell tumors of the bladder. In Genitourinary Cancer Management. Edited by DF Paulson and JB deKernion. Philadelphia, Lea & Febiger, pp. 95-106, 1987.
18. Crawford ED: Interstitial testicular cell tumors. In Current Therapy in Genitourinary Cancer. Edited by MJ Resnick and ED Kursh. St. Louis, CV. Mosby Company, 1987.
19. Crawford ED, Ahmann FR, Davis MA, and Levasseur Y: Aminoglutethimide in metastatic adenocarcinoma of the prostate. In Prostate Cancer: Research, Endocrine Treatment, and Histopathology. pp. 283-289, 1987.
20. Crawford ED, Das S, and Smith JA: Preoperative radiation therapy in the treatment of bladder cancer. Controversies in urologic oncology. Urology Clinics North America 14(4):781-787, 1987.
21. Crawford ED and Dawkins CA: Management of carcinoma of the penis. In Genitourinary Cancer. Edited by DG Skinner. Philadelphia, W.B. Saunders, p. 549, 1988.
22. Crawford ED: Ilioinguinal lymphadenectomy. In Genitourinary Cancer. Edited by DG Skinner. Philadelphia, W.B. Saunders, p. 817. 1988.
23. Crawford ED and Davis MA: Luetinizing hormone-hormone releasing analogues in the treatment of prostate cancer. In: Endocrine Therapies in Breast and Prostate Cancer. Edited by CK Osborne. Boston, Kluwer Academic Publishers, pp. 25-38, 1988.
24. Crawford ED, Ahmann FR, Kreis W, Davis MA, and Levasseur YJ: Aminoglutethimide plus hydrocortisone in the treatment of castration-refractory advanced adenocarcinoma of the prostate. In: Hormonal Therapy of Prostate Diseases: Basic and Clinical Aspects. Edited by M. Motta and M. Serio. The Netherlands, Medicom Europe, pp. 353-360, 1988.
25. Einhorn LH, Crawford ED, Shipley WU, Loehrer PJ, and Williams SD: Cancer of the testes. In: Cancer Principles and Practice of Oncology, Vol. 1. Edited by VT DeVita, S. Hellman, and S.A Rosenberg. Philadelphia, J.B. Lippincott Company, pp. 1071-1098, 1989.
26. Crawford ED: Derzeitige konzepte in der behandlung des fortgeschrittenen prostatakzinoms und zwischenbericht uber die phase III studie leuprorelin plus plazebo vs leuprorelin plus flutamid der South Western Oncology Group 8494. In: Therapie des forgeschrittenen Prostatakzinoms. Edited by JE. Altwein and G Bartsch. Frankfurt, Germany, pp. 46-65, 1989.
27. Lamm DL, Crissmann J, Blumenstein B, Crawford ED, et al.: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. In: Progress in Clinical and Biological Research Volume 310: EORTC Genitourinary Group Monograph 6--BCG in Superficial Bladder Cancer. Edited by FMJ Debruyne, L Denis, APM van der Meijden. New York: Alan R. Liss, Inc., pp. 263-270, 1989.
28. Pfister RR and Crawford ED: Disorders of the testes. In: Operative Surgery, 3d ed. Edited by PF Nora. Philadelphia, W. B. Saunders Company, pp. 1156-1189, 1990.
29. Heppe RK and Crawford ED: Radical nephrectomy: Thoracoabdominal intrapleural approach. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 39-44, 1990.
30. Crawford ED: Radical retropubic prostatectomy: Antegrade approach. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 180-192, 1990.
31. Mayer F and Crawford ED: Partial cystectomy. In: Current Genitourinary Cancer Surgery. Edited by E.D Crawford and S Das. Philadelphia, Lea & Febiger, pp 247-252, 1990.
32. Nabors W and Crawford ED: Salvage cystectomy after irradiation failure. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 253-256, 1990.

33. Das S and Crawford ED: Carcinoma of the penis: Management of the primary. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 367-372, 1990.
34. Das S and Crawford ED: Carcinoma of the penis: Management of the regional lymphatic drainage. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp 373-379, 1990.
35. Das S and Crawford ED: Hormonal therapy of advanced carcinoma of the prostate. In: Current Genitourinary Cancer Surgery. Edited by ED Crawford and S Das. Philadelphia, Lea & Febiger, pp. 499-506, 1990.
36. Crawford ED, Natale RB, and Grossman HB: Southwest Oncology Group Study 8710: Trial of cystectomy alone versus neoadjuvant MVAC and cystectomy in patients with locally advanced bladder cancer. In: Neoadjuvant Chemotherapy in Invasive Bladder Cancer. Edited by TAW Splinter and HI Scher. New York, Wiley-Liss, Inc., pp. 111-113, 1990.
37. Weiner S and Crawford ED: Complications of retroperitoneal lymphadenectomy. In Complications of Urologic Surgery: Prevention and Management, 2nd ed. Edited by R.B Smith and R.M Ehrlich. Philadelphia, W. B. Saunders, pp. 286, 1990.
38. Nabors W and Crawford ED: Carcinoma of the prostate. In: Conn's Current Diagnosis. Philadelphia, W. B. Saunders, pp.1185-1187, 1990.
39. Foote JE. and Crawford ED: Combined hormonal therapy in the management of adenocarcinoma of the prostate. In: Problems in Urology. Edited by DF Paulson. Philadelphia, J B. Lippincott, pp. 473-488, 1990.
40. Donohue RE, Davis MA, and Crawford ED: Diseases of the prostate. In: Geriatric Medicine. RW Schrier, editor. Philadelphia, W. B. Saunders, pp. 168-178, 1990.
41. Nabors W and Crawford ED: Malignant tumors of the urogenital tract. In: Conn's Current Therapy. Edited by R.E. Rakel. Philadelphia, W.B. Saunders. 1991.
42. Crawford ED: Radical cystectomy and urinary diversion. In: Current Operative Urology 1991. Edited by ED Whitehead. Philadelphia, J B. Lippincott, pp. 181-196, 1991.
43. Westmacott R and Crawford ED: Commentary: Radical cystectomy. In: Current Operative Urology 1991. Edited by E.D Whitehead. Philadelphia, J B. Lippincott, pp. 197-200, 1991.
44. Crawford ED and Heppe RK: Nephrectomy and nephroureterectomy. In: Urologic Surgery, 4th ed. Edited by J Glenn. Philadelphia, J B. Lippincott, pp. 22-41, 1991.
45. Crawford ED and Nabors WL: Total androgen ablation: American experience. Urol Clinics of No. Am., 18(1):55-63, 1991.
46. Thrasher B and Crawford ED: Minimally invasive transitional cell carcinoma. In Current Therapy in Genitourinary Surgery, 2nd edition. Edited by MA Resnick and ED Kursh New York, BC Decker, pp.74-78, 1991.
47. Leddy FF and Crawford ED: Pelvic and Inguinal Lymphadenectomy. In Surgical Management of Urologic Disease. An Anatomic Approach. Edited by MJ Droller. Mosby Year Book, pp. 677-90, 1992.
48. Thrasher JB and Crawford ED: Management of Invasive and Metastatic Bladder Cancer. In: Current Problems in Urology. Edited by LL Lipshultz. St. Louis, Mosby, 2:35-65, 1992.
49. Thrasher JD and Crawford,ED: Complication of Intravesical Chemotherapy. In: Urologic Clinics of North America ,19(3) 529-539.
50. Quinones D, Crawford ED: Seminal Vesiculectomy. In: Urologic Surgery. Ed. Fowler, JE. Boston/Toronto/London, Little, Brown and Co.
51. Crawford ED, and Das S: Penile, Urethral and Scrotal Cancer. In: The Urologic Clinics of North America, vol 19(2). W.B Saunders Co., 1992.
52. Crawford,ED and Daneshgari F: Leuprolide/Leuproline. In: Therapeutic Drugs. Edited by Sir Colin Dollery, Churchill and Livingstone, 1992.
53. Crawford ED and DeAntoni EP: PSA as a Screening Test for Prostate Cancer. In: Prostatic Tumor Markers, Urologic Clinics of North America. Edited by Joseph Oesterling.

54. Schutz M and Crawford ED: Testis Tumors. In: Surgical Decision Making. Edited by Norton, Steele and Eiseman. W. B Saunders, pp. 286-87, 1993.
55. Schutz MJ and Crawford ED: Laparoscopic Lymph Node Dissection. In: Prostate Cancer, Edited By S Das and ED Crawford, Mosby, 1992.
56. Mayer FJ and Crawford ED: Optimal Therapy for Metastatic Prostate Cancer. In: Recent Advances in Urology/Andrology by Hendry and Kirby. Churchill Livingstone Co., pp 159. 1993.
57. Schutz MJ and Crawford ED: Laparoscopic Pelvic Lymphadenectomy. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY. 1993.
58. Daneshgari F and Crawford ED: Endocrine Therapy of Advanced Carcinoma of the Prostate. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
59. DeAntoni EP and Crawford ED: Chemoprevention of Prostate Cancer: Issues and Controversies. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
60. Das S and Crawford ED: Carcinoma of the Prostate: Future Perspectives. In: Cancer of the Prostate. S Das and ED Crawford EDs. Marcel Dekker, Inc., New York, NY, 1993.
61. Vestal C and Crawford ED: Laparoscopic Retroperitoneal Lymph Node Dissection. In: Urologic Laparoscopy. S Das and E.D Crawford EDs. W. B. Saunders Company, Philadelphia, PA, 1994.
62. Crawford ED, DeAntoni ED: Early Detection of Prostate Cancer: Challenges and Controversies. In: Early Detection of Cancer: Molecular Markers by Srivastava, S, Lippman SM, Hong, WK, and Mulshine, JL. Futura Publishing Co, Inc., Armonk, NY, 1994.
63. Schutz MJ and Crawford ED: Prostate Adenocarcinoma -- The Management of Metastatic Disease. In: Clinical Urology. Edited by Krane, Siroky, and Fitzpatrick. JB Lippincott Co., Philadelphia, 1994.
64. Crawford ED: Leuprolide. In: Therapeutic Drugs. Edited by Sir Colin Dollery. Churchill Livingstone Co., 1994.
65. Mayer FJ and Crawford ED: Update on Combined Androgen Blockade for Metastatic Prostate Cancer. In: Advances in Urology, Vol 7. Mosby Year Book, Inc. 1994.
66. Mayer FJ and Crawford ED: The Prostate. In: Haskell's Cancer Treatment, 4th ed. WB Saunders, Philadelphia, PA, 1995.
67. Mayer FJ and Crawford ED: The Role of Endocrine Therapy in the Management of Local and Distant Recurrence of Prostate Cancer Following Radical Prostatectomy or Radiation Therapy. In: Evaluation and Management of Recurrent Malignant Disease, 1994.
68. Crawford ED: Is It Safe to Delay Treatment of This Patient with Low Grade Prostatic Carcinoma? In: Cancer Consultations, Vol 1, edited by Abeloff, MD and Wittes, RE. APRR Public, Huntington, NY, 1994.
69. Crawford ED: Screening des Prostatakarzinoms dokumentiert den Wert des PSA-Tests und fuhrte zur Bestatigung von Risikofaktoren. In: Screening des Prostatakarzinoms, by Faul and Altwein. Springer-Verlag, Berlin/Heidelberg/New York, 1995.
70. Waxman S and Crawford ED: Advanced Prostate Cancer. In: Surgical Technology International IV. Universal Medical Press, Inc., San Francisco, California, 1995.
71. Levin R and Crawford ED: Bladder, Renal, Pelvis and Urethral Cancers. In: Haskell's Cancer Treatment, 4th ed. WB Saunders, Philadelphia, PA, 1995.
72. Das S and Crawford ED: Laparoscopic Surgery in Urologic Oncology. In: Seminars in Surgical Oncology.
73. Waxman S and Crawford ED: Advanced Prostate Cancer. In: Surgical Techniques (International IV). Universal Medical Press Inc., San Francisco, CA, 1995.
74. Crawford ED and Debruyne FMJ: (Monograph) Superficial Bladder Cancer: Diagnosis and Treatment with Intravesical Agents. In: Bristol-Myers Squibb Oncology Medical Educational Services Update, June, 1996.
75. Crawford ED, Donohue RE, and Davis M: Diseases of the Prostate. In: Geriatric Medicine, 2d ed. DW Jahnigen and RW Schrier, eds. Blackwell Science, Cambridge, Massachusetts, 1996.

76. Heppe RK and Crawford ED: Radical Nephrectomy -- Thoracoabdominal Intrapleural Approach. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
77. Crawford ED: Radical Retropubic Prostatectomy -- Antegrade Approach. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
78. Crawford ED and Wolach M: Salvage Cystectomy and Perineal Cystoprostatectomy. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
79. Cox RL and Crawford ED: Carcinoma of the Penis -- Management of the Regional Lymph Drainage. In: Current Genitourinary Cancer, 2nd ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
80. DeAntoni EP and Crawford ED: Hormonal Therapy for Advanced Carcinoma of the Prostate. In: Current Genitourinary Cancer, 2d ed. ED Crawford and S Das, eds. Williams & Wilkins, Baltimore, Maryland, 1997.
81. Hussain MH and Crawford ED: Androgen Deprivation Strategies for Metastatic Prostate Cancer. In: Principles and Practice of Genitourinary Oncology. D Raghavan, S Leibel, H Scher, and P Lange, eds. Lippincott-Raven, Philadelphia, Pennsylvania, 1997.
82. Stenner J and Crawford ED: Combined Androgen Blockade. In: Prostate Cancer. AV Kaisary, G Murphy, L Denis, and K Griffiths, eds. Martin Dunitz, London, England, 1997.
83. Waxman S and Crawford ED: Metastatic Adenocarcinoma of the Prostate (TxNxM+): Management and Prognosis. In: Urologic Oncology. JE Oesterling and JP Richie, eds. W.B. Saunders Company, Philadelphia, 1997.
84. Crawford ED: Combined Androgen Blockade: Clinical Basis. In: New Perspectives in Prostate Cancer. A Beldegrun, RS Kirby, and T Oliver, eds. Isis Medical Media, Ltd., Oxford, UK, 1998.
85. McLeod DG, Crawford ED and DeAntoni EP: Combined Androgen Blockade: The Gold Standard of Metastatic Prostate Cancer. In: Management of Prostate Cancer. CC Schulman and ED Crawford EDs. European Urology, Brussels, Belgium, 1998.
86. Ziada A and Crawford ED: TxNxM1: The Case for Total Androgen Deprivation. In: Advanced Treatment of Prostatic Diseases. MI Resnick and IM Thompson, eds. 1999.
87. Crawford ED: The Utility of Prostate Specific Antigen as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials. In: Strategies for the Chemoprevention of prostate Cancer. CC Schulman and GJ Kelloff, eds. S Karger, AG, Basel, Switzerland, 1999.
88. Ziada A and Crawford ED: Intravesical Chemotherapy of Bladder Cancer. In: Bladder Cancer: Biology, Diagnosis, and Management. KN Syrigos and DG Skinner, eds. Oxford University Press, Inc., New York, 1999.
89. Stenner JI, Rosenblum, M, and Crawford ED: Treatment of Advanced (Stage T1-4NXM+) Prostate Cancer. In: Prostate Diseases. H Lepor, ed. W.B. Saunders Company, Philadelphia, PA, 1999.
90. Ziada A, Rosenblum M, and Crawford ED: Hormonal Therapy – Neoadjuvant, Adjuvant, Definitive, and Intermittent. In: Current Clinical Urology: Management of Prostate Cancer. EA Klein, eds. Humana Press, Inc, Totowa, NJ, 2000.
91. Abouelfadel Z and Crawford ED: Experience of Prostate Cancer Awareness Week. In: Prostate Cancer Screening. IM Thompson, MI Resnick, and EA Klein, eds. Humana Press, Totowa, NJ, 2000.
92. Crawford ED and Waxman S: The History of Prostate Specific Antigen. In: Prostate Specific Antigen. Michael K. Brawer, editor. Marcel Dekker, Inc, New York, NY, 2001.
93. Leewansangton S and Crawford ED: Prostate. In: Cancer Treatment, (fifth ed). CM Haskell, editor. W.B. Saunders Company, Philadelphia, PA, 2001.
94. Leewansangton S and Crawford ED: Bladder, Renal Pelvis and Ureters. In: Cancer Treatment, (fifth ed). CM Haskell, editor. W.B. Saunders Company, Philadelphia, PA, 2001.

95. Gamito EJ, Crawford ED, and Errejon A: Artificial Neural Networks for Predictive Modeling in Prostate Cancer. In: Prostate Cancer, Science and Clinical Practice. Jack H. Mydlo and Ciril J. Godec, eds. Academic Press/Elsevier, Oxford, Great Britain, 2003.
96. Akduman, A and Crawford ED: Radical Prostatectomy, The Retrograde Antegrade Approach. In: Prostate Cancer, Science and Clinical Practice. Jack H. Mydlo and Ciril J. Godec, eds. Academic Press/Elsevier, Oxford, Great Britain, 2003.
97. Wilson SS and Crawford ED: Screening for Prostate Cancer: Current Recommendations. In: Urologic Clinics of North America. Vol 31(2) 219-226 Elsevier Science, Great Britain, May 2004.
98. Akduman B, Errejon A, and Crawford ED: Use of PSA to Evaluate Risk and Progression of Prostate Cancer. In: Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention. G. J. Kelloff, E. T. Hawk and C. C. Sigman eds. Humana Press, Inc. Totowa, NJ. 2004.
99. Crawford ED, Holzbeierlein JM, Krongrad A, Maroni PD, and Thrasher JB: Surgery. In: American Cancer Society's Complete Guide to Prostate Cancer. David G. Bostwick, MD, E. David Crawford, MD, Celestia S. Higano, MD and Mack Roach III, MD eds. American Cancer Society, Health Promotions, Atlanta, GA 30329, 2004.
100. Oottamasathien S and Crawford ED: Testis Tumor. In: Surgical Decision Making, 5th Edition. Robert C. McIntyre Jr. MD, Gregory v. Stiegmann, MD and Ben Eiseman, MD eds. Elsevier Saunders, Philadelphia, PA, 2004.
101. Crawford ED: Editorial Commentary: Donald L. Trump, MD: Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy: When? In: Management of Prostate Cancer – Advances and Controversies. Kenneth B. Cummings ed. Marcel Dekker, New York, NY, 2005.
102. Maroni PD, Thrasher JB, and Crawford ED: Advanced Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology, 3rd Edition. Nicholas Vogelzang, Peter Scardino, William Shipley, Frans Debruyne, W. Marston Linehan eds. Lippincott, Williams and Wilkins, Philadelphia, PA 2006.
103. Phillips JM, Crawford ED: The Changing Landscape of Prostate Cancer Chemoprevention: Current Strategies and Future Directions. In: Cancer Prevention- From Mechanisms to Translational Benefits. Alexandros Georgakilas, editor. InTech, 2012.
104. Dupuy DE, Fong Y, McMullen WN, Et all. (E. David Crawford listed at section editor). Image-Guided Cancer Therapy: A Multidisciplinary Approach. New York, 2013.
105. Patient selection for focaltreatment – Springer International Publishing Switzerland 2016 – N.N. Stone, E.D. Crawford (eds.), The Prostate Cancer Dilema, DOI 10.1007/978-3-319-21485-6_1
106. Crawford, ED and Stone NN , Transperineal Biopsy Technique in The Prostate Cancer Dilema, DOI 10.1007/978-3-319-21485-6_, pp75-82, 2016

XI. PRESENTATIONS AT NATIONAL MEETINGS AND SEMINARS

1. Deep Venous Thrombosis Following Transurethral Resection of the Prostate: A New Method of Diagnosis. Presented at the Annual American Urological Association Meeting. Washington, D.C., May 1, 1978.
2. Intercostal Nerve Block Following Thoracoabdominal Incisions. Presented at the Annual Western Section of the American Urologic Association. Seattle, Washington, July, 1978.
3. Renal A-V Fistula Secondary to Bilateral Renal Cell Carcinoma. Presented at the 37th Annual South Central Section of American Urological Association Meeting. Colorado Springs, Colorado, October 10, 1978.
4. Experience with Salvage Cystectomy in the Management of Bladder Cancer. Presented at the 37th Annual South Central Section of American Urological Association Meeting. Colorado Springs, Colorado, October 10, 1978.

5. Serum HCG and AFP as Predictors of Mortality from Testicular Cancer. Presented at the 37th Annual South Central Section of American Urological Association Meeting. Colorado Springs, Colorado, October 10, 1978.
6. Salvage Cystectomy. Presented at the 17th Annual New Mexico-West Texas Urological Seminar. Albuquerque, New Mexico, March 23, 1979.
7. Operative Approach and Applied Anatomy of Urologic Surgery. Invited speaker, AUA Postgraduate Course. New York, May 15, 1979.
8. Genitourinary Oncology Seminar. Course Director: Prostate Panel Moderator; Testicular Cancer, Surgical Treatment of Bladder Cancer. Panel members: Eugene Carlton, MD, Jean G. deKernion, MD, and Malcolm Bagshaw, MD. Albuquerque, New Mexico, June 8, 1979.
9. Surgical Treatment of Calculous Disease. Postgraduate Course on Ambulatory Genitourinary Problems. Albuquerque, New Mexico, September, 1979.
10. Ultrasonic Detection of Renal Tubular Carcinoma Extending into Inferior Vena Cava. Presented at the 38th Annual South Central Section of American Urological Association Meeting. Albuquerque, New Mexico, October 8, 1979.
11. Deep Venous Thrombosis after Urological Surgery. Presented at the 38th Annual South Central Section of American Urological Association Meeting. Albuquerque, New Mexico, October 10, 1979.
12. New Instrument for Insertion of Circle Tube Nephrostomy. Presented at the 38th Annual South Central Section of American Urological Association Meeting. Albuquerque, New Mexico, October 11, 1979.
13. Renal Cell Carcinoma in Kidney with Xanthogranulomatous Pyelonephritis. Presented at Rate Lesions Hour. 38th Annual South Central Section of American Urological Association Meeting. Albuquerque, New Mexico, October, 1979 (6th Prize).
14. Prostate Cancer. Panel moderator, Annual Southern Medical Association Meeting. Las Vegas, Nevada, November 6, 1979.
15. Bladder Cancer. Panel Member, Southern Medical Association Meeting. Las Vegas, Nevada, November 5, 1979.
16. Treatment of Advanced Seminoma. New Mexico-West Texas Urological Seminar. Albuquerque, New Mexico, February 15, 1980.
17. Deep Venous Thrombosis Following Urological Surgery. New Mexico-West Texas Urological Seminar. Albuquerque, New Mexico, February 15, 1980.
18. Operative Approaches and Applied Anatomy of Urologic Surgery. Invited speaker, AUA Postgraduate Course, Annual AUA Meeting. San Francisco, California, May 20, 1980.
19. Prevention of Urinary Tract Infection and Sepsis Following Prostatic Biopsy. North Central Section of American Urological Association. Bermuda, November 11, 1980.
20. Diagnosis and Management of Urological Pain. Presented at the Taos Medical Symposium. Taos, New Mexico, February 12, 1981.
21. Update on Treatment of Stages B3 and C Seminoma. 19th New Mexico-West Texas Urological Seminar. Albuquerque, New Mexico, March 27, 1981.
22. Carcinoma Prostate Gland: Natural History, Clinical Course, Pathology, Staging. Speaker at Controversies in Surgery. Albuquerque, New Mexico, May 9, 1981.
23. Operative Approaches and Applied Anatomy. Invited speaker, AUA Postgraduate Course, Annual AUA Meeting. Boston, Massachusetts, May 10, 1981.
24. Treatment of Advanced Seminoma with Preirradiation Chemotherapy. Presented at Annual AUA Meeting. Boston, Massachusetts, May 10, 1981.
25. Genitourinary Cancer Update. Presented at the Annual Mojave County Cancer Update Seminar. Kingman, Arizona, May 30, 1981.
26. Crawford ED, deKernion JB, and Smith RB: Treatment of advanced seminoma with combined chemotherapy and radiation. Proceedings of American Society of Clinical Oncology 22:462, 1981.
27. Treatment of Renal Cell Carcinoma. Invited speaker, Out-Reach Conference. Cancer Research and Treatment Center. Albuquerque, New Mexico, May 20, 1981.

28. Treatment of Advanced Seminoma. Southwest Oncology Group Meeting. San Antonio, Texas, September 2, 1981.
29. Treatment of Advanced Seminoma with Preirradiation Chemotherapy. Annual Meeting of South Central Section of American Urological Association. Dallas, Texas, September 16, 1981.
30. Treatment of Prostatic Adenocarcinoma and Prostatitis. Invited speaker, Annual Family Practice Meeting. Las Vegas, Nevada, September 28, 1981.
31. Urinary Diversion in the Adult. United Ostomy Society. Albuquerque, New Mexico, December 15, 1981.
32. Surgical Management of Prostatic Adenocarcinoma. Presented at the 20th New Mexico-West Texas Urological Seminar. Albuquerque, New Mexico, February 12, 1982.
33. Treatment of Advanced Bladder Carcinoma with Gallium Nitrate. Presented at the Annual Western Section of the AUA. San Diego, California, February 23, 1982.
34. Ceftizoxime in the Treatment of Urinary Tract Infections. Presented at the Annual Western Section of the AUA. San Diego, California, February 23, 1982.
35. Operative Approaches and Applied Anatomy. Invited speaker, AUA Postgraduate Course, Annual AUA Meeting. Kansas City, Missouri, May 18, 1982.
36. Update on Prostate and Bladder Cancer. Invited speaker, South Coast Hospital, Laguna Beach, California, August 17, 1982.
37. Treatment of Metastatic Bladder Cancer with Gallium Nitrate: A Southwest Oncology Group Study. Annual South Central Section AUA Meeting. New Orleans, Louisiana, September 13, 1982.
38. Carcinoma of the Kidney. Panel Moderator. Panel members: Michael Leiber, M.D., and Jean deKernion, M.D. Annual South Central Section AUA Meeting. New Orleans, Louisiana, September 13, 1982.
39. Renal Infarction-Nephrectomy for Metastatic Renal Cancer: A Southwest Oncology Group Study. Annual South Central Section AUA Meeting. New Orleans, Louisiana, September 13, 1982.
40. Treatment of Localized Prostate Adenocarcinoma with Iridium-192 Template Implants. South Central Section AUA Annual Meeting. New Orleans, Louisiana, September 14, 1982.
41. Loop-end Ileostomy: Technique and Clinical Experience. Presented at the South Central Section AUA Annual Meeting. New Orleans, Louisiana, September 14, 1982.
42. Loop-end Ureterostomy. (John D. Kiker and E. David Crawford) Presented at the South Central Section AUA Annual Meeting. New Orleans, Louisiana, September 14, 1982.
43. Infarction-Nephrectomy for Metastatic Hypernephroma: A Southwest Oncology Group Study (Dr. James Gottesman). Presented at the 13th International Cancer Congress. Seattle, Washington, September, 1982.
44. Prostatitis. Presented AUA Clinical Practice Update. Keystone, Colorado, February 2, 1983.
45. Evaluation of the Patient with Urinary Tract Infection. Presented at AUA Clinical Practice Update. Keystone, Colorado, February 4, 1983.
46. Operative Approaches and Applied Anatomy. Invited speaker for AUA Postgraduate Course, Annual AUA Meeting. Las Vegas, Nevada, April 18, 1983.
47. The Role of Surgical Resection in the Management of Advanced Testicular Cancer: A Southwest Oncology Group Study. Annual AUA Meeting. Las Vegas, Nevada, April 20, 1983.
48. Current Concepts in the Management of Testicular Cancer. Visiting Professor, University of Mississippi. Jackson, Mississippi, June 3, 1983.
49. Southwest Oncology Group Protocols for Prostate, Bladder and Renal Cancers. Visiting Professor, University of Mississippi. Jackson, Mississippi, June 4, 1983.
50. Current Concepts in the Management of Testicular Cancer. University of Maryland Cancer Center. Baltimore, Maryland, June 10, 1983.
51. Current Concepts in the Management of Testicular Cancer. Good Samaritan Hospital. Cincinnati, Ohio, June 11, 1983.

52. The Role of Surgical Resection in the Management of Advanced Testicular Cancer: A Southwest Oncology Group Study. South Central Section of the American Urological Association. St. Louis, Missouri, November 7, 1983.
53. Debate Panel Moderator. Panel members: Lawrence Einhorn, MD, Willet Whitmore, MD, and John Wettlaufer, MD. South Central Section of the American Urological Association. St. Louis, Missouri, November 7, 1983.
54. Oral Cytadren for the Treatment of Advanced Prostate Cancer. South Central Section of the American Urological Association. St. Louis, Missouri, November 7, 1983.
55. Overview of Bladder and Testicular Cancer. Western Regional Oncology Conference. El Paso, Texas, January 20, 1984.
56. Infectious Disease Update--Prostatitis. Second Annual Clinical Practice Update. Lake Tahoe, California, March 9, 1984.
57. Infectious Disease Update--Urinary Tract Infection. Second Annual Clinical Practice Update. Lake Tahoe, California, March 9, 1984.
58. Current Controversies in the Management of Testicular Cancer. Annual Cancer Symposium, Good Samaritan Hospital. Vincennes, Indiana, March 30, 1984.
59. Current Controversies in Testicular Cancer, Panel Moderator. Panel members: Harry Grabstald, MD, Donald G. Skinner, MD, and Robert Flannigan, MD. Annual Meeting, Southeast Section of the American Urological Association. Nashville, Tennessee, April 2, 1984.
60. Surgical Resection of Residual Disease in Advanced Testicular Cancer. Annual Meeting, Southeast Section of the American Urological Association. Nashville, Tennessee, April 2, 1984.
61. Adjuvant Chemotherapy for Stage II Testicular Cancer. Southeast Section of the American Urological Association Annual Meeting. Nashville, Tennessee, April 2, 1984.
62. Current Management of Advanced Seminoma. Southeast Section of the American Urological Association Annual Meeting. Nashville, Tennessee, April 2, 1984.
63. Overview of Bladder and Testicular Cancer. West Texas Conference. Midland, Texas, June 8, 1984.
64. Diagnosis, Staging, and Treatment of Bladder Cancer. Southwest Oncology Group Data Managers Committee Meeting. Phoenix, Arizona, September 12, 1984.
65. Diseases of the Prostate. Invited speaker, 36th Annual Meeting of the American Academy of Family Physicians. Kansas City, Kansas, October 12, 1984.
66. Current Concepts on the Management of Testicular Cancer. Eastern Oklahoma Urology Meeting. Tulsa, Oklahoma, November 14, 1984.
67. Treatment of Hormone Refractory Metastatic Adenocarcinoma of the Prostate with Aminoglutethimide. Southeast Section of the American Urological Association Annual Meeting. Marco Island, Florida, March 17, 1985.
68. Southwest Oncology Group Protocol 8216: Intravesical Adriamycin for Recurrent Superficial Transitional Cell Carcinoma. Annual Meeting, Southeast Section of the American Urological Association. Marco Island, Florida, March 19, 1985.
69. Treatment of Advanced Seminoma with Pre-Irradiation Chemotherapy. Southeast Section of the American Urological Association Annual Meeting. Marco Island, Florida, March 19, 1985.
70. Kidney Tumor Session Co-moderator with Jean deKernion, M.D. American Urological Association Annual Meeting. Atlanta, Georgia, May 13, 1985.
71. Aminoglutethimide in Metastatic Adenocarcinoma of the Prostate. American Urological Association Annual Meeting. Atlanta, Georgia, May 13, 1985.
72. Treatment of Stages cII (N₄) and cIII Seminoma with Chemotherapy Followed by Irradiation Therapy: A Southwest Oncology Group Study. American Urological Association Annual Meeting. Atlanta, Georgia, May 16, 1985.
73. Intravesical Adriamycin for Recurrent Superficial Bladder Cancer: A Southwest Oncology Group Protocol. American Urological Association Annual Meeting. Atlanta, Georgia, May 15, 1985.

74. Prevention of Urinary Tract Infection and Sepsis Following Transurethral Resection of the Prostate. American Urological Association Annual Meeting. Atlanta, Georgia, May 15, 1985.
75. Prostate Carcinoma. American College of Physicians Postgraduate Course for Medical Oncologists. Detroit, Michigan, September 10, 1985.
76. Prevention of Urinary Tract Infections Following Transurethral Resection of the Prostate. American College of Surgeons. Chicago, Illinois, October 14-16, 1985.
77. Prevention of Urinary Tract Infections Following Transurethral Resection of the Prostate. Certificate of Merit. 79th Annual Scientific Assembly of the Southern Medical Association. Orlando, Florida, November 17-20, 1985.
78. Prostatitis. Panel member with W. Fair, M.D., J.B. deKernion, M.D., and W. Furlow, M.D. Current Concepts in Diseases of the Prostate. Lake Tahoe, Nevada, February 7, 1986.
79. Antimicrobial Prophylaxis of Urinary Tract Infection Following Transurethral Resection of the Prostate. Presented at the Southeastern Section of American Urological Association. Puerto Rico, March 17, 1986.
80. Transperineal Percutaneous Iridium-192 Implant of the Prostate. Presented at the Southeastern Section of American Urological Association. Puerto Rico, March 19, 1986.
81. Adverse Reactions to Intravesical Administration of Doxorubicin Hydrochloride. Presented at Southeastern Section of American Urological Association. Puerto Rico, March 19, 1986.
82. Kidney Tumors. Panel Co-Moderator. Annual Meeting of American Urological Association. New York, New York, May 13, 1986.
83. Diseases of the Prostate. Speaker, Symposium at American Urological Association Annual Meeting. New York, New York, May 17, 1986.
84. Problem Solving and the Prostatic Cancer Patient. Panel member with David F. Paulson, MD, Carl A. Olsson, MD, and Richard D. Williams, MD. Annual Meeting of American Urological Association. New York, New York, May 22, 1986.
85. Current Concepts in the Management of Testis Cancer. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 8, 1987.
86. Treatment of Advanced Seminoma with Pre-Irradiation Chemotherapy. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 8, 1987.
87. Expectant Therapy, Observation in Low-Stage Testis Tumor. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 9, 1987.
88. Management of Prostatitis. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 8, 1987.
89. Current Concepts in the Management of Prostate Cancer. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 10, 1987.
90. Inguinal Lymph Node Biopsy. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 11, 1987.
91. Prostate Cancer Group Discussion. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 11, 1987.
92. Southwest Oncology Group Protocols for Genitourinary Cancer. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 12, 1987.
93. BCG versus Adriamycin in the Treatment of Carcinoma in situ and Superficial Bladder Cancer. 7th Annual Wyoming Urological Conference. Jackson Hole, Wyoming, February 12, 1987.
94. SWOG Trials in Testicular Cancer. Recent Advances in Cancer Therapy. Denver, Colorado, March 10-11, 1987.
95. Germ Cell Tumors. Panel moderator, Recent Advances in Cancer Therapy. Denver, Colorado, March 10-11, 1987.
96. A Randomized Clinical Trial Comparing Cisplatin, Vinblastine Plus Either Bleomycin (PVB) or VP-16 (VPV) and Surgical Resection of Residual Disease in Advanced Testicular Cancer: A Southwest Oncology Group Study. American Urological Association. Anaheim, California, May 20, 1987.

97. Moderator, Poster Session 2, Prostate Cancer, Hormonal Therapy, with Joseph A. Smith, M.D., and Jacobi Gunter, M.D. American Urological Association. Anaheim, California, May 21, 1987.
98. A Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate, Phase III, Intergroup Study 0036. American Urological Association. Anaheim, California, May 21, 1987.
99. Plenary Session--SWOG 8494. SWOG meeting, University of Texas Health Sciences Center. Columbus, Ohio, September 13-14, 1987.
100. Diagnosis and Treatment of Prostatitis. Managing Urologic Problems in Family Practice symposium. San Francisco, California, September 12, 1987.
101. Current Concepts in the Management of Prostatic Diseases. XVIIth Annual Dialogue, American Academy of Family Physicians. San Francisco, California, September 14, 1987.
102. Prostate Carcinoma. American College of Physicians Course. "Medical Oncology: Principles of Patient Management." Wayne State University, School of Medicine. Detroit, Michigan, September 17, 1987.
103. Combination Therapy for Treatment of Advanced Carcinoma of the Prostate. Visiting lecturer, UCLA State of the Art Urology. Marina del Ray, California, November 7, 1987.
104. Treatment of Advanced Testis Tumor. Visiting lecturer, UCLA State of the Art Urology. Marina del Ray, California, November 7, 1987.
105. Controversies in the Diagnosis and Management of Prostate Cancer. Course Director. University of Colorado School of Medicine. Denver, Colorado, January 29, 1988.
106. Overview of Hormonal Therapy. Speaker and panel member. Controversies in the Diagnosis and Management of Prostate Cancer. University of Colorado School of Medicine. Denver, Colorado, January 29, 1988.
107. Member, Le Groupe des Critiques with Ralph deVere White, MD, Paul H. Lange, MD, David F. Paulson, MD, John W. Weigel, MD. 8th Annual Grand Teton Urological Conference. Jackson Hole, Wyoming, February 7-11, 1988.
108. Speaker--Approvability of the NDA for the Use of Eulexin (Flutamide) as an Adjuvant Treatment of Metastatic Prostate Cancer. FDA, Center for Drug Evaluation and Research, Endocrinologic and Metabolic Drugs Advisory Committee. Bethesda, Maryland, February 25, 1988.
109. Current Concepts in the Management of Advanced Prostate Cancer. The Eighth Annual Robert K. Womack Memorial Lectureship in Urology. Louisiana State University. Shreveport, Louisiana, April 16, 1988.
110. Treatment of Newly Diagnosed Stage D2 Prostate Cancer with Leuprolide and Flutamide or Leuprolide Alone, Phase III, Intergroup Study 0036. Plenary Session. American Society of Clinical Oncology 24th Annual Meeting. New Orleans, Louisiana, May 22-24, 1988.
111. Chemotherapy and Biologic Response Modifiers: Prostate Cancer. Scientific program for Society of Urologic Oncology. Boston, Massachusetts, June 2, 1988.
112. The Role of Ultrasound in Prostatic Imaging: Key Issues and Practical Applications. Symposium chairman, panel moderator. Panel members: Fred Lee, MD, Paul H. Lange, MD, Gary J. Miller, MD, PhD, and Peter T. Scardino, MD. American Urological Association. Boston, Massachusetts, June 2, 1988.
113. Poster Session Moderator: Kidney Tumors. American Urological Association. Boston, Massachusetts, June 4, 1988.
114. Treatment of Newly Diagnosed Stage D2 Prostate Cancer with Leuprolide and Flutamide or Leuprolide Alone, Phase III, Intergroup Study 0036. American Urological Association. Boston, Massachusetts, June 7, 1988.
115. Combined Therapy for Advanced Prostate Cancer. Presentation to GU Committee, Eastern Cooperative Oncology Group. Minneapolis, Minnesota, June 15-16, 1988.
116. Participant, Prostate Cancer Working Group Workshop--Organ Systems Program. Prouts Neck, Maine, October 16-19, 1988.

117. Panel member with Drs. Malcolm Bagshaw, MD, John Horton, MD, D Paul Lange, MD, George Prout, MD, and Peter Scardino, MD. Clinical Aspects of Prostate Cancer: Assessment of New Diagnostic and Management Procedures Conference. Prouts Neck, Maine, October 17, 1988.
118. A Randomized Prospective Trial of Preoperative Irradiation Plus Radical Cystectomy versus Surgery Alone for Transitional Cell Carcinoma of the Bladder: A Southwest Oncology Group Study. South Central Section, American Urological Association. Colorado Springs, Colorado, October 17, 1988.
119. Participant, First International Workshop on Diagnostic Ultrasound of the Prostate. Washington, D.C., October 22-23, 1988.
120. Panel member with F. Meyskens, G. Chodak, E. Messing, R. Oyasu, and M. Swanson. Approaches to Prevention of Bladder Cancer Development. Biology of Bladder Cancer. Bethesda, Maryland, March 23, 1989.
121. Panel member with M. Droller, W. Fair, E. Hammond, N. Heney, P. Lange, and W. Shipley. Impact of Bladder Cancer Biology on Clinical Management. Biology of Bladder Cancer. Bethesda, Maryland, March 23, 1989.
122. Program Chairman: Controversies in Recent Advances in the Therapy of Urological Malignancies. Dana Point, California, April 7-9, 1989.
123. Combined Therapy for Advanced Prostate Cancer. Controversies in Recent Advances in the Therapy of Urological Malignancies. Dana Point, California, April 7-9, 1989.
124. Program Chairman: Perspectives in the Management of Prostatic Diseases. Dallas, Texas, May 6, 1989.
125. Perspectives in the Management of Prostatitis. Perspectives in the Management of Prostatic Diseases. Dallas, Texas, May 6, 1989.
126. Poster Session Moderator: Kidney Tumors (Dr. Harry Herr, co-moderator). American Urological Association. Dallas, Texas, May 6, 1989.
127. Postgraduate Seminar Instructor: Therapy of Bladder Cancer. American Urological Association. Dallas, Texas, May 6, 1989.
128. Combined Therapy for Treatment of Advanced Prostate Cancer. American Urological Association. Dallas, Texas, May 6, 1989.
129. Treatment of Advanced Prostate Cancer. American Urological Association. Dallas, Texas, May 6, 1989.
130. Current Perspectives in the Treatment of Prostatitis. American Urological Association. Dallas, Texas, May 6, 1989.
131. American Society of Clinical Oncology. San Francisco, California, May 22-23, 1989.
132. Current Strategies for Treating Stage B Prostatic Carcinoma. Clinical Problems in Urology. Chicago, Illinois, June 3, 1989.
133. Antiandrogen Treatment: Current Role for Castration. Clinical Problems in Urology. Chicago, Illinois, June 3, 1989.
134. E. David Crawford, MD, and Prof. Louis Denis (Belgium), Co-coordinators: Workshop on Combined Castration and Androgen Blockade Therapy in Prostate Cancer: Results and Future Directions. American Cancer Society. Atlanta, Georgia, September 18-20, 1989.
135. Treatment of Disseminated Prostatic Carcinoma. Pearls in Office Urology. Long Island Jewish Medical Center. New Hyde Park, New York, October 15, 1989.
136. Intravesical Chemotherapy. Pearls in Office Urology. Long Island Jewish Medical Center. New Hyde Park, New York, October 15, 1989.
137. Program Chairman, Contemporary Topics in Urology Symposium. Vail, Colorado, December 8-10, 1989.
138. Perspectives in the Management of Advanced Prostate Cancer. Contemporary Topics in Urology Symposium. Vail, Colorado, December 9, 1989.
139. Management of Superficial Transitional Cell Carcinoma. Contemporary Topics in Urology Symposium. Vail, Colorado, December 10, 1989.
140. Education Leaders' Workshop, AUA Office of Education. Houston, Texas, January 5-7, 1990.

141. Chairman, le Group des Critiques, 10th Annual Grand Teton Urological Conference. Jackson Hole, Wyoming, February 3-10, 1990.
142. What Are the Most Results of the U.S. Intergroup Trial of Combined Androgen Blockade? Prostate Cancer: Controversies in Diagnosis and Treatment. Orlando, Florida, February 10, 1990.
143. Program Chairman and Speaker, Current Trends in Urologic Care Symposium. Snowbird, Utah, March 23-25, 1990.
144. Perspectives in the Management of Advanced Prostate Care. Current Trends in Urologic Care. Snowbird, Utah, March 24, 1990.
145. Management of Superficial Transitional Cell Carcinoma. Current Trends in Urologic Care. Snowbird, Utah, March 25, 1990.
146. Hormonal Management of Advanced Prostate Cancer. 42nd Annual Midwest Cancer Conference: Genitourinary Malignancies. Wichita, Kansas, March 30, 1990.
147. Surgical Management of Testicular Cancer. 42nd Annual Midwest Cancer Conference: Genitourinary Malignancies. Wichita, Kansas, March 30, 1990.
148. Bladder Cancer. Postgraduate Course, American Urological Association. New Orleans, Louisiana, May 13, 1990.
149. Cancer of the Prostate. Panelist with Fair, WR (moderator), Denis, LJ, and Trachtenberg, J. American Urological Association Annual Meeting. New Orleans, Louisiana, May 14, 1990.
150. Co-Moderator. Progress Report on the Clinical Treatment of Prostatic Cancer. Colorado Springs, Colorado, July 19-22, 1990.
151. Combined Androgen Blockade. Progress Report on the Clinical Treatment of Prostatic Cancer. Colorado Springs, Colorado, July 20, 1990.
152. Co-Moderator. Current Advances in the Management of Prostatic Disease. Snowbird, Utah, July 26-29, 1990.
153. Total Androgen Blockade. Current Advances in the Management of Prostatic Disease. Snowbird, Utah, July 28, 1990.
154. Moderator, Prostate Cancer: Diagnosis and Management of Advanced Disease (D0-D2). American College of Surgeons, 1990 Clinical Congress. San Francisco, California, October 11, 1990.
155. Current Trends in Hormonal Therapy. Prostate Cancer: Diagnosis and Management of Advanced Disease (D0-D2). American College of Surgeons, 1990 Clinical Congress. San Francisco, California, October 11, 1990.
156. Locally Advanced and Metastatic Prostate Cancer: The Role of Hormone Therapy. 63rd Annual Clinical Assembly of Osteopathic Specialists. Los Angeles, California, October 30, 1990.
157. Adrenal Hormone Manipulation of Metastatic Prostate Carcinoma: An Update. 63rd Annual Clinical Assembly of Osteopathic Specialists. Los Angeles, California, October 30, 1990.
158. New Cytotoxic Chemotherapy for Metastatic Carcinoma of the Prostate. 63rd Annual Clinical Assembly of Osteopathic Specialists. Los Angeles, California, October 30, 1990.
159. Co-Chairman. Progress Report on the Clinical Treatment of Prostatic Cancer. Scottsdale, Arizona, December 6-9, 1990.
160. Total Androgen Blockade. Progress Report on the Clinical Treatment of Prostatic Cancer. Scottsdale, Arizona, December 6-9, 1990.
161. Program Director, Urologic Malignancies: Perspectives on Recent Advances. Pebble Beach, California, January 17-21, 1991.
162. International Data on Maximal Androgen Deprivation I. NCI 0036 and Nilutamide Studies. Urologic Malignancies: Perspectives on Recent Advances. Pebble Beach, California, January 18, 1991.
163. Program Director, International Prostate Cancer Update. Vail, Colorado, January 23-27, 1991.
164. Combined Androgen Blockade. International Prostate Cancer Update. Vail, Colorado, January 26, 1991.
165. Panelist, Workshop 3, New Hormonal Agents. National Conference on New Oncologic Agents. American Cancer Society. Dallas, Texas, February 7, 1991.

166. Director of Education and Le Groupe des Critiques panel member. 11th Annual Grand Teton Urological Conference. Jackson Hole, Wyoming, March 2-9, 1991.
167. Co-Moderator, Current Advances in the Management of Prostatic Disease. Snowbird, Utah, March 14-17, 1991.
168. Medical/Surgical Management of Advanced Prostate Cancer. Current Advances in the Management of Prostatic Disease. Snowbird, Utah, March 15, 1991.
169. Prostate Cancer Awareness Week: Results of Screening, American Society of Clinical Oncology. Houston, Texas, May 21, 1991.
170. The role of combined androgen blockade in the management of prostate cancer. Workshop with Canadian Urology Residents. Toronto, Ontario, June 1, 1991.
171. Photodynamic Therapy (PDT): An investigational new treatment for bladder cancer. American Urological Association. Toronto, Ontario June 2, 1991.
172. PCAW: Results of Screening. Poster Session, American Urological Association. Toronto, Ontario, June 3, 1991.
173. Chairman, Postgraduate Course. Prostate Cancer. American Urological Association. Toronto, Ontario, June 4, 1991.
174. Current Trends in Hormonal Therapy. American Urological Association. Toronto, Ontario, June 4, 1991.
175. Report on prostate cancer screening week in 900 institutions, September 1990. Plenary Session, American Urological Association. Toronto, Ontario, June 6, 1991.
176. Bladder Cancer, Clinical. Poster session moderator with MS Soloway. American Urological Association. Toronto, Ontario, June 6, 1991.
177. Chemotherapy of Bladder Cancer-Indications and Strategies. Western Section, American Urological Association. Vancouver, British Columbia. July 29, 1991.
178. Management of Stages B and C Cancer of the Testis. Western Section, American Urological Association. Vancouver, British Columbia. July 29, 1991.
179. Prostate Disease: The Treatment Challenges for Family Physicians in the 1990s and Beyond. New Advances in Prostate Disease: Practical Approaches for the Family Physicians. American Academy of Family Physicians. Washington, D.C., September 27, 1991.
180. Combined Androgen Blockade. Prostate and Urothelial Cancer. Orlando, Florida, October 4, 1991.
181. Balloon Dilatation of the Prostate. Symposium in association with the South Central Section Meeting in Maui, Hawaii. November 16, 1991.
182. Panel Moderator. Treatment of Locally Advanced and Metastatic Prostate Cancer. South Central Section Meeting, Maui, Hawaii. November 17, 1991.
183. Treatment of Advanced Prostate Cancer. South Central Section Meeting in Maui, Hawaii. November 16, 1991.
184. Early Detection: Strategies and Results. Presented at Current Concepts in Cancer Management. Newport Beach, CA. February 13, 1992.
185. Advances in Hormonal Therapy. Presented at Current Concepts in Cancer Management. Newport Beach, CA. February 13, 1992.
186. Primary Hormonal Therapy. Presented at the National Conference on Prostate Cancer. San Francisco, CA. February 14, 1992.
187. Guidelines for Possible Intervention Strategies. Consensus Panel Moderator. Chemoprevention of Premalignant and Early Malignant Diseases of the Prostate. An NIH sponsored program, Scottsdale, Arizona, March 27-29, 1992.
188. Prostate Cancer: AUA Postgraduate Course Chairman. AUA Annual Meeting, Washington, D. C. May 12, 1992.
189. Prostate Cancer: Meeting the Therapeutic Challenges. Program Chairman. AUA Annual Meeting, Washington, D. C. May 9, 1992.
190. Superficial Bladder Cancer. AUA Annual Meeting, Washington, D. C. May 14, 1992.

191. Report on Prostate Cancer Awareness Week-1991, Presented at the Plenary Session AUA Annual Meeting, Washington, D. C. May 10, 1992.
192. Prostate Cancer: Session Moderator. AUA Annual Meeting, Washington, D. C. May 14, 1992.
193. Treatment of Newly Diagnosed Prostate Cancer with Leuprolide and Flutamide versus Leuprolide alone: Prognostic Significance of Minimal Disease. AUA Annual Meeting, Washington, D. C. May 12, 1992.
194. Management of localized and systemic prostate cancer. Presented at the annual meeting of the American Geriatrics Society, Washington, D.C. November 15, 1992.
195. Prostate Cancer Awareness Weeks. Presented at the Workshop on American Cancer Society Guidelines for Early Detection of Prostate Cancer, Chicago, Ill., September 12, 1992.
196. Carcinoma of the Prostate: Magnitude of the Problem. Plenary Session of the Southwest Oncology Group, St Louis, MI, October 18, 1992.
197. Single Agent versus Combined Therapy of Metastatic Prostate Cancer. Recent Advances in Prostate and Bladder Cancer, AUA South Central Galveston, TX, October 31, 1992.
198. Course Director: Urology Teaching Course, The Pointe. Phoenix Arizona, November 5-8, 1992.
199. Superficial Bladder Cancer, Urology Teaching Course, The Pointe. Phoenix Arizona, November 5-8, 1992.
200. Prostate Cancer, Urology Teaching Course, The Pointe. Phoenix Arizona, November 5-8, 1992.
201. Evaluation and Management of Benign Prostatic Hypertrophy. and Evaluation and Management of Prostate Cancer. Update in Family Medicine. Crested Butte, Colorado, January 25, 1993.
202. Have We Reached the Limits of Androgen Blockade? Results of Intergroup Trials and Future Directions. Clinical Implications of prostate Cancer Biology Meeting. Houston, Texas, February 12-13, 1993.
203. Genitourinary Cancer Update: Optimal Treatment of Superficial Bladder Cancer. Roswell Park Cancer Institute, NY. Sept 30, 1993.
204. Genitourinary Cancer Update: Screening/Prostate Awareness Campaigns. Roswell Park Cancer Institute, NY. Oct 1, 1993.
205. Genitourinary Cancer Update: SWOG Trials. Roswell Park Cancer Institute, NY. Oct 1, 1993.
206. Genitourinary Cancer Update: How I Treat Stage C Prostate Cancer/The Data I Use From Clinical Trials. Roswell Park Cancer Institute, NY. Oct 2, 1993.
207. American Urological Association Annual Meeting: 1) Prostate Cancer. 2) (showcase) Therapeutic Advances in Prostate Cancer. 3) Report on the 1992 Prostate Cancer Awareness Week. May 1993.
208. Selected Topics on Prostate Cancer. Phoenix Urological Society Meeting, Jul 28, 1993.
209. Prostate Cancer Today. Uniformed Services University of the Health Sciences, Palm Springs, CA. Dec 2-4, 1993.
210. Perspectives in Urology. Chairman of program, and "Benign Prostatic Hyperplasia" and "Locally Advanced Prostate Cancer". Phoenix, AZ. December 9-12, 1993.
211. Smith-Kline Advisory Board presentation, Orlando, FL. Jan 10, 1994.
212. Pre-Treatment of Metastatic Disease: Prostate Cancer in the Older Person. Presented at National Conference on Cancer and the Older Person, Atlanta, GA. Feb 11, 1994.
213. Metastatic Prostate Cancer - When and How to Begin Treatment. Presented at 4th International Conference on Prostate and Urothelial Cancer and Benign Prostatic Hyperplasia, Orlando, FL. Mar 10-12, 1994.
214. Pretreatment of Metastatic Disease: Prostate Cancer in the Older Person. Presented at the American Cancer Society National Conference on Cancer and the Older Person. Atlanta, GA. Feb 10-12, 1994.
215. Therapeutic Advances in Prostate Cancer -- An Interactive Symposium. Moderator for podium session: Prostate Cancer - Detection. Report on the 1993 Prostate Cancer Awareness Week, presented at plenary session. Moderator for evening seminar: Therapeutic Advances in Prostate Cancer. Coordinator for postgraduate course: Prostate Cancer. American Urological Association Annual Meeting. San Francisco, CA. May 13-19, 1994.

216. TAP Into the Future: Urological Consultants Meeting, by Discovery International. Hilton Head, SC, June 2-5, 1994.
217. TAP Into the Future: Urological Consultant Meeting, by Discovery International. Dallas, TX, June 9-12, 1994.
218. South Central Section meeting of the American Urological Association presentations: Age-Specific Reference Ranges for Prostate-Specific Antigen; Incorporation of Morphometric Data into Prostate Biopsy. Strategy is Needed to Improve the Detection Rate for Prostates with Low Volume Cancer; Management of Clinically Localized Adenocarcinoma of the Prostate by Transrectal Ultrasonographically Guided Cryoablation of the Prostate. Moderator of session: Diagnostic Problems & Prostate Cancer. Vancouver, Canada. August 27-29, 1994.
219. Prostate Cancer Awareness Week. The American Cancer Society National Conference on Prostate Cancer. Philadelphia, PA. Sep 29-Oct 1, 1994.
220. National Prostate Cancer Awareness Week Update. Presented at the annual American College of Surgeons. Chicago, IL. October 12, 1994.
221. Panel member, symposium sponsored by the Commission on Cancer's Prostate Cancer Panel. Other members: William J. Catalona, Curtis A. Mettlin, Gerald A. Murphy, and George W. Jones. Chicago, IL. October 12, 1994.
222. Co-chairperson of Urology in the 90s. Also presenting: Screening/Prostate Cancer Awareness, What is Advanced Prostate Cancer?, and Case Management. Orlando, FL. October 20-22, 1994.
223. Course Director: Perspectives in Urology. Also presenting: Advanced Prostate Cancer. Phoenix, Arizona, December 8-11, 1994.
224. Co-Chairman of A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer. Also presenting: Defining Advanced Prostate Cancer, and Case Study Presentation. Palm Springs, California, January 19-21, 1995.
225. Co-Chairman of A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer. Keystone, Colorado, February 9-11, 1995.
226. Management of Advanced Disease (Stages C & D). Presented at the South Central Section Annual Meeting of the American Urological Association. St. Louis, Missouri, March 3-5, 1995.
227. Symposium Coordinator: Controversies in Prostate Cancer. American Urological Association Annual Meeting, Evening Seminar. Las Vegas, NV, April 23, 1995.
228. Plenary Session Report to the American Urological Association Annual Meeting: Prostate Cancer Awareness Week 1994. Las Vegas, NV, April 25, 1995.
229. TAP Into the Future. Presentations: Welcome, Panel Discussion, Changing Concepts in the Management of Advanced Prostate Cancer, Workshop Reports, and Case Management. Captiva Island, Florida, May 5-6, 1995.
230. Changing Concepts in the Management of Advanced Prostate Cancer. Presented at Urotrend 2000. Orlando, Florida, May 6, 1995.
231. American Society of Clinical Oncologists Annual Meeting. Discuss abstracts: "The Prognostic Significance of Prostate Specific Antigen (PSA) in Stage D2 Prostate Cancer", "A Phase II Trial of Leuprolide, Flutamide, and Suramin in Previously Untreated Metastatic Prostate Cancer", and "A Randomized Double-Blind Trial in 813 Previously Untreated Metastatic Prostate Cancer Patients Comparing a New Antiandrogen Casodex with Eulexin in Combination with Lutenizing Hormone Releasing Hormone Analogue Therapy". Los Angeles, California, May 23, 1995.
232. Chairman of TAP Into The Future. Also presented Changing Concepts in the Management of Advanced Prostate Cancer, co-leader for three workshop sessions, and moderator of panel discussion. Aspen, Colorado, September 15-16, 1995.
233. The Role of PSA in Chemoprevention. Presented at the National Cancer Institute's Prospects for Chemoprevention in Cohorts with Cancer Risk Markers. Easton, Maryland, October 5-7, 1995.
234. Invited speaker at prostate cancer conference, University of Michigan, Ann Arbor, Michigan, October 21-22, 1995.

235. Chairman and speaker: Superficial Bladder Cancer; Advanced Prostate Cancer; case presentations; presented at Perspectives in Urology. Phoenix, Arizona, November 30-December 2, 1995.
236. Speaker: Palliation of Bone Pain Conference. Dallas, Texas, December 20, 1995.
237. Speaker at New Strategies in the Management of T1-T3 Carcinoma of the Prostate: New Approaches to Prostate Cancer Screening; Perineal Prostatectomy; Salvage Radical Prostatectomy. Scottsdale, Arizona, February 9-10, 1996.
238. Endocrine Therapy and Hormone Refractory Disease. Presented at Prostate Cancer & Other Neoplasms of the Genitourinary Tract. Palm Beach, Florida, February 26-27, 1996.
239. Role of PSA as a Potential Marker in Chemoprevention Trials. Presented at Prostate Cancer Prevention Workshop by National Cancer Institute. Anapolis, Maryland, March 31-April 2, 1996.
240. Chairman, Prostate Cancer Screening Seminar, at the annual meeting of the American Society of Clinical Oncology. Philadelphia, Pennsylvania, May 17-19, 1996.
241. NCI/ACS Workshop on Clinical and Research Concepts in Prostatic Intraepithelial Neoplasia. Presented Early Detection Programs/Implications for Management; and Prevalence of PIN in Prostatic Carcinoma. Bethesda, Maryland. July 1-2, 1996.
242. Chairman, Perspectives in Urology. Scottsdale, Arizona. December 5-8, 1996.
243. Controversies Regarding Early Diagnosis and Treatment of Prostate Cancer. Presented at National Managed Health Care Congress. Washington, D.C. April 14, 1997.
244. Combined Androgen Blockade. Presented at annual meeting of the Society for Urologic Oncology. New Orleans, April 14, 1997.
245. Special Design Problems in Gynecologic and Urologic Clinical Trials. and Panel Moderator: Phase II and Phase III Clinical Trials. Second Annual Workshop Co-sponsored by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR): Methods in Clinical Cancer Research. Vail, Colorado. July 26-August 1, 1997.
246. Changing Concepts in Hormonal Therapy. Presented at the Chemotherapy Foundation Symposium XV, Mount Sinai, November 12-14, 1997.
247. Prostate Cancer. Presented at American Society of Clinical Oncology Eighth Annual Fall Education Conference, Orlando, Florida, November 7-9, 1997.
248. Changing Concepts in Hormonal Therapy for Prostate Cancer and Point/Counterpoint: Androgen Blockade Monotherapy vs. Total Androgen Blockade and The Management of T3 Prostate Cancer. Course Director: Perspectives in Urology. Phoenix, Arizona. December 11-14, 1997.
249. Chairperson of Current Topics in Urology. San Diego, CA. May 29, 1998.
250. SWOG Trials in Prostate Cancer. Presented at CALGB Prostate Committee. Fort Lauderdale, FL. June 27, 1998.
251. Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. And Rising PSA Post Local Therapy Failure: Immediate vs. Deferred Treatment. Chaired and presented at Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. New Orleans, LA. July 17, 1998.
252. Rising PSA After Failed Local Therapy. Chaired at presented at Perspectives in Urology. Phoenix, AZ. November 12-15, 1998.
253. Presented at 77th Annual Meeting of the South Central Section of the American Urological Association. Ali Ziada, et al: # 17 Use of Transesophageal Echocardiography (TEE) in Avoiding Cardiopulmonary Bypass for Management of Intra-Atrial Thrombus in Patients with Renal Cell Carcinoma. Mark Rosenblum et. al.: #24 A Device for Marking Specific Dog Prostate Biopsy Sites. Robert E. Donohue et. al.: #39 Gleason 4 and 5 Tumors of the Prostate. Mark Rosenblum, et al: #40 Insights on the Direct Effects of Combined Androgen Blockade on Prostate Cancer Cell Lines. Ali Ziada, et al: #74 Salvage Prostatectomy After Radiation Therapy: Experience Using the Perineal Approach. Cancun, Mexico. October 31-November 4, 1998.
254. "An Evening Honoring Archbishop Desmond Tutu and Senator Bob Dole". Washington, DC. December 10, 1998.

255. Presented as course director of New Frontiers in the Diagnosis and Treatment of Prostate Diseases. Causes, Risk Factors, and Prevention of Prostate Cancer. Polishing Your Surgical Techniques. Moderator of two sessions of Case Studies: Questions and Answers. Washington, DC. April 9, 1999.
256. Two poster sessions at American Urological Association annual meeting: Artificial Intelligence System in Prediction of Lymph Node Involvement in Radical Prostatectomy Patients; and Pattern of Prostate Specific Antigen Change in Three Years in Men with Initial Normal Screening Tests. Dallas, Texas. May 4-5, 1999.
257. Conference Faculty of College of American Pathology Conference: Solid Tumor Prognostic Factors: Which, How, and So What? Chicago, Illinois. June 10-13, 1999.
258. Course Director: New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Chicago, IL August 20, 1999.
259. Developments in the Diagnosis and Management of Prostate Diseases. New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Chicago, IL, August 20, 1999.
260. New Frontiers in the Diagnosis and Treatment of Prostate Diseases. Course Director, Berkley, CA. August 27, 1999.
261. Patients Seeking Advice: The Dilemma of PSA Recurrence. New Frontiers in the Diagnosis and Treatment of Prostate Diseases. Berkley, CA. August 27, 1999.
262. Prost-8 for Primary Care. Course Director. American Academy of Family Physicians Annual Meeting, Orlando, FL, September 18, 1999.
263. Prostate Screening: Local Treatments. Prost-8 for Primary Care, American Academy of Family Physicians Annual Meeting, Orlando, FL, September 18, 1999.
264. GU Oncology: State of the Art Lecture. Invited presidential guest speaker. South Central Section, American Urological Association, 78th Annual Meeting, September 27, 1999.
265. New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Course Co-Director. Lake Buena Vista, FL, November 11-13, 1999.
266. Patients Seeking Advice: The Dilemma of PSA Recurrence. New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Lake Buena Vista, FL, November 13, 1999.
267. What about artificial neural network (ANN)? Initial and Nodal Evaluation, Radical and Radiation Therapy/Hormone Data Brachytherapy. Advances in the Diagnosis and Treatment of Prostate Cancer meeting. November 20, 1999.
268. SWOG – update on clinical trials and the side effects of treatment. Advances in the Diagnosis and Treatment of Prostate Cancer meeting. November 20, 1999.
269. Use of Neural Networks to Help Select Patients for RP and Neoadjuvant Hormone Therapy and RP: Should it be used? Prostate Cancer in the New Millenium meeting, Scottsdale, AZ, March 3, 2000.
270. Critical Issues in Prostate Cancer Treatment. Program Co-Chairman. April 28, 2000.
271. Prostate Cancer Redefined: What is the Prostate Cancer Patient Seeking in 2000? Critical Issues in Prostate Cancer Treatment Program. April 28, 2000.
272. Pertinent Clinical Trials in Urologic Oncology – Worldwide. Society of Urologic Oncology - subspecialty meeting - American Urological Association Annual Meeting, Atlanta, GA, April 29, 2000.
273. Prognostic Values of Serum PSA in Patients with Newly Diagnosed Metastatic Prostate Cancer. American Urological Association Annual Meeting, Atlanta, GA, May 2, 2000.
274. Prostate Cancer Awareness Week Data. American Cancer Society National Conference on Prostate Cancer Screening. Atlanta, GA, May 5, 2000.
275. Use of the Ligasure Device in Urologic Cancer Surgery. South Central Section Annual Meeting, Montreal, Quebec, Canada, September 11, 2000.
276. State of the Art Lecture: Chemoprevention and Complimentary Medicine for Prostate Cancer. South Central Section Annual Meeting, Montreal, Quebec, Canada, September 13, 2000.
277. The Role of the Urologist in Hormone Refractory Prostate Cancer. South Central Section Annual Meeting, Montreal, Quebec, Canada, September 13, 2000.
278. Multidisciplinary approach to the treatment of hormone refractory prostate cancer. New Perspectives on Prostate Disease: Redefining Patient Care, Phoenix, AZ, September 15, 2000.

279. PSA Recurrence. New Perspectives on Prostate Disease: Redefining Patient Care, New York, NY, September 23, 2000.
280. Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy. New Perspectives on Prostate Disease: Redefining Patient Care, San Francisco, CA, October 6, 2000.
281. New Perspectives on Prostate Disease: Redefining Patient Care. Course Director. San Francisco, CA, October 7, 2000.
282. Immediate Hormone Therapy compared with Observation. New Perspectives on Prostate Disease: Redefining Patient Care. San Francisco, CA, October 7, 2000.
283. PSA Recurrence, New Perspectives on Prostate Disease: Redefining Patient Care, San Francisco, CA, October 7, 2000.
284. Prostate-Specific Antigen Recurrence. Postgraduate Course. American College of Surgeons Annual Meeting, Chicago, IL, October 25, 2000.
285. Neoadjuvant Hormonal Therapy. New Perspectives on Prostate Disease: Redefining Patient Care. Miami, FL, November 3, 2000.
286. New Perspectives on Prostate Disease: Redefining Patient Care. Course Director, Miami, FL, November 3, 2000.
287. PSA Recurrence. New Perspectives on Prostate Disease: Redefining Patient Care. Miami, FL, November 3, 2000.
288. Surgery vs brachytherapy: point/counterpoint debate. Perspectives in Urology, Point/Counterpoint, November 9, 2000.
289. Interactive Q&A session on early prostate cancer. Co-moderator, Perspectives in Urology, Point/Counterpoint, November 10, 2000.
290. Cooperative Group Clinical Trials: GU Oncology (SWOG). Society of Urologic Oncology/National Cancer Institute Mid-winter Scientific Meeting, Bethesda, MD, December 2, 2000.
291. Issues and Controversies in Stages T3 and T4 Prostate Cancer: What's on the Horizon? Phoenix, AZ Co-moderator, February 10, 2001.
292. The Role of Nephrectomy in Advanced Disease. Perspectives in Urology, Point/Counterpoint, November 8, 2001.
293. Benign Prostatic Hyperplasia: Case Presentations and Panel Discussion – moderator. Perspectives in Urology, Point/Counterpoint, November 8, 2001.
294. Early Hormonal Therapy Better than Late. Perspectives in Urology, Point/Counterpoint, November 9, 2001.
295. Prostate Cancer I: Session Moderator. Perspectives in Urology, Point/Counterpoint, November 9, 2001.
296. Prostate Cancer II: Case Presentations and Panel Discussion – moderator. Perspectives in Urology, Point/Counterpoint, November 9, 2001.
297. Oncology 101 - Case Presentations and Panel Discussion – moderator. Perspectives in Urology, Point/Counterpoint, November 10, 2001.
298. Urinary Tract Infection and Prostatitis - Case Presentations and Panel Discussion: Pediatric Issues – moderator. Perspectives in Urology, Point/Counterpoint, November 10, 2001.
299. Rising PSA: Rising PSA: Selection for Early Therapy. Recent Advances in the Management of Prostate Cancer Meeting, Dallas, TX, February 22, 2002.
300. Radical Prostatectomy. 7th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, March 1, 2002.
301. Open Radical Prostatectomy. 7th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, March 3, 2002.
302. National Cooperative Group Studies. The 4th Great Lakes Urology Seminar, Detroit, MI, March 8, 2002.
303. Rising PSA: Selection for Early Therapy. Recent Advances in the Management of Prostate Cancer Meeting, Chicago, IL, March 22, 2002.
304. Alternative screening intervals using PSA, Surgical/Medical Oncology Conference, Harvard Medical School, April 16, 2002.

305. Rising PSA: Selection for Early Therapy. Recent Advances in the Management of Prostate Cancer Meeting, Phoenix, AZ, April 26, 2002.
306. Prostate Cancer Review. Urology Nursing 2002 meeting, Denver, CO, May 2, 2002.
307. Anti-androgen withdrawal in prostate cancer: results from SWOG 9426. American Society for Clinical Oncology annual meeting, Orlando, FL, May 20, 2002.
308. PSA testing interval reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. (Plenary session) American Society for Clinical Oncology annual meeting, Orlando, FL, May 20, 2002.
309. An artificial neural network to predict prostate biopsy outcome: a prospective study. American Society for Clinical Oncology annual meeting, Orlando, FL, May 19, 2002.
310. Ten-year survival in patients with metastatic (M+) prostate cancer (CaP): analysis of Southwest Oncology Group (SWOG) 8894. American Society for Clinical Oncology annual meeting, Orlando, FL, May 20, 2002.
311. A neural network model to predict prostate biopsy outcome using readily available clinical variables. American Society for Clinical Oncology annual meeting, Orlando, FL, May 20, 2002.
312. Vitamin D, dexamethasone and carboplatin for hormone refractory prostate cancer, a phase II study. American Society for Clinical Oncology annual meeting, Orlando, FL, May 20, 2002.
313. The emerging role of intravenous bisphosphonates in the management of patients with bone metastases meeting, Panel Discussion. Orlando, FL, May 24, 2002.
314. Early versus late hormonal therapy: debating the issues. Hormonal therapy for prostate cancer: Controversies and advances meeting, Orlando, FL, May 24, 2002
315. Lessons learned (so far) from prostate cancer trials: Screening: PLCO. Society of Urologic Oncology meeting, Orlando, FL, May 25, 2002.
316. PSA Testing Interval, Reduction in Screening Intervals: Data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. 100th Annual American Urological Association Meeting, Orlando, FL, May 26, 2002.
317. Ten-Year Survival in Patients with Metastatic (M+) Prostate Cancer (Cap): Analysis of Southwest Oncology Group (SWOG) 8894. 100th Annual American Urological Association Meeting, Orlando, FL, May 28, 2002.
318. The relationship of Gleason sum and survival in patients with metastatic prostate cancer: Analysis of SWOG 8894, 100th Annual American Urological Association Meeting, Orlando, FL, May 28, 2002.
319. PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial (abstract #44) SWOG update: new results and new trials. Second International Prostate Cancer Congress, St. Thomas, US Virgin Islands, July 17, 2002.
320. Novel hormonal/chemotherapy combinations in the high-risk patient. Second International Prostate Cancer Congress, Thomas, US Virgin Islands, July 17, 2002.
321. Timing and type of hormonal therapy. Prostate Cancer 2002: New perspectives meeting, Baltimore, MD, September 28, 2002.
322. Optimal management of hormone-sensitive disease. Prostate Cancer 2002: New perspectives meeting, Baltimore, MD, September 28, 2002.
323. Biochemical failure: is there a role for early therapy? Recent advances in the management of prostate cancer: The year in review meeting, San Diego, CA, October 18, 2002.
324. Case studies panel discussion/question and answer session – moderator. Recent advances in the management of prostate cancer: The year in review meeting, San Diego, CA, October 18, 2002.
325. Case studies panel discussion/question and answer session – moderator. Recent advances in the management of prostate cancer: The year in review meeting, San Diego, CA, October 19, 2002.
326. Minimally invasive vs medical therapy: point/counterpoint debate: Medical therapy is best, Perspectives in Urology 2002, Point/Counterpoint, Scottsdale, AZ, November 7, 2002.
327. Early vs late therapy: point/counterpoint debate: Early therapy is best, Perspectives in Urology 2002, Point/Counterpoint, Scottsdale, AZ, November 8, 2002.

328. Case presentations and panel discussion – moderator. Perspectives in Urology 2002, Point/Counterpoint, Scottsdale, AZ, November 8, 2002.
329. How often should you screen for prostate cancer. Perspectives in Urology 2002, Point/Counterpoint, Scottsdale, AZ, November 8, 2002.
330. Superficial disease: advances in management. Perspectives in Urology 2002, Point/Counterpoint, Scottsdale, AZ, November 9, 2002.
331. Management of Biochemical Failure. Urologic Oncology – Extraordinary Opportunities for Discovery. National Cancer Institute, Bethesda, MD, December 13-14, 2002.
332. The antegrade prostatectomy using the PK Seal device. 8th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, February 28, 2003.
333. Role of early hormonal therapy in the adjuvant setting and biochemical failure. 8th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, March 2, 2003.
334. Learn new developments in hormone therapy! Addressing Clinical Challenges in Symptomatic Prostate Cancer Patients (Chairman), Chicago, IL, April 25, 2003.
335. Managing bone complications in patients with prostate cancer, Keynote speaker, Chicago, IL, April 25, 2003.
336. Screening and Prevention – Today’s understanding of mammography, spiral computerized tomography, and prostate-specific antigen. ASCO/European Society for Medical Oncology Joint Symposium, American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1, 2003.
337. The current state of prostate cancer. Recent advances in the management of prostate cancer, Chicago, IL, June 27, 2003.
338. Biochemical failure: is there a role for early therapy? Recent advances in the management of prostate cancer, Chicago, IL, June 27, 2003.
339. The current state of prostate cancer. Recent advances in the management of prostate cancer, Los Angeles, CA, August 22, 2003.
340. Biochemical failure: is there a role for early therapy? Recent advances in the management of prostate cancer, Los Angeles, CA, August 22, 2003.
341. State of the Art Lecture on BPH. South Central Section Annual Meeting, Boston, MA, September 10, 2003.
342. Recent advances in the management of prostate cancer: the year in review. Course Co-Director. New York, NY, November 14, 2003.
343. Radical nephrectomy for metastatic disease – Point-Counterpoint. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 20, 2003.
344. Medical therapy for BPH: what have we learned from the MTOPs study? Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 20, 2003.
345. Minimally Invasive Therapy vs. Medical Therapy – Medical therapy is best – Point-Counterpoint. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 20, 2003.
346. How often should you screen for prostate cancer? Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 21, 2003.
347. The role of bisphosphonates in prostate cancer. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 22, 2003.
348. Superficial disease (bladder cancer): advances in management. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 22, 2003.
349. Advances in Hormonal Therapy of Prostate Cancer. Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology; State-of-the-Art, New York University, New York, NY, December 12, 2003.
350. Possible focal therapies for localized prostate cancer. Seventh Annual Advanced Prostate Brachytherapy Conference, Seattle, WA, April 2-3, 2004.
351. Cryotherapy controversies. Seventh Annual Advanced Prostate Brachytherapy Conference, Seattle, WA, April 2-3, 2004.

352. The current state of prostate cancer. Recent Advances in the Management of Prostate Cancer, Atlanta, GA, April 16, 2004.
353. Optimal integration of hormone therapy and chemotherapy in men with biochemical failure D 1.5, Recent Advances in the Management of Prostate Cancer, Atlanta, GA, April 16, 2004.
354. What's new and in the news: Early stage treatment for prostate cancer 2004. Perspectives in Men's Health, Los Angeles, CA, April 30, 2004.
355. Andriole GL, Pinsky PF, Levin DL, Gelmann EP, Crawford ED, Reding DJ, Prorok PC, Gohagan JK: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Biopsy Rates and Cancer Characteristics of Initial (T0) Screen. Poster presentation, American Urological Association Annual Meeting, New Orleans, LA, May, 2004.
356. Should androgen deficiency be treated in the patient post radical prostatectomy and/or XRT? American Urological Association Annual Meeting, New Orleans, LA, May 10, 2004.
357. Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa). American Society of Clinical Oncology Annual Meeting, New Orleans, LA, June 5, 2004.
358. Crawford ED, Pauler D K, Tangen CM, Hussain MHA, Small EJ, Taplin ME, Burch PA, Greene GF, Lara, P Jr, Petrylak DP: Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916 (Abstract #4505). American Society of Clinical Oncology annual meeting, New Orleans, LA, June 5, 2004.
359. Maroni P, Crawford ED and Donohue RE: Previous negative prostate biopsies predict lower Gleason grade and lower percentage of positive cores in patients with prostate cancer (abstract #23). South Central Section Annual Meeting, Dublin, Ireland, September 8, 2004.
360. Crawford ED, Barqawi A, Maroni P, and Lucia MS: A retrospective analysis of a second opinion pathological evaluation of patients referred with positive TRUS biopsy before radical prostatectomy (abstract #24). South Central Section Annual Meeting, Dublin, Ireland, September 8, 2004.
361. Donohue RE, Crawford ED and Lucia MS: Gleason sum of PCPT and historic and current University and VA biopsies – any difference? (abstract #25) South Central Section Annual Meeting, Dublin, Ireland, September 8, 2004.
362. Glode LM, Johnson MA and Crawford ED: A survey of urologist's participation in adjuvant therapy for high risk prostate cancer. (abstract #59) South Central Section Annual Meeting, Dublin, Ireland, September 8, 2004.
363. Crawford ED: State-of-the-Art Lecture: Pharmacotherapy for BPH. South Central Section Annual Meeting, Dublin, Ireland, September 9, 2004.
364. Crawford ED: A video demonstration of mini laparotomy antegrade nerve-sparing radical prostatectomy assisted by Plasmakinetics (PK) Seal Lyons Dissector Device© (video #5). South Central Section Annual Meeting, Dublin, Ireland, September 9, 2004.
365. Golden B, Barqawi A, O'Donnell C, and Crawford ED: Effect of age and BMI on total PSA and complexed PSA: Data from Prostate Cancer Awareness Week (poster #1). South Central Section Annual Meeting, Dublin, Ireland, September 10, 2004.
366. Barqawi A, O'Donnell C and Crawford ED: The relationship between testosterone, BMI and cholesterol: data from the Prostate Cancer Awareness Week (poster #2). South Central Section Annual Meeting, Dublin, Ireland, September 10, 2004.
367. Management of primary: role of the radical prostatectomy. Visiting Professor, Washington University in St. Louis, School of Medicine, St. Louis, MO September 17, 2004.
368. The aging male and andropause: is it real? The Jefferson Urology Centennial Symposium, Thomas Jefferson University, Philadelphia, PA, October 30, 2004.
369. New treatments for advanced prostate cancer. The Jefferson Urology Centennial Symposium, Thomas Jefferson University, Philadelphia, PA, October 30, 2004.
370. Role of medical therapy in the treatment of BPH. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 4, 2004.

371. Point-Counterpoint: Medical therapy vs. minimally invasive therapy – medical therapy is best. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 4, 2004.
372. Controversies in erectile dysfunction and testosterone replacement therapies. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 4, 2004.
373. Point-counterpoint: TRT raises the risk of prostate cancer vs TRT protects – TRT protects against the development. Perspectives in Urology, Point-Counterpoint, Phoenix, AZ, November 5, 2004.
374. Controversies with TRT: what do I tell my patients? Perspectives in Men's Health. US Micron, Boston, MA January 28, 2005.
375. Cooperative Groups – Directions and Plans in Prostate Cancer. ASCO 2005 Multidisciplinary Prostate Cancer Symposium; Current Status and Future Directions for Prevention and Management. Orlando, FL, February 19, 2005.
376. US Experience with Prostate Cancer Screening. 10th Annual Scottsdale Prostate Cancer Symposium 2005, Scottsdale, AZ, March 4, 2005.
377. PSA as a Surrogate for Survival. 10th Annual Scottsdale Prostate Cancer Symposium 2005, Scottsdale, AZ, March 4, 2005.
378. Recent advances in the management of prostate cancer. Co-Course Director. Los Angeles, CA, April 22, 2005.
379. Hormone manipulation and treatment options for PSA recurrence. Recent advances in the management of prostate cancer. Los Angeles, CA, April 22, 2005.
380. Recent Advances in Management of Prostate Cancer. Los Angeles, CA, April 22, 2005.
381. Program Director: Urology Updates – Emerging data from 2005 urology and oncology annual meetings, New York, NY, July 9, 2005.
382. Targeted therapy for prostate cancer: the future? State-of-the-Art Lecture. 84th Annual Meeting, South Central Section of the American Urologic Association, Austin, TX September 15, 2005.
383. The predictive value of PSA derivatives in predicting prostate cancer using artificial neural network model based on age, volume and digital rectal exam. 84th Annual Meeting, South Central Section of the American Urologic Association, Austin, TX September 15, 2005.
384. The effect of age, race, obesity, diabetes and family history of prostate cancer on the diurnal variation of testosterone levels in the aging male. 84th Annual Meeting, South Central Section of the American Urologic Association, Austin, TX, September 15, 2005.
385. pamoate and 7.5 mg. leuprorelin acetate in men with advanced prostate cancer. 84th Annual Meeting, South Central Section of the American Urologic Association, Austin, TX September 17, 2005.
386. The effect of active lifestyle and co-morbidities on the overall sexual health in the aging male. 84th Annual Meeting, South Central Section of the American Urologic Association, Austin, TX September 18, 2005.
387. Testosterone replacement and the aging male: simplifications for prostate cancer. Evolving Strategies in Prostate Cancer, New York, NY, September 23, 2005.
388. Targeted Therapy for Prostate Cancer, Evolving Strategies in Prostate Cancer, New York, NY, September 23, 2005.
389. Course Director: Perspectives in Men's Health: Straight to the Point. San Francisco, CA, October 7, 2005.
390. Cryotherapy Perspectives in Men's Health: Straight to the Point. San Francisco, CA, October 7, 2005.
391. Testosterone replacement therapy. Perspectives in Men's Health: Straight to the Point. San Francisco, CA, October 7, 2005.
392. Perspectives in Men's Health: Straight to the Point. Chicago, IL, October 21, 2005.
393. Perspectives in Men's Health: Straight to the Point. Las Vegas, NV, October 28, 2005.
394. Perspectives in Urology: Point/Counterpoint. Scottsdale, AZ, November 10, 2005.
395. Targeting Bone Health: Reducing Complications of Prostate Cancer. 2006 American Urological Association Annual Meeting, Atlanta, GA, May, 20-25, 2006.
396. Cryoablation, Prostate. AUA Post Graduate course, 2006 Annual Meeting, Atlanta, GA, May 22, 2006.

397. Ablative Oncology: Radio Frequency, Cryosurgery & HIFU. Course Faculty, American Urological Association Annual Meeting, Atlanta, GA, May 22, 2006.
398. Perspectives in Men's Healthcare: A Cooperative Approach. Las Vegas, NV, June 23-24, 2006.
399. Issues and Controversies in the Management of Prostate Cancer with Hormonal Therapy. North Central Section, Coronado, California, September 15, 2006.
400. Targeting Bone Health: Reducing Complications of Prostate Cancer. Satellite Symposium at the 2006 American Urological Association Annual Meeting, Atlanta, GA, Supplement to Urology Times, September, 2006.
401. T3-4 Disease: Is there a role for surgery? Perspectives in Prostate Cancer: An Educational Activity for Practicing Urologists and Medical Oncologists. Chicago, Illinois, September 22-23, 2006.
402. Testosterone Replacement Therapy. Perspectives in Urology 2006: Point-Counterpoint, Scottsdale, AZ, November 9-11, 2006.
403. Alternatives to Radical Prostatectomy: Targeted Therapy. Perspectives in Urology 2006: Point-Counterpoint, Scottsdale, AZ, November 9-11, 2006.
404. New Frontiers in Prostate Cancer: Novel New Agents – Atrasenten, Sipuleucel-T, Satraplatin. Perspectives in Urology 2006: Point-Counterpoint, Scottsdale, AZ, November 9-11, 2006.
405. Special Session: Video-Mini-Laparoscopic Radical Prostatectomy. Perspectives in Urology 2006: Point-Counterpoint, Scottsdale, AZ, November 9-11, 2006.
406. The Aging Male: What's New In BPH. Perspectives in Urology 2006: Point-Counterpoint, Scottsdale, AZ, November 9-11, 2006.
407. Targeted Therapy for Localized Prostate Cancer. GU Oncology Conference, University of Colorado, Aurora, Colorado, November 18, 2006.
408. Benign Prostatic Hyperplasia (BPH): From Finasteride to Botox. Sharp Healthcare's 2006 Primary Care Conference, Kauai, Hawaii, November 30-December 4, 2006.
409. Prostate Cancer: To Screen or Not to Screen? Sharp Healthcare's 2006 Primary Care Conference, Kauai, Hawaii, November 30-December 4, 2006.
410. Erectile Dysfunction: It Is More Than NASCAR, Football and Baseball. Sharp Healthcare's 2006 Primary Care Conference, Kauai, Hawaii, November 30-December 4, 2006.
411. Treatment for Pathologic T3 Disease: Now, Later, or Never. ASCO Prostate Cancer Symposium, Orlando, Florida, February 22-24, 2007.
412. Androgen Deprivation in Advanced Disease: Sooner or Later? ASCO Prostate Cancer Symposium, Orlando, Florida, February 22-24, 2007.
413. Saturation Biopsy Technique. 12th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona, March 1-4, 2007.
414. Update on Prostate Screening. 12th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona, March 1-4, 2007.
415. Use of Hormonal Therapy in High-Risk Prostate Cancer. 12th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona, March 1-4, 2007.
416. Results of Adjuvant Radiotherapy Following Prostatectomy. 12th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona, March 1-4, 2007.
417. PSA Velocity Predicts Prostate Cancer Risk and Outcome. 14th EDRN Steering Committee Meeting, Denver, Colorado, March 13-15, 2007.
418. Panel Discussion: Incorporation of Biomarker Kinetics into Cancer Prediction. 14th EDRN Steering Committee Meeting, Denver, Colorado, March 13-15, 2007.
419. New Therapies for Advanced Prostate Cancer. Oncology Educational Symposia, Houston, Texas, March 17, 2007.
420. New Therapies for Advanced Prostate Cancer. Oncology Educational Symposia, Los Angeles, California, March 31, 2007.
421. CME Symposium: Hypogonadism and Testosterone Replacement Therapy: the Controversy and the Evidence. Urology Congress, San Francisco, California, April 4-7, 2007.

422. Testosterone Replacement Therapy and the Prostate. Urology Congress, San Francisco, California, April 4-7, 2007.
423. New Therapies for Advanced Prostate Cancer. Oncology Educational Symposia, New York, New York, April 21, 2007.
424. Advances in Oncology –Genitourinary Cancers: Innovations and Challenges in Prostate Cancer Management. One-Day Symposium, New York, New York, April 21, 2007.
425. The Changing Dynamics of Advanced Prostate Cancer: Maintaining Skeletal and Bone Health. 2007 AUA Meeting, Anaheim, California, May 18, 2007.
426. Prostate Specific Antigen: It's Utility Across the Prostate Cancer Continuum. Clinical Science Symposium, 2007 ASCO Annual Meeting, Chicago, Illinois, June 2, 2007.
427. Prostate Cancer Update – Clinical Investigator “Think Tank.” Miami, Florida, June 21, 2007.
428. No – Davinci Is Not Better. South Central Section of the AUA, 2007 Annual Meeting, Colorado Springs, Colorado, September 5-9, 2007.
429. Prevention of Prostate Cancer – Why We are Not Implementing: Controversies Regarding Screening for Prostate Cancer. 2007 Urology Symposium, West Lake Village, California, October 5-7, 2007.
430. Biochemical Failure – Defining the High Risk Patient. 2007 Urology Symposium, West Lake Village, California, October 5-7, 2007.
431. Hormone-Refractory Prostate Cancer: New Strategies for Improving Patient Management. Western Section, AUA Annual Meeting, Scottsdale, Arizona, October 29, 2007.
432. Monitoring and Treatment after Prostatectomy or Brachytherapy, TU Testosterone Update, 1st Annual Conference on Improving Clinical Outcomes in Hypogonadism, New York, New York, November 3, 2007.
433. Alternatives to Radical Prostatectomy-Perineal Prostatectomy. Perspectives in Urology-Point/Counterpoint, Scottsdale, Arizona, November 8-10, 2007.
434. New Frontiers in Prostate Cancer- Are We Overtreating Prostate Cancer? Perspectives in Urology-Point/Counterpoint, Scottsdale, Arizona, November 8-10, 2007.
435. Video Urology – Technique for Mapping Biopsies and Targeted Focal Therapy. Perspectives in Urology-Point/Counterpoint, Scottsdale, Arizona, November 8-10, 2007.
436. 4th Annual Radiation Oncology Refresher Course, Debate-“Radical Prostatectomy Will Eventually Be Obsolete in the Management of Prostate Cancer,” Denver, Colorado, January 24, 2008.
437. Advances and Controversies in Cryotherapy, “Clinical Experience with Targeted Focal Therapy and SCORE Study,” Miami, Florida, February 2-4, 2008.
438. CME Symposium, “Case Study: Approach to the Multidisciplinary Management of High Risk and Hormone-refractory Prostate Cancer,” San Francisco, California, February 15, 2008.
439. 13th Annual Scottsdale Prostate Cancer Symposium, “Robotic Prostatectomy – A Lot of Marketing Hype,” Scottsdale, Arizona, February 28-March 2, 2008.
440. 13th Annual Scottsdale Prostate Cancer Symposium, “Testosterone Replacement Therapy: Risks for Prostate Cancer,” Scottsdale, Arizona, February 28-March 2, 2008.
441. 13th Annual Scottsdale Prostate Cancer Symposium, “Radical Prostatectomy,” Scottsdale, Arizona, February 28-March 2, 2008.
442. Interdisciplinary Prostate Cancer Congress, “Advanced Surgical Techniques for the Treatment of Localized Prostate Cancer,” New York, New York, March 8, 2008.
443. Testosterone Update-1st Annual Conference on Improving Clinical Outcomes in Hypogonadism, “Clinical Debate: Impact of Testosterone on Prostate Cancer,” Los Angeles, California, March 15, 2008.
444. 2008 Urology Congress, “Testosterone and the Prostate,” Philadelphia, Pennsylvania, April 24-25, 2008.
445. 3rd AUA/Japanese Urological Association (JUA) Symposium, “Medical Treatment to Cancer – Who Does It?” Orlando, Florida, May 18, 2008.

446. 2008 American Urological Association (AUA), Plenary Session, “What are the Most Important On-going Clinical Trials in Urologic Oncology Worldwide? (SWOG, ECOG, CALGB), “ Orlando, Florida, May 20, 2008.
447. 2008 American Urological Association (AUA), “Prostate Cancer: Detection and Screening (III),” Session Moderator, Orlando, Florida, May 21, 2008.
448. Urology Nursing Society, “Testosterone Replacement Therapy,” Denver, Colorado, September 25, 2008.
449. Rush University Medical Center, “Maximizing the Clinical Efficacy of Advanced Prostate Cancer Treatment by Integrating the Specialties: An Interactive, Case-based Program,” San Diego, California, September 20, 2008.
450. Perspectives in Urology: Point-Counterpoint, “Managing the Man with the Enlarged Prostate,” Scottsdale, Arizona, November 6, 2008.
451. Perspectives in Urology: Point-Counterpoint, “Point-Counterpoint: BPH – Medical Therapy is Best,” Scottsdale, Arizona, November 7, 2008.
452. Perspectives in Urology: Point-Counterpoint, “Latest Strategies in the Prevention of Prostate Cancer,” Scottsdale, Arizona, November 7, 2008.
453. Perspectives in Urology: Point-Counterpoint, “Hormonal Therapy: New Horizons,” Scottsdale, Arizona, November 7, 2008.
454. Perspectives in Urology: Point-Counterpoint, “Prospects in Bone Health – RANK-Ligand Inhibition,” Scottsdale, Arizona, November 7, 2008.
455. Perspectives in Urology: Point-Counterpoint, “Mapping Biopsies: A Technique to Detect Significant Cancers,” Scottsdale, Arizona, November 8, 2008.
456. Perspectives in Urology: Point-Counterpoint, “10 Years from Now...Locally Advanced and Metastatic Prostate Cancer Will be Treated by?” Scottsdale, Arizona, November 8, 2008.
457. St. Mary’s Hospital, “Prognostic Value of Prostate-Specific Antigen Kinetics in Prostate Cancer Patients with Biochemical Recurrence,” Grand Junction, Colorado, December 2, 2008.
458. 29th Annual Conference Clinical Hematology and Oncology, “Preventing Prostate Cancer: Update 2009”, San Diego, California, February 16, 2009.
459. 2009 American Urologic Association Annual Meeting Abstract, “PCA3: A Urine-Based Genetic Assay for Detection of Prostate Cancer in Men with Elevated PSA”, Presenter, May 31, 2009.
460. 4th Annual Interdisciplinary Prostate Cancer Congress (IPCC): “Targeting Therapy for Localized Disease”, New York City, NY, March 26, 2011.
461. 5th Annual Interdisciplinary Prostate Cancer Congress (IPCC): “Targeted Focal Therapy Emerges as Alternative to Active Surveillance or Definitive Treatment,” New York City, NY, March 31, 2012.
462. 2012 American Urological Association (AUA): “Prostate Cancer: Localized IV on Factors Influencing Initial Treatment Decisions in PLCO: comparison of screening and control arms,” Atlanta, GA, May 21, 2012.
463. Portuguese Urology Program, “Localized Prostate Cancer,” Atlanta, GA, May 21, 2012.
464. North East Section of the AUA, “Bone Scans Associated with Prolonged Overall Survival in Patients with Metastatic Castrate Resistant Prostate Cancer Treated with Sipuleucel-T.” Niagra Falls, NY, September 13, 2012.
465. Western Section of the AUA, “Practical Considerations for Bone Health in Patients with Prostate Cancer.” Kona, HI, October 8th, 2012.
466. Frontiers in Cancer Prevention: “Finding Common Ground on the Prostate Cancer Screening Controversy.” Anaheim, California, October 17, 2012.
467. 88th Annual Meeting of the Western Section of the AUA. “Bone Scan Findings Associated With Prolonged Overall Survival (OS) In Patients (PTS) with Metastatic Castrate-Resistant Prostate Cancer (CRPC) Treated with Sipuleucel-T.” Kona, HI, October 7, 2012.
468. 91st Annual Meeting of the South Central Section of the AUA. “Bone Scan Findings Associated With Prolonged Overall Survival (OS) In Patients (PTS) with Metastatic Castrate-Resistant Prostate Cancer (CRPC) Treated with Sipuleucel-T.” Colorado Springs, CO, October 25, 2012.

469. 21st Annual Perspectives in Urology: Point-Counterpoint, “Low Risk Prostate Cancer- The Treatment Choice is: Male Lumpectomy.” Scottsdale, Arizona, November 8, 2012.
470. 21st Annual Perspectives in Urology: Point-Counterpoint, “A Refined AUA Symptom Score:UWIN.” Scottsdale, Arizona, November 9, 2012.
471. 21st Annual Perspectives in Urology: Point-Counterpoint, “Testosterone Replacement Therapy.” Scottsdale, Arizona, November 10, 2012.
472. Genitourinary Cancers Symposium. “Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials.” Orlando, Florida. February 14, 2013.
473. 6th Symposium on Emerging Treatments and Advances in Novel Cancer Therapies for Practicing Physicians and Healthcare Professionals, “Advances in the Treatment Options of Prostate Cancer.” Dallas, Texas, March 2nd, 2013.
474. 18th Annual Scottsdale Prostate Cancer Symposium, “Controversy in Early Prostate Cancer Detection: PRO: European Data.” Scottsdale, Arizona, March 7th, 2013.
475. 18th Annual Scottsdale Prostate Cancer Symposium, “Update on New Forms of Androgen Deprivation.” Scottsdale, Arizona, March 7th, 2013.
476. 18th Annual Scottsdale Prostate Cancer Symposium, “Targeted Focal Therapy for Low Volume Disease.” Scottsdale, Arizona, March 8th, 2013.
477. 18th Annual Scottsdale Prostate Cancer Symposium, “Beyond Gleason Score for Predictiong Outcome of Radical Prostatectomy.” Scottsdale, Arizona, March 9th, 2013.
478. 6th Annual Interdisciplinary Prostate Cancer Congress, “Active Surveillance: Pros, Cons and Optimal Candidates.” New York, New York, March 16th, 2013.
479. AUA Annual Meeting. “State –of-the-Art Lecture: Innovations in Advanced Prostate Cancer.” San Diego, California, May 5th, 2013.
480. AUA Annual Meeting. “Historical SWOG Trials for Localized Prostate Cancer.” San Diego, California, May 6th, 2013.
481. 61st Annual James C. Kimbrough Urological Seminar. “Protects Biomarkers.” San Diego, California. January 16th, 2014
482. 19th Annual Scottsdale Prostate Cancer Symposium. “Epigenetic Assays to Predict Cancer.” Scottsdale, Arizona. February 27th, 2014.
483. 19th Annual Scottsdale Prostate Cancer Symposium. “Role of Transperineal Mapping Biopsy.” Scottsdale, Arizona. February 28th, 2014.
484. 19th Annual Scottsdale Prostate Cancer Symposium. “HIFU and Cryoablation.” Scottsdale, Arizona. February 28th, 2014.
485. 19th Annual Scottsdale Prostate Cancer Symposium. “New Forms of Androgen Withdrawal.” Scottsdale, Arizona. March 1st, 2014.
486. AUA Annual Meeting. “Improving Survival in Advanced Prostate Cancer: The Changing Role of the Urologist.” Orlando, Florida. May 17th, 2014.
487. AUA Annual Meeting. “Biomarkers in Prostate Cancer: Integration & Utility.” Orlando, Florida. May 20th, 2014.
488. 7th International Symposium on Focal Therapy and Imaging in Prostate & Kidney Cancer. Poster Presentation: “CCP Score stratifies risk for postate cancer patients at biopsy: Initial commercial results.” Pasadena, Claifornia. August 21, 2014.
489. ASTRO 56th Annual Meeting. “CCP Score Stratifies Risk For Prostate Cancer Patients At Biopsy: Initial Commercial Results.” San Francisco, California. September 14, 2014.
490. South Central Section of the AUA. “CCP Score Stratifies Risk For Prostate Cancer Patients at Biopsy: Initial Commercial Results.” Rancho Mirage, California, October 9, 2014.
491. South Central Section of the AUA. “Cell Cycle Progression (CCP) Score Significantly Modifies Treatment Decisions in Prostate Cancer: Results of Ongoing Registry Trial.” Rancho Mirage, California, October 9, 2014.

492. South Central Section of the AUA. "First-In-Human Clinical Trial Data Show Optically Adjunct Biopsy Needles Can Increase Diagnostic Yield of Prostate Biopsies." Rancho Mirage, California, October 10, 2014.
493. Western Section AUA. "Biomarkers in Prostate Cancer: Integration & Utility." Maui, Hawaii. October 28th, 2014.
494. Society of Urologic Oncology. "Biomarkers in Prostate Cancer: Integration and Utility." Bethesda, Maryland. December 5, 2014
495. Society of Government Service Urologists. "Biomarkers in Prostate Cancer: Integration and Utility." San Diego, California. January 16, 2015
496. The 25th Annual Prostate Cancer Update. "Where Have We Evolved From Over the Past 25 Years?" Vail Colorado. January 22, 2015
497. The 25th Annual Prostate Cancer Update. "Radiopharmaceuticals: The Past 25 Years and the Future" Vail Colorado. January 24, 2015
498. The 25th Annual Prostate Cancer Update. "Prostate Cancer Panel Discussion: Where Will We Be in 5, 10 and 25 Years from Now?" Vail Colorado. January 24, 2015
499. Genitourinary Cancers Symposium. "Performance of CCP Assay in an Updated Series of Biopsy Samples Obtained from Commercial Testing." Orlando, Florida. February 26, 2015
500. Genitourinary Cancers Symposium. "Evaluation of the Economic Impact of the CCP Assay in Localized Prostate Cancer." Orlando, Florida. February 26, 2015
501. The 20th Anniversary Scottsdale Prostate Cancer Symposium. "Intermittent or Continuous Hormone Therapy." Scottsdale Arizona. March 5, 2015
502. The 20th Anniversary Scottsdale Prostate Cancer Symposium. "Role of Transperineal Mapping Biopsy." Scottsdale Arizona. March 6, 2015
503. The 20th Anniversary Scottsdale Prostate Cancer Symposium. "Genetic Markers: Can They Guide Treatment?" Scottsdale Arizona. March 6, 2015
504. The Utah Urological Society Annual CME-Accredited Symposium: Improving Quality of Care. "Integrating Genomic Markers into the Management of Men with Prostate Cancer: The Way Forward." Salt Lake City, Utah. March 7, 2015
505. Crawford ED. A Primary Care Approach to Prostate Cancer- The Role of Shared Decision Making in Screening and Treatment: Prevalence and Screening- Those at Risk. Emerging Challenges in Primary Care. May 2, 2015.
506. Poage W, Stone N, Crawford ED. Testosterone Replacement Therapy Infrequently used in Hypogonadal Men. American Urological Society Annual Meeting. May 15, 2015
507. Crawford ED. Prostate Health Index Predicts Upgrading of Men on 5-Alpha Reductase Inhibitors. *Winner: Best poster in session.* American Urological Society Annual Meeting. May 15, 2015
508. Leapman M, Crawford ED. Declining use of Urinary Herbal and Vitamin Supplements Among U.S. Men in Longitudinal National Prostate cancer Screening Cohorts. American Urological Association Annual Meeting. May 16, 2015
509. Shore N, Bockzo J, Kella N, Moran J, Bianco J, Crawford ED. Significant Reduction in Therapeutic Burden from use of CCP test in Treatment Decisions Among Newly Diagnosed Prostate Cancer Patients in a Large Prospective Registry. American Urological Association Annual Meeting. May 17, 2015
510. Crawford ED. Fluorescence Spectroscopy can Increase Diagnostic Yield of Prostate Biopsies. *Winner: Best poster in session.* American Urological Society Annual Meeting. May 17, 2015
511. Crawford ED. What do we have Available to Treat Metastatic Prostate Cancer? AUA/Brazilian/Portuguese Urology Program. American Urological Association Annual Meeting. May 18, 2015
512. Crawford ED. What Urologists Need to Know about CRPC Management. American Society for Men's Health. American Urological Association Annual Meeting. May 18, 2015

513. Crawford ED. Unsuspected Metastases Found During Screening for a Trial of Patients with Non-Metastatic Castrate Resistant Prostate Cancer. *Winner: Best poster in session.* American Urological Association Annual Meeting. May 18, 2015
514. Crawford ED. Prostate Health Index is an Effective Marker for Risk Stratification of Prostate Cancer Patients. American Urological Association Annual Meeting. May 18, 2015
515. Surveillance or Treatment: The 3 MS- Markers, Mapping and MRI for Localized Prostate Cancer. American Urological Association Annual Meeting. May 19, 2015 Crawford ED, Shore N, Higano C, Sartor O. Advancing Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: The Urologists Role. CME Meeting. Monday May 18, 2015.
516. Development of a 3D Prostate Mapping System. Nelson N. Stone, MD, Vasileios Skouteris, MD, Paul Arangua*, Scott Lucia, MD, Erin Smith*, Craig Baer*, PhD, E. David Crawford, MD: Vail, CO. October 25, 2015 91st Annual Meeting WSAUA
517. Variation in Serum Alkaline Phosphatase Levels and Skeletal Outcomes in Men With Prostate Cancer Treated With a LHRH Agonist or a GnRH Antagonist. E. David Crawford, MD, Dennis C. Marshall, RN, MS, PhD, Bo-Eric Persson, MD, Anders Malmberg, PhD, Anders Neijber, MD: Aurora, CO. October 25, 2015 91st Annual Meeting WSAUA
518. Androgen Sensitive Prostate Cancer: Are All ADT Similar? Presentation: E. David Crawford, MD University of Colorado Health Science Center, Aurora – 2015 LUGPA SME Course November 5th 2015
519. Chairman, Perspectives in Urology. 24th Annual Perspectives in Urology Scottsdale, Arizona. November 13-15, 2015.
520. Genetic Influences on PSA Levels: Will Regular screening of Men with Genetic Mutations for PSA Lead to Better Prostate Cancer Diagnoses? “SNP-ing Away At CaP” E. David Crawford, MD - 24th Annual Perspectives in Urology Scottsdale, Arizona. November 13-15, 2015.
521. What Are Currently the Best Decision Markers for Biopsy and Re-biopsy of the Prostate? E. David Crawford, MD - 24th Annual Perspectives in Urology Scottsdale, Arizona. November 13-15, 2015.
522. Lunch Symposium Supported by Bayer HealthCare Incorporating Xofigo (radium Ra 223 dichloride) Into Clinical Practice: Speaker E. David Crawford, MD - 24th Annual Perspectives in Urology Scottsdale, Arizona. November 13-15, 2015.
523. Session #4: Advanced Prostate Cancer: A 25 Year Journey in Advanced Prostate Cancer – E. David Crawford, MD - Issues and Controversies in Urologic Cancer, Whistler British Columbia, February 17-20, 2016
524. Session #4: Advanced Prostate Cancer – Panel Moderator – E. David Crawford, MD – Issues and Controversies in Urologic Cancer, Whistler British Columbia, February 17-20, 2016
525. Genetic Markers: Can They Exclude High Risk Disease? E. David Crawford, MD – 21st Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona March 10, 2016.
526. Is PSA Still the Best Test For Early Detection? Presenter - E. David Crawford, MD – 21st Annual Scottsdale Prostate Cancer Symposium, Scottsdale, Arizona March 11, 2016.
527. Who To Biopsy, Who To Treat: Role of Prostate Cancer Markers (PCM’s) E. David Crawford, MD – 21st Annual Scottsdale Prostate Cancer Symposium, Scottsdale Arizona March 12, 2016.
528. Determination of Time For Hormonal Therapy - E. David Crawford, MD – 21st Annual Scottsdale Prostate Cancer Symposium/Session V, March 12, 2016.
529. Prostate Cancer: Localized Prostate Cancer – E. David Crawford, MD – 9th Annual Interdisciplinary Prostate Cancer Congress, New York, NY March 19, 2016.
530. Podium Session 4: American Society for Men’s Health-Management of Castrate Resistant Prostate Cancer: What is the Place of the Urologist? – E. David Crawford, American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
531. Moderated Poster Session 39: Abstract # MP 39-01: Use of PSA Screening Guidelines Among Primary Care Physicians - E. David Crawford, Matt Rosenberg*, Jay Newmark, Mitch Steiner, American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.

532. Moderated Poster Session 39-Abstract # MP39-07: The 4K Score Can Potentially Reduce Unnecessary Prostate Biopsies in Men With Suspicious PSA in a Screening Population- Michael Maccini, Nicholas Westfall*, Priya Werahera, Adrie van Bokhoven, Paul Maroni, Shandra Wilson, Michael Glode, Paul Arangua, E. David Crawford, American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
533. Moderated Poster Session 39-Abstract # MP39-16: Detecting High Grade Cancer and Reducing Prostate Biopsy Among PLCO Participants Using A Pre-Specified Statistical Model Based on Levels of 4K Markers and Microseminoprotein Beta in Blood, Gerald Andriole*, Daniel Sjoberg, Andrew Vickers, E. David Crawford, Hans Lilja. American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
534. 13th International Prostate Forum- Repeat Biopsy: State of the Art Patient Selection and Technique - E. David Crawford. American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
535. Podium Session 26-07: Does Digital Rectal Exam Affect the 4K Score Test for Aggressive Prostate Cancer?: Michael Maccini*, Nicholas Westfall, Priya Werahera, Adrie van Bokhoven, Paul Maroni, Shandra Wilson, Michael Glode, Paul Arangua, E. David Crawford, American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
536. Podium Session 26-12: Complications Associated With Transrectal and Transperineal Prostate Mapping Biopsy – Vasilos Skouteris*, Nelson Stone, Paul Arangua, E. David Crawford, American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
537. Podium Session 28: Moderator-E. David Crawford, Lance Pagliaro: American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
538. Moderated Poster Session 50-20: Impact of Arbiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Arbiraterone Acetate and Low Dose Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate – Charles Ryan*, E. David Crawford, Neal D. Shore, Willie Underwood, Anil Londhe, Shawn Black, Tracy McGowan, Phillip W. Kantoff. American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
539. Moderated Poster Session 57-07: Transperineal Prostate Mapping Biopsy Correctly Identifies Candidates for Radical Prostatectomy – E. David Crawford, Vasilos Skouteris, Paul Arangua, Nelson Stone. American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016.
540. Clinical Controversies in Men’s Health: The Decline in Prostate Cancer Following U. S. Preventive Services Task Force (USPSTF) Recommendations against PSA Testing Is a Good Thing, Or a Return to the Dark Ages? – Debater Pro: Peter Carroll Debater Con: E. David Crawford. American Urologic Association Annual Meeting, San Diego, California May 6-10, 2016
541. Prostate Cancer: Identifying the Toothless Lions – E. David Crawford – 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 6, 2016
542. Industry Breakfast Symposium Supported by Ambry Genetics and MDx Health – E. David Crawford - 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 7, 2016
543. Markers for Biopsy and Re-biopsy of the Prostate – E. David Crawford - 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 7, 2016
544. Industry Lunch Symposium Bone Metastases and Mortality in Prostate Cancer: Can We Be Doing More? – E. David Crawford – Supported by Bayer Healthcare Pharmaceuticals - 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 7, 2016
545. Point Counterpoint: Best Method of Localized Treatment – MRI Is Preferred: Mitchell R. Humphreys, MD Cryotherapy Is Preferred: E. David Crawford, MD - 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 7, 2016
546. Novel Hormonal Therapies for Prostate Cancer – E. David Crawford - 25th Annual Perspectives in Urology Point-Counterpoint – Scottsdale, AZ – November 8, 2016
547. The “Who’s” of Genomic Markers: Who to Biopsy – E. David Crawford, MD. – 27th IPCU, Beaver Creek, CO – January 24-27, 2017.

548. Breakthroughs with Biomarkers and Risk Stratification in Prostate Cancer: Genetics and Genomics – E. David Crawford, MD. Scottsdale, AZ. – Annual Scottsdale Prostate Cancer Symposium March 17, 2017.
549. Who to Biopsy and who to Re-Biopsy. – E. David Crawford, MD. New York GU: 10th Annual Interdisciplinary Prostate Cancer Congress and other Genitourinary Malignancies Manhattan, NY - March 18, 2017
550. Brain Trust on Precision DX for Prostate Cancer/Radiogenomics – May 12, 2017 1:00-3:30 p.m. Review In Vitro Diagnostics/Genomic Testing - David Crawford, MD, Urology, Univ. Colorado, Denver.
551. Boston AUA May 12, 2017 – “Smarter” PSA Screening David Crawford, MD
552. Boston AUA May 13, 2017 – E. David Crawford, MD - PD24: Prostate Cancer: Advanced (Including Drug Therapy) – May 14, 2017 – E. David Crawford, MD. – A Multidisciplinary Approach to the Treatment of Prostate Cancer: Providing Therapies that Improve Overall Survival and Quality of Life, May 16, 2017- E. David Crawford, MD. – PD65-06: Patient NCCN Risk Classification Based on Combined Clinica Cell Risk (CCR) Score.
553. Omni Rancho Las Palmas – Rancho Mirage, CA 2017 Urology Symposium – October 6-7, 2017 – Prostate Cancer Screening “An Approach using PSA Level 1.5 as Cut Off for Cancer Screening” – E. David Crawford, MD. Role of Prostate Cancer Biomarkers in 2017, E.David Crawford , MD
554. Prostate Cancer Academy (PCA October 12-14, 2017 Los Angeles, CA. – LHRH Antagonist vs Agonists – E. David Crawford, MD University of Colorado, Anschutz Medical Campus.
555. RMUS April 7, 2018 – E. David Crawford - Prostate Cancer Therapeutic Layering – Radar II, CPRC: Panel Discussion Moderator - E. David Crawford.
556. PCF, La Costa 10/19 Microbiome and prostate cancer
557. Western Section of AUA, Monterey, 11/04-08-19 State of Art, Advanced CaP, Late LHRH injections
558. Perspectives in Urology, Phoenix , AZ 11-14-16-19, RADAR 1 and 2 , nmCPRC Navigating the Space the next moon shot?
559. Southwest Prostate Cancer Symposium, Scottsdale, AZ ,4.11.2019 Use of genomic markers, Management of CRPC
560. International Prostate Cancer Update. Beaver Creek CO,1.25.2019. Program Chairman. Biomarkers in prostate cancer.
561. 12th Annual Prostate Conference, NY City , 3.15.19 Molecular Markers
562. Astro annual meeting(virtual) Miami, 10.27.2020, Management of CRPC
563. Innovations in Prostate Cancer, Sante Fe, NM (Virtual) 09.26.20 , Molecularr Markers, Transperineal biopsies .
564. Program Chair: 29th Annual Point-Counterpoint, Scottsdale,AZ(Virtual), November 11-12, 2020
565. 29th Annual Point-Counterpoint, Scottsdale,AZ(Virtual), November 11-12, 2020, Moderator and presenter panel discussion, molecular markers.
566. Florida Urological Association, Destin, Florida Jan 23, 2021 The Merle Striger annual Excellence in Medicine Address, Early Detection of Prostate Cancer.
567. Western Section of AUA, Indian Wells, CA, Oct. 30-Nov. 4, 2021. Impact of Late Dosing on Testosterone Suppression for In Situ Gel Compared to Microsphere Delivered Leuprolide Acetate – An Analysis of US Clinical Data. Second Place Poster.
568. Western Section of AUA, Indian Wells, CA, Oct. 30-Nov. 4, 2021. 6-Month GnRHa Formulations Are a God Choice During the COVID-19 Pandemic and Beyond.
569. American Urological Association Annual Meeting, New Orleans, LA, May 13-16, 2022. SelectMDx Urine Test Diagnose Men with High-Grade Prostate Cancer
570. American Urological Association Annual Meeting, New Orleans, LA, May 13-16, 2022. Scientific Evidence Supporting Micro-Ultrasound

571. American Urological Association Annual Meeting, New Orleans, LA, May 13-16, 2022. Overall Safety and Incidences of Adverse Events by Time Interval With Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in the Phase 3 ARASENS Trial
572. American Urological Association Annual Meeting, New Orleans, LA, May 13-16, 2022. Antimicrobial Resistance and Microbial Patterns Within the Chronic Prostatitis Urobiome Compared To Asymptomatic Healthy Controls

XII. PRESENTATIONS AT INTERNATIONAL MEETINGS AND SEMINARS

1. Update on Prostatitis. Panel member with Drs. William Fair, Paul Madsen and David Mobley. St. Thomas, March 27, 1981.
2. Treatment of Urinary Tract Infections with Ceftizoxime. Symposium, Bermuda, November 16, 1981.
3. Urinary Tract Infections. Panel member with Keith Waterhouse, Lowell Parsons, Anthony Schaffer and Morton Goldfarb. Cancun, Mexico, November 12, 1982.
4. Treatment of Metastatic Bladder Cancer. Presented at the 13th International Congress of Chemotherapy. Vienna, Austria, August 25, 1983.
5. Prevention of Urinary Tract Infections Following Transurethral Resection of the Prostate. Presented at the 13th International Congress of Chemotherapy. Vienna, Austria, August 25, 1983.
6. Urinary Tract Infection Following Transrectal Biopsy of the Prostate. Presented at the 13th International Congress of Chemotherapy. Vienna, Austria, August 25, 1983.
7. Chemotherapy: Cis-platinum. First International Symposium on Testicular Tumors. Paris, France, October 9, 1984.
8. Chemotherapy of Advanced Seminoma. First International Symposium on Testicular Tumors. Paris, France, October 9, 1984.
9. Objective Responses and Adrenocorticosteroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide (AG) plus Hydrocortisone (HC). Yvan J. Levasseur, MD and E. David Crawford, MD. 14th International Congress of Chemotherapy. Kyoto, Japan, June 24, 1985.
10. VI Congreso de Cancerologia de Centroamerica, Panama y el Caribe. Invited speaker. Presentations: Radical Retroperitoneal Lymph Node Dissection; Advanced Prostate Cancer; Superficial Bladder Cancer; Metastatic Renal Cancer; In-situ Bladder Cancer; Testicular Cancer; Nerve-Sparing Radical Prostatectomy and Advanced Seminoma. San Jose, Costa Rico, December 4-6, 1985.
11. Intraarterial Chemotherapy for Advanced Pelvic Malignancies. Southeast Section of the AUA, Puerto Rico, March 16-19, 1986.
12. Chemical Inhibition of the Adrenal Gland. Invited speaker, Second International Symposium on Prostatic Carcinoma. Paris, France, June 16-18, 1986.
13. Medical Adrenalectomy with Aminoglutethimide and Hydrocortisone in the Treatment of Advanced Prostate Cancer. International Symposium on Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Milano, Italy, April 6-8, 1987.
14. A Comparison of Leuprolide (L) with Flutamide (F) and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate, Phase III, Intergroup Study 0035. ED Crawford, MD, D McLeod, MD, A Door, MD, J Spaulding, MD, Ralph Benson, MD, M Eisenberger, MD, and Brent Blumenstein, MD. Invited speaker, cooperation with the 66th Annual Meeting, South Central Section of the American Urological Association in British Association of Urological Surgeons. London, England, October 25-28, 1987.
15. A Randomized Clinical Trial Comparing Cisplatin, Vinblastine plus Either Bleomycin (PVB) or VP-16 (VPV) and Surgical Resection of Residual Disease in Advanced Testicular Cancer: A Southwest Oncology Group Study (SWOG). E. David Crawford, MD, Michael K. Samson, MD, Ronald Natale, MD, N.T. Shaw, MD, Brent Blumenstein, MD, and Marilyn A. Davis, RN. Invited speaker, 66th Annual Meeting, South Central Section of the American Urological Association in cooperation with the British Association of Urological Surgeons. London, England, October 25-28, 1987.

16. Flutamide in Combination with LHRH for Advanced Prostate Cancer. Nordic Urologic Symposium. Hotel Scandinavia, October 30, 1987.
17. Moderator, Surgical Management, with K. Matsumoto. The Second Tokyo Symposium on Prostate Cancer. Tokyo, Japan, December 12, 1987.
18. Treatment of Newly Diagnosed Stage D2 Prostate Cancer with a Combination of LHRH Analogue and Flutamide. Invited speaker, The Second Tokyo Symposium on Prostate Cancer. Tokyo, Japan, December 12, 1987.
19. Current Concepts in the Treatment of Advanced Prostate Cancer. Frankfurt, Germany, February 19, 1988.
20. Newly diagnosed metastatic prostate cancer: Treatment with Leuprolide and Flutamide versus Leuprolide Alone. International Symposium on GnRH Analogues in Cancer and Human Reproduction. Geneva, Switzerland, February 20, 1988.
21. Review of International Studies. Congress--Flutamide: From Clinical Research to Practice Results and Perspectives. Monte Carlo, Monaco, May 5, 1988.
22. Poster session presentation. International Symposium on Endocrine Therapy. Monte Carlo, Monaco, November 19-21, 1988.
23. Panel member with W.B. Peeling, G. Lunglmayr, L. Denis, M. Soloway, M. Namer, A. Bono, and H. Becker. Therapy of Advanced Prostate Cancer. International Symposium on Endocrine Therapy. Monte Carlo, Monaco, November 21, 1988.
24. Treatment of Advanced Prostate Cancer. Austrian Urological Society, Vienna, Austria, November 22, 1988.
25. Treatment of Advanced Prostate Cancer. Prostate Cancer--State of the Art 1989 Symposium. Luxembourg, Belgium, April 15, 1989.
26. Advances in the Treatment of Prostate Cancer. French Urological Society. Paris, France, April 17, 1989.
27. Current Concepts in the Surgical Treatment of Testicular Tumors. Frontiers in Uro-Oncology, Toronto, Ontario, Canada, April 21, 1989.
28. Panel member with A. Hussey, I. Tannock, A.T. Porter, C. Brendler, and G. Murphy. Prostate Cancer Case Discussions. Frontiers in Uro-Oncology, Toronto, Ontario, Canada, April 22, 1989.
29. Boloqueo androgenico completo: actualizacion del estudio del N.C.I. Simposium Internacional, Asociacion Espanola de Urologia. Vigo, Spain, June 16, 1989.
30. Cystectomy \pm MVAC: A Southwest Oncology Group Experience. Urologic Oncology Meeting. Toronto, Ontario, Canada, October 13, 1989.
31. Combined versus Conventional Hormonal Therapy: Intergroup Study. Urologic Oncology Meeting. Toronto, Ontario, Canada, October 14, 1989.
32. LHRH Analogues in the Management of Prostatic Cancer: Recent Clinical Advances in the U.S.A. Monte Carlo, Monaco, January 20, 1990.
33. Second International Symposium on Hormonal Manipulation of Cancer: peptides, Growth Factors, and New Anti-Steroidal Agents. Rotterdam, April 9-11, 1990.
34. Long-Term Follow-Up of Patients treated by Leuprolide and Flutamide or Leuprolide Alone, Phase III, Int. 0036). Diagnostic Procedures for Early and Advanced Prostate Cancer. IXth European Association of Urology. Amsterdam, The Netherlands, June 12, 1990.
35. Second International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris, France, June 27-29, 1990.
36. Overview Randomized Trials M1 Prostate Cancer with Combination Treatment. Paris, France, June 30, 1990.
37. Total Androgen Blockade: The NCI Study. International Testicular and Prostatic Cancer Conference. Toronto, Canada, October 6, 1990.
38. Current Concepts in the Hormonal Therapy of Advanced Prostate Cancer. Royal Society of Medicine, Urology Section. Vail, Colorado, February 24, 1991.

39. Etiology and Historical Perspective. Recent Advances in the Usage of Mitomycin. Kona, Hawaii, March 23, 1991.
40. Future Directions. Recent Advances in the Usage of Mitomycin. Kona, Hawaii, March 23, 1991.
41. Does Total Androgen Ablation Confer any Advantage? Prostate Cancer: Management Trends in the 90s. University College Dublin. Dublin, Ireland, April 20, 1991.
42. Current Concepts in the Management of Prostatic Cancer. Royal Society of Medicine. London, England, April 25, 1991.
43. Value of Screening for Prostatic Carcinoma. Royal Society of Medicine. London, England, April 25, 1991.
44. International Prostate Disease Symposium. Co-moderator with Marco Caine M.S., FRCS. 22nd Congress of Societe Internationale D'Urologie. Seville Spain November 1, 1991.
45. Challenges in the Management of Prostate Cancer. Symposium held in association with the Societe Internationale D'Urologie, November 1, 1991.
46. Program Chairman. Second International Prostate Cancer Update. Beaver Creek Colorado, January 19-22, 1992
47. Prostate Cancer Screening. Presented at the Second International Prostate Cancer Update. Beaver Creek Colorado, Jan 21, 1992.
48. United States Experience in Screening for Prostate Cancer. Presented at the International Conference on Screening for Prostate Cancer, Munich, Germany, March, 20, 1992.
49. Is Screening for Prostate Cancer Worthwhile? University Hospital, Vienna, Austria, March 23, 1992.
50. Challenges in Prostate Cancer. Plenary Session presentation at the 3rd International Conference on Geriatric Nephrology and Urology. Toronto, Canada, April 3, 1992.
51. Management of Localized Prostate Cancer. 3rd International Conference on Geriatric Nephrology and Urology. Toronto, Canada, April 4, 1992.
52. Hormonal Therapy of Advanced Prostate Cancer. Presented at the Princess Margaret Hospital Oncology Conference. April 3, 1992, Toronto, Canada.
53. State of the Art: The Challenge of Total Androgen Blockade. Euro-American Conference on Urological Cancer. September 17, 1992.
54. Keynote Lecture: What is the optimal therapy for Stages C and D prostate Cancer . International Controversies in Bladder and Prostate Cancer Management. Mexico City, November 19, 1992
55. Is Laparoscopic lymph node dissection useful in the management of Prostate Cancer? Presented at the International Controversies in Bladder and Prostate Cancer Management. Mexico City, November 19, 1992.
56. Benign Prostatic Hyperplasia: TULIP - National Human Cooperative Study Results. Presented at South Central Section of American Urological Association, Acapulco, Mexico. Oct 2-7, 1993.
57. Prostate Cancer: Prostate Cancer Forum. Presented at South Central Section of American Urological Association, Acapulco, Mexico. Oct 2-7, 1993.
58. Prostate Cancer Awareness Week: Benefits and Shortcomings of Community-Based Screening for Prostate Cancer. Presented at South Central Section of American Urological Association, Acapulco, Mexico. Oct 2-7, 1993.
59. Neoadjuvant Hormonal Therapy of Patients with Clinical Stage C Prostate Cancer. Presented at South Central Section of American Urological Association, Acapulco, Mexico. Oct 2-7, 1993.
60. Prostate Cancer Awareness. Presented as Special Guest Lecturer at Leicester Medical Society, Leicester, England. Nov 15, 1993.
61. Aspects of Bladder Cancer; and Aspects of Prostate Cancer. Presented at Trent Urology Group Meeting, Leicester, England. Nov 17, 1993.
62. Introduction and Overview; Hormonal Therapy: Intergroup Trials, presented at Fourth International Prostate Cancer Update. Beaver Creek, CO. Jan 27-30, 1994.
63. Management Strategies for Locally Advanced Metastatic Prostate Cancer. Presented at Royal Society of Medicine, Section of Urology, Breckenridge, CO. Feb 9, 1994

64. Treatment Consensus Group Chairman of Consensus Workshop on Screening and Global Strategy for Prostate Cancer, Antwerp, Belgium, Mar 5-7, 1994.
65. Fourth International European Urological Summer Forum presentations: Prostate Cancer Awareness; Age-Specific PSA; Superficial Bladder Cancer Treatment Strategies; Diagnosis and Treatment of Prostate Cancer; Prostate Awareness versus Prostate Ignorance. Vaals, Netherlands. June 12-19, 1994.
66. Fourth International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment presentations: Adding Antiandrogen to Castration - Is the Controversy Resolved?; session chairman for Is BCG the First Choice Intravesical Therapy? For How Long Should Treatment Be Administered? Paris, France. June 22-24, 1994.
67. Eleventh Annual Congress of the European Association of Urologists presentations: Cryosurgical Management of Localized Prostate Cancer; interactive session on Metastatic Prostate Cancer. Berlin, Germany. July 13-17, 1994.
68. Urology in the Americas: Update on Prostatic Diseases Management, presentations: State of the Art - Lasers, Balloons, and Watchful Waiting; Outcome of Prostate Cancer Awareness Weeks; State of the Art - Current Concepts in Advanced Prostate Cancer. Ixtapa, Mexico. July 27-30, 1994.
69. Defining Advanced Prostate Cancer. Presented at Zeneca's Casodex meeting. United Kingdom. Sep 25-29, 1994.
70. Chairman of Fifth International Prostate Cancer Update. Also presenting: Chemo Prevention and Prostate Cancer Awareness, and An Overview of Advanced Disease. Vail/Beaver Creek, CO, February 2-5, 1995.
71. International Conference on Androgenic Hormones, Prostate Cancer, and Benign Prostatic Hyperplasia. Poster Session and Discussion Period. New Orleans, LA, March 12-13, 1995.
72. Pan African Urological Surgeons Association and the section of urology, Royal Society of Medicine. Presented New Options for Advanced Prostate Cancer. Zimbabwe, Africa, March 24-25, 1995.
73. Co-chairman of Therapeutic Innovations in BPH and Prostate Cancer. Also presented Watchful Waiting--The VA Cooperative Study, and Challenges in Early Diagnosis and Treatment of Prostate Cancer. Charlestown, Nevis, West Indies, July 13-15, 1995.
74. Fifth International Congress on Hormones and Cancer. Presented Recent American Multicenter Trials for Patients with Metastatic Prostate Cancer. Quebec, Canada, September 20, 1995.
75. International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer. Presented Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate. Also chairman of symposium: Impact of PSA for Early Detection. Quebec, Canada, September 23, 1995.
76. Prostate Cancer -- Current Issues, New Approaches. Presented Combined Androgen Blockade. London, England, October 19, 1995
77. Chairman and speaker: Sixth International Prostate Cancer Update. Vail/Beaver Creek, Colorado, February 1-4, 1996.
78. Speaker at Urologic Academic Physicians Forum. Cancun, Mexico, February 22-25, 1996.
79. Co-Chairman of Prostatic Disease: Insights and Innovations. Banff, Canada, February 29-March 2, 1996; Vail, Colorado, June 27-29, 1996; Hamilton, Bermuda, July 25-27, 1996; and Palm Desert, California, October 3-5, 1996.
80. State of the Art Lecture: Diagnosis and Management of Prostate Cancer. Grand Rounds, University Hospital, Nijmegen, The Netherlands, June 4, 1996.
81. Screening and Early Detection of Prostate Cancer. University Hospital, Nijmegen, The Netherlands. June 5, 1996.
82. National Association of Spanish Urologists. Presented Challenges in the Management of Prostate Cancer. May 30, 1996.
83. T3 Prostate Cancer. Presented at Urotrends 2000 Meeting. Bermuda, June 7, 1996.
84. Special Invited Guest Lecture: Treatment of Advanced Prostate Cancer. Annual Meeting of the Japanese Society of Urologic Oncologists. July 13, 1996.
85. International Meeting of the European Association of Urology. Chairman of the Inter-active Workshop. Lecture: Prostatic Disease Management. Paris, France. August 30-September 4, 1996.

86. Chairman of the Management of Prostate Cancer: A European/American Encounter. Also presented lectures: (keynote) Redefining the Nature of Advanced Prostate Cancer; Review of Clinical Trials with Combined Androgen Blockade; and Rising PSA After Radical Prostatectomy: Clinical Implications. Munich, Germany. November 2-3, 1996.
87. Second International Forum on Prostate Cancer. Lecture: Maximum Androgen Blockade -- Clinical Basis. London, England. December 10-12, 1996.
88. Controversies in Prostate Cancer: Diagnosis & Management. Mexico City, Mexico. January 9-12, 1997.
89. Seventh International Prostate Cancer Update. Vail/Beaver Creek, Colorado. January 22-26, 1997.
90. Sixth European Urological Winter Forum. Lectures: Interactive Workshop and Case Discussion; State of the Art Lecture -- Screening and Early Detection of Prostate Cancer; participant in Teaching Session #3 -- Bladder Cancer; participant in Teaching Session #4 -- Prostate Cancer; Round Table Discussion on Superficial Bladder Cancer in the Daily Urological Practice; participant in Teaching Session #9 -- Prostate Oncology. Davos, Switzerland. February 16-21, 1997.
91. Combination Therapy for Advanced Prostate Cancer. Presented to Prostate Cancer Trialists Collaborative Group. Amsterdam, The Netherlands. April 24-25, 1997.
92. Management of Stage T3 Prostate Cancer. Changing Paradigms of Advanced Prostate Cancer. Presented at 17th Annual Athenian Days of Urology. Athens, Greece. May 15-18, 1997.
93. Screening: Who, When, How? Structured Debate on Screening. T1-T2 Disease Panel. The Role of Antiandrogens Today. Presented at the International Baltic Uro-Oncologic Symposium on Prostate Cancer. Kiel, Germany. June 26-28, 1997.
94. Screening in the United States. USA National Prostate Cancer Awareness Week program. First International Meeting on Advances in the Knowledge of Cancer Management. Vienna, Austria. June 28-July 1, 1997.
95. Screening for Prostate Cancer -- Is It Feasible? Is It Sensible? The U.S. Experience. and Combined Androgen Blockade -- Status and Current Recommendations. Presented at the International Conference on Prostatic Carcinoma. Copenhagen, Denmark. August 22-23, 1997.
96. Chemoprevention of Prostate Cancer. Presented at the Roche Laboratories Research Conference. Basel, Switzerland. August 25, 1997.
97. Chemoprevention of Prostate Cancer. Presented at Cancer Chemoprevention: A New Dimension of Oncology. St. Gallen, Switzerland. August 28-30, 1997.
98. Symposium Moderator: Controversies in the Treatment of Prostate Cancer and Long-Term Efficacy and Safety of Maximal Androgen Blockade with Nilutamide and Castration in Stage D2 Cancer (poster session). Society of International Urologists 24th Annual Congress. Montreal, Canada. September 7-11, 1997.
99. Sociedad Mexicana de Urologia. Forty-eighth Congreso Nacional. Invited Guest Speaker. Acapulco, Mexico. November 19, 1997.
100. The Future of Hormonal Therapy. Presented at: Early Prostate Cancer - Developing a Strategy for the Next Two Decades. Miami, Florida. January 3, 1998.
101. Eighth International Prostate Cancer Update. Chairman. Presentations: PSA As a Surrogate Marker. Neoadjuvant Hormonal Therapy. Defining Advanced Prostate Cancer. Vail/Beaver Creek, Colorado. January 28-February 1, 1998.
102. Prostate Specific Antigen. And Results of Prostate Cancer Awareness Week. And Neoadjuvant Hormonal Therapy. And Stage T3 Prostate Cancer. And Management of Superficial Bladder Cancer. Presented at the Fourth Congress of Urologic Oncology. Caracas, Venezuela. February 19-21, 1998.
103. The Effect of MAB on Survival and progression-Free Survival End-Points - An Assessment of Major Trials. Thirteenth Congress of the European Association of Urology. Barcelona, Spain. March 21-25, 1998.
104. Eighth National Symposium of Endourology. Special Invited Guest Speaker. Bucharest, Romania. May 6-9, 1998.

105. Current Findings on Prostate Specific Antigen and Its Role in Chemoprevention Trials. And Panel Moderator: Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention. Presented at Strategies for the Chemoprevention of Prostate Cancer. Brussels, Belgium. October 30-31, 1998.
106. 24th Congresso de la Confederacion Americana de Urologie. Special Invited Guest Speaker on prostate and bladder cancers. Cancun, Mexico. November 8-12, 1998.
107. Presented as chairman of the 9th International Prostate Cancer Update. PSA: Use in Defining High Risk Population Cohorts. Neural Networks: Predicting Outcomes. Rising PSA after Failed Local Therapy: Stage D₁. Moderator of Special Session on Benign Prostatic Hyperplasia Update. Moderator of Special Session on Advanced Disease. Beaver Creek, CO. January 20-24, 1999.
108. Presented at the 8th European Urological Winter Forum. State of the Art Lecture: Hormone Therapy of Prostate Cancer in the Next Millenium. Screening for Prostate Cancer: Sense or Nonsense? Intravesical Chemotherapy for Superficial Bladder Cancer Revisited. How I Manage T₃ Prostate Cancer. Davos, Switzerland. February 21-25, 1999.
109. The 3rd International Symposium on Prostatic Surgery: Radical Prostatectomy: Retropubic vs. Perineal. Also live surgery: Nerve-Sparing Retropubic Radical Prostatectomy. L'Aquila, Italy. May 23-25, 1999.
110. The 2nd International Consultation on Prostate Cancer: Computer-aided Decision-Making for Patient Consultation: ANNs (artificial neural networks) in Prostate Cancer. Also committee chairman: Management of Newly-Diagnosed Metastatic Prostate Cancer. Paris, France. June 27-29, 1999.
111. Workshop on Prostate Markers: Use of ANN (artificial neural network) for Diagnosis and Staging. Whistler, British Columbia, Canada. July 17-18, 1999.
112. Course Chairman: Tenth International Prostate Cancer Update. Vail, Colorado, February 2-6, 2000.
113. Use of Artificial Neural Networks in Predicting the Presence of Prostate Cancer. Tenth International Prostate Cancer Update. Vail, Colorado, February 2, 2000.
114. Use of PSA to Define High-Risk Cohorts. Tenth International Prostate Cancer Update. Vail, Colorado, February 3, 2000.
115. Ligasure – Surgery into the Next Millenium. Tenth International Prostate Cancer Update. Vail, Colorado, February 4, 2000.
116. Prediction of Prostate Cancer Clinical Outcome and Pathology Using Artificial Intelligence. (abstract #147) XVth Congress of the European Association of Urology, Brussels, Belgium, April, 2000.
117. Three Dimensional Prostate Cancer Imaging: Artificial Neural Network Analysis (ANNA) of Subvisual Transrectal Ultrasound Information (abstract #466). XVth Congress of the European Association of Urology, Brussels, Belgium, April 2000.
118. Androgen Deprivation Using Low Dose Flutamide and Finasteride in the Treatment of Prostate Cancer Failures. (abstract #515) XVth Congress of the European Association of Urology, Brussels, Belgium, April, 2000.
119. The Complete Prostatectomy: Role of the Ligasure Device, 11th International Prostate Cancer Update, Vail, CO, February 2, 2001.
120. Scientific Session VII: Advanced Disease, Moderator. 11th International Prostate Cancer Update, Vail, CO, February 3, 2001.
121. Early Vs Late Endocrine Therapy: The Jury Is In. Is There A Role For Earlier Chemotherapy? The Jury Is About To Reach A Verdict. 1th International Prostate Cancer Update, Vail, CO, February 3, 2001.
122. Patient Selection for Chemotherapy in Prostate Cancer. Invited speaker: European Association of Urology, Geneva, Switzerland, April 9, 2001.
123. Bone Metastases Prevention Programme (The Future). Symposium 17: New Management Options for the Treatment of Prostate Cancer Related Bone Metastases. XVIII EAU Congress, Birmingham, England, February 26, 2002.
124. PSA Testing Interval, Reduction In Screening Intervals: Data From The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. 18th UICC International Cancer Congress, Oslo, Norway, July 2, 2002.

125. Survey of Ongoing Clinical Trials – United States. First International Conference on Chemoprevention of Prostate Cancer, San Antonio, TX, March 7, 2003.
126. Bone complications and their impact on patient quality of life. Bone Complications in Prostate Cancer: The Clinical Role of Zoledronic Acid. Rome, Italy, September 8, 2003.
127. Is there a role for early hormonal/chemotherapy in prostate cancer? Special guest lecturer: The Charles Higgins, MD Lecture, 54th Annual Puerto Rico Urological Association meeting, San Juan, Puerto Rico, November 15, 2003.
128. Screening for prostate cancer is beneficial. 54th Annual Puerto Rico Urological Association meeting, San Juan, Puerto Rico, November 15, 2003.
129. Men over 80 – the growing challenge: Cancer detection and management. Third World Congress on Men’s Health, Vienna, Austria, October 25, 2003.
130. Hormone Replacement Therapy: Monitoring results and risks. Third World Congress on Men’s Health, Vienna, Austria, October 25, 2003.
131. Screening intervals for prostate cancer: Data from PCAW and PLCO. 14th International Prostate Cancer Update, Vail, CO February 4, 2004.
132. Managing biochemical failure: Making progress? 14th International Prostate Cancer Update, Vail, CO February 4, 2004.
133. Prostate: State of the science – Surgery. Third International Symposium on Genitourinary Cancers, Santa Barbara, CA, February 28, 2004.
134. Screening in Cancer of Prostate. Controversies and Advances. International Symposium: Advances In Urologic, 2004, Buenos Aires, Argentina, May 28, 2004.
135. Routine PSA screening for early detection of prostate cancer (Pro). Fourth International Prostate Cancer Congress, Grand Bahama Island, July 18, 2004.
136. Detection and Prevention of prostate cancer in 2004: where do we stand? Impact of PCPT. Global GU Oncology Conference, Honolulu, HI October 2, 2004.
137. The relationship between testosterone, BMI and cholesterol: data from Prostate Cancer Awareness Week. 27th Congress of the Society of International Urology, Honolulu, HI October 3, 2004.
138. Crawford ED, Barqawi A, Maroni PD, O’Donnell C, Chandhoke R and Zurawel A: A video demonstration of mini laparotomy antegrade nerve-sparing radical prostatectomy assisted by Plasmakinetics (PK) Seal Lyons Dissector Device©. 27th Congress of the Society of International Urology, Honolulu, HI October 3, 2004.
139. LUTS/BPH management: the central role of the patient risk profile. 27th Congress of the Society of International Urology, Honolulu, HI October 4, 2004.
140. Donohue R, Crawford ED and Lucia S: Gleason sum of PCPT and historic and current university and VA biopsies – any difference? (Abstract 1.11) 27th Congress of the Society of International Urology, Honolulu, HI October 4, 2004.
141. A 12-month clinical study of La-2585 45.0 mg: a new 6-month subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. 27th Congress of the Society of International Urology, Honolulu, HI October 4, 2004.
142. PSA as a predictor of outcomes in prostate cancer. Changing Paradigms in Prostate Cancer meeting. London, England October 9, 2004.
143. Why is Screening Controversial? 15th Annual International Prostate Cancer Update, Vail, CO February 9, 2005.
144. Immunology Drugs. 15th Annual International Prostate Cancer Update, Vail, CO February 9, 2005.
145. PSA as a surrogate marker for advanced disease. 15th Annual International Prostate Cancer Update, Vail, CO February 9, 2005.
146. TRT and the prostate. European Association of Urology Satellite Symposium, Istanbul, Turkey, July 17, 2005.
147. Targeted therapies in prostate cancer. State-of-the-art Lecture. 5th International Prostate Cancer Congress, Rio Mar Beach, Puerto Rico, July 1, 2005.

148. All men should undergo PSA screening for prostate cancer: Pro. Targeted therapies in prostate cancer. 5th International Prostate Cancer Congress, Rio Mar Beach, Puerto Rico, July 21, 2005.
149. New answers from PCPT on the chemoprevention of prostate cancer. First International Conference on Urogenital Disorders – from Gene to Clinics. Malmö, Sweden, September 2, 2005.
150. 5-year bNED and morbidity of high dose rate brachytherapy (HDR), conformal radiotherapy (3D-CRT), and androgen deprivation (AD) for intermediate (IR) and high risk (HR) prostate cancer: results of a prospective multicenter phase I/II dose escalation trial. 47th Annual American Society for Therapeutic Radiology and Oncology, Denver, CO, October, 2005.
151. Complications of Hormonal Therapy: Osteoporosis, Hot Flashes, and Others. 16th International Prostate Cancer Symposium, Vail, Colorado, January, 2006.
152. Targeted Therapy: Is there a Role? 16th International Prostate Cancer Symposium, Vail, Colorado, January, 2006.
153. Minimally invasive mini-lap radical retropubic prostatectomy. 16th International Prostate Cancer Symposium, Vail, Colorado, January 18, 2006.
154. The PCPT: The Latest Analysis. European Association of Urology Conference, Davos, Switzerland, February 10, 2006.
155. Targeting Bone Health: Reducing Complications of Prostate Cancer. Southeast Section of AUA Annual Meeting, Rio Grande, Puerto Rico, March 4, 2006.
156. Hormone Therapy for Prostate Cancer. Takeda Meeting, Tokyo, Japan, February 25, 2006.
157. Screening for Prostate Cancer. 2006 Prostate Cancer Update Conference, Budapest, Hungary, September 29-October 1, 2006.
158. Chemoprevention of Prostate Cancer: Lessons Learned. 2006 Prostate Cancer Update Conference, Budapest, Hungary, September 29-October 1, 2006.
159. Why the Controversy Regarding Screening. International Conference on Prostate Cancer 2006, Reston, Virginia, October 19-22, 2006.
160. Long-Term Survival in Patients with Bone Mets on Hormonal Therapy. International Conference on Prostate Cancer 2006, Reston, Virginia, October 19-22, 2006.
161. The Cooperative Groups Have Contributed Significantly to Global Clinical Research. Urology Beyond Boundaries Symposium, European Association of Urology, Nijmegen, The Netherlands, October 26-27, 2006.
162. Clinical Practice Guidelines for Prostate Cancer Early Detection. 50th Phillippine Urological Association, Annual Convention and Golden Anniversary Celebrations, Mandaluyong City, Phillippines, November 28-December 1, 2007.
163. The Role of Open Surgery and its Modification in Localized Prostate Cancer in the 21st Century. 50th Phillippine Urological Association, Annual Convention and Golden Anniversary Celebrations, Mandaluyong City, Phillippines, November 28-December 1, 2007.
164. Treatment of the Primary Prostate Cancer in Metastatic Disease. 50th Phillippine Urological Association, Annual Convention and Golden Anniversary Celebrations, Mandaluyong City, Phillippines, November 28-December 1, 2007.
165. Why Is There a Demand for Targeted Focal Therapy? Proposed Selection Criteria. 1st International Targeted Focal Therapy Conference, Phoenix, Arizona, February 10, 2008.
166. Current and Future Modalities for Imaging of Prostate Cancer Foci-The Role of 3-D Mapping Biopsy of the Prostate: Early Results. 1st International Targeted Focal Therapy Conference, Phoenix, Arizona, February 10, 2008.
167. Evolution of Modern Hormonal Treatment. 23rd Annual European Association of Urology (EAU) Congress, Milan, Italy, March 26-29, 2008.
168. Cryosurgery of Kidney Cancer. 23rd Annual European Association of Urology (EAU) Congress, Milan, Italy, March 26-29, 2008.
169. Focal Therapy: Has Its Time Arrived? Eighth International Congress on Genitourinary Malignancies, Washington, DC, July 17-19, 2008.

170. 12th Congress Association Mexican Urologic Oncology Symposium International, Acapulco, Mexico, July 21-24, 2010.
171. Invited Speaker: “Prostate Cancer I – Active Surveillance: in whom and how?” Men’s Health World Congress, Nice, France, October 28, 2010.
172. Invited Speaker: “Prostate Cancer II – Innovations for the treatment of prostate cancer.” Men’s Health World Congress, Nice, France, October 29, 2010.
173. Invited Speaker: “Evolving role of hormonal therapy in the management.” 21st National Congress of Urology, Istanbul, Turkey, October 31, 2010.
174. Invited Speaker: “Nomograms in urooncology.” 21st National Congress of Urology, Istanbul, Turkey, November 1, 2010.
175. Invited Speaker: “The role of medical treatment in locally advanced prostate cancer.” 21st National Congress of Urology, Istanbul, Turkey, November 1, 2010.
176. Advances in Hormonal Therapy. 22nd International Prostate Cancer Update. Vail, Colorado. January 27, 2012.
177. Invited Speaker: “PSA and new prostate markers.” XII Paulisa Congress of Urology. Sao Paulo, Brazil. September 5, 2012.
178. Invited Speaker: Prague at Stop 4 International Prostate Cancer Meeting. Prague, Czech Republic. October 13, 2012.
179. Invited Speaker: “The Future Sequencing of Treatment Agents for CRPC.” Asia-Pacific Urology Consortium. January 12, 2013.
180. “Advances in Hormonal Therapy.” 23rd International Prostate Cancer Update. Vail, CO. January 25, 2013.
181. “Novel marker strategies for prostate cancer diagnosis and prognosis.” 13th Annual Congress; Futurology: Shifting the paradigms in urology. December 7, 2013.
182. “State-of-The-Art Advanced Treatment Landscape.” 24th International Prostate Cancer Update. February 21st, 2014.
183. The 2nd Friends of Israel Urological Symposium. “Upgrading and Upstaging in Patients Undergoing a Radical Prostatectomy: Rate, Need for Salvage Therapy, Effect on Survival.” July 2nd, 2014.
184. The 2nd Friends of Israel Urological Symposium. “Saturation Biopsies.” July 2nd, 2014.
185. The 2nd Friends of Israel Urological Symposium. “Targeted Technique Will Replace the Standard Random Prostate Biopsy.” July 3rd, 2014.
186. Multi-Disciplinary Approach to Problems in Uro-Oncology. “The Role of Androgen Deprivation Therapy Across All Stages of Prostate Cancer.” September 27, 2014.
187. Multi-Disciplinary Approach to Problems in Uro-Oncology. “Point-Counterpoint: The Role of Cytoreductive Nephrectomy in the Management of Advanced Renal Cell Carcinoma: Point For.” September 27, 2014.
188. Multi-Disciplinary Approach to Problems in Uro-Oncology. “Trends in the Management of Castrate Resistant Prostate Cancer: Evolving Therapeutic Paradigm.” September 27, 2014.
189. Will Regular Screening of men with Genetic Mutations Lead to a Better Survival in Prostate Cancer? Special Session of the Prostate Cancer Prevention Group. The European Association of Urology. March 20th, 2015.
190. The Truth about TRT (Testosterone Replacement Therapy) for the Treatment of Hypogonadism. TRT: Controversies vs. Reality. 30th Annual European Urology Association Congress. March 21st, 2015
191. State of the Art Lecture- What are currently the Best Decision Markers for Biopsy and Re-biopsy of the prostate? The European Association of Urology Plenary Session 4. March 24th, 2015.
192. Special Symposium: 3-dimensional Trans perineal Mapping Biopsy and Targeted Focal Therapy for the Management of Organ Confined Prostate Cancer. The 13th Korean Urological Oncology Society. March 28th, 2015
193. Androgen Annihilation as a new Therapeutic Paradigm in Advanced Prostate Cancer. The 13th Korean Urological Oncology Society. March 28th, 2015

194. Session II: Benefits of GnRH Antagonist for the Treatment of Prostate Cancer – E. David Crawford, MD, 66th Annual Meeting of the Puerto Rican Urologic Association, San Juan, Puerto Rico, September 24-26, 2015
195. Session II: Markers and Screening in Prostate Cancer - E. David Crawford, MD, 66th Annual Meeting of the Puerto Rican Urologic Association, San Juan, Puerto Rico, September 24-26, 2016
196. Advanced Prostate Cancer: Androgen Deprivation Therapy. E. David Crawford, MD University of Colorado, Denver USA November 1st 2015 Caribbean Urological Association – 17th Annual International Conference.
197. Session I: Prevention, Screening, And Genomic Markers- What Are Currently the Best Decision Markers for Biopsy and Re-Biopsy of the Prostate? – E. David Crawford, MD – International Prostate Cancer Update Vail, CO January 20-23, 2016
198. Session 1: Video 2: A Better Biopsy – E. David Crawford, MD – 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer – Durham, North Carolina June 23-25, 2016
199. Session 3: Late Breaking News – E. David Crawford, 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer – Durham, North Carolina June 23-25, 2016
200. Session 4: Epigenetic Aspects of Focal Therapy - E. David Crawford, 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer – Durham, North Carolina June 23-25, 2016
201. WUOF October 23-28, 2016- Buenos Aires – Agenda – Prostate Cancer prevention is dead – Pro: |E. David Crawford MD | USA – Con: | Neil Fleshner MD | Canada
202. WUOF October 23-28, 2016 – E. David Crawford, MD – pg.56 – Does Digital Rectal Exam Affect the 4Kscore Test for Aggressive Prostate Cancer? – Michael A. Maccini, MD; Nicholas J. Westfall, MD; Adrie Van Bokhoven, PhD; Priya N. Werahera, PhD; Paul Maroni, MD; Shandra S. Wilson, MD; L. Michael Glode, MD, Paul Arangua; E. David Crawford, MD: Denver, CO.
203. WUOF October 23-28, 2016 – E. David Crawford, MD – Role of FSH in the Musculoskeletal Side Effects Associated With Androgen Deprivation Therapy (ADT) For Prostate Cancer. – E. David Crawford MD, Andrew V. Schally, PhD, MDhc (Multi), D.Sc., hc, John H. Hoeneimyer, MD, Neal D. Shore, MD, FACS, CPI, Phillip A. Saccone, PhD, Thomas J. Beveridge, PhD, Dennis C. Marshall, RN, MS, PhD: Aurora, CO.
204. WUOF October 23-28, 2016 – E. David Crawford – Direct Pharmacokinetic and Pharmacodynamics Comparison of Subcutaneous Versus Intramuscular Leuprorelin Acetate Formulations in Male Subjects. – E. David Crawford, MD, John A. McLane, PhD, Stuart Atkinson, MB, Alex Yang, MD, Franklin Chy, MD: Aurora CO.
205. WUOF October 23-28, 2016 – State Of The Art Lecture – Breakthroughs With Biomarkers and Risk Stratification in Prostate Cancer. – E. David Crawford, MD, University of Colorado, Anschutz Medical Campus
206. Bayer Toyoko Japan November- Dcember 2016 – Comparing Sequencing of Enzalutamide and Abiraterone, Metastatic Prostate Cancer: Navigating the Challenges of Early Diagnosis and Management of Bone Metastasis – E. David Crawford, MD
207. Xian Janssen Pharmaceuticals Ltd. Beijing China – Advanced Prostate Cancer: Navigating the Challenges of CRPC – E. David Crawford, MD
208. SGSU January 13, 2017 Kimbrough Meeting – Session IX; Men’s Health, Session X: Prostate Cancer – Breakthroughs with Biomarkers and Risk Stratification in Prostate Cancer. – E. David Crawford, MD.
209. AUA Boston - May 13, 2017 PD24: Prostate Cancer: Advanced (including Drug Therapy) I – E. David Crawford, MD
210. AUA Boston – May 14, 2017 A Multidisciplinary Approach to the Treatment of Prostate Cancer: Providing Therapies that Improve Overall Survival and Quality of Life – E. David Crawford, MD
211. AUA Boston – May 16, 2017 - PD65-06: Patient NCCN Risk Classification Based on Combined Clinical Cell Cycle Risk (CCR) Score – E. David Crawford, MD
212. Annual AUA Meeting, Washington, DC , 05.03.2019, Plenary session speaker, Molecular Markets, Post graduate course, Presidential Citation

213. Annual Chinese Urological meeting, Beijing 07.06.2019
214. Future Directions in Urology, Colorado Springs, 08.06.2019. Program coordinator and speaker
215. Columbian Urologic Society, Bogat 9.26.19 Update in ADT in Porstate
216. American Brachtherapy Sociiety annual meeting, 11.01.19 Denver, CO Keynote Speaker Disruptive technologies
217. International Prostate Cancer Update, Beaver Creek CO, 1.23.2020-1.26.2020. Program Coordinator, Talks, markers , and CRPC
218. Asian Urological, Hong Kong and Macau, Invited keynote speaker, GNRH agonist or antagonist for prostate cancer patients
219. 12th International Focal therapy meeting, Washington, DC 02.10.20, Microultrasound . MRI in local prostate cancer
220. Austrailain Urological, Melbourne/Sydney 03.15.20, ADT in prostate cancer.

XIII. SCIENTIFIC PRESENTATIONS AND LECTURES (Local and Regional Meetings)

1. Deep Venous Thrombosis. Urology Rounds. University of Texas, Dallas, Texas, December, 1977.
2. Venous Thromboembolism Following TUR-Prostate. Urology Resident's Rounds. University of New Mexico, Albuquerque, New Mexico, January, 1978.
3. Truform Orthotics School. Cincinnati, Ohio, August, 1978.
4. Testicular Cancer. Urology Grand Rounds. Good Samaritan Hospital, Cincinnati, Ohio, September 22, 1978.
5. Urologic Diagnosis. Family Practice Seminar, September 24, 1978.
6. Bladder, Prostate and Testicular Cancer. Student Core Block. University of New Mexico, Albuquerque, New Mexico, October, 1978.
7. Genitourinary Exam. Family Practice Seminar, 1979.
8. Bladder Cancer. Cancer Research and Treatment Center Seminars, March, 1979.
9. Children and Teenagers with Ostomy. Presented at the United Ostomy Society Meeting. Albuquerque, New Mexico, March 3, 1979.
10. Prostate Cancer. Oncology Grand Rounds. BCMC, April 16, 1979.
11. Testicular Cancer. Oncology Grand Rounds. BCMC, April 23, 1979.
12. Bladder Cancer. Oncology Grand Rounds. BCMC, April 30, 1979.
13. Case Presentation. Oncology Grand Rounds. BCMC, May 1, 1979.
14. Truform Orthotics School. Cincinnati, Ohio, October 1-5, 1979.
15. Bladder, Prostate and Testicular Cancer. Core Grant Meeting, September 26, 1979.
16. Why Patients Get Ostomies. Albuquerque Ostomy Society. Anna Kaseman Hospital, November 20, 1979.
17. Prostate Cancer. Los Alamos Tumor Board, February 2, 1980.
18. Testicular Cancer. Los Alamos Tumor Board, September 8, 1980.
19. The Role of Antimicrobials in Prostatic Biopsy. Albuquerque Urology Meeting, July 24, 1980.
20. Current Status of Prostate, Bladder and Testicular Cancer. BCMC, Intracity Surgical Conference Grand Rounds, April 4, 1981.
21. Prostate and Testis Cancer Overview. Surgical Grand Rounds. Albuquerque, New Mexico, April 11, 1981.
22. Prostate and Testis Cancer Overview. Cannon Air Force Base, Clovis, New Mexico, November 10, 1981.
23. Prostate Cancer. Lea County Medical Society. Hobbs, New Mexico, January 14, 1982.
24. Testicular Cancer. Phoenix Oncology Society. Phoenix, Arizona, January 27, 1982.
25. Current Trends in Prostate and Testis Cancer. Georgia Baptist Medical Center, June 17, 1982.
26. Urologic Oncology. Laguna Beach, California, August 17, 1982.

27. The Chemotherapy of Testis Cancer. University of New Mexico, Albuquerque, New Mexico, May 19, 1983.
28. Treatment of Testicular Cancer. Cancer Update, CRTG, June 16, 1983.
29. Current Management of Renal Cell Carcinoma. Visiting Surgical Group, University of Mississippi, October 24, 1983.
30. The Cure of Testicular Cancer. Los Alamos Council on Cancer Annual Symposium. Los Alamos, New Mexico, November 18, 1983.
31. Current Concepts in the Management of Testicular Cancer. Touro Infirmary. New Orleans, Louisiana, December 6, 1983.
32. Advances in Genitourinary Cancer. Urology Grand Rounds, Good Samaritan Hospital. Cincinnati, Ohio, June 23, 1984.
33. Bladder Cancer. Southwest Oncology Group Meeting. Phoenix, Arizona, September 12, 1984.
34. Update on Cancer of the Bladder and Testis. North Florida AUAA Seminar. Atlantic Beach, Florida, September 22, 1984.
35. Advances in the Treatment and Chemotherapy of Testicular and Bladder Cancer. Mississippi Society of Hospital Pharmacists Oncology Seminar. Natchez, Mississippi, October 28, 1984.
36. Southwest Oncology Group Protocols for Genitourinary Tumors. Annual Meeting of Mississippi Urological Association. Vicksburg, Mississippi, November 10, 1984.
37. Management of Superficial Bladder Cancer with 5-FU. Southwest Oncology Group Meeting. Houston, Texas, March 8, 1985.
38. Management of Advanced Seminoma. St. Joseph's Hospital Tumor Board Conference. Albuquerque, New Mexico, March 14, 1985.
39. Prostate Cancer. American Cancer Society Cancer Update. Jackson, Mississippi, September 19, 1985.
40. Genitourinary Cancer, Testis Cancer: Etiology, Diagnosis and Staging. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
41. Genitourinary Cancer, Testis Cancer: Surgical Management of Stages A, B, B₂; Adjuvant Chemotherapy. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
42. Genitourinary Cancer, Testis Cancer: Combined Chemotherapy and Irradiation for Advanced Stage Seminoma. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
43. Genitourinary Cancer, Testis Cancer: Panel Discussion with Drs. Paul Duncan, Larry Einhorn, Stephen Bush, and E. David Crawford. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
44. Bladder Cancer: Etiology, Diagnosis and Staging. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
45. Bladder Cancer: Panel Discussion with Drs. Richard L. Conn, E. David Crawford, Mark Soloway, Malcolm Bagshaw, and Larry Einhorn. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
46. Prostate Cancer: Surgical Therapy in Localized Disease. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
47. Prostate Cancer: New Treatment Modalities for the Treatment of Advanced Disease. Panel Discussion with Dr. Mark Soloway. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
48. Prostate Cancer: Panel Discussion with Drs. Edward L. Johnson, Malcolm Bagshaw, E. David Crawford, Larry Einhorn, and Mark Soloway. New Mexico Cancer Symposium. Albuquerque, New Mexico, October 11, 1985.
49. Panel on Prostate Cancer. Mississippi Urological Society. Natchez, Mississippi, October 19, 1985.

50. Challenges of Urinary Tract Disease--1986. Houston, Texas, May 9, 1986.
51. Carcinoma of the Prostate. University of Colorado Health Sciences Center, Department of Surgery Grand Rounds. Denver, Colorado, August 23, 1986.
52. Panel Member. Recent Advances in Combined Anti-Androgen Therapy. Memorial Hospital. Colorado Springs, Colorado, September 13, 1986.
53. Urology Clinical Investigations. Southwestern Surgical Congress, Fall Festival. Denver, Colorado, September 26-27, 1986.
54. Clinical Investigative Presentation. University of Colorado Health Sciences Center, Department of Surgery Research Conference. Denver, Colorado, September 27, 1986.
55. Prostatitis. Fort Levinworth Veterans Administration Medical Center. Fort Levinworth, Kansas, December 17, 1986.
56. Management of Disseminated Testicular Cancer. St. Joseph's Hospital, Surgery Grand Rounds. Denver, Colorado, April 21, 1987.
57. Prostate Cancer: Epidemic on Colorado's Front Range. University of Colorado School of Medicine. Denver, Colorado, April 29, 1987.
58. Follow-up and Sequelae of Treatment of Testicular and Prostate Cancers. 41st Annual Rocky Mountain Cancer Conference, American Cancer Society. Denver, Colorado, July 31, 1987.
59. Panel member. 41st Annual Rocky Mountain Cancer Conference, American Cancer Society. Denver, Colorado, July 31, 1987.
60. Current Concepts in Management of Prostate Cancer. Topic in Clinical Ultrasound, University of Colorado Health Sciences Center. Denver, Colorado, September 2, 1987.
61. Panel moderator. Topic in Clinical Ultrasound, University of Colorado Health Sciences Center. Denver, Colorado, September 2, 1987.
62. Male and Female Urological Problems. University Hospital Health Program for seniors. University Hospital, Denver, Colorado, October 14, 1987.
63. Treatment of Advanced Prostate Cancer. Invited speaker, Cincinnati Urological. Cincinnati, Ohio, November 30, 1987.
64. Advanced Adenocarcinoma of the Prostate: Present Concepts in Management. Guest faculty, 33rd Annual Urology Seminar, University of Missouri-Columbia. Kansas City, Missouri, December 7, 1987.
65. Current Concepts in the Management of Testicular Tumors. Guest faculty, 33rd Annual Urology Seminar, University of Missouri-Columbia. Kansas City, Missouri, December 7, 1987.
66. Combined Therapy in Adenocarcinoma of the Prostate. Guest faculty, 33rd Annual Urology Seminar, University of Missouri-Columbia. Kansas City, Missouri, December 8, 1987.
67. Prostatitis 1987. Guest faculty, 33rd Annual Urology Seminar, University of Missouri-Columbia. Kansas City, Missouri, December 8, 1987.
68. Etiology, Diagnosis, and Staging of Prostate Cancer. Eleventh Annual Winter Symposium: Cancer for the Primary Care Physician. Grand Junction, Colorado, January 22, 1988.
69. Treatment of Prostate Cancer--The Urologist's Approach. Eleventh Annual Winter Symposium: Cancer for the Primary Care Physician. Grand Junction, Colorado, January 22, 1988.
70. Treatment of Advanced Carcinoma of Prostate. Eleventh Annual Vail Urology Conference. Vail, Colorado, February 15, 1988.
71. Diagnosis and Treatment of Prostatitis. Eleventh Annual Vail Urology Conference. Vail, Colorado, February 15, 1988.
72. Prostate Cancer in the Elderly. Eighth Annual Cancer Symposium. Youngstown, Ohio, April 7, 1988.
73. Speaker, Dale Tooley Cancer Luncheon. University of Colorado Health Sciences Center, Denver, Colorado, April 19, 1988.

74. Moderator and Speaker: Current Concepts in the Management of Prostate Cancer-Prostatitis. Urology Symposium--An Update in the Management of Renal Disease. Denver, Colorado, May 14, 1988.
75. Evaluation and Management of Incontinence in the Elderly. 24th Annual Family Practice Review. Estes Park, Colorado, June 13, 1988.
76. Considerations in Screening for Early Prostate Cancer and Advances in Therapy for Advanced Disease. Medical Education Conference, Poudre Valley Hospital. Fort Collins, Colorado, June 28, 1988.
77. Current Concepts in the Diagnosis and Management of Prostate Cancer. Hospital Grand Rounds, McKee Medical Center. Loveland, Colorado, July 15, 1988.
78. Participant, Phase III Protocols for Photodynamic Therapy Using Photofrin(R) II for the Treatment of Transitional Cell Carcinoma of the Urinary Bladder. Sponsored by Quadra Logic Technologies, Inc. Newark, New Jersey, June 23, 1988.
79. Current Concepts in the Management of Bladder Cancer. Atlanta Urological Society. Atlanta, Georgia, July 28, 1988.
80. Intravesicle Chemotherapy for Superficial Bladder Cancer. Kaiser Permanente Urology Group. Hollywood, California, August 17, 1988.
81. Current Controversies in the Clinical Management of Bladder Cancer. San Diego County Urological Society. San Diego, California, August 18, 1988.
82. Controversies in the Therapy of Carcinoma of the Bladder; Treatment of Advanced Prostate Cancer. Arkansas Urologic Society. Hot Springs, Arkansas, September 10, 1988.
83. Current Concepts in the Diagnosis and Management of Localized Prostate Cancer. Arkansas Urologic Society. Hot Springs, Arkansas, September 11, 1988.
84. Current Concepts in the Management of Bladder Carcinoma. Greater Miami Urological Society. Miami, Florida, September 29, 1988.
85. Current Issues and Future Directions in the Clinical Development of Biologicals. Palm Springs, California, October 14, 1988.
86. Current Issues and Future Directions in the Clinical Development of Biologicals. Rancho Mirage, California, October 15, 1988.
87. Intravesical Therapy of Superficial Bladder Cancer. West Virginia University. Morgantown, West Virginia, October 21, 1988.
88. Pacific Presbyterian Medical Center, Invited speaker San Francisco, California, October 26, 1988.
89. Medical Treatment of Advanced Prostate Cancer. Gilbert C. Tomskey Lecture in Urology, Medicine Grand Rounds. Louisiana State University. New Orleans, Louisiana, November 10, 1988.
90. Treatment of Localized Prostate Cancer. Louisiana Urological Society. New Orleans, Louisiana, November 10, 1988.
91. Treatment of Early Prostatic Cancer and Controversies of Screening and TRUS. Orange County Urological Society. Long Beach, California, January 19, 1989.
92. Current Concepts in the Management of Localized Bladder Cancer. Midwinter Cancer Seminar at Breckenridge sponsored by American Cancer Society. Breckenridge, Colorado, January 26, 1989.
93. New Treatment for Prostatic Cancer. Rocky Mountain Urological Society. Denver, Colorado, February 2, 1989.
94. Update on Southwest Oncology Group Protocols. Kaiser Permanente Grand Rounds. Los Angeles, California, February 17, 1989.
95. Superficial Carcinoma of the Bladder. Vail Urology Conference. Vail, Colorado, February 20, 1989.
96. Management of Advanced Carcinoma of the Prostate. Vail Urology Conference. Vail, Colorado, February 20, 1989.

97. Impotence: Advances in Therapy. 35th Annual Family Practice Review. University of Colorado School of Medicine. Denver, Colorado, February 23, 1989.
98. Course Director and Speaker: Therapeutic Options for Stage D Prostate Cancer; Overview of Superficial Bladder Cancer. Third Annual Genitourinary Cancer Update. University of Colorado School of Medicine. Denver, Colorado, March 11, 1989.
99. Current Concepts in the Treatment of Advanced Prostate Cancer. Advances in the Biological Therapy of Cancer Symposium. Wesley Chapel, Florida, March 18, 1989.
100. Treatment of Advanced Prostate Cancer. University of Oklahoma. Oklahoma City, Oklahoma, March 27, 1989.
101. Latest Advances in Urological Cancer. North Colorado Family Medicine. Greeley, Colorado, March 28, 1989.
102. What is Cancer? In Conquest of Cancer Series. University of Colorado Health Sciences Center. Denver, Colorado, April 4, 1989.
103. Early Diagnosis and Treatment of Prostate Cancer. University of California at Los Angeles, April 6, 1989.
104. VA Cooperative Studies Program #246: Study Group Meeting, Chicago, Illinois, April 13, 1989.
105. Prostate Cancer: Risk Factors and Treatment Options. Prostate Cancer Education Council: Confronting Prostate Cancer, the Ignored Male Disease. New York, New York, April 27, 1989.
106. New Treatment for Prostate Cancer. New York Medical College. New York, June 8, 1989.
107. Update on Prostate Cancer. Columbia Presbyterian. New York, New York, June 8, 1989.
108. Options for the Treatment of Prostate Cancer. Sheridan, Wyoming, June 23, 1989.
109. Management of Superficial Bladder Cancer. Tyler, Texas, July 11, 1989.
110. Overview of Prostate Cancer. NCI Cancer Information Service. Denver, Colorado, July 12, 1989.
111. Treatment of Advanced Prostate Cancer. Kansas City Urological. Kansas City, Kansas, July 18, 1989.
112. Controversies in the Management of Prostate Cancer. Rose Medical Center. Denver, Colorado, August 11, 1989.
113. Current Strategies in the Treatment of Advanced Prostate Cancer. St. Louis University. St. Louis, Missouri, August 21, 1989.
114. Roundtable discussion: Treatment for Prostate Cancer. Dallas, Texas, August 29, 1989.
115. Treatment of Prostate Cancer. Grand Junction, Colorado, September 6, 1989.
116. Guest Speaker, Tumor Board. Grand Junction, Colorado, September 7, 1989.
117. Controversies in the Management of Advanced Prostate Cancer. Southern California Academy of Clinical Oncology. Los Angeles, California, September 12, 1989.
118. What is Cancer? University of Colorado Health Sciences Center, Department of Surgery, Secretarial Grand Rounds. Denver, Colorado, October 2, 1989.
119. Prostate Cancer. Rocky Mountain Poison and Drug Center. Denver, Colorado, October 6, 1989.
120. Overview of Prostate Cancer. Arvada Presbyterian Church. Arvada, Colorado, October 21, 1989.
121. Treatment Options in Metastatic Prostate Cancer. Urologic and Gynecological Cancers, 8th Annual Cancer Symposium. Sutter Cancer Center. Sacramento, California, November 3, 1989.
122. Management of Superficial Transitional Cell Carcinoma of the Bladder. Urologic and Gynecological Cancers, 8th Annual Cancer Symposium. Sutter Cancer Center. Sacramento, California, November 3, 1989.
123. Hormonal Therapy of Prostate Cancer. Inland Urological Group. Spokane, Washington, November 3, 1989.
124. Superficial Bladder Cancer. Birmingham Urological Group. Birmingham, Alabama, February 28, 1990.

125. Hormonal Management of Advanced Prostate Cancer. Oncology Grand Rounds. Wayne State University Medical Center. Detroit, Michigan, March 7, 1990.
126. Current Treatment Modalities for Prostate Cancer. Cleveland Urological Society. Cleveland, Ohio, March 8, 1990.
127. Prostate Cancer: An Overview. Cincinnati Urological Society. Cincinnati, Ohio, March 9, 1990.
128. Combined Androgen Blockade. Surgery Grand Rounds. Ohio State University Hospital. Columbus, Ohio, March 10, 1990.
129. Coordinator and Course Director. Fourth Annual Genitourinary Cancer Update. University of Colorado Health Sciences Center. Denver, Colorado, March 16, 1990.
130. Combined Androgen Blockade. Fourth Annual Genitourinary Cancer Update. University of Colorado Health Sciences Center. Denver, Colorado, March 16, 1990.
131. Where We Stand in Prostate Cancer. Sun Valley, Idaho, March 31, 1990.
132. The Battle Within: What is Cancer? In Conquest of Cancer Series, University of Colorado Health Sciences Center. Denver, Colorado, April 17, 1990.
133. Current Concepts in the Management of Prostate Cancer. Urology Workshop, National Conference, Mountain Region. Denver, Colorado, April 19, 1990.
134. Contemporary Issues in the Treatment of Hormonally Dependent Prostate Cancer. Grand Rounds, University of California. San Francisco, California, April 20, 1990.
135. Prostate Carcinoma: An Overview. Sequoia Hospital. Redwood City, California, April 20, 1990.
136. Total Androgen Blockade in Advanced Prostate Cancer. Napa Valley, California, April 21, 1990.
137. Bladder Cancer: A Discussion of CIS and High-Grade, High-Stage Tumors. GU Oncology Update. Albuquerque, New Mexico, May 25, 1990.
138. The Role of Prostatectomy in Early Stage Prostate Cancer. GU Oncology Update. Albuquerque, New Mexico, May 25, 1990.
139. Management of Advanced Stage Prostate Cancer. GU Oncology Update. Albuquerque, New Mexico, May 25, 1990.
140. Academic Urologic Cooperative Group. University of Iowa. June 4, 1990.
141. Overview of Bladder, Testis, and Renal Cancers. Cancer Information Network. Denver, Colorado, June 18, 1990.
142. Treatment of Localized Prostate Cancer. New Directions in Urology: Contemporary Management of Prostatic Cancer, BPH, and Common Pediatric Urologic Disorders. San Antonio, Texas, June 22, 1990.
143. Total Androgen Ablation in Stage D2 Disease. New Directions in Urology: Contemporary Management of Prostatic Cancer, BPH, and Common Pediatric Urologic Disorders. San Antonio, Texas, June 22, 1990.
144. Prostate Cancer. Panel Member. New Directions in Urology: Contemporary Management of Prostatic Cancer, BPH, and Common Pediatric Urologic Disorders. San Antonio, Texas, June 22, 1990.
145. Treatment of Advanced Prostate Cancer. Sun River, Oregon. July 15, 1990.
146. Prostatitis. Family Practice Group. Las Vegas, Nevada, August 1, 1990.
147. Treatment of Advanced Prostate Cancer, NCI Study. Panama City, Florida, August 7, 1990.
148. Northwestern University. Chicago, Illinois, August 21, 1990.
149. Treatment of Advanced Prostate Cancer. University of Chicago. Chicago, Illinois, August 22, 1990.
150. Current Concepts in the Diagnosis and Management of Localized Prostate Cancer. Tufts University. Boston, Massachusetts, September 6, 1990.
151. Therapeutic Challenges in Local and Advanced Bladder Cancer. New England Medical Center Hospital. Boston, Massachusetts, September 7, 1990.

152. Update on Hormonal Therapy of Advanced Prostate Cancer. Harvard University. Boston, Massachusetts, September 8, 1990.
153. Treatment of Advanced Prostate Cancer. Denver, Colorado, September 11, 1990.
154. Diagnosis and Management of Prostate Cancer. Coors Medical Center. Denver, Colorado, September 14, 1990.
155. The Role of Anti-Androgens in the Management of Advanced Prostate Cancer. Invited Speaker, Malnoti Symposium honoring John T. Grayhack, M.D. Chicago, Illinois, October 4, 1990.
156. Management of Localized Prostate Cancer. Prostatic Disease: A Review of Current Management. Cleveland, Ohio, October 5, 1990.
157. The Treatment of Prostate and Bladder Cancer in 1990. L'Hôtel Dieu de Québec, Université of Laval. Quebec City, Canada, October 5, 1990.
158. Diagnosis and Management of Prostatic Diseases. Englewood Lion's Club. Denver, Colorado, October 16, 1990.
159. Prostate Cancer. Nevada Urological Society. Las Vegas, Nevada, October 17, 1990.
160. Recent Developments in Total Androgen Ablation Treatment of Prostate Cancer. Missouri Baptist Hospital. St. Louis, Missouri, October 27, 1990.
161. Advances in the Treatment of Prostate Cancer. Puget Sound Urology. Seattle, Washington, November 9, 1990.
162. Management of Advanced Prostate Cancer. Prostatic Disease: A Review of Current Management. Chicago, Illinois, November 14, 1990.
163. Contemporary Management of Prostatic Cancer. Advances in Cancer Management in the Last Decade of the 20th Century. Tenth Manuel Levin Cancer Symposium. Fresno, California, November 17, 1990.
164. Advanced Prostate Cancer. Medical Oncology Grand Rounds. Cincinnati, Ohio, November 21, 1990.
165. Treatment of Localized Prostate Cancer. Case Western Reserve Oncology Conference. Cleveland, Ohio, December 5, 1990.
166. Overview of Localized Bladder Cancer. University of New Jersey, Hackensack, New Jersey, December 21, 1990.
167. Overview of Prostate Cancer. Naples, Florida, January 10-12, 1991.
168. Hormonal Management of Advanced Prostate Cancer. Sixth Annual West Texas Cancer Conference. Midland, Texas, January 12, 1991.
169. Diagnosis and Treatment of Prostate Cancer. Grand Rounds, University of California, Department of Urology. San Diego, California, February 20, 1991.
170. Treatment and Management of Advanced Prostate Cancer. San Diego, California, February 20, 1991.
171. Total Androgen Ablation. Spokane Urological Society. Spokane, Washington, February 25, 1991.
172. Maximal Androgen Deprivation. British Columbia Section of Urology. Vancouver, British Columbia, February 26, 1991.
173. Current Concepts in the Management of Prostate Cancer. Grand Rounds, Vancouver General Hospital. Vancouver, British Columbia, February 27, 1991.
174. Combined Hormonal Therapy of Prostate Cancer. 8th Annual Advances in Cancer Treatment Research, Albert Einstein College of Medicine. Manhattan, New York, March 13, 1991.
175. Co-Chairman, 5th Annual Genitourinary Cancer Update. Denver, Colorado, March 22, 1991.
176. Highlights of Therapy. 5th Annual Genitourinary Cancer Update. Denver, Colorado, March 22, 1991.
177. Current Concepts in the Management of Prostate Cancer. University of Washington. Seattle, Washington, April 6, 1991.

178. Diagnosis and Treatment of Superficial Bladder Cancer. University of Illinois. Chicago, Illinois, April 9, 1991.
179. Prostate Cancer: What the Men of Colorado Need to Know. In Conquest of Cancer lecture series, University Hospital. Denver, Colorado, April 16, 1991.
180. Advanced Stages of Prostate Cancer: Can We Make an Impact? State University of New York/Health Science Center at Brooklyn. Brooklyn, New York, May 14, 1991.
181. Current Concepts on Hormone Therapy of Prostate Cancer. University of Madison Hospital and Clinics. Madison, Wisconsin, May 18, 1991.
182. Overview of Prostate and Bladder Cancers. St. Joseph Hospital Tumor Board. Albuquerque, New Mexico, May 24, 1991.
183. GI/GU Day. Colorado Springs, Colorado, May 29, 1991.
184. Diagnosis and Management of Prostate Cancer. Denver Skyline Lions Club. Denver, Colorado, June 24, 1991.
185. Treatment of Advanced Prostate Cancer. Montgomery, Alabama, August 8, 1991.
186. T.U.L.I.P. Minimally Invasive Treatment of BPH. Urology in the 90s: New Treatment Modalities for BPH. Denver, Colorado, August 23, 1991.
187. Current Rationale for the Use of BCG in Bladder Cancer. Grand Rounds, Cleveland Clinic Cancer Center. Cleveland, Ohio, September 10, 1991.
188. Prostate Cancer--Screening. Prostate Cancer 1991: Diagnostic and Treatment Options, Good Samaritan Hospital and Medical Center. Portland, Oregon, September 14, 1991.
189. Hormonal Treatments. Prostate Cancer 1991: Diagnostic and Treatment Options, Good Samaritan Hospital and Medical Center. Portland, Oregon, September 14, 1991.
190. Screening for Prostate Cancer. Jefferson Medical College. Philadelphia, Pennsylvania, September 19, 1991.
191. Controversies in screening for Prostate Cancer. Birmingham
192. Urologic Society. Birmingham, Alabama, September 18, 1991.
193. Overview of the treatment of Prostate Cancer. Bristol-Meyers regional meeting. Colorado Springs, Colorado. October 2, 1991.
194. Treatment of Prostatitis. Shreveport Urological. October 3, 1991. Shreveport, Louisiana.
195. Prostate Cancer: Diagnosis and Management of Advanced Disease. The Prostate Clinical Forum. Houston, Texas. October 6, 1991.
196. Prostate Cancer: Charlotte Urological Association. Charlotte, North Carolina. October 7, 1991.
197. Challenges in the Management of Prostate Cancer. University of Hawaii Cancer Center. November 19, 1991
198. Changing concepts in the hormonal therapy of prostate cancer. Michael Reece Medical Center. January 21, 1992.
199. Early Diagnosis of Prostate Cancer. Colorado Chapter of the American College of Physicians. January 23, 1992.
200. Critique Panel Member, Grand Teton Meeting. January 24-27, 1992.
201. Urologic Malignancies: Further Advances in Clinical Research and Treatment. Program Director, Santa Barbara CA, February 6-9, 1992.
202. Update of the International Experience with Combined Androgen Blockade.
203. Urologic Malignancies: Further Advances in Clinical Research and Treatment. Santa Barbara CA, February 7, 1992.
204. Prostate Awareness Week: A National Screening Event. Santa Barbara CA, February 8, 1992.
205. Advances in Hormonal Therapy. Long Beach Memorial Hospital. February 12, 1992.
206. How to Manage Advanced Prostate Cancer. Appleton WI, February 28, 1992.
207. Treatment of Advanced Prostate Cancer. Green bay Urological Society. February 28, 1992.
208. Update on Minimal Disease. NCI Conference on Localized Prostate Cancer. Rockville, MD, March 5, 1992.
209. Sixth Annual GU Cancer Update: Co-Coordinator. March 6, 1992.

210. Advances in the Treatment of Advanced Prostate Cancer. Presented at the Sixth Annual GU Cancer Update, Denver CO, March 6, 1992.
211. Modalities of Therapy for Metastatic Transitional Carcinoma. Presented at the Sixth Annual GU Cancer Update, Denver CO, March 6, 1992.
212. Recent Advances in the Diagnosis and Treatment of Prostate Cancer. Presented at the American College of Physicians Downstate Meeting. New York, March 14, 1992.
213. Clinical Trials in Superficial Bladder Cancer. Presented at the Nursing Advisory Board Meeting. New York, New York. March 13, 1992.
214. In Conquest of Cancer. Prostate and Bladder Cancer. Presented University of Colorado, April 8, 1992.
215. Treatment of Prostate Cancer. Savannah Urological Society. April 15, 1992.
216. Diagnosis and Treatment of Prostate Cancer. Charleston Urological Society April 15, 1992.
217. Diseases of the Prostate. Medical Grand Rounds, University of New Mexico Department of Medicine, Albuquerque, N.M. April 22, 1992.
218. Overview of the Diagnosis and Management of Prostate Cancer. Combined Georgetown and Walter Reed Urology Conference. Washington, D.C., April 30, 1992.
219. Screening for Prostate Cancer. Mary Mulready Symposium. Hartford, CT. May 7, 1992
220. Prostate Cancer. Portland, ME Urological Association, Portland, ME, May 1, 1992.
221. Androgen Deprivation: Past, Present, and Future. Ed Bixby Institute for Postgraduate Medical Education. Kansas City, June 5, 1992.
222. Treatment of Locally Advanced and Metastatic Prostate Cancer. Post-Graduate Course in Urology. Charleston, S.C., June 6, 1992.
223. Diagnosis and Management of Prostate Cancer. Presented at Renal Disease for the Internist and Nephrologist, Aspen, CO July 20, 1992.
224. Management of Prostatitis. Grand Rounds, Texas Tech., Odessa TX, July 23, 1992.
225. Advances in the Management of Bladder Cancer. Memphis Urological Society, July 28, 1992.
226. Treatment Options for Bladder Cancer. Central Arkansas Urological Society, July 29, 1992.
227. What is Cancer? Lakewood Rotary Club. August 4, 1992.
228. Prostate Cancer. Tallahassee Urological Society. August 6, 1992.
229. Management of Superficial Bladder Cancer. Panama City Urological Group, August 7, 1992.
230. Prostate Cancer Awareness Week. Presented at Workshop on American Cancer Society Guidelines for Early Detection of Prostate Cancer. September 12, 1992.
231. Update on Carcinoma of the Prostate. Presented at St. Joseph Hospital Grand Rounds, September 4, 1992.
232. Bladder Cancer and Prostate Problems. Presented at Longevity Lectures, University of Colorado Health Sciences Center, and June 17 1992.
233. Renal Disease for the Internist and Nephrologist. July 20-24, 1992, Aspen, CO
234. Prostate Disease. Presented at Littleton Lions Club meeting. September 3, 1992.
235. Management of BPH. Practical Therapeutics Western Regional Symposium, Oct 2, 1992
236. New Approaches to the treatment of GU Malignancies. Presented at the American Society of Clinical Oncology pre-meeting, Nov, 1992.
237. Management of bladder, prostate, and testis cancer. Presented at the Southern California Academy of Clinical Oncology. November 17, 1992.
238. Endocrine Manipulations in Advanced Prostate Cancer. Presented at Medical Management of Advanced Prostate Cancer, Chicago. Oct 9, 1993
239. Palliative Measures and Treatments for Prostate Cancer. Presented at Medical Management of Advanced Prostate Cancer, Chicago. Oct 9, 1993
240. Beyond Hormonal Therapy: Ongoing Protocols and Research Topics. Presented at Medical Management of Advanced Prostate Cancer, Chicago. Oct 9, 1993.
241. Update on Prostate Cancer. Presented at Montrose Fall Clinics, Montrose, CO. Sept 25, 1993

242. Medical Treatment of Benign Prostatic Hypertrophy. Presented at Montrose Fall Clinics, Montrose, CO. Sept 25, 1993.
243. Politics of the Prostate. Presented at University of Colorado Back to Campus Day for Legislators. Boulder, CO. Oct 29, 1993.
244. Bladder Cancer and Prostate Problems. The University Longevity Lectures, in conjunction with Delta County Memorial Hospital and the Western Colorado Area Health Education Center. Delta, CO, Apr 2, 1993.
245. 1993 Perspective on Prostate Cancer. Presented at Cancer in Men for the Primary Care Physician. Scott & White/Texas A&M University Health Science Center, Austin, TX, Jun 4-5, 1993.
246. Controversies in the Management of Prostate Cancer. Presented at the 10th Annual West Texas Cancer Conference, Midland, TX. Feb 19, 1994.
247. The Treatment of Metastatic Prostate Cancer - A State of the Art Lecture. Also moderator of panel discussion, what is The Gold Standard for Treatment of Stage M₁ Disease Today? Presented at 1994 Eulexin Speakers Update Meeting, Naples, FL. Feb 24-27, 1994.
248. Current Status of Screening for and Treatment of Prostate Cancer. Presented to HMO Colorado, Golden, CO. Feb 28, 1994.
249. Benign Prostatic Hypertrophy Update. Presented to Valley View Hospital Grand Rounds, Glenwood Springs, CO. Mar 16, 1994.
250. Challenges in the Management of Locally Advanced and Metastatic Prostate Cancer. Presented to Minnesota Urological Society, Inc., Minneapolis, MN. Mar 18, 1994.
251. Prostate Screening. Presented to the Symposium on Prostate Screening, Minneapolis, MN. Mar 19, 1994.
252. Update in Maximum Androgen Blockade. Presented at Eighth Annual GU Update, Denver, CO. Mar 25, 1994.
253. Current Concepts in the Management of Prostate Cancer. Presented at the Sixth Annual Copley Cancer Symposium, Lisle, IL. Apr 16, 1994.
254. Diagnosis and Management of Localized Prostatic Carcinoma. Presented at Vanderbilt University, April 8-9, 1994.
255. Controversies in Early Diagnosis and Treatment of Prostate Cancer. Presented to Nebraska Urological Association, Omaha, NE. Apr 22, 1994.
256. Management Strategies for Advanced Prostate Cancer. Presented at University of Nebraska Grand Rounds, Omaha, NE. Apr 23, 1994.
257. University Opinion Lecture Series. University of Colorado Health Sciences Center, Denver, CO. May 5, 1994.
258. Prostate, Lung, Colorectal, and Ovarian Cancer Trial. Presented at the University Longevity Series. University of Colorado Health Sciences Center, Denver, CO. May 6, 1994.
259. Prostate Cancer Update. Los Angeles, CA. May 11, 1994.
260. Changing Concepts in Prostate Cancer. New Orleans, LA, May 24, 1994.
261. Charlotte, NC, Sep 12, 1994.
262. Current Rationale for Using BCG in Bladder Cancer. Duke University, Sept 13, 1994.
263. Changing Concepts in Advanced Prostate Cancer. Urotrend 2000, Manalapan, FL, Sep 17, 1994.
264. Urology in the 90s. Orlando, FL. October 20-22, 1994.
265. Update on Prostate Cancer. Colorado Society of Hospital Pharmacists Annual Meeting. Denver, Colorado, October 27, 1994.
266. Course Director: Techniques in Laparoscopy. Denver, Colorado, October 29, 1994.
267. Current Controversies in the Diagnosis and Management of Prostate Cancer. 1994 Health ONE Oncology Seminar Program. Denver, Colorado, November 1, 1994.
268. Changing Concepts in Advanced Prostate Cancer. El Paso Urological Society. El Paso, Texas, November 7, 1994.

269. Current Challenges in the Diagnosis and Management of Benign Prostatic Hypertrophy. Laramie, Wyoming, November 14, 1994.
270. Managing Superficial and Advanced Bladder Cancer. Medical Oncology Grand Rounds at the University of Arizona. Tucson Cancer Center, Arizona, December 12, 1994.
271. Seventh Annual Advances in Urology. Presentations: Screening, Early Diagnosis and Treatment of Localized Prostate Cancer; and Changing Paradigms in Treatment of Metastatic Prostate Cancer. Tampa, Florida, January 25-27, 1995.
272. 33rd Annual Mexico Urologic Seminar. Presentations: Management Issues in Low Stage Prostate Cancer, and Cryotherapy for Localized Prostate Cancer. Albuquerque, New Mexico, March 31, 1995.
273. Controversies in Prostate Cancer, presented at the Cancer Forum of the Cancer Foundation of Santa Barbara (California). Management Strategies for Localized and Advanced Prostate Cancer, present to the San Fernando Valley (California) Urological Group. April 18, 1995.
274. New Technology in Prostate Cancer: Disease Staging and Treatment Options. Presented to the Kansas Medical Foundation. Topeka, Kansas, May 13, 1995.
275. Presented to Valley Hospital personnel. Montclair, New Jersey, May 17, 1995.
276. Manhattan, New York, May 18, 1995.
277. Controversies in Prostate Cancer. Presented to the Kansas Medical Education Foundation, Topeka, Kansas, May 13, 1995.
278. Prostate Cancer. Presented to Valley Hospital Urological Society, Ho-Ho-Kus, New Jersey, May 17, 1995.
279. Prostate Cancer. Presented to Coney Island Hospital, Brooklyn, New York, May 18, 1995.
280. Newer Advances in Hormonal Therapy of Prostate Cancer. Presented to Sibley Hospital, Washington, DC, May 22, 1995.
281. Screening the Prostate for Cancer; Newer Treatment Modalities for Prostate Cancer; and panel discussion on Management of Prostatic Cancer. Presented at Cancer Screening for the Primary Care Physician, Kansas City, Missouri, June 9, 1995.
282. Early Detection and Management of Prostate Cancer. Presented at University of California at Davis, July 27, 1995.
283. Update on Bladder Cancer; and Update on Prostate Cancer. Presented at Halifax Medical Center Urology Dinner Meeting and Halifax Medical Center Grand Rounds, Daytona Beach, Florida, August 17-18, 1995.
284. Update on Metastatic Prostate Cancer. Presented at University of Arkansas Medical School Grand Rounds and a dinner program for community urologists. Little Rock, Arkansas, September 1, 1995.
285. New Advances in the Diagnosis and Treatment of Prostate Cancer. Presented at American Foundation for Urologic Disease, Inc. Town Meeting, Tampa, Florida, September 18, 1995.
286. Update in Prostate Cancer. Presented to dinner program for community urologists. Bricktown, New Jersey, September 19, 1995.
287. Press conference for the Us Too! /Harris Survey of prostate cancer survivors and physicians. New York, New York, September 19, 1995.
288. Screening for Prostate Cancer. Presented to faculty of University of Gratz, Gratz, Austria, October 16, 1995.
289. Presentation to the New Jersey Urological Conference. Morristown, New Jersey, March 28, 1996.
290. Prostate Cancer: Disease Staging & Treatment Options. Presented to the Washington Hospital Center. Washington, DC, April 19, 1996.
291. The Challenges, Diagnosis, and Management of Prostate Cancer. Presented to the Army-Navy Urology Conference. Bethesda, Maryland, April 20, 1996.
292. Presentation to the Cleveland Clinic: Stage T3 Prostate Cancer. Cleveland, Ohio, April 18, 1996.

293. Early Detection of Prostate Cancer. Concord, California, April 29, 1996.
294. Presentation for Discovery International in Vail, Colorado, June 27, 1996.
295. Co-Chairman of TAP into the Future. Santa Barbara, California. August 9-10, 1996.
296. Presented at Partners in Urologic Surgery. Chicago, Illinois, August 11, 1996.
297. Advanced Prostate Cancer: Redefining the Challenge. Englewood, Colorado. September 20, 1996.
298. Redefining the Challenges. San Diego, California. October 2-5, 1996.
299. Redefining the Challenges. Atlanta, Georgia. October 10-11, 1996.
300. Redefining the Challenges. Chicago, Illinois. October 25, 1996.
301. Co-chairman of TAP into the Future. West Palm Beach, Florida. October 30-November 1, 1996.
302. Presentation to local urologists. Oklahoma City, Oklahoma. November 15, 1996.
303. Presentation to local urologists. Cincinnati, Ohio. November 16, 1996.
304. Redefining the Challenges. Phoenix, Arizona. November 23, 1996.
305. Controversies in Early Detection and Treatment. Oklahoma City's Annual Fall Symposium. November 15, 1996.
306. Prostate Cancer: General Overview and Scope of the Problem; Prevention and Screening; Initial Management of Advanced Prostate Cancer. Health Alliance of Greater Cincinnati. November 16, 1996.
307. Steamboat Springs, Colorado. December 26, 1996.
308. T3: Redefining the Challenge. Panel Moderator: Ethical Issues and Treatment Dilemmas. Presented at Advanced Prostate Cancer: Redefining the Challenge. Dearborn, Michigan, Jan 17, 1997.
309. Patients Progressing After Definitive Therapy. Presented at Patients At Risk: The Challenge of the 90s. Naples, Florida. January 31, 1997.
310. Techniques of Radical Prostatectomy: Perineal Prostatectomy. Treatment Results and Morbidity: Radical Retro pubic Prostatectomy. Presented at New Strategies in the Management of T1-T3 Carcinoma of the Prostate. Scottsdale, Arizona. February 7-9, 1997.
311. Redefining T3 Disease. Radical Prostatectomy. Panel Moderator: Multimodality Therapy for Locally Advanced Prostate Cancer. Presented at Mount Sinai's Prostate Brachytherapy and New Therapeutic Strategies in the Management of Early Stage and Locally Advanced Prostate Cancer Seminar. New York, New York. March 6-7, 1997.
312. Panel Participant: Frequency and Extent of Screening/Early Detection Methods. Presented at American Cancer Society Workshop on Guidelines for Prostate Cancer. Phoenix, Arizona. March 10, 1997.
313. Antiandrogen Monotherapy for Advanced Prostate Cancer. Phoenix Speakers Update. January 18, 1997.
314. Overview of GU and Bladder Cancer Therapies. Scottsdale, Arizona. February 14, 1997.
315. New Strategies in the Management of T1-T3 Carcinoma of the Prostate: Brachytherapy, Cryoablation, Perineal Radical Prostatectomy, and Neoadjuvant Therapy. Scottsdale, Arizona. February 7-9, 1997.
316. Prostate Cancer -- What You Don't Know Could Kill You. University of Colorado Longevity Series for seniors. Denver, Colorado. March 3, 1997.
317. New Developments in the Fight against Prostate Cancer. Denver, Colorado. March 27, 1997.
318. Swedish Hospital Man-to-Man Prostate Cancer Support Group. Denver, Colorado. April 22, 1997.
319. Innovations in Diagnosis and Management of Prostate Cancer. Denver, Colorado, May 9-10, 1997.
320. The Role of Hormone Therapy in the Management of Advanced Prostate Cancer: When and How? USC/Kenneth Norris Comprehensive Cancer Center Symposium in Honor of Doctor Donald Skinner. Los Angeles, California. May 22, 1997.

321. Stage T3 Cancer of the Prostate. Presented at TAP Into The Future Conference. Palm Beach, Florida. May 29-June 1, 1997.
322. T3 -- Defining the Challenge. Presented at the Urology Update Symposium. Seattle, Washington. July 19, 1997.
323. T3 -- Defining the Challenge and Surgical Treatment vs. Radiation Therapy. Presented at Innovations in the Diagnosis and Management of Prostatic Carcinoma. New York, New York. August 8-9, 1997.
324. New Developments in the Fight against Prostate Cancer. Presented at the Congregation Emanuel, Denver, Colorado. September 17, 1997.
325. PSA Screening, Early Detection, and Staging and Surgical Treatment of Prostate Cancer. Presented at Controversies in Prostate Cancer. Manchester, New Hampshire. September 19, 1997.
326. Changing Concepts in Hormonal Therapy. Presented at Chemotherapy Foundation Symposium XV: Innovative Cancer Therapy for Tomorrow. New York, NY. November 12-14, 1997.
327. Costs and Outcomes of Prostate Cancer Screening and Treatment. Medical Grand Rounds, University of Colorado Health Sciences Center, Denver, CO, October, 1977.
328. Course Director: New Frontiers in the Medical Treatment of Benign Prostatic Hyperplasia. Denver, Colorado. February 13, 1998.
329. Distinguishing T1/T2 Disease from T3 Disease. Presented at Prostate Brachytherapy: Issues Related to Successful Outcomes and Comparison to Radical Prostatectomy and External Beam Irradiation. New York, New York. March 5-6, 1998.
330. Prostate Cancer: New Strategies for Diagnosis, Staging, and Management and Radical Prostatectomy: Techniques, Neoadjuvant Hormonal Therapy and Comparison of Results. Presented at Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. Seattle, WA. March 13, 1998.
331. Prostate Cancer: New Strategies for Diagnosis, Staging, and Management and Radical Prostatectomy: Techniques, Neoadjuvant Hormonal Therapy and Comparison of Results. Presented at Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. Houston, TX. April 17, 1998.
332. Controversies in Androgen Blockade. Presented at Addressing the Controversies of Prostate Cancer Management (for Case Western Reserve University and University Hospitals of Cleveland). Cleveland, OH. May 8, 1998.
333. The Prostate Cancer Education Council, Its Origin, Work, and Accomplishments since 1988. Presented at EHI (Ethnic Health Institute) Prostate Cancer Symposium. Oakland, CA. June 11, 1998.
334. Prostate Cancer: New Strategies for Diagnosis, Staging, and Management and Radical Prostatectomy: Techniques, Neoadjuvant Hormonal Therapy and Comparison of Results. Presented at Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. San Francisco, CA. August 7, 1998.
335. BPH Update. Presented to annual meeting of Colorado Academy of Physician Assistants. Snowmass, CO. August 14, 1998.
336. Prostate Cancer: New Strategies for Diagnosis, Staging, and Management and Radical Prostatectomy: Techniques, Neoadjuvant Hormonal Therapy and Comparison of Results. Presented at Prostate Cancer: New Strategies for Diagnosis, Staging, and Management. Atlanta, GA. August 21, 1998.
337. Management of Advanced Prostate Cancer. Presented at the University of Pennsylvania Cancer Center. Philadelphia, PA. December 9, 1998.
338. Chairman, Recent Advances in the Management of Prostate Cancer. Newport Coast, CA. March 9, 1999.
339. Controversies in the Diagnosis and Management of Localized Prostate Cancer. Cincinnati, OH. April 17, 1999.

340. The Diagnosis and Impact of Prostate Cancer. Presented at Milestones in Oncology, University of California at Irvine. April 26, 1999.
341. Rising PSA after Failed Local Therapy. Prostate Cancer Symposium, Kansas City, MO, September 25, 1999.
342. The Use of Artificial Neural Networks and Outcomes in Prostate Cancer Diagnosis and Treatment. Conference on Prognostic Factors and Staging in Cancer Management: Contributions of Artificial Neural Networks and Other Statistical Methods. Arlington, VA, September 28, 1999.
343. Rising PSA's. Prostate Cancer Support Group, University of Colorado Health Sciences Center, Denver, CO, November 9, 1999.
344. Prost-8 for the Urologist. Austin (Texas) Urological Society, February 2, 2000.
345. Overview of a clinical trial using proscar and flutamide to treat rising PSA's. Prostate Cancer Support Group, University of Colorado Health Sciences Center, Denver, CO, March 14, 2000.
346. Neoadjuvant Hormonal Therapy. New Perspectives on Prostate Disease: Redefining Patient Care meeting, Beverly Hills, CA, June 24, 2000.
347. PSA Recurrence. New Perspectives on Prostate Disease: Redefining Patient Care meeting, Beverly Hills, CA, June 24, 2000.
348. Recent Advances in Prostate Cancer. Course Director. Chicago, IL, April 20, 2001.
349. Immediate vs. Deferred Hormonal Therapy: Challenging Watchful Waiting. Recent Advances in Prostate Cancer. Chicago, IL, April 20, 2001.
350. Case Studies Panel Discussion – Question & Answer Session Moderator. Recent Advances in Prostate Cancer. Chicago, IL, April 20, 2001.
351. Early versus Late Chemotherapy. Prostate Cancer Support Group, University of Colorado Health Sciences Center, Denver, CO, May 8, 2001.
352. Immediate vs. Deferred Hormonal Therapy: Challenging Watchful Waiting. Recent Advances in Prostate Cancer, Seattle, WA, June 22, 2001.
353. Advanced Prostate Cancer: An Aggressive Approach to PSA Recurrence. Recent Advances in Prostate Cancer, Seattle, WA, June 22, 2001.
354. Advances in prostate cancer treatments. The 5th Annual Prostate Cancer Patient's Forum, University of Colorado Health Sciences Center, Denver, CO, February 8, 2003.
355. Update on Local Therapies and Prevention. Prostate Cancer Support Group, University of Colorado Health Sciences Center, Denver, CO, October 7, 2003.
356. Highlights from the 2004 ASCO meeting re: Prostate Cancer. Prostate Cancer Support Group, University of Colorado Health Sciences Center, Denver, CO, December 7, 2004.
357. Chemoprevention & Screening for Prostate Cancer. Mountain States Cancer Conference, University of Colorado Anschutz Medical Campus, Aurora, CO, November 5, 2011.
358. Controversies Surrounding the Prevention and Screening for Prostate Cancer. Yampa Valley Medical Center. Steamboat Springs, CO, September 10, 2012.
359. New Markers in Prostate Cancer, Changing the Management Paradigm. University of Colorado Hospital. Aurora, CO, October 1, 2013.
360. Genetic Influences on PSA levels: With regular screening of Men with Genetic Mutations for PSA Lead to Better Prostate Cancer Diagnosis? "SNG-ing Away At CaP" E. David Crawford, MD - 24th Annual PIU - Scottsdale, AZ. November 2015
361. What Are Currently the Best Decision Markers for Biopsy and Re-biopsy of Prostate E. David Crawford, MD - 24th Annual PIU – Scottsdale, AZ. November 2015
362. Lunch Symposium Supported by Bayer HealthCare – Incorporating Xofigo Radium Ra 223 dichloride) Into Clinical Practice Speaker: E. David Crawford, MD – 24th Annual PIU – Scottsdale, AZ. November 2015
363. Asociacion Mexicana de Urologia Oncologica XVIII Congreso Annual XXII Simposio Internacional de Urologia Oncologica – July 2016 – (Who to Biopsy who to treat? Role of

- biomarkers), (To screen or not to screen for prostate cancer?), (ADT: Timing and outcomes), (CRPC: role of Urologists), - Dr. E. David Crawford
364. XVIII Congreso de Urologia Oncologica – XXII Simposio Internacional de Urologia Oncologica July 2016 – 1) Who to biopsy and who to treat 2) Prostate who to screen and what to screen for 3) Hormonal blockade in present time and results 4) Urologist role in the management of patients with castrate resistant prostate cancer. – Dr. E. David Crawford
 365. SCS AUA 95th Annual meeting Colorado Springs, CO – September 2016 – Prostate Cancer: The role of the PCP in Screening – Dr. E. David Crawford
 366. 25th Perspectives in Urology Scottsdale, AZ – November 6, 2016 – Prostate for Primary Care – El Teatro, E. David Crawford, MD and Matt T. Rosenberg, MD. Prostate Physiology: The most Diseased Organ in the Male Body, E. David Crawford, MD. Prostate Cancer: Identifying the Toothless Lions, E. David Crawford, MD. Point Counterpoint: Primary Care Physicians Should be the Gatekeepers in Prostate Cancer – Pro: E. David Crawford, MD, Con: Erik P. Castle, MD. November 7, 2016 – Biomarkers In Genitourinary Cancers E. David Crawford, MD – Moderator, Markers for Biopsy and Re-Biopsy of the Prostate, E. David Crawford, MD. Point/Counterpoint: Best Method of Localized Treatment MRI Is Preferred: TBD, Cryotherapy Is Preferred: E. David Crawford, MD. November 8, 2016 – Novel Hormonal Therapies for Prostate Cancer, E. David Crawford, MD. – Invited Faculty – Program Chair: E. David Crawford, MD Professor of Surgery, Urology and Radiation Oncology, E. David Crawford Endowed Chair in Urologic Oncology, University of Colorado Denver School of Medicine Aurora, CO
 367. SNMMI 2017 Annula Meeting June 11, 2017 - Patient Education Day Breakout – Prostate (non-CE) By Invitation Only – E. David Crawford

XIV. ABSTRACTS AND REVIEWS OF PERSONAL SCIENTIFIC PAPERS AND PRESENTATIONS

1. CT Scan and Pelvic Lipomatosis. Urologic Capsule and Comment. March, 1979.
2. Phleborrhography Spots Venous Thrombosis. Urology Times 6:8, 1978.
3. Intercostal Nerve Block. Urology Times 6:12, 1978.
4. Salvage Cystectomy. Urology Times 7:15, 1979.
5. Phleborrhography and Deep Venous Thrombosis. Journal Club, Urology 7:32, 1979.
6. Renal Cell Carcinoma, A-V Shunting and Hemodynamic Changes. Urology Times 7:32, 1979.
7. Salvage Cystectomy. American Urological Association, Meeting Manual, 1979.
8. Salvage Cystectomy. Clinical Trends in Urology 1:6, 1979.
9. Pelvic Lipomatosis Diagnosed by Computerized Tomography Scan. Urological Survey 29:139, 1979.
10. Ultrasonic Detection of Renal Cell Carcinoma in Inferior Vena Cava. Urology Times 3:1, 1979.
11. Phleborrhography Offers Early Detection of Deep Vein Thrombosis in Urology Patients. Urology Times 3:1, 1979.
12. Deep Venous Thrombosis Following Transurethral Resection of the Prostate. Current Surgery May-June, 1979.
13. Salvage Cystectomy after Irradiation Failure. Current Surgery 38:1, 1981.
14. New Instrument for Introduction of Circle Tube Nephrostomy. Urology Times 8:7, 1980.
15. Geocillin Offers Significant Control Over Transrectal Prostate Biopsy Complications. Urology Times 10:1, 1982.
16. Geocillin Offers Significant Control Over Transrectal Prostate Biopsy Complications. International Journal, 1982.

17. Prevention of Urinary Tract Infection and Sepsis Following Transrectal Prostatic Biopsy. International Synopses, 1982.
18. Antitumor Activity of Gallium Nitrate in the Treatment of Bladder Cancer. *Urology Times* 10:9, 1982.
19. Infarction-Nephrectomy for Metastatic Hypernephroma: A Southwest Oncology Group Study. Proceedings of 13th International Congress, 1983.
20. Hexamethylmelamine (HEX) vs. Fluorouracil, Adriamycin and Cytosan (FAC) in Advanced Bladder Cancer, A SWOG Study. American Society of Clinical Oncology, 1983.
21. Promise of Gallium Nitrate in Advanced Bladder Cancer. *Urology Reporter* 8:2, 1982.
22. VM-26 in Advanced Renal Cell Carcinoma, a Southwest Oncology Group Study. American Society of Clinical Oncology, 1984.
23. Iridium for Carcinoma of the Prostate: Technique for Isotope Implant: Find Good Control of Doses. *Urology Times*, 11:1, 1983.
24. Planting Radiation Outside the OR Advanced Bladder Cancer. *Urology Reporter* 8:2, 1982.
25. Fine Needle Aspiration of Testicular Masses: Safe or Unsafe? *Your Patient and Cancer* 3:17, 1983.
26. Prevention of Urinary Tract Infection and Sepsis Following Transrectal Prostatic Biopsy. *Urology Digest*, August, 1983.
27. Aminoglutethimide Seems Effective in Fight Against Advanced Prostate Cancer. *Urology Times* 12:2, 1984.
28. Testicular Cancer - All the Way is the Best Way. *Welcome Trends in Urology* 6:11, 1984.
29. Total Resection for Post chemo Residual Cancer. *Urology Times* 12:6, 1984.
30. SWOG Study: High-Dose Cisplatin is best for Advanced Testicular Cancer. *Oncology Times* 6:15, 1984.
31. Radical Retropubic Prostatectomy. *Prostate Cancer - Analysis of the most relevant papers published in the international literature* 1:92, 1984.
32. Objective Responses and Adrenocorticosteroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide (AG) and Hydrocortisone (HC). European Conference on Clinical Oncology, January, 1985. Submitted.
33. Evaluation of Fludarabine Phosphate (NSC 312887) in Renal Cell Carcinoma. Proceedings of American Society of Clinical Oncology 4:110, 1985.
34. BCG versus Adriamycin in Bladder Cancer: A Southwest Oncology Group Study. Proceedings of American Society of Clinical Oncology 4:109, 1985.
35. Treatment of Stage D₂ Adenocarcinoma of the Prostate with Doxorubicin, Mitomycin C and 5-Fluorouracil (DMF): A Southwest Oncology Group Study. Proceedings of American Society of Clinical Oncology 4:108, 1985.
36. Cis-platinum in Advanced Squamous Cell Penile Carcinoma: A Southwest Oncology Group Study. Proceedings of American Society of Clinical Oncology 4:96, 1985.
37. Aminoglutethimide in Metastatic Adenocarcinoma of the Prostate. *AUA Abstracts* #164 133:154A, 1985.
38. Treatment of Stages cII (N₄) and cIII Seminoma with Chemotherapy Followed by Irradiation Therapy: A Southwest Oncology Group Study. *AUA Abstracts* #531 133:246A, 1985.
39. Intravesical Adriamycin for Recurrent Superficial Bladder Cancer: A Southwest Oncology Study. *AUA Abstracts* #397 133:213A, 1985.
40. Prevention of Urinary Tract Infection and Sepsis Following Transurethral Resection of the Prostate. *AUA Abstracts* #375 133:207A, 1985.
41. BCG versus Adriamycin: A Southwest Oncology Group Study Abstract of the Inter-American Society for Chemotherapy No. E-7, 1985.
42. Prophylaxis of Urinary Tract Infection and Sepsis Following TURP. *Recent Advances in Chemotherapy*. #2476, 1985.

42. Early stage testis cancer: The testicular cancer intergroup studies. 5th International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona, March, 1987.
43. BCG vs. Adriamycin in the treatment of transitional cell carcinoma in situ: A Southwest Oncology Group Study. AUA Abstracts #283, 133:184A, 1985.
44. A randomized comparison of Cisplatin, Vinblastine (VLB) plus either Bleomycin (PVB) or VP-16 (VPV) in patients with advanced testicular cancer. Proceedings of American Society of Clinical Oncology #373 5:96, 1986.
45. Combination Cisplatin and Dichloromethotrexate in advanced bladder cancer: A Southwest Oncology Group Study. Proceedings of American Society of Clinical Oncology #402 5:104, 1986.
46. Spirogermanium in the treatment of stage D2 adenocarcinoma of the prostate: A Southwest Oncology Group Study. Proceedings of American Society of Clinical Oncology #433, 5:111, 1986.
47. Williams S, Muggia F, Einhorn L, Hahn R, Donohue J, Brunner K, Stablein D, DeWys W, Crawford D, and Spaulding J. for the Testicular Cancer Intergroup Study. Resected stage III testicular cancer: Immediate adjuvant chemotherapy versus observation. Proceedings of American Society of Clinical Oncology 5:90 (380), 1986.
48. Crawford ED: Bacterial prostatitis--Expert opinion. Roerig-Pfizer, Inc., 1987.
49. Aminoglutethimide plus hydrocortisone in the treatment of castration refractory advanced adenocarcinoma of the prostate. J. Endocrinol. Invest. 10 (Suppl. 2):1987.
50. Southwest Oncology Group comparison of bacillus calmette-guerin and doxorubicin in the treatment and prophylaxis of superficial bladder cancer. American Urological Association. Anaheim, California, May 20-21, 1987.
51. Phase II trial of combination chemotherapy in patients with extragonadal germ cell tumors (SWOG 8231): Southwest Oncology Group Study. J. Urol, 139:207A, 1988.
52. Randomized prospective trial of pre-operative irradiation plus radical cystectomy versus surgery alone for transitional cell carcinoma of the bladder. A Southwest Oncology Group study. J. Urol, 139:266A, 1988.
53. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III, Intergroup Study 0036. J. Urol, 139:339A, 1988.
54. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III, Intergroup Study 0036. Proceedings Am. Soc. of Clin. Oncology, 7:119, 1988.
55. Intergroup study finds flutamide used with leuprolide gets better results. Clin. Cancer Letter, 11:6, 1988.
56. Lamm DL, Crissman J, Crawford ED, Blumenstein B, Montie JE, Scardino PT, Grossman HB, Stanisic T, Smith JA, and Sarosdy M: BCG versus Adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group Study. Proceedings American Society of Clinical Oncology, 8:130, 1989.
57. Eisenberger M, Crawford ED, Blumenstein B, Benson R, McLeod D, Dorr A, and Spaulding J: Significance of pre-treatment stratification by extent of disease (ED) in stage D2 prostate cancer (PC) patients treated with leuprolide plus flutamide (LF) or leuprolide plus placebo (LP): A Southwest Oncology Group Study. Proceedings Am. Soc. of Clin. Oncology, 8:132, 1989.
58. Samson MK, Crawford ED, Altman S, Natale R, Shah NT, and Blumenstein B: A randomized trial of cisplatin (P), vinblastine (VLB) plus either bleomycin (PVB) or VP-16 (VPV) in patients with advanced testicular cancer: A Southwest Oncology Group Study. Proceedings Am. Soc. of Clin. Oncology, 8:134, 1989.
59. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Baker L, and Neidhart J: Phase II evaluation of recombinant interleukin-2 (rIL-2) in metastatic renal cell carcinoma (RCC): SWOG 8617. Proceedings Am. Soc. of Clin. Oncology, 8:143, 1989.
60. Taylor S, Pistone B, Stephens RL, and Crawford ED: Phase II trial of didemnin B (Did-B) in advanced adenocarcinoma of the kidney: A Southwest Oncology Group Study. Proceedings Am. Soc. of Clin. Oncology, 8:145, 1989.

61. Craig J and Crawford E Phase II trial of amonafide in advanced prostate cancer: A Southwest Oncology Group Study. *Proceedings Am. Soc. of Clin. Oncology*, 8:147, 1989.
62. Bilik J, Sosnowski JT, Lamm DL, Blumenstein B, Crawford ED, Montie JE, Scardino PT, Stanisic TH, and Grossman HB: Comparison of second primaries in bladder tumor patients treated with BCG or doxorubicin: A Southwest Oncology Group Study. *American Society of Clinical Oncology*, 1989.
63. Prostate cancer combination therapy achieves 27 percent survival increase. *The Clinical Cancer Letter*, 12:9, 1989.
64. New combined drug therapy improves survival time for prostate cancer patients. *Oncology*, October 1989.
65. Crawford ED: Combination therapy for advanced prostate cancer. *Prostate Cancer: The Second Tokyo Symposium*, 267-272, Elsevier Sciences Publishing Company, Inc, 1989.
66. Crawford ED, Smith JA, Soloway MS, et al: A randomized controlled clinical trial of leuprolide and Anandron versus leuprolide and placebo for advanced prostate cancer. *J. Urol suppl*, 143:221A (abstr 129), 1990.
67. McLeod DG, Blumenstein BA, Spice D, Crawford ED, et al: The use of flutamide in hormone-refractory metastatic prostate cancer. *J. Urol suppl*, 143:221A (abstr 130), 1990.
68. Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, et al: Phase I trial of oral bropirimine (ABPP) in superficial bladder cancer. *J. Urol suppl*, 143:256A (abstr 270), 1990.
69. Blumenstein BA, Lamm D, Jewett MAS, Humphries G, Bous L, Montie JE, Scardino PT, Grossman HB, Crawford ED, Smith JA, and Stanisic T: Effect of colony-forming unit dose of Connaught BCG on outcome to immunotherapy in superficial bladder cancer. *J. Urol suppl*, 143:340A (abstr 608), 1990.
70. Lamm DL, Sarosdy MF, Grossman HB, Bohl RD, Hatch T, Moon TD, Crawford ED, et al: Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: A Southwest Oncology Group Study. *J. Urol suppl*, 143:341A (abstr 610), 1990.
71. Einhorn L, Williams S, Loehrer P, Crawford D et al.: Phase III study of cisplatin dose intensity in advanced germ cell tumors (GCT): A Southeastern and Southwest Oncology Group Protocol. *Proceedings Am. Soc. of Clin. Oncology*, 9:132 (abstr 510), 1990.
72. Loehrer PJ, Elson P, Kuebler JP, Crawford ED, et al: Advanced bladder cancer: A prospective intergroup trial comparing single agent cisplatin (CDDP) versus M-VAC combination therapy (Int 0078). *Proceedings Am. Soc. of Clin. Oncology*, 9:132 (abstr 511), 1990.
73. McLeod D, Blumenstein B, Eisenberger M, Crawford ED, et al.: Evaluation of "complete androgen blockade" (CAB) with flutamide (F) added to leuprolide (L) after progression on leuprolide (L) alone: Results of Int 0036 study in stage D2 cancer of the prostate (CP). *Proceedings Am. Soc. of Clin. Oncology*, 9:136 (abstr 526), 1990.
74. Bukowski RM, Montie J, Crawford D, and Wolf M: Cisplatin (CDDP) and mitotane in metastatic adrenal carcinoma. *Proceedings Am. Soc. of Clin. Oncology*, 9:136 (abstr 527), 1990.
75. Merrit J, Lamm D, Williams R, Moon T, Flanigan R, Crawford E, and Sarosdy M: Phase I/II trial of oral bropirimine (BROP) in superficial bladder cancer. *Proceedings Am. Soc. of Clin. Oncology*, 9:143 (abstr 555), 1990.
76. Eisenberger M, Blumenstein B, Scardino P, and Crawford ED: Evaluation of chemotherapy (CT) in endocrine-resistant prostate cancer (ERPC) patients (Pts) with measurable (MD) versus bone disease only (BDO): The SWOG experience. *Proceedings Am. Soc. of Clin. Oncology*, 9:153 (abstr 596), 1990.
77. Crawford ED, Berger N., Davis M, Donohue R, et al.: Lomefloxacin. Poster presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia, October 1990.
78. Crawford ED, Eisenberger M, McLeod D et al.: Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, Phase III, Intergroup study 0036. *Gynecol. Endocrin.*, 4(suppl 2):82 (abstr 144), 1990.

79. Crawford ED, Moon T, Stone NN, et al.: Prostate cancer awareness week: Results of Screening. American Urological Association, abstr 307, 1991.
80. Smith JA, Crawford ED, Lange PH, et al.: PSA correlation with response and survival in advanced carcinoma of the prostate. American Urological Association, abstr 685, 1991.
81. Donatucci, CF., Donohue, R.E, Crawford ED, et al.: A randomized, community-based study of balloon dilatation of the prostate versus transurethral resection: Rocky Mountain Urological Society study. American Urological Association, abstr 714, 1991.
82. Crawford ED, Schutz M, Clejan S, et al: The effect of digital rectal examination on prostate specific antigen. American Urological Association, abstr 743, 1991.
83. Janknegt RA, Fernandez DM, Abbou C, Bracken B, Bartioletti R, Hann LB, Brisset JM, deSilva FC, Chisholm G, Crawford E, et al.: Efficacy and tolerance of a total androgen blockade with anandron and orchidectomy: A double-blind, placebo-controlled, multicenter study. American Urological Association, abstr 852, 1991.
84. Benson RC, Crawford ED, Eisenberger MA et al : A Controlled Clinical Trial of Leuprolide with and without Flutamide in the Treatment of Advanced Prostate Cancer. Societe Internationale D'Urologie: 120:43, 1991
85. Crawford ED: Leuprolide with and without Flutamide in Advanced Prostate Cancer. Uro/Nephro 5:12-13, 1991.
86. Lamm DL, Crawford ED, and Blumenstein B: Maintenance BCG Immunotherapy of Superficial Bladder Cancer: A Randomized Prospective Southwest Oncology Group Trial. J. Urol 147:274A, 1992.
87. Schutz MJ, Crawford ED, and Miller GJ: Prediction of Tumor Volume and Capsular Penetration with Prostate Specific Antigen in Patients Undergoing Radical Prostatectomy. J. Urol, 147:303A, 1992.
88. McCullough DL, et al : TULIP Transurethral Ultrasound-Guided Laser Prostatectomy. J. Urol, 147:375A, 1992.
89. Kreder KJ, Donatucci CF, and Crawford ED: Balloon Dilatation of the Prostate versus transurethral Resection of the Prostate: A Continuing Prospective, Randomized Clinical Trial. J. Urol, 147:378A, 1992.
90. Treatment of Newly Diagnosed Prostate Cancer with Leuprolide and Flutamide or Leuprolide alone, Phase III: Prognostic Significance of Minimal Disease J. Urol, 147:819A, 1992.
91. Crawford ED, DeAntoni EP: Benefits and Challenges of Early Detection of Prostate Cancer (CaP) in Older Men. Proceedings of American Society of Clinical Oncology, vol 13, March 1994.
92. Glode LM, Crawford ED, Majeski S, Schmidt R, Cook S, Murphy J: Sinusoidal Floxuridine (FUDR) Infusions for Treatment of Advanced Hormone Refractory Prostate Cancer. Proceedings of American Society of Clinical Oncology, vol 13, March 1994.
93. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Earhart RH: Bropiramine Immunotherapy of Bladder CIS: Positive Phase II Results of an Oral Interferon Inducer. Proceedings of American Society of Clinical Oncology, vol 13, March 1994.
94. Babayan RK, Roth RA, McCullough DL, Gordon JO, Reese JH, Fuselier A, Crawford ED, et al: TULIP - Two Year Results. J. Urol 151:228A, 1994.
95. Crawford ED, Eisenberger MA, Blumenstein B, McLeod DG, Culkin DJ, Bueschen AJ, Thompson IM, and Lowe BA: Treatment of Histologically Confirmed D2 Prostate Cancer - A Comparison of Bilateral Orchiectomy with or without Flutamide (Intergroup Study 0105). J. Urol 151:228A, 1994.
96. Stone NN, Blum DS, DeAntoni EP, Crawford ED et al.: Prostate Cancer Risk Factor Analysis Among >50,000 Men in a National Study of Prostate-Specific Antigen (PSA). J. Urol 151:228A, 1994.
97. Staggers FM, DeAntoni EP, Crawford ED, et al: A Profile of African-American Participants in Prostate Cancer Awareness Week (PCAW). J. Urol 151:228A, 1994.

98. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham Jr SD, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED and Earhart RH: Bropiramine Immunotherapy of Bladder CIS - Positive Phase II Results of an Oral Interferon Inducer. *J. Urol* 151:228A, 1994.
99. Andriole G, Block N, Boake R, Cox C, Crawford ED et al: Two Years of Treatment with Finasteride After Radical Prostatectomy. AUA Abstract, 1994.
100. Crawford ED and DeAntoni EP: Prostate Cancer Awareness Week (PCAW)--Advances in Early Detection. American Society of Clinical Oncology Abstract, 1995.
101. Sarosdy MF, Lamm DL, Williams AD, Moon TD, Flanigan RC Crawford ED, et al: Phase I trial of oral bropiramine in superficial bladder cancer. *J. Urol* 147 (1): 31-33, 1992.
102. Crawford ED Challenges in the Management of Prostate Cancer. *British J. Urol* 70 (1):33-38, 1992.
103. Eisenberger M, Crawford ED, McLeod D, Hussain M, Loehrer P and Blumenstein B: The Prognostic Significance of Prostate Specific Antigen (PSA) in Stage D2 Prostate Cancer (interim evaluation of intergroup study 0105). *American Society of Clinical Oncology* 14:235 (#613), 1995.
104. Snow P, Crawford ED, DeAntoni EP and Gordon S: Prostate Cancer Diagnosis from Artificial Neural Networks Using the Prostate Cancer Awareness Week (PCAW) Database. *J. Urol* 157:4, 1997.
105. Crawford ED, Hirano D, Werahera PR, DeAntoni EP, Daneshgari F, Stenner J, Lucia MS and Miller G: How Many Positive Prostate Cancer Biopsies Are Due to Chance; How Many Are Due to Tumor Burden? *J. Urol* 157:4, 1997.
106. Andros E, DeAntoni EP, Holthaus K, Ross CA and Crawford ED: Comparison of Quality of Life Among Men Treated with Radical Prostatectomy and Cryoablation of the Prostate. *J. Urol* 157:4, 1997.
107. Optenberg S, Thompson IM, Friedrichs PA, Moul J, Klein E and Crawford ED: Development of a Model for the Prediction of Extraprostatic (pT3) Disease in Carcinoma of the Prostate: Highest Risk in the Hispanic Male -- No Impact of Neoadjuvant Hormonal Therapy (NHT). *J. Urol* 157:4, 1997.
108. McConnell JD, Andriole G, Crawford ED, Slawin K, Kusek J, Miller G and Bain R: Prostate Cancer Detection: Preliminary Analysis of Baseline Biopsy Data from the NIH BPH Trial. *J. Urol* 157:4, 1997.
109. DeAntoni EP, Holthaus K, Crawford ED, Stone NN, Blum D, Berger ER, Gambert S, Eisenberger M, Staggers F and McCloud DG: Prostate-Specific Antigen (PSA) Velocity in a National Cohort Tested Serially with Three Annual Tests. *J. Urol* 157:4, 1997.
110. DeAntoni EP and Crawford ED: The Effect of Prostate Cancer Screening on Detection and Stage of Disease at Diagnosis. *J. Urol* 157:4, 1997.
111. Lepor H, Dixon C, Crawford ED, Steidl C and Oesterling J: A Randomized Double Blind Placebo Controlled Phase II Study of the Safety and Efficacy of Cetrorelix in Men with BPH. *J. Urol* 157:4, 1997.
112. Lamm DL, Blumenstein B, Sarosdy M, Grossman HB and Crawford ED: Significant Long-Term Patient Benefit with BCG Maintenance Therapy: A Southwest Oncology Group Study. *J. Urol* 157(4):213 (Suppl #831) 1997.
113. Hirano D, Werahera P, Crawford ED, Stenner J, Lucia MS, DeAntoni EP, Miller GJ, Brawn P and Speights VO: Classification of Prostate Cancer Based on Tumor Doubling Time and Life Expectancy. *J. Urol* 157:4, 1997.
114. Kish J, Wolf M, Schellhammer P, Hussain M, Einstein A and Crawford ED: High Dose Cisplatin and Continuous Infusion 5 Fluorouracil for the Treatment of Advanced/Recurrent Transitional Cell Cancer of the Bladder. Final report of a Southwest Oncology Group trial. Proc. Seventh International Congress on Anti-Cancer Treatment #254, 1997.
115. McConnell TS, Smith AY, Haines LA, Cushing T, Crawford ED and Slovak M: Comparison of Fluorescence *In-Situ* Hybridization (FISH) and Bladder Tumor Antigen Test (BTA®) in Bladder Cancer: A Pilot Study. Proc. Seventh International Workshop on Chromosomes in Solid Tumors #A22, 1997.

116. Snow PB, Brandt J, Crawford ED, DeAntoni, EP and Levine R: Prostate Cancer Diagnosis From Artificial Neural Networks Using the Prostate Cancer Awareness Week (PCAW) Database. VA National Cancer Symposium Compendium: Multidisciplinary Approaches to Cancer Care in the 21st Century, 1997.
117. Donohue RE, Miller GJ, Lucia S and Crawford ED: Gleason Sum of the Radical Prostatectomy and the Final Pathologic Stage. *British J. of Urol* 80 (2): #1007, 1997.
118. Crawford ED, Janknegt RA and Maastricht NL: Long-Term Efficacy and Safety of Maximal Androgen Blockade with Nilutamide and Castration in Stage D2 Prostate Cancer. *British J. of Urol* 80 (2): #1090, 1997.
119. Crawford ED, Eisenberger M, McLeod DG, Wilding G, and Blumenstein BA: Comparison of Bilateral Orchiectomy With or Without Flutamide for the Treatments of Patients with Stage D2 Adenocarcinoma of the Prostate: Results of NCI Intergroup Study 0105 (SWOG and ECOG). *British J. of Urol* 80 (2): #1092, 1997.
120. Crawford ED, Stenner J and Rosenblum M: Changing Concepts in Hormonal Therapy. *Cancer Investigation* 16 (1): 60, 1998.
121. Ziada A, Lisle T, Handel LA, Moul J, Crawford ED: Androgen Deprivation using Low Dose Flutamide and Finasteride in the Treatment of Prostate Cancer Failures. *Euro Urol*; 37 (suppl 2) Annual Meeting, Abstract #515, April, 2000.
122. Flanigan RC, Blumenstein BAS, Salmon S, and Crawford E: Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949. *Proceedings of American Society of Clinical Oncology* 19:2a (3), 2000.
123. Flanigan RC, Blumenstein BAS, Salmon S, and Crawford E: Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949. *J of Urology*, 163(4) Suppl:154, 2000.
124. Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Hooda M, Donohue RE, Nedrow A, Crawford ED: High Gleason Sums and Lower PSA in a Single Institution over the Past Decade. *Proceedings of American Society of Clinical Oncology* 20:153b (Abstract #756), 2001.
125. Eisenberger MA, Laufer M, Sokoll L, Sinibaldi V, Zahurak M, Crawford D: Sequential Evaluation of Multiple Potential Bio-Markers in Patients with Metastatic Prostate Cancer (PCA) Following Androgen Deprivation. *Proceedings of American Society of Clinical Oncology* 20:153b (Abstract #758), 2001.
126. Schroder LE, Glass T, Eisenberger M, Culkin D, Bukowski R, Crawford E: Phase II Evaluation of Suramin in Advanced Adrenal Carcinoma: Southwest Oncology Group (SWOG) Trial 9427. *Proceedings of American Society of Clinical Oncology* 20:153b (Abstract #2361), 2001.
127. Akduman B, Crawford ED, Abouelfadel Z, Robischon M: Low dose flutamide in patients with rising PSA after a definitive therapy for localized prostate cancer. *Proceedings of American Society of Clinical Oncology* 20:158b (Abstract #2383), 2001.
128. O'Donnell C, Errejon A, Crawford ED, Kolvenbag G, Carroll K, Tewari A, Batuello J, Gamito E: Artificial Neural Network Model For Predicting Survival In Men With Advanced Prostate Cancer. *Proceedings of American Society of Clinical Oncology* 20:158b (Abstract #3131), 2001.
129. Porter C, Crawford ED, O'Donnell C, Gamito E, Genega E, Tewari A, Errejon A: Artificial Neural Network Model To Predict Biochemical Failure Following Radical Prostatectomy. *Proceedings of American Society of Clinical Oncology* 20:158b (Abstract #3132), 2001.
130. Gamito E, O'Donnell C, Han M, Partin AW, Tewart A, Errejon A, Raben D, Crawford ED: Artificial neural network model to predict risk of non-organ confined disease and risk of lymph node spread in men with clinically localized prostate cancer. *Proceedings of American Society of Clinical Oncology* 20:177a (Poster #704), 2001.
131. Crawford ED, Chia D, Andriole GL Jr, Reding D, et al: PSA changes as related to the initial PSA: Data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. *Proceedings of American Society of Clinical Oncology* 20:177a (Poster #706), 2001.

132. Natale RB, Grossman HB, Blumenstein B, Vogelzang N, Trump DL, Speights VO, de Vere White R, Crawford ED: Randomized Phase III Trial of Neoadjuvant MVAC + Cystectomy Versus Cystectomy Alone in Patients with Locally Advanced Bladder Cancer. *Proceedings of American Society of Clinical Oncology* 20:177a (Plenary Presentation #3), 2001.
133. Petrylak DP, Fisher E, Seligman, PA, Gross HM, Raghavan D, Bueschen AJ, Shellhammer PF, Buys S, Crawford ED: 9142 Phase II Study of Continuous Infusion Gallium Nitrate in Platinum-Refractory Urothelial Tract Tumors: A Southwest Oncology Group study. Accepted pending revisions by *Cancer*, 10/31/02.
134. Hussain M, Tangen CM, Lara PN, Vaishampayan, UN, Petrylak, DP, Colevas, AD, Sakr WA. Crawford ED: Ixabepilone (Epothilone B Analogue BMS-247550) is Active in Chemotherapy-Naïve Patients with Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial SO111. *Journal of Clinical Oncology* 23:8724-8729, 2005.
135. Swanson, G, Thompson, I, Tangen, C, Miller, G, Lucia, MS, Troyer, D, Paradelo, J, Chin, J, Messing, E, Canby-Hagino, E, Forman, J, Crawford, ED. 8794 Phase III Randomized Study of Adjuvant Radiation Therapy Versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG) Trial #8794. *Proc ASTRO, Int J Radiat Oncol Biol Phys* 63(Suppl1): S1 (#1), 2005.
136. O'Rourke TJ, Weiss GR, Quick DP, Thompson, Jr. IM, Crawford, ED. Locally-Advanced Prostate Cancer Treated with Concomitant Radiation and 5FU. A Southwest Oncology Group Study #9024. Accepted by the *Journal of Urology*, 11/18/05.
137. Petrylak D, Pauler Ankerst D, Jiang CS, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin, ME, Burch, PA, Kohli M, Benson MC, Small EJ, Raghavan, D, Crawford, ED: S9916 (2189) Evaluation of Post Treatment PSA Declines for Surrogacy Using Prentice's Criteria in Patients Treated on SWOG. Submitted to the *Journal of the National Cancer Institute*, 5/27/05.
138. Hussain, M, Tangen, C, Schellhammer, P, Crawford, ED, Higano, C, Wilding, G, Akdas, A, Small, EJ, Donnelly, B, Raghavan, D. 9346 Change in PSA Is a Strong Independent Predictor of Survival in Newly-Diagnosed Metastatic (D2) Prostate Cancer (PCa). Data from Southwest Oncology Group (SWOG) Trial 9346 (INT-0162). *Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology*, 24 (18S): #4517, 2006.
139. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. 8794 Adjuvant Radiotherapy for Pathologically-Advanced Prostate Cancer: Results of a randomized, prospective clinical trial. Submitted to the *Journal of the American Medical Association*, 6/1/06.
140. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman F, De Vere White RW, Karnad AB, Glode M, Crawford ED. 9458 Evaluation of Ki67, P53 and Angiogenesis in Patients in a Randomized Study of Neoadjuvant Chemotherapy with or Without Cystectomy. A Southwest Oncology Group study. Accepted by *Oncology Reports*, 6/1/06.
141. Berry, DL, Moinpour, CM, Jiang, CS, Ankerst, DP, Petrylak, DP, Vinson, LV, Lara, PN, Jones, S, Taplin, ME, Burch, PA, Hussain, MHA, Crawford, ED. S9916 Quality of Life and Pain in Advanced Stage Prostate Cancer. Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. *Journal of Clinical Oncology*, 24 (18): 2828-2835, 2006.
142. Ryan, CW, Goldman, BH, Lara Jr, PN, Beer, TM, Drabkin, HA, Crawford, ED. S0412 Sorafenib Plus Interferon-a2b (IFN) As First Line Therapy for Advanced Renal Cell Carcinoma (RCC): SWOG 0412. *Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology*, 24 (18S): #4525, 2006.
143. Crawford ED. Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. *Genitourinary Cancers Symposium* #68, 2013.
144. Measurement of Testosterone: how important is a morning blood draw. Article ST-0212.R2/1082994
145. DorffTB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic

Castrate-resistant prostate cancer. <http://www.ncbi.nlm.nih.gov/pubmed/22831986>

146. Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy. Nelson N. Stone, MD, Vladimir Mouraviev, MD, PHD, David Schechter, BS, MBA, Josh Goetz, MS M. Scott Lucia, MD, E. Erin Smith, BA, and E. David Crawford, MD, PMID: 27708117 DOI: [10.1177/1533034616671007](https://doi.org/10.1177/1533034616671007)
147. E. David Crawford, B. Tombal, T. Keane, F. Boccardo, K. Miller, N. Shore, J. W. Moul, J.-E. Damber, L. Collette & B.-E. Persson (2019) FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist, Scandinavian Journal of Urology Published online: 09 Jan 2019, <https://doi.org/10.1080/21681805.2018.1522372>

XV. SCIENTIFIC EXHIBITS

1. Deep Venous Thrombosis Following Transurethral Resection of the Prostate: A New Method of Diagnosis. American Urological Association Meeting. Washington, D.C., May 1978 (Third Prize).
2. Treatment of Cystinuria with Acetylcysteine. American Urological Association Meeting. New York, May, 1979.
3. Intercostal Nerve Block after Flank Surgery. American Urological Association Meeting. New York, May, 1979.
4. Intercostal Nerve Block after Flank Surgery. South Central Section American Urological Association Meeting. Albuquerque, New Mexico, October, 1979.
5. Treatment of Cystinuria with Acetylcysteine. South Central Section American Urological Association. Albuquerque, New Mexico, October, 1979.
6. Intercostal Nerve Block after Flank Surgery. American College of Surgeons. Chicago, Illinois, October, 1979.
7. Intercostal Nerve Block after Flank Surgery. Southern Medical Association Meeting. Las Vegas, Nevada, November, 1979.
8. Intercostal Nerve Block after Flank Surgery. Western Section of American Urological Association. Honolulu, Hawaii, March 4-7, 1980 (Second Prize).
9. Prevention of Urinary Tract Infection and Sepsis Following Prostatic Biopsy. South Central Section of American Urological Association. Kansas City, Kansas, October, 1980.
10. Prevention of Urinary Tract Infection and Sepsis Following Prostatic Biopsy. American College of Surgeons. Atlanta, Georgia, October, 1980.
11. Prevention of Urinary Tract Infection Following Prostatic Biopsy. Annual AUA Meeting. Boston, Massachusetts, May 9-14, 1981.
12. Prevention of Urinary Tract Infection Following Prostatic Biopsy. Annual South Central Section of American Urological Association. Dallas, Texas, September 14-17, 1981 (Honorable Mention in Clinical).
13. Urinary Tract Infection and Sepsis after Prostatic Biopsy. Exhibit at 13th International Congress of Chemotherapy. Vienna, August 22, 1983.
14. Bioautography of Carbenicillin-Derived Antimicrobial Activity in Human Prostate. Exhibit at Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, Nevada, October 23-26, 1983.
15. Aminoglutethimide in Metastatic Adenocarcinoma of the Prostate. American Society of Clinical Oncology Annual Meeting. Toronto, Ontario, Canada, May 6, 1984.
16. Prevention of Urinary Tract Infections and Sepsis Following Transurethral Resection of the Prostate. American Association of Microbiology Annual Meeting. Las Vegas, Nevada, March 4-6, 1985.

17. Endocrine Manipulation of Advanced Prostate Cancer. Presented by Marilyn A. Davis, R.N., and E. David Crawford, M.D Southwest Oncology Group Meeting. Houston, Texas, March 7, 1985.
18. Prophylaxis of Urinary Tract Infection and Sepsis Following Transurethral Resection of the Prostate. 14th International Congress of Chemotherapy. Kyoto, Japan, June 24, 1985.
19. Prevention of Urinary Tract Infection Following Transurethral Resection of the Prostate. American College of Surgeons. Chicago, Illinois, October 14-16, 1985.
20. Prevention of Urinary Tract Infection Following Transurethral Resection of the Prostate, Certificate of Merit. 79th Annual Scientific Assembly of the Southern Medical Association. Orlando, Florida, November 17-20, 1985.
21. Intra-arterial Chemotherapy for Advanced Pelvic Malignancies. Southeastern Section of American Urological Association. Puerto Rico, March 16-19, 1986.
22. A Phase I Study of Intravesical Therapy of Refractory Bladder Cancer with Tumor Necrosis Factor (TNF). South Central Section of American Urological Association. Colorado Springs, Colorado, October 16-19, 1988.
23. Lomefloxacin versus Cefotaxime as Prophylaxis for Transurethral Surgery. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia, October 1990. (Presented by N. Berger).
24. The Effect of Digital Rectal Examination on Prostate Specific Antigen. American Urological Association. Toronto, Ontario, June 5, 1991. (Presented by M. Schutz).
25. Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate. International Symposium on Recent Advances in Diagnostic and Treatment of Prostate Cancer. Quebec, Canada, Sept 21-23, 1995.

XVI. BOOK REVIEWS

1. The Prostatic Cell: Structure and Function (GP Murphy, AA Sandberg, and JP Karr). Reviewed for Oncology Times, 4(9):2, 1982.
2. Prostate Cancer (GM Jacobi and R Hohenfellner). Reviewed for Oncology Times, 4(11):25, 1982.
3. Progress in Clinical and Biologic Research, Vol. 2, 69: Progress and Controversies in Oncological Urology, II. (FH Schroder, GM Klin, KH Kurther, et al.). Reviewed for Journal of the National Cancer Institute, 1988.
4. Uro-oncology: Current Status and Future Trends (HGW Frommuller and MP Wirth, eds.). M. Schutz and ED Crawford: Reviewed for Journal of the National Cancer Institute, 1991.
5. Doxazosin Gastrointestinal Therapeutic System: A Review of its Use in Benign Prostatic Hyperplasia (Goldsmith DR, Plosker GL). Reviewed for Drugs, 65 (14), 2005.
6. The Prostate Cancer Dilemma 2016 (Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy) Editors: Nelson N. Stone, E. David Crawford
<http://link.springer.com/book/10.1007/978-3-319-21485-6>



E. David Crawford, MD
 Professor of Urology

UC San Diego Health
University of Colorado
9400 Campus Point Dr #7897
La Jolla, CA 92037-7897
Fax 858-249 0905 / E 90899
Email: edc@edavidcrawford.com

10/28/2022